

000137749-24-02636710-Q Moleculin Biotech, Inc. 2024081320240813160031160031160031 0 0001437749-24-026367 10-Q 54 20240630 20240813 20240813 Moleculin Biotech, Inc. 0001659617 2834 474671997 1231 10-Q 34 0001-37758 241201187 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 10-Q 1 mbrx20240630 10q.htm FORM 10-Q mbrx20240630 10q.htm 0001659617 Moleculin Biotech, Inc. false --12-31 Q2 2024 0.001 0.001 5,000,000 5,000,000 0 0 0 0 0.001 0.001 100,000,000 100,000,000 2,560,785 2,560,785 2,227,516 2,227,516 3 1 10 0 0 0 0 12,000 38,000 59,000 117,000 false false 00016596172024-01-012024-06-30 xbrli:shares 00016596172024-08-01 thunderdome:item iso4217:USD 00016596172024-06-30 00016596172023-12-31 iso4217:USDbxli:shares 00016596172024-04-012024-06-30 00016596172023-04-012023-06-30 00016596172023-01-012023-06-30 00016596172022-12-31 00016596172023-06-30 0001659617us-gaap:CommonStockMember2023-12-31 0001659617us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001659617us-gaap:RetainedEarningsMember2023-12-31 0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0001659617us-gaap:CommonStockMember2024-01-012024-03-31 0001659617us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0001659617us-gaap:RetainedEarningsMember2024-01-012024-03-31 0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-31 00016596172024-01-012024-03-31 00016596172024-01-012024-03-31 0001659617us-gaap:CommonStockMember2024-03-31 0001659617us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-30 0001659617us-gaap:RetainedEarningsMember2024-04-012024-06-30 0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-30 0001659617us-gaap:CommonStockMember2024-06-30 0001659617us-gaap:AdditionalPaidInCapitalMember2024-06-30 0001659617us-gaap:RetainedEarningsMember2024-06-30 0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-30 0001659617us-gaap:CommonStockMember2022-12-31 0001659617us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001659617us-gaap:RetainedEarningsMember2022-12-31 0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0001659617us-gaap:CommonStockMember2023-01-012023-03-31 0001659617us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0001659617us-gaap:RetainedEarningsMember2023-01-012023-03-31 0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-31 0001659617us-gaap:CommonStockMember2023-03-31 0001659617us-gaap:AdditionalPaidInCapitalMember2023-03-31 0001659617us-gaap:RetainedEarningsMember2023-03-31 0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-31 00016596172023-03-31 0001659617us-gaap:CommonStockMember2023-04-012023-06-30 0001659617us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-30 0001659617us-gaap:RetainedEarningsMember2023-04-012023-06-30 0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-30 0001659617us-gaap:CommonStockMember2023-06-30 0001659617us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001659617us-gaap:RetainedEarningsMember2023-06-30 0001659617us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30 xbrli:pure 0001659617mbrx:AnimalLifeSciencesIncMember2024-06-30 00016596172023-05-05 utr:D 00016596172023-11-022024-04-29 0001659617mbrx:ReverseStockSplitMember2024-03-212024-03-21 0001659617mbrx:ReverseStockSplitMember2024-03-222024-03-22 00016596172022-01-012022-12-31 0001659617us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-30 0001659617us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-30 0001659617us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-30 0001659617us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-30 0001659617mbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-30 0001659617us-gaap:FairValueInputsLevel1Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-30 0001659617us-gaap:FairValueInputsLevel2Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-30 0001659617us-gaap:FairValueInputsLevel3Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-30 0001659617mbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001659617us-gaap:FairValueInputsLevel1Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001659617us-gaap:FairValueInputsLevel2Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001659617us-gaap:FairValueInputsLevel3Membermbrx:WarrantLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0001659617mbrx:WarrantLiabilityLongTermMember2024-03-31 0001659617mbrx:WarrantLiabilityLongTermMember2024-04-012024-06-30 0001659617mbrx:WarrantLiabilityLongTermMember2024-06-30 0001659617mbrx:WarrantLiabilityLongTermMember2023-12-31 0001659617mbrx:WarrantLiabilityLongTermMember2024-01-012024-06-30 0001659617us-gaap:RelatedPartyMember2024-06-30 0001659617us-gaap:RelatedPartyMember2023-12-31 0001659617us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2024-06-30 0001659617us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2024-06-30 0001659617us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2023-12-31 0001659617us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2023-12-31 0001659617us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2024-06-30 0001659617us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2024-06-30 0001659617us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2023-12-31 0001659617us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2023-12-31 0001659617us-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2024-06-30 0001659617us-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2024-06-30 0001659617us-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2023-12-31 0001659617us-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2023-12-31 0001659617mbrx:LiabilityClassifiedWarrantsMember2023-12-31 0001659617mbrx:LiabilityClassifiedWarrantsMember2023-12-31 0001659617mbrx:LiabilityClassifiedWarrantsMembersrt:MinimumMember2023-12-31 0001659617mbrx:LiabilityClassifiedWarrantsMembersrt:MaximumMember2023-12-31 utr:Y 0001659617mbrx:LiabilityClassifiedWarrantsMember2023-01-012023-12-31 0001659617mbrx:LiabilityClassifiedWarrantsMember2024-01-012024-06-30 0001659617mbrx:LiabilityClassifiedWarrantsMembersrt:MinimumMember2024-01-012024-06-30 0001659617mbrx:LiabilityClassifiedWarrantsMembersrt:MaximumMember2024-01-012024-06-30 0001659617mbrx:LiabilityClassifiedWarrantsMembersrt:WeightedAverageMember2024-01-012024-06-30 0001659617mbrx:LiabilityClassifiedWarrantsMember2024-06-30 0001659617mbrx:EquityClassifiedWarrantsMember2024-06-30 0001659617mbrx:EquityClassifiedWarrantsMember2023-12-31 0001659617mbrx:EquityClassifiedWarrantsMember2024-04-012024-06-30 0001659617mbrx:EquityClassifiedWarrants

[illegible]

development of and statements regarding the Company's drug candidate for the treatment of COVID-19. The Company has received, and expects to continue to receive, periodic further requests from the SEC staff with respect to this matter. The Company is not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that it has made, the Company believes in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to the Company states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. The Company cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. The company expensed approximately \$0.1 million and \$0.4 million in related general and administrative fees and expenses for the three months ended June 30, 2024 and 2023, respectively, and \$0.1 million and \$0.9 million for the six months ended June 30, 2024 and 2023, respectively. The Company is in the process of filing a claim with its insurance carriers related to this loss which may cover a portion of the related expenses but not all. The claim is currently under review by the insurance company. The claim has not yet been approved nor has a reimbursement amount been determined which, if any, would be limited by the applicable retention as defined under the policy. Accordingly, the Company has not recorded any provision for insurance reimbursement. The Company expects to record the insurance reimbursement at the time that the amount to be reimbursed is determined and approved by the insurance carrier. Any insurance reimbursement receivable will be recorded at an amount not to exceed the recorded loss and only if the terms of the legally enforceable insurance contracts support that the insurance recovery will not be disputed and is deemed collectible, or if recovery of the loss is probable. Cash and Cash Equivalents - Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains cash accounts principally at one financial institution in the U.S., which at times, may exceed the Federal Deposit Insurance Corporation's limit. The Company has not experienced any losses from cash balances in excess of the insurance limit. The Company's management does not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institution where its cash is held. Prepaid Expenses and Other Current Assets - Prepaid expenses and other current assets consist of the following (in thousands): June 30, 2024 December 31, 2023 Prepaid sponsored research \$1,277.4 \$1,515.4 Prepaid insurance \$1,143.4 \$564.4 Vendor prepayments and deposits \$457.4 \$545.4 Non-trade receivables \$5.4 \$95.4 Related party receivables \$4.4 \$4.4 Total prepaid expenses and other current assets \$2,886.4 \$2,723.4 Fair Value of Financial Instruments - The Company's financial instruments consist primarily of non-trade receivables, accounts payable, accrued expenses and its warrant liability. The carrying amount of non-trade receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such. Table of Contents 8 The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Level 1 - Unadjusted quoted prices in active markets of identical assets or liabilities. Level 2 - Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 - Unobservable inputs for the asset or liability. The Company's financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. The following table provides the financial liabilities reported at fair value and measured on a recurring basis at June 30, 2024 and December 31, 2023 (table in thousands): Description Fair Value Level 1 Level 2 Level 3 Fair value of warrant liability as of June 30, 2024: \$1,704.4 \$ - \$ - \$1,704.4 Fair value of warrant liability as of December 31, 2023: \$4,855.4 \$ - \$ - \$4,855.4 The table below of Level 3 liabilities (table in thousands) begins with the valuation as of the beginning of the second quarter and then is adjusted for changes in fair value that occurred during the second quarter. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments. Three Months Ended June 30, 2024 Warrant Liability Long-Term Balance, March 31, 2024 \$3,400.4 Change in fair value - net \$1,696 Balance, June 30, 2024 \$1,704.4 The table below of Level 3 liabilities (table in thousands) begins with the valuation as of December 31, 2023 and then is adjusted for changes in fair value that occurred during the six months ended June 30, 2024. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments. Six Months Ended June 30, 2024 Warrant Liability Long-Term Balance, December 31, 2023 \$4,855.4 Change in fair value - net \$1,151 Balance, June 30, 2024 \$1,704.4 Loss Per Common Share - Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock units subject to vesting and warrants to purchase common stock are considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. For the three and six months ended June 30, 2024 and 2023, approximately 1.6 million and 0.4 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect. Subsequent Events - The Company's management reviewed all material events through the date of these unaudited condensed consolidated financial statements. Recent Accounting Pronouncements - There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company. Table of Contents 9 3. Accrued expenses and other current liabilities - Accrued expenses and other current liabilities consist of the following components (in thousands): June 30, 2024 December 31, 2023 Accrued payroll and bonuses \$1,157.4 \$765.4 Accrued research and development \$1,060.4 \$2,845.4 Accrued legal, regulatory, professional and other \$540.4 \$547.4 Operating lease liability - current \$112.4 \$100.4 Accrued liabilities due to related party \$44.4 \$60.4 Total accrued expenses and other current liabilities \$2,913.4 \$4,317.4 Additionally, accounts payable includes \$20,000.4 and \$67,000.4 as of June 30, 2024 and December 31, 2023, respectively, for related party payables. 4. Warrants - Liability Classified Warrants - The Company uses the Black-Scholes option pricing model (BSM) to determine the fair value of its warrants at the date of issue and outstanding at each reporting date. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds linearly interpolated to obtain a maturity period commensurate with the term of the warrants. Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Only the volatility of the Company's own stock is used in the Black-Scholes option pricing model. The assumptions used in determining the fair value of the Company's outstanding liability classified warrants are as follows: June 30, 2024 December 31, 2023 Risk-free interest rate 4.3% to 5.2% 3.8% to 5.4% Volatility 87.9% to 94.9% 79.5% to 108.7% Expected life (years) 0.6 to 4.5 0.3 to 5.0 Dividend yield 0% 0% Summary of the Company's liability classified warrant activity during the six months ended June 30, 2024 and related information follows: Number of Shares Range of Warrant Exercise Weighted Average Weighted Average Remaining Contractual Under Warrant Price per Share Exercise Price Life (Years) Balance at January 1, 2024 1,082,895.4 \$9.60 \$157.50 \$24.32 5.1 Expired warrants (75,909) \$99.00 \$99.00 \$99.00 \$ - Balance at June 30, 2024 1,006,986.4 \$9.60 \$94.50 \$ - Exercisable at June 30, 2024 1,006,986.4 \$9.60 \$94.50 \$15.31 4.4 For a summary of the changes in fair value associated with the Company's warrant liability for the six months ended June 30, 2024, see Note 2 - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Financial Instruments. Equity Classified Warrants - In March 2024, the Company granted equity-classified warrants to purchase up to 3,334 shares of Company common stock with a ten-year term and an exercise price of \$9.15. The warrants vest annually over four years while services are being performed. At June 30, 2024, the Company had 63,105 equity classified warrants outstanding and 40,658 warrants were exercisable. At December 31, 2023, the Company had 289,276 equity classified warrants outstanding and 266,350 warrants were exercisable. Table of Contents 10 The Company recorded stock compensation expense for the non-employee consulting agreements of \$35,000.4 and \$46,000.4 for the three months ended June 30, 2024 and 2023, respectively, and \$68,000.4 and \$92,000.4 for the six months ended June 30, 2024 and 2023, respectively. At June 30, 2024, there was \$309,000.4 of unrecognized stock compensation expense related to the Company's equity classified warrants. 5. Equity - Lincoln Park Equity Line - The Company did not utilize the 2021 Lincoln Park purchase agreement during the six months ended June 30, 2024. The 2021 Lincoln Park Agreement terminated in June 2024. Other Components of Equity - In March 2024, the Company issued 6,834 shares of common stock to consultants in exchange for services to be provided. In addition, during the six months ended June 30, 2024, the Company issued 19,743 shares of common stock related to the vesting of restricted stock units. Stock-Based Compensation and Outstanding Awards - The 2015 Stock Plan provides for the grant of stock options, stock awards, stock unit awards, and stock appreciation rights to employees, non-employee directors and consultants. In May 2023 and 2022, the 2015 Stock Plan (the Plan) was amended to authorize an additional 116,667 shares and 133,334 shares, respectively, such that 366,667 total shares may be issued under the Plan. As of June 30, 2024, there were 1,053 shares remaining to be issued under the 2015 Stock Plan. Stock-based compensation expense for the three and six months ended June 30, 2024 and 2023, respectively, is as follows (table in thousands): June 30, 2024 June 30, 2023 Three Months Ended June 30, 2024 \$45.4 \$40.4 \$85.4 \$79.4 In September 2023, the Company executed an amendment to extend the corporate office lease until August 31, 2029, with an option to renew. The Company is required to remit base monthly rent of approximately \$4,700.4 which will increase at an average approximate rate of 2% each year. The Company is also required to pay additional rent in the form of its pro-rata share of certain specified operating expenses of the building. In June 2022, the Company extended the lab lease until September 30, 2027, with no further right or option to renew. The Company recorded approximately \$12,000.4 in sublease income from a related party for the three months ended June 30, 2024 and 2023, respectively, and \$24,000.4 and \$25,000.4 for the six months ended June 30, 2024 and 2023. Sublease income is recorded as other income, net on the Company's condensed consolidated statement of operations and comprehensive loss. Operating cash flows from operating leases was \$38,000.4 for the three months ended June 30, 2024 and 2023, respectively, and \$68,000.4 and \$75,000.4 for the six months ended June 30, 2024 and 2023, respectively. Licenses - MD Anderson - Total expenses related to the Company's license agreements with MD Anderson were \$63,000.4 and \$64,000.4 for the three months ended June 30, 2024 and 2023, respectively, and \$117,000.4 and \$129,000.4 for the six months

ended June 30, 2024 and 2023, respectively. A HPI - The Company has two agreements with a related party, Houston Pharmaceuticals, Inc. (HPI) with total expenses of \$59,000 for each of the three months ended June 30, 2024 and 2023, respectively, and \$117,000 for the six months ended June 30, 2024 and 2023, respectively. A Sponsored Research Agreements - The expenses recognized under the agreements were \$377,000 and \$176,000 for the three months ended June 30, 2024 and 2023, respectively, and \$533,000 and \$331,000 for the six months ended June 30, 2024 and 2023, respectively. A 12 Table of Contents A ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS A This Form 10-Q, including the Management's Discussion and Analysis of Financial Condition and Results of Operations, contains certain forward-looking statements. Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events, are based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by these statements. A Forward-looking statements include, but are not limited to, statements about: A A Our ability to continue our relationship with MD Anderson, including, but not limited to, our ability to maintain current licenses and license future intellectual property resulting from our sponsored research agreements with MD Anderson; A A The success or the lack thereof, including the ability to recruit subjects on a timely basis, for a variety of reasons, of our clinical trials through all phases of clinical development; A A Our ability to satisfy any requirements imposed by the US Food & Drug Administration (FDA) (or its foreign equivalents) as a condition of our clinical trials proceeding or beginning as planned; A A World-wide events including the wars in Ukraine and in Israel, the COVID-19 pandemic, and the general supply chain shortages effects on our clinical trials, clinical drug candidate supplies, preclinical activities and our ability to raise future financing; A A Our ability to obtain additional funding to commence or continue our clinical trials, fund operations and develop our product candidates; A A The need to obtain and retain regulatory approval of our drug candidates, both in the United States and in Europe, and in countries deemed necessary for future trials; A A Our ability to complete our clinical trials in a timely fashion in line with our stated milestones and within our expected budget and resources; A A Our ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market; A A Our ability to source our drug products at reasonable prices; A A Compliance with obligations under intellectual property licenses with third parties; A A Any delays in regulatory review and approval of drug candidates in clinical development; A A Potential efficacy of our drug candidates; A A Our ability to commercialize our drug candidates; A A Market acceptance of our drug candidates; A A Competition from existing therapies or new therapies that may emerge; A A Potential product liability claims; A A Our dependency on third-party manufacturers to successfully, and timely, supply or manufacture our drug candidates for our preclinical work and our clinical trials; A A Our ability to establish or maintain collaborations, licensing or other arrangements; A A Our ability and third parties' abilities to protect intellectual property rights; A A Our ability to adequately support future growth; and A A Our ability to attract and retain key personnel to manage our business effectively. A We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements. A Our Business A We are a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 and 3 clinical programs for hard-to-treat cancers and viruses. A We have three core technologies, each of which have had one or more drugs successfully complete a Phase 1 clinical trial, based substantially on discoveries made at and licensed from the University of Texas MD Anderson Cancer Center (MD Anderson) in Houston, Texas. Three of our six drug candidates have shown human activity in clinical trials and are currently or have been in Phase 1B/2 or Phase 2 clinical trials. Since our inception and as of March 2024, our drugs have completed, are currently in, or have been permitted to proceed in, thirteen clinical trials. Annamycin is our lead molecule and is in three Phase 1B/2 clinical trials - one for treating Acute Myeloid Leukemia (AML) and two for treating Soft Tissue Sarcoma metastasized to the lungs (STS lung metastases, STS lung mets, or Advanced STS). A One of our core management beliefs is that anthracyclines represent the most important treatment for AML and Advanced STS, and we believe Annamycin may, for the first time ever, allow a majority of these patients to benefit from this treatment. This belief, coupled with our limited resources, leads us to currently focus mainly on the development of Annamycin. We intend to advance our other drug candidates via investigator led studies both clinically and preclinically. A 13 Table of Contents A Our Core Technologies A Our core technologies consist of the following programs: A a) Annamycin or L-Annamycin is a next generation anthracycline (one of the most widely used classes of chemotherapy), designed to be different than currently approved anthracyclines, which are limited in utility because of cardiotoxicity risks and their susceptibility to multidrug resistance mechanisms. Annamycin was designed to avoid multidrug resistance and to be non-cardiotoxic and has shown no cardiotoxicity in subjects treated in our clinical trials to date. Furthermore, we have demonstrated safe dosing beyond the dose limitations imposed by regulatory authorities upon commonly prescribed anthracyclines due to their inherent cardiotoxicity. Annamycin has demonstrated efficacy in two of its Phase 1B/2 trials in subjects with AML and Advanced STS. We believe that Annamycin has potential to fill an unmet need as a second line therapy (2nd line or 2L) in AML and potentially as first line therapy in Advanced STS. A As part of our Annamycin clinical trials, we have engaged an independent expert to assess cardiotoxicity associated with chemotherapy at the Cleveland Clinic (Expert or Independent Expert). The data made available to the Expert includes left ventricular ejection fraction (LVEF) as determined by echocardiograms, and ECHO strain imaging, as well as Troponin levels (a biochemical marker of acute heart damage). ECHO strain imaging is a method in echocardiography (medical ultrasound) for measuring regional or global deformation (contraction or beating) of the myocardium (heart muscle). By strain rate imaging, the simultaneous function of different regions can be displayed and measured. Cardiac health biomarkers such as blood Troponin levels are considered an indicator of potential long-term heart damage. The Expert has issued and will continue to issue periodic reports as additional data are provided to him in batches of subject data. Such data include some data which are preliminary and subject to change. In our discussions regarding the lack of Annamycin's cardiotoxicity, we rely on the Expert's assessment. A Annamycin benefits from a promising advancement in lipid enabled drug delivery developed in collaboration with and exclusively licensed from MD Anderson. The unique patented lipid composition allows us to combine a new concept in chemotherapeutic agents within a lipid structure that helps target the delivery of the payload and reduce the potential for toxicity. In the case of Annamycin, our unique use of lipid technology enables improved tissue/organ distribution, and as demonstrated in multiple clinical trials, dramatically reduced toxicity, including cardiotoxicity. A b) Our WP1066 Portfolio includes WP1066, WP1193 and WP1220, three of several Immune/Transcription Modulators in the portfolio designed to inhibit p-STAT3 (phosphorylated signal transducer and activator of transcription) among other transcription factors associated with tumor activity. These also stimulate a natural immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs). WP1066, in oral formulation, has been in two clinical trials for central nervous system (CNS) tumors, including compassionate use cases, in pediatric subjects. WP1066 and WP1193 are being tested in preclinical programs in intravenous (IV) formulations. WP1066 and WP1220 have been in clinical trials in a topical formulation. WP1066 and WP1220 have both independently successfully completed Phase 1 clinical trials and have demonstrated efficacy in their varied indications. A c) Our WP1122 Portfolio contains compounds (including WP1122, WP1096, and WP1097) designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG). We believe such compounds may provide an opportunity to cut off the energy supply of tumors by taking advantage of their high degree of dependence on glucose in comparison to healthy cells, as well as viruses that also depend upon glycolysis and glycosylation to infect and replicate. WP1122 has completed a Phase 1 clinical study in normal volunteers, successfully establishing a Recommended Phase 2 Dose or RP2D. A Recent Business Developments A Below are recent business developments. A Annamycin A We held a conference call on August 6, 2024, along with Dr. Michael Andreeff, a member of our Science Advisory Board, to discuss the results of the most recent meeting with the FDA and the plans for the MIRACLE trial. That meeting, the MIRACLE trial and the current data from the MB-106 trial are discussed further below. A On August 1, 2024, we announced the discussion in and our resulting plans from our End of Phase 1B/2 (EOP1B/2) meeting held in late June with the FDA supporting the advancement of Annamycin in combination with Cytarabine (also known as Ara-C and for which the combination of Annamycin and Ara-C is referred to as AnnAraC) to a Phase 3 pivotal trial for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML). This Phase 3 AnnAraC trial (derived from Molecule (R)/(r) AML (AnnAraC) (Clinical Evaluation)) will be a global trial, including sites in the US. Consistent with the FDA's recommendations, the adaptive Phase 3 trial is expected to rely solely on CR (complete remission) at day 35 (+/- 14 days) as the primary endpoint versus placebo. We plan to utilize a double-blind, placebo-controlled design, where the control arm is high dose cytarabine (HiDAC) plus placebo. The MIRACLE trial will initially focus on 2nd line treatment for R/R AML subjects and then follow-up with treatment for 3rd line R/R AML. A Based on our discussions with the FDA, we intend to amend our current investigational new drug application or IND to allow dosing above the lifetime maximum allowable dose (LTMAD) for currently prescribed anthracyclines in this trial in the US. The MIRACLE study, subject to appropriate future filings with and potential additional feedback from the FDA and their foreign equivalents, is expected to initially utilize an adaptive design whereby the first 75 subjects will be randomized to receive HiDAC combined with either placebo, 190 mg/m2 of Annamycin, or 230 mg/m2 of Annamycin. At that point, the trial will be unblinded to select the optimum dose for Annamycin. For the second half of the trial, approximately 120 subjects will be randomized to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin. The selection of the optimum dose will be based not only on the absence of dose limiting toxicities but also on the overall balance of safety, pharmacokinetics and efficacy, consistent with the FDA's new Project Optimus initiative. A 14 Table of Contents A We believe the FDA wants to see the durability of response (DoR) and overall survival (OS) as secondary endpoints. In addition, we believe the FDA wants to see data for subjects beyond 2nd line and, accordingly, our plan includes a follow-on MIRACLE2 trial in 3rd line subjects starting once the optimum dose is established in the MIRACLE trial. A We have established plans for the following milestones with regard to the MIRACLE trial: A A - 2024 2H A Begin contracting with MIRACLE trial sites A - 2025 Q1 A First subject treated in MIRACLE trial A - 2025 Q4 A Recruitment update (n=40) A A - Mid 2026 A Interim data (n=75) unblinded and Optimum Dose set for MIRACLE trial A - 2026 A A Begin enrollment of 3rd line subjects in MIRACLE2 A - 2027 A A Enrollment ends in 2nd line subjects A - 2028 A A Final Data for 2nd line subjects in MIRACLE A - 2028 2H A Begin submission of a new drug application (NDA) the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLE A A Clinical Trial for the Treatment of AML in Combination with Cytarabine (MB-106) A A Table 1 Line of Therapy All Lines (Range 1st-7th) 1st Line 2nd Line 2nd and 3rd Line Subjects Evaluable To Date 22 4 10 14 Subjects Evaluable Not Dosed Per Protocol 2 0 1 1 Median Age - Years (Range) 67.5 (19-78) 56.5 (19-69) 71 (53-78) 69.5 (53-78) Complete Remission (CR) 8 (36%) 2 (50%) 5 (50%) 6 (43%) Complete Remission Composite (CRC) 9 (41%) 2 (50%) 6 (60%) 7 (50%) Partial Response (P) 2 0 1 2 CRc Relapsed To Date 3 0 3 3 BMT To Date 4 2 0 1 2 See Note 1 below A A A Note 1 for Table 1: Data from MB-106 is for Intent To Treat (ITT) subjects; is as of August 3, 2024; A and, is preliminary and subject to change. Median Durability of all CRCs is ~7 months and climbing. A On May 7, 2024, our management held a Key Opinion Leader conference call with Dr. Martin Tallman and Dr. Michael Andreeff. Management made a presentation of the data above and discussion ensued with Drs Tallman and Andreeff on the significance of this data. Both Drs. Tallman and Andreeff are members of our Science Advisory Board. A The call included a discussion of the results to date for MB-106. We believe that the Phase 1B/2 trial has been successful in establishing safety and efficacy of Annamycin in combination with Cytarabine (AnnAraC) for the treatment of AML, and in providing sufficient data to support a Phase 3A registration-directed clinical trial (MB-108) to further provide data for efficacy which we intend to use to support an eventual application for New Drug Approval (NDA). A Preliminary Safety, Efficacy and Durability Data A The preliminary data for MB-106 demonstrate a CR rate of 36% and a CRc rate of 41% for all subjects (N=22), regardless of the number of prior treatments, up to 6 prior treatments. Segmenting the MB-106 subject population for 2nd line subjects (N=10) yields a CR rate of 50% and CRc rate of 60%. Further segmenting for 2nd and 3rd line subjects (N=14) yields a CR rate of 43% and a CRc rate of 50%. We believe the results demonstrated by AnnAraC in 2nd line subjects substantially exceeds the performance reported by any drug currently approved for use in 2nd line AML. A Median durability of remission (DoR) for the 9 CRCs is approximately 7 months and developing with one death (related to pneumonia) and two relapses to date out of the ten CRCs. The first subject with a CR (and who has yet to relapse) was treated in February 2023. The DoR is being measured from the initiation of treatment to relapse or death. A Cardiovascular safety of Annamycin is thoroughly monitored as independent assessments are made by an independent expert cardiologist from Cleveland Clinic. As of April 1, 2024, data from 84A subjects across five trials (AML & STS, internal and externally funded trials) have been reviewed. Of note, most of these subjects have received greater than the lifetime cumulative anthracycline dose above 550 mg/m2 associated with increased risk of cardiomyopathy. Some subjects have received four times this amount following Annamycin administration(s). No signal of cardiotoxicity has been identified. A 15 Table of Contents A U.S. Patents for Annamycin A On April 9, 2024, the United States Patent and Trademark Office (USPTO) issued U.S. Patent number 11,951,118 titled, "Preparation of Preliposomal Annamycin Lyophilizate" (the "118 patent") to Moleculin and The University of TexasA System Board of Regents. Additionally on May 14, 2024, the USPTO issued an additional patent (U.S. Patent number 11,980,634) titled "Method of Reconstituting Liposomal Annamycin" (the "634 patent"). We have global, exclusive licenses to both patents. A The "118A patent provides claims to compositions that contain Annamycin, and the "634 patent, when issued, will provide claims to liposomal Annamycin suspension compositions, both with a base patent term extending until June 2040, subject to extension to account for time

required to fulfill regulatory requirements to FDA approval. Molecularlin™'s novel candidate for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets) uses a unique lipid-based delivery technology. In addition to the issued 118 and expected 634 U.S. patents, we have 4 additional patent applications pending in major jurisdictions worldwide. A EMA issues ODD to Annamycin for the treatment of AML. We announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to Annamycin for the treatment of AML. Combined with the Orphan Drug Designation we have in the US and with the new composition of matter and formulation patents just awarded by the US Patent and Trademark Office with coverage through 2040, we believe the commercial exclusivity of Annamycin is now well protected. The EMA grants orphan drug designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare, life-threatening or chronically debilitating diseases or conditions that affect fewer than five in 10,000 people in the European Union. Orphan designation potentially allows companies certain benefits, including reduced regulatory fees, clinical protocol assistance, research grants and up to 10 years of potential market exclusivity in the European Union if approved. A AACRA Presentation of Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties A Preclinical data regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting, which took place April 5-10, 2024 in San Diego, CA. The poster titled, A Non-cardiotoxic Properties of Annamycin, a Clinically Evaluated Anthracycline and Potent Topoisomerase 2¹ Poison, A was presented in the Late-Breaking Research: Experimental and Molecular Therapeutics 2a session held on Monday, April 8th. The presented poster outlined results from the assessment and comparison of the potency of doxorubicin (a commonly prescribed anthracycline) and Annamycin, Molecularlin™'s next-generation anthracycline, against topoisomerase II-alpha and II-beta and determine their impact on physiology of human cardiomyocytes demonstrating no pathologic changes in mice hearts following chronic in vivo exposure. A WP1066 A We continue discussions with two US academic institutions and another foreign academic institution for externally funded trials for the use of WP1066 for the treatment of glioblastomas and/or pediatric brain tumors. Of note, we have finalized an agreement with Northwestern University (NU) and NU has begun recruitment in an investigator initiated glioblastoma study. NU should be treating the first subject in the near-term (ClinicalTrials.gov ID: NCT05879250). We do not expect a pediatric study to begin until this adult brain tumor trial commences and generates additional data. A Regarding an intravenous formula for WP1066, we believe that substantial progress has been made and that we will be able to announce a patent application process being initiated and a license to us for an IV formulation in the near term. A WP1122 A With the data generated from the MB-301 clinical trial setting an RP2D for WP1122 and additional sponsored research, we continue to explore avenues of external funding for further development of this portfolio. For this study, we submitted the final clinical study report in late October 2023. A A 16 Table of Contents A Results of Operations A The following table sets forth, for the periods indicated, data derived from our statement of operations (table in thousands) and such changes in the periods are discussed below in approximate amounts: A Moleculin Biotech, Inc. Condensed Consolidated Statements of Operations (Unaudited) A A Three Months Ended June 30, A A Six Months Ended June 30, A A 2024 A A 2023 A A 2024 A A 2023 A Revenues A \$ 6,185 A A (6,411) A A (6,411) A A (12,862) A A (14,766) Other income: A A A A A A A A A A A A A A Operating expenses: A A A A A A A A A A A A A A Research and development A A 4,090 A A 3,888 A A 8,342 A A 9,576 A General and administrative A A 2,064 A A 2,492 A A 4,457 A A 5,129 A Depreciation and amortization A A 31 A A 31 A A 63 A A 61 A Total operating expenses A A 6,185 A A 6,411 A A 12,862 A A 14,766 A Loss from operations A A (6,185) A A (6,411) A A (12,862) A A (14,766) Other income: A A A A A A A A A A A A A A Gain from change in fair value of warrant liability A A 1,696 A A 36 A A 3,151 A A 75 A Other income, net A A 11 A A 9 A A 22 A A 17 A Interest income, net A A 159 A A 390 A A 400 A A 783 A Net loss A A (4,319) A A (5,976) A A (9,289) A A (13,891) A A Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023 A Research and Development Expense. Research and development (R&D) expense was \$4.1 million and \$3.9A million for the three months ended June 30, 2024 and 2023, respectively. The increase of \$0.2A million is mainly related to sponsored research costs. A General and Administrative Expense. General and administrative expense was \$2.1 million and \$2.5A million for the three months ended June 30, 2024 and 2023, respectively. The decrease of \$0.4A million is mainly related to a decrease in regulatory and legal fees. A Gain from Change in Fair Value of Warrant Liability. We recorded a net gain of \$1.7 million in the second quarter of 2024 as compared to a net gain of \$0.04 million in the second quarter of 2023, for the change in fair value on revaluation of our warrant liability associated with our warrants issued in conjunction with certain of our previous stock offerings. We are required to revalue our liability-classified warrants at the time of each warrant exercise, if applicable, and at the end of each reporting period and reflect in the statement of operations a gain or loss from the change in fair value of the warrant in the period in which the change occurred. We calculated the fair value of the warrants outstanding using the Black-Scholes model. A gain results principally from a decline in our share price during the period and a loss results principally from an increase in our share price. A Interest income, net A Interest income, net A decreased by approximately \$0.2A million for the comparable quarterly periods due to a decreasing cash balance during the past year. A Six Months Ended June 30, 2024 Compared to Six Months Ended June 30, 2023 A Research and Development Expense. Research and development (R&D) expense was \$8.3A million and \$9.6A million for the six months ended June 30, 2024 and 2023, respectively. The decrease of \$1.3 million is mainly related to the WPD sublicense termination in 2023, which enabled the reacquisition of our intellectual property rights in certain territories including parts of the European Union. The decrease was slightly offset by increased sponsored research costs in 2024. A General and Administrative Expense. General and administrative expense was \$4.5A million and \$5.1A million for the six months ended June 30, 2024 and 2023, respectively. The decrease of \$0.6A million is mainly related to a decrease in regulatory and legal fees. A Gain from Change in Fair Value of Warrant Liability. We recorded a net gain of \$3.2A million in the six months ended 2024 as compared to a net gain of \$0.1A million in the six months ended 2023, for the change in fair value on revaluation of our warrant liability associated with our warrants issued in conjunction with certain of our previous stock offerings. We are required to revalue our liability-classified warrants at the time of each warrant exercise, if applicable, and at the end of each reporting period and reflect in the statement of operations a gain or loss from the change in fair value of the warrant in the period in which the change occurred. We calculated the fair value of the warrants outstanding using the Black-Scholes model. A gain results principally from a decline in our share price during the period and a loss results principally from an increase in our share price. A Interest income, net A Interest income, net A decreased by approximately \$0.4A million for the comparable quarterly periods due to a decreasing cash balance during the past year. A 17 Table of Contents A Liquidity and Capital Resources A The following table sets forth our primary sources and uses of cash for the period indicated (table in thousands): A A Six Months Ended June 30, A A 2024 A A 2023 A Net cash used in operating activities A \$ (12,666) A \$ (11,143) Net cash used in investing activities A A (13) A A (15) Net cash (used in) provided by financing activities A A (25) A A 190 A Effect of exchange rate changes on cash and cash equivalents A A (1) A A (5) Net decrease in cash and cash equivalents A \$ (12,705) A \$ (10,973) A As of June 30, 2024, there was \$0.4A millionA of cash on hand in a bank account in Australia and we know of no related limitations impacting our liquidity in Australia. A Cash used in operating activities A Cash used in operations was \$12.7 million for the six months ended June 30, 2024. This \$1.6 million increase over the prior year period of \$11.1 million was primarily due to the timing of costs incurred and associated payments for drug production and clinical trial expenses. A Cash provided by financing activities A We did not sell any stock during the six months ended June 30, 2024. A We believe that our cash on hand and cash equivalents as of June 30, 2024, is sufficient to fund our planned operations into the fourth quarter of this year. A This takes into account cash outlays for preparations for clinical trials beyond the current active trials. The continuation of our Company as a going concern is dependent upon our ability to obtain necessary financing to continue operations and the attainment of profitable operations. We may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. We cannot provide assurance that such events or a combination thereof can be achieved. A An S-1 was recently filed with the SEC indicating our intentions to raise additional cash via the issuance of equity in the amount of \$12 million. We believe that our existing cash and cash equivalents as of June 30, 2024, along with the cash expected from this raise will be sufficient to fund our planned operations into the second quarter of 2025. The amount of this raise may increase or decrease. Additionally, there is no guarantee that the Company will be successful in this raise. A In March 2022, we received a subpoena from the SEC requesting information and documents, including materials related to certain individuals (none of which are our officers or directors) and entities, and materials related to the development of and statements regarding our drug candidate for the treatment of COVID-19. We have received, and expect to continue to receive, periodic further requests from the SEC staff with respect to this matter. We are not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that we have made, we believe in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to us states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. A We cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. We expensed approximately \$0.1A million and \$0.4 million in related general and administrative fees and expenses for the three months ended June 30, 2024 and 2023, respectively, and approximately \$0.1A million and \$0.9 million for the six months ended June 30, 2024 and 2023, respectively. A Critical Accounting Policies and Significant Judgments and Estimates A There have been no material changes to our critical accounting policies and use of estimates from those disclosed in our Form 10-K for the year ended December 31, 2023. For a discussion of our critical accounting policies and use of estimates, refer to Management's Discussion and Analysis of Financial Condition and Results of Operations 6 Critical Accounting Policies and Significant Estimates in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2023. A 18 Table of Contents A ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS A Not applicable as we are a smaller reporting company. A ITEM 4. CONTROLS AND PROCEDURES A Evaluation of Disclosure Controls and Procedures A We maintain disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that material information is accumulated and communicated to our management, including our Chief Executive Officer (CEO), who is our principal executive officer, and Chief Financial Officer (CFO), who is our principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosures. Our CEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q and have determined that such disclosure controls and procedures were effective as of June 30, 2024. A Changes in Internal Control Over Financial Reporting A There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15-d-15(f) under the Exchange Act) during the three months ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. A 19 Table of Contents A PART II 6 OTHER INFORMATION A ITEM 1. LEGAL PROCEEDINGS A None. A ITEM 1A. RISK FACTORS A For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled Risk Factors in Part I, Item 1A in our annual report on Form 10-K for the year ended December 31, 2023. Except as updated below, there have been no material changes from the risk factors previously disclosed in our annual report on Form 10-K for the year ended December 31, 2023, and in Item II, Item 1A in our prior quarterly reports on Form 10-Q filed during this fiscal year, as filed with the SEC. A ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS A None. A ITEM 3. DEFAULTS UPON SENIOR SECURITIES A None. A ITEM 4. MINE SAFETY DISCLOSURE A Not applicable. A A ITEM 5. OTHER INFORMATION A During the period covered by this Quarterly Report, none of the Company's directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended). A 20 Table of Contents A ITEM 6. EXHIBITS A Exhibit No. A Description A A 31.1* A Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002 A A 31.2* A Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002 A A 32.1*+ A Certification of Principal Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 A A 32.2*+ A Certification of Principal Accounting and Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 A A 101.INS* A Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) A A 101.SCH* A Inline XBRL Taxonomy Extension Schema Document A A 101.CAL* A Inline XBRL Taxonomy Extension Calculation Linkbase Document A A 101.DEF* A Inline XBRL Taxonomy Extension Definition Linkbase Document A A 101.LAB* A Inline XBRL Taxonomy Extension Label Linkbase Document A A 101.PRE* A Inline XBRL Taxonomy Extension Presentation Linkbase Document A A 104 A Cover

the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â MOLECULIN BIOTECH, INC. Â Â Date: August 13, 2024 By: /s/ Walter V. Klemp Â Â Walter V. Klemp, Â Â Chief Executive Officer and Chairman (Principal Executive Officer) Â Â Date: August 13, 2024 By: /s/ Jonathan P. Foster Â Â Jonathan P. Foster, Â Â Executive Vice President & Chief Financial Officer (Principal Financial and Accounting Officer) Â Â 22 EX-31.1 2 ex 676400.htm EXHIBIT 31.1 ex 676400.htm Â Exhibit 31.1 Â OFFICERâ€™S CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â Â I, Walter V. Klemp, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Moleculin Biotech, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): Â Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and Â Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Â 8 August 13, 2024 Â By: /s/ Walter V. Klemp Â Walter V. Klemp Â Chief Executive Officer (Principal Executive Officer) Â Â EX-31.2 3 ex 676401.htm EXHIBIT 31.2 ex 676401.htm Â Exhibit 31.2 Â OFFICERâ€™S CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â Â I, Jonathan P. Foster, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of Moleculin Biotech, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): Â Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and Â Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Â 8 August 13, 2024 Â By: /s/ Jonathan P. Foster Â Jonathan P. Foster Â Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) Â Â EX-32.1 4 ex 676402.htm EXHIBIT 32.1 ex 676402.htm Â Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â Â In connection with the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 of Moleculin Biotech, Inc. (the â€œCompanyâ€) as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Walter V. Klemp, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: Â Â a. Â The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and Â Â b. Â The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Â Date: August 13, 2024 Â Â By: /s/ Walter V. Klemp Â Walter V. Klemp Â Chief Executive Officer (Principal Executive Officer) Â Â A signed original of this written statement required by Section 906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. Â Â EX-32.2 5 ex 676403.htm EXHIBIT 32.2 ex 676403.htm Â Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â Â In connection with the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 of Moleculin Biotech, Inc. (the â€œCompanyâ€) as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Jonathan P. Foster, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: Â Â a. Â The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and Â Â b. Â The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Â Date: August 13, 2024 Â Â By: /s/ Jonathan P. Foster Â Jonathan P. Foster Â Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) Â Â A signed original of this written statement required by Section 906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. Â Â EX-101.SCH 6 mbrx-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Warrants link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Equity link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 995459 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995460 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity (Tables) link:calculationLink link:definitionLink link:presentationLink 995461 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995462 - Disclosure - Note 4 - Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 995463 - Disclosure - Note 5 - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Note 7 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Note 1 - Nature of Business (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 4 - Warrants (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 4 - Warrants - Assumptions Used (Details) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 4 - Warrants - Warrant Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 5 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 5 - Equity - Stock based Compensation (Details) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 6 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 7 - Commitments and Contingencies - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 mbrx-20240630 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 mbrx-20240630 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 mbrx-20240630 lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value of Financial Instruments, Policy [Policy Text Block] Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity mbrx_LicenseAgreementsExpense License Agreements Expense The amount of expense for licensing agreements. Note 3 - Accrued Expenses and Other Current Liabilities Houston Pharmaceuticals, Inc [Member] Represents Houston Pharmaceuticals, Inc. Note 4 - Warrants Note 5 - Equity Subsequent Events, Policy [Policy Text Block] Note 7 - Commitments and Contingencies Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Prepaid Expenses and Other Current Assets (Details) Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) Income Tax Disclosure [Text Block] Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) (Parentheticals) Change in fair value of warrant liability Gain from change in fair value of warrant liability Note 4 - Warrants - Assumptions Used (Details) Note 4 - Warrants - Warrant Activity (Details) us-gaap_ShareBasedCompensation Stock-based compensation Note 5 - Equity - Stock based Compensation (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 7 - Commitments and Contingencies - Lease Cost (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Earnings Per Share, Policy [Policy Text Block] The 2015 Stock Plan [Member] Represents the 2015 stock plan. Non-trade receivables Exercisable (in shares) Class of Warrant or Right,

Vested and Exercisable (in shares) Number of warrants or rights vested and exercisable. Revenues Exercisable, warrant exercise price (in dollars per share) Exercise price per share or per unit of warrants or rights vested and exercisable. Operating expenses: Balance, weighted average remaining contractual life (Year) The weighted average remaining contractual life of warrants or rights outstanding. mbrx_ClassOfWarrantOrRightCancelledDuringPeriod Expired warrants (in shares) The number of warrants or rights cancelled during period. Expired warrants (in dollars per share) Exercise price per share of warrants or rights cancelled during period. Foreign currency translation Cumulative translation adjustment Liability Classified Warrants [Member] Represents liability classified warrants. Exercisable, weighted average remaining contractual life (Year) The weighted average remaining contractual life of warrants or rights vested and exercisable. Equity Classified Warrants [Member] Represents equity classified warrants. us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio Fair value of warrant liability Depreciation and amortization Accumulated other comprehensive loss Reverse Stock Split [Member] Related to the reverse stock split. Prepaid Expenses and Other Current Assets [Policy Text Block] Disclosure of the accounting policy for prepaid expenses and other current assets. us-gaap_AssetsCurrent Total current assets Equity [Text Block] Interest income, net Common stock, \$0.001 par value; 100,000,000 shares authorized; 2,560,785 and 2,227,516 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Common stock, par or stated value per share (in dollars per share) Accrued Liabilities, Current Accrued expenses and other current liabilities Accrued payroll and bonuses us-gaap_OperatingLeasePayments Operating Lease, Payments Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Accounts payable Accounts Payable, Current Weighted Average [Member] Statistical Measurement [Axis] Investment, Name [Domain] Preferred stock, \$0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding Preferred stock, shares issued (in shares) Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] us-gaap_PolicyTextBlockAbstract Accounting Policies Investment, Name [Axis] Preferred stock, shares authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Preferred stock, par value (in dollars per share) Prepaid insurance Fair Value, Inputs, Level 3 [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of fixed assets us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) Fair Value Hierarchy and NAV [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Fair Value Hierarchy and NAV [Axis] mbrx_OperatingLeaseMonthlyRentPayment Operating Lease, Monthly Rent Payment Represents the amount of monthly rent payment on an operating lease. Liabilities, Current [Abstract] us-gaap_Assets Total assets Plan Name [Axis] Related party receivables The amount of related party receivables. Plan Name [Domain] us-gaap_SubleaseIncome Sublease Income Cash flows from operating activities: License rights expense settled in stock The amount of common stock issued for license rights under license agreement. Statement [Line Items] us-gaap_NumberOfOperatingSegments Number of Operating Segments Accrued legal, regulatory, professional and other Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal, regulatory, professional and other costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Share-based Payment Arrangement, Expensed, Amount [Table Text Block] Tabular disclosure of allocation of amount expensed for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. Additional paid-in capital AOCI Attributable to Parent [Member] Stockholders' equity Other income, net Current assets: Net loss Net loss us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash and cash equivalents, - beginning of period Cash and cash equivalents, - end of period us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash (used in) provided by financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies (Note 7) Effect of exchange rate changes on cash and cash equivalents Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] us-gaap_OperatingIncomeLoss Loss from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Other income: Prepaid expenses and other current assets Total prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Counterparty Name [Axis] Counterparty Name [Domain] Commitments and Contingencies Disclosure [Text Block] Furniture and equipment, net us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment of tax liability for vested restricted stock units mbrx_SharebasedPaymentArrangementNonvestedAwardCostNotYetRecognizedAmount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Amount of cost not yet recognized for nonvested award under share-based payment arrangement. us-gaap_EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage Cash flows from investing activities: Retained Earnings [Member] Proceeds from sale of common stock, net of issuance costs us-gaap_RelatedPartyTransactionAmountsOffTransaction Related Party Transaction, Amounts of Transaction Additional Paid-in Capital [Member] Common Stock [Member] us-gaap_IncomeTaxExpenseBenefit Income Tax Expense (Benefit) us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses and other current liabilities Equity Components [Axis] Reverse stock split The cost of reduction in shares during the period as a result of a reverse stock split. Equity Component [Domain] us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Balance, warrant exercise price (in dollars per share) Balance, warrant exercise price (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding (in shares) Balance (in shares) Balance (in shares) us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_OperatingExpenses Total operating expenses General and administrative Other comprehensive loss: us-gaap_Cash Cash Cash and cash equivalents Share-Based Payment Arrangement, Expense Share-Based Payment Arrangement, Expense us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Change in fair value - net us-gaap_LegalFees Legal Fees Cash and Cash Equivalents, Policy [Policy Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss Document Transition Report City Area Code Basis of Accounting, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current Related Party [Member] Reverse stock split (in shares) us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date Variable lease cost us-gaap_LeaseCost Total Research and Development Expense [Member] Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Lease, Cost [Table Text Block] Document Period End Date Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expenses and other current assets Entity File Number Nonmonetary Transaction Type [Domain] Reverse Stock Split [Policy Text Block] Disclosure of the company's policy regarding reverse stock splits. Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Nonmonetary Transaction Type [Axis] Document Information [Line Items] Accrued research and development Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Document Information [Table] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Entity Filer Category Going Concern Policy [Policy Text Block] Disclosure of accounting policy for going concern. Entity Current Reporting Status us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Stock-based compensation Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Liability Class [Axis] Fair Value by Liability Class [Domain] Entity [Domain] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Weighted average common shares outstanding, basic and diluted (in shares) ecd_NonRule10b51ArrTrmndFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Warrant Liability Long Term [Member] Information pertaining the long term warrant liability. Entity Address, City or Town ecd_Rule10b51ArrTrmndFlag Rule 10b5-1 Arrangement Terminated [Flag] us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Net loss per common share - basic and diluted (in dollars per share) Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Material Terms of Trading Arrangement [Text Block] Statement of Cash Flows [Abstract] Entity Common Stock, Shares Outstanding mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent Operating Lease, Rent Expense, Annual Increase In Rent, Percent Represents percentage of annual increase in rent for operating lease rent expense. Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Schedule of Accrued Liabilities [Table Text Block] Trading Symbol Nature of Operations [Text Block] Local Phone Number us-gaap_TableTextBlock Notes Tables Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares) Warrants exercised The amount of stock issued during the period for warrant exercises. Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) Warrants exercised (in shares) The number of shares of stock issued during the period for warrant exercises. Related and Nonrelated Parties [Axis] Operating lease, net The amount of noncash expense for operating lease, net. Related and Nonrelated Parties [Domain] Warrants Disclosure [Text Block] The entire disclosure for warrants. Schedule of Warrants or Rights, Assumptions Used [Table Text Block] The tabular disclosure for assumptions used for warrants or rights. Asset Acquisition, Contingent Consideration, Liability, Current Common stock issued for license rights The amount of stock issued during the period for license rights. Common stock issued for license rights (in shares) The number of shares of stock issued during the period for license rights. Warrants, assumptions Cash flows from financing activities: us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in shares) Schedule of Warrant Activity [Table Text Block] The tabular disclosure for warrant activity. Issuance of common stock in connection with Consulting Agreements (in shares) Animal Life Sciences, Inc [Member] Represents Animal Life Sciences, Inc. mbrx_NumberOfCoreDrugTechnologies Number of Core Drug Technologies The number of core drug technologies. us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Stock Issued During Period, Shares, Issued for Services (in shares) us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' equity Issuance of common stock in connection with Consulting Agreements Warrant liability - long-term Warrant Liability [Member] Represents warrant liability. Accumulated deficit Retained Earnings (Accumulated Deficit) Research and development Significant Accounting Policies [Policy Text Block] Disclosure of significant accounting policies of the reporting entity. Prepaid sponsored research The amount of prepaid sponsored research classified as current. Vendor prepayments and deposits Amount of consideration and deposits paid in advance to vendors. Measurement Input, Price Volatility [Member] Changes in operating assets and liabilities: us-gaap_StockholdersEquity Total stockholders' equity Balance Balance Measurement Input, Risk Free Interest Rate [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements mbrx_NASDAQComplianceExtensionPeriod NASDAQ Compliance, Extension Period (Day) Information pertaining to the extension period granted. Operating lease liability - long-term, net of current portion mbrx_NASDAQComplianceMinimumClosingBidPricePerShare NASDAQ Compliance, Minimum Closing Bid Price Per Share (in dollars per share) Information pertaining to Nasdaq Global minimum bid price requirement. Measurement Input, Expected Term [Member] Class of Stock [Axis] Intangible assets MD Anderson [Member] Represents MD Anderson. Operating lease liability - current Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating lease right-of-use asset Measurement Input Type [Axis] Measurement Input Type [Domain] EX-101.PRE 10 mbrx-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 moleculelinnewlogoresized.jpg begin 644 moleculelinnewlogoresized.jpg M JC X 02D9J1@ ! 0 E@ "6 # X0",17A19@ 34T *M @ !0\$2 , M ! \$: 4 ! 2@; , 4 ! 4@ \$H , ! (= I M ! 0 !6@ "6 0 J8 ! .@ 0 # 0 ! " @ M @ 0 . V @ P \$ 0 0 & \ \$0 @ 9@ # M P&B (1 0 1 M ? ! @X% ! \$! @ !08" D*" _ \$ +40 (! P , M ! , % !00\$! ?0\$ P \$ \$042(3% !A-180"EZx22%A#> (B)J2DY25EI>8F9J)BHZ2EI>HJ|JRL[2UMK>XN;K" MP%3QL?<(R;GZ.GJ)?>+S|7VJ_CY~% \$!\ , ! M 0\$! 0\$! 0\$! @ !08" D*" _ \$ +41 (! @0\$ P0!00\$ \$" M=P ! @, !!

[illegible]

days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: [\text{\\\$ } 10,845 \text{ } \\\$ 23,550 Prepaid expenses and other current assets 2,886 2,723 Total current assets 13,731 26,273 Furniture and equipment, net 221 272 Intangible assets 11,148 11,148 Operating lease right-of-use asset 475 524 Total assets 25,575 38,217 Liabilities, Current \[Abstract\] \$\text{\\$ } 2,833 \text{ } \\$ 2,498\$ Accrued expenses and other current liabilities 2,913 4,317 Total current liabilities 5,746 6,815 Operating lease liability - long-term, net of current portion 420 474 Warrant liability - long-term 1,704 4,855 Total liabilities 7,870 12,144 Commitments and contingencies \(Note 7\) Stockholders' equity \$\text{\\$ } 0.001 \text{ } \\$ 5,000,000\$ Preferred stock, \$\text{\\$ } 0.001\$ par value; 5,000,000 shares authorized, no shares issued or outstanding 0 0 Common stock, \$\text{\\$ } 0.001\$ par value; 100,000,000 shares authorized; 2,560,785 and 2,227,516 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 3 33 Additional paid-in capital 158,605 157,653 Accumulated other comprehensive loss \(10\) \(9\) Accumulated deficit \(140,893\) \(131,604\) Total stockholders' equity 17,705 26,073 Total liabilities and stockholders' equity \$\text{\\$ } 25,575 \text{ } \\$ 38,217\$ X - DefinitionCarrying value as of the balance sheet date of liabilities incurred \(and for which invoices have typically been received\) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities \(due within one year or within the normal operating cycle if longer\). + ReferencesReference 1:](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Exchange Act-Number 240-Section 12-Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <a href=)

10-50-7Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30:

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28):

Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: https://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized (in shares) 5,000,000 5,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par or stated value per share (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 100,000,000 100,000,000 Common stock, shares issued (in shares) 2,560,785 2,227,516 Common stock, shares outstanding (in shares) 2,560,785 2,227,516 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PREFERREDStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PREFERREDStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PREFERREDStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock \(or preferred stock redeemable solely at the option of the issuer\) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1">http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PREFERREDStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(24\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PREFERREDStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenues $ 0 $ 0 $ 0 $ 0 Operating expenses: Á Á Á Research and development 4,090 3,888 8,342 9,576 General and administrative 2,064 2,492 4,457 5,129 Depreciation and amortization 31 63 61 Total operating expenses 6,185 6,411 12,862 14,766 Loss from operations (6,185) (6,411) (12,862) (14,766) Other income: Á Á Á Gain from change in fair value of warrant liability 1,696 36 3,151 75 Other income, net 11 9 22 17 Interest income, net 159 390 400 783 Net loss $ (4,319) $ (5,976) $ (9,289) $ (13,891) Net loss per common share - basic and diluted (in dollars per share) $ (1.7) $ (3.02) $ (3.71) $ (7.13) Weighted average common shares outstanding, basic and diluted (in shares) 2,543,244 1,979,258 2,504,709 1,948,135 Net loss $ (4,319) $ (5,976) $ (9,289) $ (13,891) Other comprehensive loss: Á Á Á Foreign currency translation 8 (1) (1) (5) Comprehensive loss $ (4,311) $ (5,977) $ (9,290) $ (13,896) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(26\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)

Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32): [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37):

SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10> + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$ \$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities: $\text{\$ (4,319) \$ (5,976) \$ (9,289) \$ (13,891)}$ Adjustments to reconcile net loss to net cash used in operating activities: $\text{\$ (12,666) (11,143) (12,666) (11,143)}$ Depreciation and amortization 31 31 63 61 Stock-based compensation $\text{\$ 946 1,012}$ License rights expense settled in stock $\text{\$ 0 772}$ Change in fair value of warrant liability (1,696) (36) (3,151) (75) Operating lease, net $\text{\$ 108 104}$ Changes in operating assets and liabilities: $\text{\$ (1,515) (410) (1,515) (410)}$ Prepaid expenses and other current assets $\text{\$ (163) (757)}$ Accounts payable $\text{\$ 335 2,041}$ Accrued expenses and other current liabilities $\text{\$ (1,515) (410)}$ Net cash used in operating activities $\text{\$ (12,666) (11,143)}$ Cash flows from investing activities: $\text{\$ (12,666) (11,143)}$ Purchase of fixed assets $\text{\$ (13) (15)}$ Net cash used in investing activities $\text{\$ (13) (15)}$ Cash flows from financing activities: $\text{\$ (13) (15)}$ Payment of tax liability for vested restricted stock units $\text{\$ (25) (21)}$ Proceeds from sale of common stock, net of issuance costs $\text{\$ 0 211}$ Net cash (used in) provided by financing activities $\text{\$ (25) 190}$ Effect of exchange rate changes on cash and cash equivalents $\text{\$ (1) (5)}$ Net decrease in cash and cash equivalents $\text{\$ (12,705) (10,973)}$ Cash and cash equivalents, - beginning of period $\text{\$ 23,550 43,145}$ Cash and cash equivalents, - end of period $\text{\$ 10,845 \$ 32,172 \$ 10,845 \$ 32,172}$ X - DefinitionThe amount of common stock issued for license rights under license agreement. + ReferencesNo definition available. + Details Name: mbrx_CommonStockIssuedForLicenceRightsUnderLicenseAgreement Namespace Prefix: mbrx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of noncash expense for operating lease, net. + ReferencesNo definition available. + Details Name: mbrx_OperatingLeaseNoncashExpenseNet Namespace Prefix: mbrx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubParagraph 1 -SubTopic 10 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubParagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubParagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -SubParagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -SubParagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -SubParagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -SubParagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22) + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13> + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -SubParagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -SubParagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -SubParagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -SubParagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -SubParagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -SubParagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -SubParagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -SubParagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -SubParagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubParagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubParagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -SubParagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -SubParagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -SubParagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -SubParagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -SubParagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -SubParagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -SubParagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -SubParagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -SubParagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -SubParagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubParagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubParagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -SubParagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -SubParagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>

FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD (\$) \$ in Thousands Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Total Balance (in shares) at Dec. 31, 2022 1,908,522 Á Á Á Balance at Dec. 31, 2022 \$ 29 \$ 153,985 \$ (101,835) 12 \$ 52,191 Issuance of common stock in connection with Consulting Agreements (in shares) 10,026 Á Á Á Issuance of common stock in connection with Consulting Agreements \$ 0 141 0 0 141 Stock-based compensation 0 499 0 0 499 Net loss 0 0 (7,915) 0 (7,915) Cumulative translation adjustment \$ 0 0 0 (4) (4) Common stock issued for license rights (in shares) 54,808 Á Á Á Common stock issued for license rights \$ 1 771 0 0 772 Balance (in shares) at Mar. 31, 2023 1,973,356 Á Á Á Balance at Mar. 31, 2023 \$ 30 155,396 (109,750) 8 45,684 Balance (in shares) at Dec. 31, 2022 1,908,522 Á Á Á Balance at Dec. 31, 2022 \$ 29 153,985 (101,835) 12 52,191 Net loss Á Á Á (13,891) Cumulative translation adjustment Á Á Á (5) Balance (in shares) at Jun. 30, 2023 1,985,957 Á Á Á Balance at Jun. 30, 2023 \$ 30 155,957 (115,726) 7 40,268 Balance (in shares) at Mar. 31, 2023 1,973,356 Á Á Á Balance at Mar. 31, 2023 \$ 30 155,396 (109,750) 8 45,684 Issuance of common stock in connection with Consulting Agreements (in shares) 5,013 Á Á Á Issuance of common stock in connection with Consulting Agreements 69 69 Stock-based compensation 0 513 0 0 513 Net loss 0 0 (5,976) 0 (5,976) Cumulative translation adjustment \$ 0 0 0 (1) (1) Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) (in shares) 7,588 Á Á Á Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) \$ 0 (21) 0 0 (21) Balance (in shares) at Jun. 30, 2023 1,985,957 Á Á Á Balance at Jun. 30, 2023 \$ 30 155,957 (115,726) 7 40,268 Balance (in shares) at Dec. 31, 2023 2,227,516 Á Á Á Balance at Dec. 31, 2023 \$ 33 157,653 (131,604) (9) 26,073 Issuance of common stock in connection with Consulting Agreements (in shares) 6,834 Á Á Á Issuance of common stock in connection with Consulting Agreements \$ 0 37 0 0 37 Reverse stock split (in shares) 77,186 Á Á Á Reverse stock split \$ (31) 31 0 0 0 Stock-based compensation 0 456 0 0 456 Net loss 0 0 (4,970) 0 (4,970) Cumulative translation adjustment \$ 0 0 0 (9) (9) Balance (in shares) at Mar. 31, 2024 2,311,536 Á Á Á Balance (in shares) at Dec. 31, 2023 2,227,516 Á Á Á Balance at Dec. 31, 2023 \$ 33 157,653 (131,604) (9) 26,073 Net loss Á Á Á (9,289) Cumulative translation adjustment Á Á Á \$ (1) Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) (in shares) Á Á Á 19,743 Balance (in shares) at Jun. 30, 2024 2,560,785 Á Á Á Balance at Jun. 30, 2024 \$ 3 158,605 (140,893) (10) \$ 17,705 Balance (in shares) at Mar. 31, 2024 2,311,536 Á Á Á Stock-based compensation \$ 0 453 0 0 453 Net loss 0 (4,319) 0 (4,319) Cumulative translation adjustment \$ 0 0 0 8 Warrants exercised (in shares) 229,506 Á Á Á Warrants exercised \$ 1 0 0 0 1 Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) (in shares) 19,743 Á Á Á Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) \$ 0 (25) 0 0 (25) Balance (in shares) at Jun. 30, 2024 2,560,785 Á Á Á Balance at Jun. 30, 2024 \$ 3 \$ 158,605 (140,893) (10) \$ 17,705 X - DefinitionThe number of shares of stock issued during the period for license rights. + ReferencesNo definition available. + Details Name: mbrx_StockIssuedDuringPeriodSharesLicenseRights Namespace Prefix: mbrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares of stock issued during the period for warrant exercises. + ReferencesNo definition available. + Details Name: mbrx_StockIssuedDuringPeriodSharesWarrantExercises Namespace Prefix: mbrx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of stock issued during the period for license rights. + ReferencesNo definition available. + Details Name: mbrx_StockIssuedDuringPeriodValueLicenseRights Namespace Prefix: mbrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cost of reduction in shares during the period as a result of a reverse stock split. + ReferencesNo definition available. + Details Name: mbrx_StockIssuedDuringPeriodValueReverseStockSplits Namespace Prefix: mbrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of stock issued during the period for warrant exercises. + ReferencesNo definition available. + Details Name: mbrx_StockIssuedDuringPeriodValueWarrantExercises Namespace Prefix: mbrx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting

Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19> + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Number of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Number of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Definition Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Definition Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

<https://asc.fasb.org/1943274/2147480058/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\)](https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\)](https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\)](https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\)](https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\)](https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\)](https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\)](https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)](https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii))) -Publisher FASB -URI

lossÂ which may cover a portion of the related expenses but not all. The claim is currently under review by theÂ insuranceÂ company. TheÂ claimÂ hasÂ not yet been approved nor has a reimbursementÂ amount been determined which, if any, would be limited by the applicable retention as defined under the policy. Accordingly,Â the Company has not recorded any provision for insurance reimbursement. The Company expects to record the insurance reimbursement at the time that the amount to be reimbursed is determined and approved by the insurance carrier. Any insurance reimbursement receivable will be recorded at an amount not to exceed the recorded loss and only if the terms of the legally enforceable insurance contracts support that the insurance recovery will not be disputed and is deemed collectible, or if recovery of the loss is probable. Â Cash and Cash Equivalents - Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains cash accounts principally at one financial institution in the U.S., which at times, may exceed the Federal Deposit Insurance CorporationÂs limit. The Company has not experienced any losses from cash balances in excess of the insurance limit. The CompanyÂs management does not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institution where its cash is held.Â Â Prepaid Expenses and Other Current Assets - Prepaid expenses and other current assets consist of the following (in thousands): Â Â June 30, 2024 Â Â December 31, 2023 Â Prepaid sponsored research Â \$1,277Â Â \$1,515Â Prepaid insurance Â Â 1,143Â Â Â 564Â Vendor prepayments and deposits Â Â 457Â Â Â 545Â Non-trade receivables Â Â 5Â Â Â 95Â Related party receivables Â Â 4Â Â Â 4Â Total prepaid expenses and other current assets Â \$2,886Â Â \$2,723Â Â Fair Value of Financial Instruments - The Company's financial instruments consist primarily of non-trade receivables, accounts payable, accrued expenses and its warrant liability. The carrying amount of non-trade receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such. Â The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Â Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Â Level 1 Â Unadjusted quoted prices in active markets of identical assets or liabilities. Level 2 Â Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 Â Unobservable inputs for the asset or liability. Â The CompanyÂs financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. Â The following table provides the financial liabilities reported at fair value and measured on a recurring basis at June 30, 2024 and December 31, 2023 (table in thousands):Â Â Description Â Fair Value Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Fair value of warrant liability as of June 30, 2024: Â \$1,704Â Â ÂÂ Â Â \$1,704Â Fair value of warrant liability as of December 31, 2023: Â \$4,855Â Â ÂÂ Â Â Â Â Â \$4,855Â Â The table below of Level 3 liabilities (table in thousands) begins with the valuation as of the beginning of theÂ second quarter and then is adjusted forÂ changes in fair value that occurred during the secondÂ quarter. The ending balance of the Level 3 financial instrument presented above represents the Company'sÂ best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.Â Â Three Months Ended June 30, 2024 Â Warrant Liability Long-Term Â Balance, March 31, 2024 Â \$3,400Â Change in fair value - net Â Â (1,696) Balance, June 30, 2024 Â \$1,704Â Â The table below of LevelÂ 3Â liabilities (table in thousands) begins with the valuation as of December 31, 2023 and then is adjusted forÂ changes in fair value that occurred during theÂ six months endedÂ June 30, 2024. The ending balance of the Level 3 financial instrument presented above represents the Company'sÂ best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.Â Â Six Months Ended June 30, 2024 Â Warrant Liability Long-Term Â Balance, December 31, 2023 Â \$4,855Â Change in fair value - net Â Â (3,151) Balance, June 30, 2024 Â \$1,704Â Â Loss Per Common Share - Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock units subject to vesting and warrants to purchase common stock are considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. For the three and six months ended June 30, 2024 and 2023, approximately 1.6Â millionÂ and 0.4 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect.Â Â Subsequent Events - The CompanyÂs management reviewed all material events through the date of these unaudited condensed consolidated financial statements.Â Â Recent Accounting PronouncementsÂ - There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company.Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/235/tableOfContent> + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 3 - Accrued Expenses and Other Current Liabilities 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] 3.Â Accrued expenses and other current liabilities Â Accrued expenses and other current liabilitiesÂ consist of the following components (in thousands): Â Â June 30, 2024 Â Â December 31, 2023 Â Accrued payroll and bonuses Â \$1,157Â Â \$765Â Accrued research and development Â Â 1,060Â Â Â 2,845Â Accrued legal, regulatory, professional and other Â Â 540Â Â Â 547Â Operating lease liability - current Â Â 112Â Â Â 100Â Accrued liabilities due to related party Â Â 4Â Â Â 60Â Total accrued expenses and other current liabilities Â \$2,913Â Â \$4,317Â Â Additionally, accounts payable includes \$20,000Â and \$67,000Â as of June 30, 2024Â and December 31, 2023, respectively, for related party payables. X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 720-SubTopic 3-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483384/720-30-45-1> + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 4 - Warrants 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Warrants Disclosure [Text Block] 4. Warrants Â Liability Classified Warrants Â The Company uses the Black-Scholes option pricing model (BSM) to determine the fair value of its warrants at the date of issue and outstanding at each reporting date. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds linearly interpolated to obtain a maturity period commensurate with the term of the warrants. Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Only the volatility of the Company's own stock is used in the Black-Scholes option pricing model.Â Â The assumptions used in determining the fair value of the Company's outstanding liability classified warrants are as follows: Â Â June 30, 2024 Â Â December 31, 2023 Â Risk-free interest rate Â 4.3% to 5.2% Â Â 3.8% to 5.4% Â Volatility Â 87.9% to 94.9% Â Â 79.5% to 108.7% Â Expected life (years) Â 0.6 to 4.5 Â Â 0.3 to 5.0 Â Dividend yield Â Â % Â Â % Â Â A summary of the Company's liability classified warrant activity during the six months ended June 30, 2024 and related information follows:Â Â Â Â Number of Shares Â Â Range of Warrant Exercise Â Â Weighted Average Â Â Weighted Average Remaining Contractual Â Â Under Warrant Â Â Price per Share Â Â Exercise Price Â Â Life (Years) Â Balance at January 1, 2024 Â Â 1,082,895Â Â \$9.60Â Â \$157.50Â Â \$24.32Â Â Â 5.1Â Expired warrants Â Â (75,909)Â Â \$99.00Â Â \$99.00Â Â \$99.00Â Â ÂÂ Balance at June 30, 2024 Â Â 1,006,986Â Â \$9.60Â Â \$94.50Â Â ÂÂ Â Â 4.4Â Exercisable at June 30, 2024 Â Â 1,006,986Â Â \$9.60Â Â \$94.50Â Â \$15.31Â Â Â 4.4Â Â For a summary of the changes in fair value associated with the Company'sÂ warrant liability for the six months ended June 30, 2024, see Note 2 - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Financial Instruments. Â Equity Classified Warrants Â In March 2024, the Company granted equity-classified warrants to purchase up to 3,334 shares of Company common stock with a ten-year term and an exercise price of \$9.15. The warrants vest annually over four years while services are being performed. Â At June 30, 2024, the Company had 63,105Â equity classified warrants outstanding and 40,658Â warrants were exercisable. AtÂ December 31, 2023, the Company had 289,276Â equity classified warrants outstanding and 266,350 warrants were exercisable. Â The Company recorded stock compensation expense for the non-employee consulting agreements of \$35,000Â and \$46,000 for the three months endedÂ June 30, 2024 and 2023, respectively, and \$68,000Â and \$92,000 for the six months ended June 30, 2024 and 2023, respectively. AtÂ June 30, 2024, there was \$309,000Â of unrecognized stock compensation expense related to the Company's equity classified warrants. X - DefinitionThe entire disclosure for warrants. + ReferencesNo definition available. + Details Name: mbrx_WarrantsDisclosureTextBlock Namespace Prefix: mbrx_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Equity 6 Months Ended Jun. 30, 2024 Notes to Financial Statements Â Equity [Text Block] 5. EquityÂ Â Lincoln Park Equity Line Â The Company did not utilize the 2021 Lincoln Park purchase agreement during the six months ended June 30, 2024. The 2021 Lincoln Park Agreement terminatedÂ in June 2024.Â Â Other Components of EquityÂ Â In March 2024, the Company issued 6,834 shares of common stock to consultants in exchange for services to be provided. In addition, during theÂ six months ended June 30, 2024, the Company issued 19,743Â shares of common stock related to the vesting of restricted stock units. Â Stock-Based Compensation and Outstanding Awards Â The 2015 Stock Plan provides for the grant of stock options, stock awards, stock unit awards, andÂ stock appreciation rights to employees, non-employee directors and consultants. In May 2023 and 2022, the 2015 Stock Plan (the Plan) was amended to authorize an additional 116,667 shares and 133,334 shares, respectively, such that 366,667 total shares may be issued under the Plan.Â As of June 30, 2024, there were 1,053Â shares remaining to be issued under the 2015 Stock Plan.Â Â Stock-based compensation expense for the three and six months ended June 30, 2024 and 2023, respectively, is as follows (table in thousands):Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â General and administrative Â \$340Â Â \$379Â Â \$721Â Â \$748Â Research and development Â Â 113Â Â Â 134Â Â Â 225Â Â Â 264Â Total stock-based compensation expense Â \$453Â Â \$513Â Â \$946Â Â \$1,012Â Â On May 8, 2024 the Company issued 1,000 options to purchase the company stock under the 2015 Stock Plan to a Science Advisory Board member.Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrli.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrli.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrli.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrli.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrli.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: <http://www.xbrli.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6>Reference 7: [http://www.xbrli.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrli.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrli.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrli.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(e\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(e)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-Name Accounting Standards Codification-Publisher FASB-URI>

https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Income Taxes 6 Months Ended Jun. 30, 2024 Notes to Financial Statements A Income Tax Disclosure [Text Block] 6. Income TaxesÂ Â Â Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Â The Company does not expect to pay any significant federal, state, or foreign income taxes in 2024Â as a result of the losses recorded during theÂ three and six months ended June 30, 2024 and the additional losses expected for the remainder of 2024Â and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is æœmore likely than notÂ that some component or all of the benefits of deferred tax assets will not be realized. As a result, as of June 30, 2024Â andÂ December 31, 2023 the Company maintained a full valuation allowance for all deferred tax assets. Â The Company recorded no income tax provision for the three and six months ended June 30, 2024 and 2023, respectively. The effective tax rate for the six months ended June 30, 2024 and 2023Â is nil. The income tax rates vary from the federal and state statutory rates primarily due to the change in fair value of the stock warrants, Internal Revenue Code Section 162(m) limitations and ISO activity, as well as theÂ valuation allowances on the Companyâ€™s deferred tax assets. The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where no tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections. Â X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 7 - Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Notes to Financial Statements A Commitments and Contingencies Disclosure [Text Block] 7. Commitments and ContingenciesÂ Â In addition to the commitments and contingencies described elsewhere in these notes, see below for a discussion of the Company's commitments and contingencies as of June 30, 2024. Â Lease Obligations Payable Â The following summarizes quantitative information about the Company's operating leases for the three and six months ended June 30, 2024 and 2023, respectively (table in thousands): Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Lease cost: Â Â Â Â Â Â Â Â Â Â Â Operating lease cost Â \$38Â Â \$33Â Â \$75Â Â \$65Â Variable lease cost Â Â 7Â Â 7Â Â 10Â Â 14Â Total Â \$45Â Â \$40Â Â \$85Â Â \$79Â Â In September 2023, the Company executed an amendment to extend the corporate office lease until August 31, 2029, with an option to renew. The Company is required to remit base monthly rent of approximately \$4,700Â which will increase at an average approximate rate of 2%Â each year. The Company is also required to pay additional rent in the form of its pro-rata share of certain specified operating expenses of the building.Â Â In June 2022, the Company extended theÂ lab leaseÂ until September 30, 2027, with no further right or option to renew. The Company recorded approximatelyÂ \$12,000Â in sublease income from a related party for the three months ended June 30, 2024 and 2023, respectively, and \$24,000 and \$25,000 for the six months ended June 30, 2024 and 2023. Sublease income is recorded as other income, net on the Company's condensed consolidated statement of operations and comprehensive loss. Operating cash flows from operating leases wasÂ \$38,000 for the three months endedÂ June 30, 2024 and 2023, respectively, and \$68,000Â and \$75,000 for theÂ six months ended June 30, 2024 and 2023, respectively. Â LicensesÂ Â MD Anderson - Total expensesÂ related to the Company's license agreements with MD Anderson wereÂ \$63,000Â and \$64,000 for the three months ended June 30, 2024 and 2023.Â respectively, and \$117,000Â and \$129,000 for theÂ six months ended June 30, 2024 and 2023, respectively. Â HPI - The Company has two agreements with a related party, Houston Pharmaceuticals, Inc. (HPI) with total expensesÂ of \$59,000Â forÂ each of theÂ three months ended June 30, 2024 and 2023, respectively, and \$117,000 for theÂ six months ended June 30, 2024 and 2023, respectively. Â Sponsored Research AgreementsÂ -Â The expenses recognized under the agreements were \$377,000Â and \$176,000 for the three months ended June 30, 2024 and 2023, respectively, and \$533,000Â and \$331,000 for theÂ six months ended June 30, 2024 and 2023, respectively. Â X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureTextBlockAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Insider Trading Arr Items Â Â A Material Terms of Trading Arrangement [Text Block] Â ITEM 5. OTHER INFORMATION.Â Â During the period covered by this Quarterly Report, none of the Companyâ€™s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a Non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended). Â Rule 10b5-1 Arrangement Adopted [Flag] false Â Non-Rule 10b5-1 Arrangement Adopted [Flag] false Â Rule 10b5-1 Arrangement Terminated [Flag] false Â Non-Rule 10b5-1 Arrangement Terminated [Flag] false Â X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd InsiderTradingArrLineItems Namespace Prefix: ecd Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmtdFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmtdFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Reverse Stock Split [Policy Text Block] Reverse Stock SplitÂ -Â On March 22, 2024, the Company completed a reverse stock split of all the issued and outstanding shares of the Company's common stock at a ratio of 1 to 15. The accompanying consolidated financial statements and notes to the consolidated financial statements gives retroactive effect to the reverse stock split for all periods presented. Certain amountsÂ previously reported includeÂ rounding up of fractional shares as a result of the reverse stock split. Â Basis of Accounting, Policy [Policy Text Block] Basis of Presentation æ“ Condensed Consolidated Financial Information - The accompanying condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for financial information, and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC) with respect to Form 10-Q and Article 8Â of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements furnished reflect all normal adjustments, which are, in the opinion of management, necessary for a fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These condensed consolidated financial statements should be read in conjunction with the audited financial

statements of the Company as of December 31, 2023 and for the year then ended, including the notes thereto contained in the Form 10-K filed with the SEC on March 22, 2024. A Consolidation, Policy [Policy Text Block] Principles of Consolidation - The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. All material long-lived assets of the Company reside in the U.S. A Significant Accounting Policies [Policy Text Block] Significant Accounting Policies - The Company's significant accounting policies are described in Note 2, Basis of Presentation, principles of consolidation and significant accounting policies, to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to the significant accounting policies during the six months ended June 30, 2024. A Use of Estimates, Policy [Policy Text Block] Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes. A Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Intangible Assets A The company evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. Due to the sustained decline in the Company's stock price, the Company engaged a third-party valuation firm to complete a quantitative assessment of in-process research and development (IP&D) asset as of June 30, 2024. We performed our impairment test by comparing the carrying value of the IP&D asset to its estimated fair value, which was determined by the income approach, using a discounted cash flow model. Based on our quantitative assessment, the carrying value of the IP&D asset did not exceed its estimated fair value, noting no impairment. A Going Concern Policy [Policy Text Block] Going Concern and Liquidity - These condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations. As of June 30, 2024, the Company had an accumulated deficit of \$140.9 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of \$10.8 million as of June 30, 2024 is not sufficient to fund its planned operations for a period of at least one year from when these consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company intends to seek additional funding through one or more of the following: a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. There can be no assurance that such events or a combination thereof can be achieved. A In March 2022, the Company received a subpoena from the SEC requesting information and documents, including materials related to certain individuals (none of which are the Company's officers or directors) and entities, and materials related to the development of and statements regarding the Company's drug candidate for the treatment of COVID-19. The Company has received, and expects to continue to receive, periodic further requests from the SEC staff with respect to this matter. The Company is not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that it has made, the Company believes in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to the Company states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. The Company cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. The company expensed approximately \$0.1 million and \$0.4 million in related general and administrative fees and expenses for the three months ended June 30, 2024 and 2023, respectively, and \$0.1 million and \$0.9 million for the six months ended June 30, 2024 and 2023, respectively. The Company is in the process of filing a claim with its insurance carriers related to this loss which may cover a portion of the related expenses but not all. The claim is currently under review by the insurance company. The claim has not yet been approved nor has a reimbursement amount been determined which, if any, would be limited by the applicable retention as defined under the policy. Accordingly, the Company has not recorded any provision for insurance reimbursement. The Company expects to record the insurance reimbursement at the time that the amount to be reimbursed is determined and approved by the insurance carrier. Any insurance reimbursement receivable will be recorded at an amount not to exceed the recorded loss and only if the terms of the legally enforceable insurance contracts support that the insurance recovery will not be disputed and is deemed collectible, or if recovery of the loss is probable. A Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents - Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains cash accounts principally at one financial institution in the U.S., which at times, may exceed the Federal Deposit Insurance Corporation's limit. The Company has not experienced any losses from cash balances in excess of the insurance limit. The Company's management does not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institution where its cash is held. A Prepaid Expenses and Other Current Assets [Policy Text Block] Prepaid Expenses and Other Current Assets - Prepaid expenses and other current assets consist of the following (in thousands): A June 30, 2024 A December 31, 2023 A Prepaid sponsored research A \$1,277 A \$1,515 A Prepaid insurance A 1,143 A 564 A Vendor prepayments and deposits A 457 A 545 A Non-trade receivables A 5 A 95 A Related party receivables A 4 A 4 A Total prepaid expenses and other current assets A \$2,886 A \$2,723 A Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments - The Company's financial instruments consist primarily of non-trade receivables, accounts payable, accrued expenses and its warrant liability. The carrying amount of non-trade receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such. A The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). A Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: A Level 1 A Unadjusted quoted prices in active markets of identical assets or liabilities. Level 2 A Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 A Unobservable inputs for the asset or liability. A The Company's financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. A The following table provides the financial liabilities reported at fair value and measured on a recurring basis at June 30, 2024 and December 31, 2023 (table in thousands): A Description A Fair Value A Level 1 A Level 2 A Level 3 A Fair value of warrant liability as of June 30, 2024: A \$1,704 A A \$1,704 A Fair value of warrant liability as of December 31, 2023: A \$4,855 A A \$4,855 A The table below of Level 3 liabilities (table in thousands) begins with the valuation as of the beginning of the second quarter and then is adjusted for changes in fair value that occurred during the second quarter. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments. A Three Months Ended June 30, 2024 A Warrant Liability Long-Term A Balance, March 31, 2024 A \$3,400 A Change in fair value - net A (1,696) A Balance, June 30, 2024 A \$1,704 A The table below of Level 3 liabilities (table in thousands) begins with the valuation as of December 31, 2023 and then is adjusted for changes in fair value that occurred during the six months ended June 30, 2024. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments. A Six Months Ended June 30, 2024 A Warrant Liability Long-Term A Balance, December 31, 2023 A \$4,855 A Change in fair value - net A (3,151) A Balance, June 30, 2024 A \$1,704 A Earnings Per Share, Policy [Policy Text Block] Loss Per Common Share - Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock units subject to vesting and warrants to purchase common stock are considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. For the three and six months ended June 30, 2024 and 2023, approximately 1.6 million and 0.4 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect. A Subsequent Events, Policy [Policy Text Block] Subsequent Events - The Company's management reviewed all material events through the date of these unaudited condensed consolidated financial statements. A New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements - There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company. A X - Definition/Disclosure of accounting policy for going concern. + ReferencesNo definition available. + Details Name: mbrx_GoingConcernPolicyPolicyTextBlock Namespace Prefix: mbrx Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition/Disclosure of the accounting policy for prepaid expenses and other current assets. + ReferencesNo definition available. + Details Name: mbrx_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock Namespace Prefix: mbrx Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition/Disclosure of the company's policy regarding reverse stock splits. + ReferencesNo definition available. + Details Name: mbrx_ReverseStockSplitPolicyTextBlock Namespace Prefix: mbrx Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition/Disclosure of significant accounting policies of the reporting entity. + ReferencesNo definition available. + Details Name: mbrx_SignificantAccountingPoliciesPolicyTextBlock Namespace Prefix: mbrx Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition/Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition/Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: https://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition/Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income

current treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1:

accounted for under the equity method of accounting. + ReferencesReference 1:

gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1:

À Minimum [Member] À À Balance, warrant exercise price (in dollars per share) \$ 9.6 À Expired warrants (in dollars per share) 99 À Balance, warrant exercise price (in dollars per share) 9.6 \$ 9.6 Exercisable, warrant exercise price (in dollars per share) 9.6 À Maximum [Member] À À Balance, warrant exercise price (in dollars per share) 157.5 À Expired warrants (in dollars per share) 99 À Balance, warrant exercise price (in dollars per share) 94.5 157.5 Exercisable, warrant exercise price (in dollars per share) 94.5 À Weighted Average [Member] À À Balance, warrant exercise price (in dollars per share) 24.32 À Expired warrants (in dollars per share) 99 À Balance, warrant exercise price (in dollars per share) 0 \$ 24.32 Exercisable, warrant exercise price (in dollars per share) \$ 15.31 À X - DefinitionThe number of warrants or rights cancelled during period. + ReferencesNo definition available. + Details Name: mbrx_ClassOfWarrantOrRightCancelledDuringPeriod Namespace Prefix: mbrx_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionExercise price per share of warrants or rights cancelled during period. + ReferencesNo definition available. + Details Name: mbrx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice Namespace Prefix: mbrx_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights vested and exercisable. + ReferencesNo definition available. + Details Name: mbrx_ClassOfWarrantOrRightVestedAndExercisable Namespace Prefix: mbrx_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights vested and exercisable. + ReferencesNo definition available. + Details Name: mbrx_ClassOfWarrantOrRightVestedAndExercisableExercisePrice Namespace Prefix: mbrx_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe weighted average remaining contractual life of warrants or rights vested and exercisable. + ReferencesNo definition available. + Details Name: mbrx_ClassOfWarrantOrRightVestedAndExercisableWeightedAverageRemainingContractualLife Namespace Prefix: mbrx_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mbrx_LiabilityClassifiedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Equity (Details Textual) - shares 3 Months Ended 6 Months Ended May 08, 2024 May 31, 2023 May 31, 2022 Mar. 31, 2024 Jun. 30, 2024 Stock Issued During Period, Shares, Issued for Services (in shares) À À À 6,834 À Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares) À À À 19,743 The 2015 Stock Plan [Member] À À À À Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) À 116,667 133,334 À À Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) À 366,667 À À Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) À À À 1,053 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in shares) 1,000 À À À X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) \(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) (01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=mbrx_The2015StockPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 5 - Equity - Stock based Compensation (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-Based Payment Arrangement, Expense \$ 453 \$ 513 \$ 946 \$ 1,012 General and Administrative Expense [Member] À À À Share-Based Payment Arrangement, Expense 340 379 721 748 Research and Development Expense [Member] À À À Share-Based Payment Arrangement, Expense \$ 113 \$ 134 \$ 225 \$ 264 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 14.F\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 6 - Income Taxes (Details Textual) - USD (\$) Pure in Thousands, \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Tax Expense (Benefit) \$ 0 À \$ 0 À \$ 0 \$ 0 Effective Income Tax Rate Reconciliation, Percent À 0.00% À 0.00% À À X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231> + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.I.7\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 7 - Commitments and Contingencies (Details Textual) - USD (\$) 1 Months Ended 3 Months Ended 6 Months Ended Sep. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Operating Lease, Monthly Rent Payment \$ 4,700 À À À Operating Lease, Rent Expense, Annual Increase In Rent, Percent 2.00% À À À Sublease Income À \$ 12,000 \$ 12,000 \$ 24,000 Operating Lease, Payments À 38,000 38,000 68,000 75,000 License Agreements Expense À 377,000 176,000 533,000 331,000 Houston Pharmaceuticals, Inc [Member] À À À À Related Party Transaction, Amounts of Transaction À 59,000 59,000 117,000 117,000 MD Anderson [Member] À À À À License Agreements Expense À \$ 63,000 \$ 64,000 \$ 117,000 \$ 129,000 X - DefinitionThe amount of expense for licensing agreements. + ReferencesNo definition available. + Details Name: mbrx_LicenseAgreementsExpense Namespace Prefix: mbrx_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionRepresents the amount of monthly rent payment on an operating lease. + ReferencesNo definition available. + Details Name: mbrx_OperatingLeaseMonthlyRentPayment Namespace Prefix: mbrx_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionRepresents percentage of annual increase in rent for operating lease rent expense. + ReferencesNo definition available. + Details Name: mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent Namespace Prefix: mbrx_ Data Type: dtr-types:percentItem Type Balance Type: na Period

Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/21474783326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/21474783326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOffTransaction Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mbrx_HoustonPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mbrx_MDAndersonMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Note 7 - Commitments and Contingencies - Lease Cost (Details) - USD ($) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Operating lease cost $ 38 $ 33 $ 75 $ 65 Variable lease cost 7 7 10 14 Total $ 45 $ 40 $ 85 $ 79 X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: <a href=)Reference 2: [=SB^IZMBO\[4X,7\\$5;UD^<2&-D MDAN!0^<Q%LC? \[W.IS?K\\$;/#;\]!I_!IU!+ P04_ " . @ U9H<0;Y\)X%_ M%0 & 'AL+W=O40TO;VE.RY2A-Q-8H5?K6DI6:G3M M!<9^<ES2.N!@<K-T;@<C5B?H!>\(E^<K03M;\)EI!9S#?#;C\\$S Y2W>RAD M_J=70F&?&^B\\$<^&^A MZW/T=2\\$=-^<^JPL:~?;OY+9,3>#* \[S49A\]^M G^POCK!P;_!>3\]TJ/V\[LO#OK2X;^M \\$AP.\(TD#X\]K7K^G&^J\]A\]\\$K%<7-3-9-\(T:B6W+J!+2C,-E;-K;&!<3KDW\\$8 MQ0,~!W=B>5\) N5DA\[E^X^2\\$ZM#\\$S,V,OZ.\(UK8\(D^JUXEJ!3W-?\);=@R M^R^Q=QE4!,"A,<#6TTT,^+HAK411<+ZG;>\[!4E^946\)D^7/3JZ\\$9BEV\[<8&\] M=O!YG B&UH!^TYEKOA.3_ML@SZA^CXE^ME&KB0^\(\[W@<K^<K^F3\];XZWZ^C,Y7YU\(P 9E=BFMN&@/T#3 M\[TfZB5X@,@TC;QH68;QR\)20>IKB;\]>+&V.J/\(P3F4M>20Q@\).EJS8+<I M^"^^G^\\$4K+^F^R\)TU=^!V,A?US; 81Y 2/;!=X!#\(VV^<^?83VS8/CW.\(PW#7@>V.%\[>H 4\\$L#!0 \(Z #5G\) MKO?SP\(^<^ \)8>6P>VJR:W-H965T&ULG99KJHP M%\(G; BA7M03MYAU \(A4\\$&DE6K;DU^K\]I,!=L>K8F>U MU^<8R->H\\$VVE @ MRWF@G<^<QJEMIT?B18 ASR47>NX5QE3Z0J^S DJJ!<@<3,K4JL^O6OJ4 MT-R\)2NY^08^<V2J\\$E\[|VW7\]60E",RF\(M7<^<Q>+<Z8BVW>78K\\$5.VUBG3Q^*60f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f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http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration EXCEL Data Information Report.xlsx IDEA: XBRL DOCUMENT begin 644 M4$!#!!0 (Z #5D'04UB@0 + $ 0 9&J'C4')O<' ,O87!P+GAM M, $V, /OL', !1$!IQO; =!P4)B0!2L+(/>QLOD&1#LD' !OCG!CVX>;QA&WPIG M*N*I#BV&5(C(II(/ !47BK9.?;=N')=HI6-Y #OGDK7A.YN]Q<&4GP24A!0W_]=0U!R;UEA 6#MI7E!+ P04 M)

```

M&=+F QRE1+!$?S@KGJH+T=UBU'=BPBW9,*==EE61 798 80=QD6 9L#8M M*PQ5J,$R8ORSCD$4"@X820S.G871FNC# #821F34H+T=176+4=T2+#+
<|AOJJI1NJ@12" M;.,Q>LS,80,QEM3LP T5F VGXMZ201(*)YF)=CF?D1#@*AYB;PQN-3J6 MIRHJ@H61P(YW728^@|CKV L8DF2^<+/,?E/5+ M8D1BK"Y
<@CTLBI#8 [PYR,('V#1" F40<9@W .J)N#J&XQJEN"Y:9 3T;Q,9 MNJ.7AIR L%?@D'E.52W1.M-SZ3B.8I'< P'GN,7AR@@WD.J1CJ%|:LQ?Q7 MJ,?
=/:>R#Q#AQZN0G5;H+K46j)&C|ITX S^GLS.3"8MQ\QX-LJ|YU>PY.(NJI M7E2W6+4MX=17.<|D>3J;EVXL .%VI-S'=PY4-U2U&=4LX<^<AY'O%SHI%B
M3NYFS@NV2L#E|I<ICPHY9C'MF =|OJ,?>HY952W1.M-SZ1B9NYFYC-;?7#V MIO:BPR.#;#S'>A>2P?T(T)V=S9JXY(*)S)CT#2#212%9PX*G04/S/W?SO7$[;C&]=OU>R
1|CSLC+Y@'I0EJ|K#1 MUUH +>+>#3NC@+XD1B7F7UBG1@U(5+@A|>TEK&OZ[CL:U8O@U'<S:$-S1$1 M="Y"Y"4@FFSOTJ|@8(F^MCMNR5Q'Y) M DC.((QO$ "H$|/J#(BR
OJ)ZNAO Q1P57?=-8E2W1.M-[Q>+<6A:GA&G#^# MR00XBGDO-U30@LNY" ZE73U5ZG$|'-WN=E4%U- U-CJ|:(BNNY?EPM>1366|
M_S', 9NVVO8_WGA7M6VUZ5^NLW25U9U?GY?5>WW-JWO01Y DO3FOU!+ P04 M ". @ U9/S:2UA8# ^|^@ & 'AL+W=O|R.Q1M9E8J"UY$EVW
11|F7MD.4A,44=|A+U+L+M;FW!2+18U4N|P67R#HOHD#&U68"7L5>H>+>K M326(EV87VMJ@R'U0589)%V%E9 J6"~|I:LEJ|A4B|J,6";JA+F.8.E;E=1' M'
R.SW)7D_.SZV4M=GB|+1+6,.*P1Y9<5JBLU H,J,E?H1P7RRF3N|WR3V1G M-KA"K2^<=XN+?1$53A"6F)%C$|QXP,L2T?;G.JUG,&8T@4"MP?V#|YVKNX.
M6#S7X7>94|S$*%@'DN!5-29|U?Q|>E+^E^G2^G|JH.^QL'D#66-5|P**JFZ MIWCLS^%9P"+Z3T#21R1>=>Y?(JWP62*#R71K=O|)'K9G.%+|=L3BKW4F|)'D M.%I?:T*
(X0U<@'VH,@M|'IK$,LG89$B=PL#~#KR38=6)?(V'L.XTHH^?|^J5C0G+ M^")C@J20?TF.4AXV:@IS*())$R$ WZ>N=>;[9@6HMD(8/4@F525"++0E' M|C+6V|J'
|J|YR;|B:@A|JN;X1%|X#1^06K^>@|Z|V|H|?|V? WTCGVHT MPC6QAI|)%C@>4^KL N<@P0;Z2|N%9^H.3 M6#6N|J|HIWY,FRU^*|V9@S"7H@T(C=G5Q:8S&'
@U*Y5X*WT>S-K,X8>D|H>1O M3B|OR9MK4NCM1J"273?G$|1.GS$#|('Y^6@U*D |J|4WNK00E MH,<3^*3@2CQ|ZIMS-N$VA31-
(T@+>|W$W$|+FWKN@7|@X$R=K O=02P,$@ #H -6=>29Y@M)Q|@ B1 !>|J|JW;WZKH1V3<OH,MA4+)>|JDWV^'8|RY%|)'4*>U.J.GW^6&_[(^4,%Z)D=>-,W-
C,^|U2|Z M+K$00#WBI23C$OT2A1878;D;RQ 5RC7P7>29Y>AA MU>#>9^|D!X|)!>B4|/|Z.E3X3QH.N-M*CO|S(9AM6$8>)>^
LPH/PHO38VL>?P|JON.H&K83>2D9J=,O:592?OZ6?C M$8:P."?>20=F^K<6'HOV&A=I,ZEKG|,'=AM#^1)M6DT E.Y4+>N8R%|G 6 MQZ;07NH%W^R6-(N7G,C?
QORD7YYW?F27WXXK>?;.(L1?7#5U@+150 M,?Z(C06N=YOT+>+>F^X|P|>F(FZ>3L|'N G=,|Z+>P=-$6L.N@|;^NE; MSOK|I|G|G L3?
|_G$>MZ)NY#WMPAP|JH'9="!>FN9*> NZ3L'$P^V|B2Y$ MFT,0/KS;T;1$<=>+0L4 DU84TLNSV|J6-.XTPY$ |B'OWJ@C0^ CQAC-D,+ MHRA|('&*50Z|;=$.1N.;P4Y
K^110H(20X$K$7?AJ P M$1|/K@?FG6M1Y|;Q045DMX|'A$W$S|G-(G78-QU,D,5@F+I^&BV%#J|1^957 MZ;P5W=">CE?Q7FZ>18F(6+8U|<$>7<%V.H<^H9;>6 _(+*?
EA@<V W|P$ |DGAH|AD;132|K-(G&6|J-(G^6|J|<9 J93=,45|6&K;8+>M<6W*F53Q5D?WVWCNDY60KX$824;I2X;E|@B'W' PN@!| P9WD/I3S.4-
****)LS4)9DYKB1E09 M$,&H]M6G%+/LU26K+W5>!&TH M$Q4=)MTAW|M|G442D?(?5.&I)+2/O2:U%CO%7LTI'_*+$|S$*M=?>.X9$R
M8CMXK;R$1|HZR+G2&N&^2YSNE2+03V'#&2T@TR'9|!|=Y5C;J P09$5R510 MA>66R=;Z|J'H H8BO+@MT'O=-L2/6&V#4IA6AAR$K|P9C'H-?
AC#G=B^M|J,+,2/5'CGR/W?BB7?6=5V2G UJ57TJ|J-|VUSVFD1O:W03S+6NVX; M.HK64;1,*$4| |PIG L1QJETC2 M" E4@
3FUF0A8V,J,$5U;"6$S(OFJ2UIRD,1,$")0QJ$|(QF 3^EW&A$X MGQ,|DR+F<,>?|>+>R>X>JSM^13=<.GM9H>H|+VP8?EC9=$OJMVZ&=&A$NP=0F M&*6)*39?
FWOB67F7?Y>7M(|@A42+AG+H.>GN3#MCMXRN<@>).R';>+JZ MALC4J7>7D#S,R6,[JW5>SE5K|9=X|<T=|L; NDK5U2V|UQIEP$L1 $ @OK M$!@~
WV.OC@>DO&S&QPM2NVNFH| N/QO UKA2V M=J^>QCV?B| HEC'^76;|U|TQJJZ=RR8%-9?>R&|I@R+O|H|I9YW1^157C%+ ME6.M|J=
:YB80 >5.Y,X+EU1KJRF4T?>=OE1680,GL|94>@62W42 4V:.(# M$C|'C617S;RA/(XA#2,.V/X&5#)C^EQW|A &KX|6731<.;BR5"+=
M^MOO|UTRGIF$+@>Z+0;U;0+>1P^2?SBB-A|S|L0UJ2M51+NN^2 M|=E:8+C4;U2D<3%T39<<%,951;H?;?O^O 960A67|'X+>|KB<[&3@Q_|
M49Z|Z#G$2$.A$Z?T;VH#9;):@|>+FE@(|11TN4<G-JAZHU|&6>G J5'<# MPP466*|)DO|3C9(-A>5Y7L%R;H=H+A(FDQF L^EDL'2#8;JHO&F)-J2C
ME&E=O,HZG;.3AL S.6"6B9Y|WJ@SNEJ|'(U6&S2N03$Q"GB2Q 2:P<<+>J,N M^4.78F|.F|9^2|DD<7S,DI2V|>D|J$|S>ER37@|15M91 E'2U)$ M$Y.,QCS,DAF'^JQV-
N&E- M>NM|L+L1-8UJF9M|J-G77>|,^^^>+>9WG|)*T;JU M.V6|<I19|J, Z SC>*7GG |3^9Q?Y'U!+P04 ". @U9|S|D&G;4$ M"N" @'AL+W=OET^|QDVE@X<;
="O?K;^RT:8%2Z;XD?IEY MYIGQ>^RG"ZGN=8%HX^D4E3[S'F|JDWY?9P663|NRQHV9E5$S-14S?NZ5LAR MIU2?*A0$@W|>6.3JW:C1?RL8(7N&-
MV4)5|5|Q1R<>.>GWFKAE|L+8Q?Z|N|S'.S?S<= Z1M&LWZ?DO,1^3|K|P1^<5SHC3&83292VM0| ME S,"RPA@|@9B#H|X@7*(0%AH/2TRO,VDS-2/6&:YZ8X
MX8>Y#ACCR3"WO|U@CRZ4R,2AYU|?9T$S,&PK# MX1V#^D0.=ZM(=I^CE3V4,Z-HEY>+&7^7|B@; M|C(E&5*5T=|@J|VLVYM(28M1/0.Q
"N964*5=5COE+&_3|123A$*TZ3"?@ MUZ;R(OYZ$ 51L@,O|GR,5ZAPT<-1L)G7K$|XTS G6$&;>V^J|O")=OA|4Y MT37+L,RC>Z11:(W O@A' 2?
=I1.K+>+O3QZAS@DNH,2-THA+|X|I|B9#9 M_3_|.Y$W,XW>S;9U,NM'F&^&TYC..>9<#&^N)IES|IG>+2K>RU,|ON MC^ZRO@1E;D;6|6+7B@;I41TXFX:U)B#4Y4
W1A|86G(209075@J5|H8|U>LO.IH?|C89#87A% M-E$;41.G&K^B67|N|T@FT-OTDU,7A|RE|E4P; HI -=VOKOY7M7+>FWSIE MUA|0|@|<=I|F4M(K,UUAK,^*j4^
TA^|[(=+S+^P 27H@^1$N F9H|CAXX=A%$;?|M>#U6|PQN= M71%*I7=RQNU"K7F3N|["UO82^HNX|J, &657-W$_.L<|F=095PC :UF2R<
M^*B^BI^;MPBW@:NP:NZ!|IHA|0U7B|Q4TU<=,4)XCU+3B#^|AVXUO
```

U9Q4IDV6H" !S!0 &'!AL+W=O>ZYL[^\G3G9WMD9TL]=~V7E4.]=XJB641F5W6# MBG;6VDCF:^\HVL6T,LBJ I(C3!)G%DG\$5%;.P=F6F=XZP15>&;!;*9GYNT"A M=- #~#TL7?/!Q?7".P:ML\$;=&#^:~T.SN&>IN\$1EN59<#~V/W@VFB]J3<=; MCCCMI8//9*U7G9\KN91X@6AP;YID: >[Q (3P1R?C3<49J2 \M! 8/X;< M*9<5LWBHAQ4]>N7H>32*H< ,VVPEWKW2?LAEZOE(+&T8M;XY.9=-[Zl3LP*1 MI"<)OV\$5.63&:1)FI @R. H*9(\$O M.U.\$!"VU~Q)]KT7EQM.^9j6U8B?. (FL*BN<>H>)/%L, \$K>GM"6"]KKR4^\$S5Z0+ M=T9G81W\A)AB7L^X+~N^N^'U)]D.ZYV61O\$1Z<=\$5&,.;[A^R=V?7]D!U8 M02Z418*WQLTS- \&\$/TJ/(-LXH>,A0&OAM\$0;IGA& ,#0S%[@P0&.2RU8X< M<~^~^=)S1.0#F5<~?*&QI@D25?>UNB7.K7-L3 6K HKQK&^ F2 >L<73*SS&ULK9AK<^ (V% (; RAFWTYVYG:~SAEJ3? &# SF^ZRI:~7#YU^4&R!;~\$M MKR1#^~^=[9#LNI. - ,H^MJSWU>71.;(VVG/Q+&~%;RD22;5JQ4?7 ,H_Q! M2N0- SVF&S3941^4H36S/<09V2EAF349EV4I,1KQ0"@?;L35U M[Q=WNGY9X2]&+ H&O1(GCA_UBC<)HDVPFY[3VM MIDD\+Y^=5^48>Q/!%)YSSYFT4J^ENW%D1TOXI\$/? +1]UJ/JZ _j0I[(A?V M5=TA5@X+7)A;B\$J%*M?BWHQO%KEP2#6C HYI.Z%*F?;+(9"3X^H2NC6JZHL15]G&^6:87UEH)?,10 MIR:~N^+@PL PF.A^4. ;F142*TD)W]RJ"\$LD_\$%? 5\$&2GT:VPB:UT^K>[~R M]R[8#V#],Q5+~+*(1)=Z&O/]= []> .:S5<\$G\$#GM>B?&M\$A _Z9?+GP/-LB8""I;9K7;K)N2=R[MM J"](D*#7 . <1^XHM@B]#>.*>YK?Z3%:=61YT/[V5.0CJV.~%G;4FOSP MG3MP?CE\$S.29;[LJ.SZ19G.TKM)=V3OC]\$9:NX\$7^!UVL^UW[7]16IHG MC&0A[<"292PM4I@G^.- X"\$S,6P4]PD,(\$\$_ UDH\$+/(.)PD1\$G(L+1?2N"> MM39 +6639KY)L"D\:(R&QPM&:=,9,B>4^PWE_K64@Q=5[^Y(E?\$(DS4YG"78 M:GTM09-F? ON@W5/L(G\KEWL"DJU8&#&[(I(3MHR Y:1 E=[U1("FO%PV=8(UX% M_RRISL; GH/9Z4G8M3)-FODFSP*39P!#9)=!APW?8RK?D&O,D0LH_00^E8.H M^IVK4TQ3V3/")?;3 60T8QQH\&A:52V>EX;C2;~?)F(4FSA2&S\$UW M#>6[5LIU_ "VIB"?;."ODPH/R1A_O^TS#+&^Y87H\&^?D'1W(WM^H6B-IDO^<MLOT~%LWI.% [(B.A^P;ZH2U@&3D<2%6+8&QS? A:W\$C#@<1N^XS *P3>I8)6 M(6B=+^S^&4[\$+1/!=X90:<0="Z-T"TSW4LCW16"N]=-(>H6@=VF\$?B^H M9W;(QR;)?!*!.IPM@= S>I4I)>@ /4?ZQ5*B(H%#J#H& MZ,(3(M^P:V5!W5S;7#HE-~WBG03?=:X(%1N1-@1B,45>B#>GWW9_I%O=[U M:@^V&J%RF+RW89IXM<0'R)O _QVK <[QV18.FE(C=LW* 70Y^2IN@Y>1R!7M M@Y/LM5(5!=FE);[2j03+1+JF91BWJ,3X*%62: T5Z%?FY _\$PKCNS3F=YM^<Y M^<.VS|WR- 'Y"7. @QY+&839#UVBK&BU9=AFM32] MZ+I(9H:"7Z8<%?D#7Z M]1>WZ_Q>94V3,-D;&82%IB\$S4W%CFLD%T\O,R<@2VRZ\$K#84[F;[&[MUIN/>D6@* (SR^DRl@ W:AU)Y1 J4I]I874^OFXJ06?U<3+~^8N.4J M W;~;3Z]> , S_9-#@P!JSID7J?+JAZT5.5VV8,CBW5^BW5]+3:~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~!7 A8\$#P""I D6J[E%+D(<02CX><,<1^7T8I^7Q3)+~* M/J&Z[G]/U2A1.#E^SR0@#YVC"19\$+9\$,PX"]J,ZZ+&>J16A\$L@2*L2FC@B4D MK@8QC@&AR Q20;>Q75QJ^+7KJZ@ M5XA0]&^28?/[AB5:X^I#^?+B!&=&WX&U5 MD+HJWJX\$J](^.=.+Y#OG""A8^V^?P0+H#_ TU8T(ZM=\$%I%AB,869FV+~^?J] M-[? O_-&6L2D])PHI[(K(QU-D,C-FH=I87\$*PKLU0)](H^3-X:8KT_74J[FV])>=>49)ODJ?07D/NIJ_Z M1ZJ;HGRWYQZL-L[K1-7J6G7_U+~+V^TS>072"(X77/Q)-4SA1X&4M(-D<+ 8 M-]?WW?./_D4/EPG3XF^V4L7AR])PHI(#[\I]),>#KJY1.CWJ_*J]+J-M MB1PQUW/"OH^YI7E0-15+>CJ5[E1[VB6Z]W%+6P@0:[17,8YO=1<79% M^9\$=U,)UJIM%IVM[58Q-ZQR_D9X."8TAAV(_U_WO?&69[26>5]O;G;&%7 M;(<%)?8%3IWE>_TNYX,"8TAAV+V>U[7O.GJ5>[RS>A]_,<~5O8%MA0?; M9M>];S?%70_WRBWOQF=%A2U1+6J]N _\$EGP)625?=U;G|K<=&= MJCZ+^YPPWQJ]>+!74N;JN;E^4C9D^PKS@463\$]6%I=KP#P^:#&EXS) M74/? H#Z+&O\4\$!L#!0 (Z #5E:*(P\$5@(< ,<% 9>@PO=VJR M:W-H965T_KB;,[H&,<1> 72<"6) MAOF070>O1HF+JP\$ _.:S,SIHX)S.E'MSF.+U?"^~^=9 MM;S)7EC4\$^4M^P]JHN-R^V;K-PPZ@GQP!1^T@^EJ W)B;W2KS-L,V19JM^6 M!:=MV=S^KY:CK1L716GJ.TMMSC,OBDS\$1.WYK=L;0,%&,"^VX@!0Y(L)_D_X*3RPZ>AR\$G4YB3Q?

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~W7(_5? =FW[CU@B^O9UIFH3][\C@>:2NFI=]2N62IPM.\0)SV<~I ME66;+"=-:9\$6GF0F-?:L8QOAE =(8X/I^8+>I)J9YU=]JHW]02P,\$% @_M#H -6&UL MK51M;],P,\$/X\$K.SA3=J6MVZ#T4;:6A @7JJ-P0?I\$>Y-M8<[.A._XJ9R>+>+ M.M%-(/E)OGN>7+V?7? CC3(WMD)T<=+92>LZP;5.19:E-S M1Z991;8QR,L JF64QO%I5^A6#X.9W.3CW7KI% X-V#;NN;FUR5^O9FPA-T? M7(E5Y? Q!E(\;OL)K=#?-W) 5#2REJ]%9H1487\$[817(^S7Q!"/@J<&W]N^5 M++2^]<[.B)*XV?/R89?>N#V_I][3=!.6A;G- 6^XUG^B^0DL;OK#18V,&16N=KGLP95 +U;W\KJ_ # M%B 9/0)(>T^ZMXM^LIX3*15UF0=,.,YZ/C=Z _='YC>A-@&:_H3RMWCM#<D< M55S^23N\$#([@HBA,BR6OJ,'8M^5R5)=A4F+J;^H^+P0?%D,(O)OX\$8^& MC@MI^H^_SKVW0B<^[@^X.9Z!OM![['0L&72K>6R.PX!^CV\$!Y178?BID-QT?/7<~WI?P^;KW MBX5UA!|OCUWZ.L+1;D+?T#N>VX05.&/6L1;-&EC] EIS&KW[I_4]D# [1G@;_L M*?; _GGLJL\$NX1W;:6#SHV>=IR(3NH3UMJ_ @T99Z=E^R47%N=30=A#6; , M%5AW=XF3_O7=14RP(=1.][XDL,Q[\-['F!6T*_L#4 1T])G+*QMN9\I-AGE:W=T,B(9CZ,4 M[BAB69)@^GP,-=F.-5;+=O^J\$S67" _JDM,\$K> #^<7-'Q9E>L811 BF+2(HH M+;?E7DY-W- 'O\$I@BVK^2/9RH^0+~+DCW^L\$(BB^)"@D@*+^X^PA3B63**_ MKR6I5N64P/KQCGV6-R^&6&4Q)_CD^*^FL#~#86PQ%G,[\GV Y0-]21? 0&*6 M_T7;M;04) Q3I(2+!"(HK3XCY_~U\$#")YV@4^K\$. _PK +@^VL1F<N<C< MFZ?7 GK MP2XIX+Z>? BY6<7=S:3S,61\$R191&2W8Y\$&N;XX6BD2IM.(# MI^)J)^!][1Y\QI3CE#)UYP'\$4,_0W//,\$Q^_ \$Q8V^CKI]=U(YR^E M!.I!27]=T%NOT- OHAJ1\S9"?AA^VX+UNO-N!UT6K5;_6KM[KJY/PSRR]0+9Q MCBS#9(B.[PLYAO^%U)\$ZY ^TC_TD,7 9MKBN8W9Q93MO^B=.S#<,8 MZ8]U,9MAJ; ,9YC7#AH;]'/_;8:9A6HVX66?;^MERR38X+&^F^AX,Z^_HDJ]^_M,5WCJ]S9-)'M*>14"CF="OE? LX@_HVF,&8N6D="IFA+~_WD^R /I?FSB=I"?V M/U5Y)JDD\U62S522S161[7FF5WFFU^F9W^R(+^=6082B_7G'-UFTC+RV@,\$ M&8UX! Q<-1P+8RV>7[RU0XAG490B]L<=\$WVV=%9RM%4DGDJ7R59+,"K%<; M8K9M._L3;^XHXZY\W,I,j>1^AO@-- SYX*^, ,R].HW1U+MY+:(+ _.@%,6TW1 MR7ZJ\$522>2K)?5DLVY%3 ,]B[O-VD:-HC+VG-*OG-) _ZZCQGX &\$0-T1Z, M:C&'TR4D<2Q:0QLQF/)T^JISCL]91*,D^EF: ^2%;0#>L051=F[V#0*,JX M9Y]!99 _!6^U3FS< _>@8- O/0/4M4WCH,]I96G:GY42EJ]ERIE^LGFS?FLPM/IN MU< ">G,-*SN%;Y?P\$C(MW#^E_*0<#7L3P(V6^C3(=P^T-#I3M+&I498)*Z:M, M.5-) _F_6;[FNW3/[E36-EIT^XW _]5"RIZY]MHJ+&IV)+6,LWH-<2Y@Z:GXHM M8<_6+~\7NMD^] ^ZK8]D6J[2291XBT>%VD6Y(^%K \$JRVFX3F:\$L,%A>O%QS= M0T!6:?0-Q(6KA&0I;U73;*II%OD[*SUU- _ED5E]I5EG2MGFJM@*=^BU+<<\$ MZ^K?368HD+H56T#5:K5C?97OTQZL7YN74]-EW3,O_6(^H6^VIZ_P705I0S% ML!2IC(N^F#>TV^N3CC9YIN>^(Y2?+#+> 0J_P0UY<=\$\V)3%#M^T^~ U!+ M_P04 " .@_U9+, M-HJ^&[3M) 4,B^E^X!.[GGV>4^*YIOQ4*~_9)O% M=G#%V5HJ^N5@G\$^W!S0^JTL3>N&^AKT!=\2 MH:.130]2;5(T9L-B;,>.=GB7(4X%/[@^X!%Y)\$*06,E<7@ET=1\$JRS)080Y M^7 _BK)Q?NR;"M?42'.6UIG_X)N_KN\$5\$&! *G(A*).+Z@J&6K7U2_Ci4SH# 8&OFT2Q_>X/T[NVU]KA^E;(*2 M1&XAD5LKTQJ[H:8FYRG52Z_E^YN81?D^0<=?0_@)]<^HA\$5 M2X8- =0@+Q_#W\$[\$B.V-D\$[63M\$V?&ULO5AM;JLV\$XKA#8,+=!(FWY);,~)Z+;:B+H,46#,, ^ MT-+9)BJ)&DG;R;]^?F+^&P^S9G1@/ M^4I+&(\$[@>0J]CJEXO(&C;T8.=K8/OK^4ID^[GB8T@5\!_5G>B?TG5NBA^R M1#*;>('SD7.- KR:D;0RR?7QV,B;=V2HS8C_86Y^X^T>.9R**" E(^C^MX8) M1)%ITG^5X_ZI4[CN^N]1?^~2SOVA3K/4<%^RDXG%AK".(69+_IP]% (G8,B' \$@!0&9-^@?<2@17AD MF7/SR#):MU31\5#P#1)FM48S%UEN,FO-AB6FC-^5T&^9ME/CKUP!ZJ"/Z)X^* M01,EJTMT;5+,"U"- Z=PN^LDB^UR^_#ICD7DZB:B4;,X@K(S_F4(_&O7O@S MMH33+LO6SO_Z1_!N:\$23-[MEA1)?M^4Y1S\$ST#,AEZ/L= [P5N=14ER)5;,P,C1HT^*6(_S_N4G MW/5^M5#IE%0ZIU^Y@#;9EM/=1-<@] C14\+,(98L4^+~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~^?50Y%P,L4].GNH^01EQ^BU4BD-#35!?FTW^ 5!+ P04 M^ _@_U9QHCN4R0#""*P_&O^'AL+W=O]J\$34Q^*V ^V G^V\$ M\$%^V9?P";,=? W^L2YW35E\$SP&\$_.@I2PGO&;\$0RXY\^C"&#/,KN@0BG^QI MR^[^04]8P^9(C3COI2TW^LEIFAA-B]+MZ;<+Z79J+>

"\$P88CG68;9/Q!2NNX9 MMK%9N\$L6L5 +9K^[Q N8@KA?3IB\$(0)8C#O&0.[,VXKO 9\3V#- MM\9(93*C)%- /D<[PU(;@A1"H12P"%O!)-4"9 MRPO&-"T1Q*)N&=<&RB".X@ M2TCQCY_*.FP1I\$XSP2D)3IW@O4\!P2X)[; 20)'C'1O1+@D]=+7A0NPP/TN MHVO\$%][J]8&NOF;+>B5\$'60JF'R:2)[H?24"D(NT?@Q3I2S\$P%#1]T2,T MHIDT),? Z3,|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| ,73O\|>@<6X.]\&I [U" 7P\0P&7>#RT#L\$-2 X5.&J M!ER98%7>:-.98XFCd+,- XOJT8M,#\$U^#5A\$A5+\$. \G5+E\$X&7UG\$E" /J\$; M&K,"T#W>@D"G8Y"8Y +=PU:6.#]3\Q\NQNCTY S-2PZ(4'2?L5)@FHAS=/)J M'MI2&;.I\;@V8E@9X>TQHH=N&9690!..0-*GW;C@PZ\K1S2>,5[|JLK0ZR3\ M5M(+U'/D>=X?HL\HV[X+>8*[NZ%CP]7\|7)X>KM\G_W?WV3\ RH40>.! M\J@R?OX?OY5VBR5;E7P'H= @44B+VEY:Q188-IV&UY\$3VNO=V'7JZDQ\69' M(JNB;> 4A+@XTI1\@6)64EG\Y05IK.X@7US?K0\4 R/"/*3'FTZ)OR>93 M>A\92F#)\$# D.680\Y#1X\RPC=>.QW2[\$ZK#G\$_W> LK\$% V2R9;9LV2I#D0 MGE**&&QFQIU\&]D%H(CX\X4C;UPC-90UI5\5XV,R,RSU1)!!+!0%EG\|L(L M4TSR.? ZI2(TZIP(VKU_9HV+PZ?#\$5 ,: M*[Z89KSX1< MZ\;4K]:1.=5Q'NGDW %^VOD6E?(L1RW;3S=1%\I(;/6N#IY?"V\.' RQ\] MY^PG6KKUA'0+OM\$9OM WP+";>@3R!7C\J00J>T&[/PSBK78I\#FU>=1#W'NAAK-6W+ M+=.;H@XNB@KU*&>D144M4>- FU(EL7BV;UZ\DJF6,MPG82=57P)\LW\B.>Z, + M>%4]\$=Y>E2D1_GG\!P1K ?U. 3^EL5H\T-V6 91[E&I!:5.PDZNO@KZNC>_K M\$NIAMN I&NIA8\2516Q\ZMIG5;R15;S15/\$#5?M)\@I8\+/?D,1Q\$&N.,7ZEJ M1G\|0+X&|G>;H)V?T? 04=DBP8DBPA%=%!7J4;.M5V3TW; 3:6WK MVP>3U2GN0R#W, DP+BNIJVBZ.?H*."A;."A;."A;-!3;J;V-[V%P%=-UEO MDVUM\^T;X>@+4S?RH0M8;V%TA;G3\1* 1NG##FP;7\$>Q%&L%I3R^Z\NK<^< M\HJ3EC?"] LVL%OZ0W5&59Q\]?*O#[@>,- NFA*,-C*\$=>W+LF;EF5'9\$'1? MG&LJ1 T+RYW@&65J\!Y?T.I>&VH\!7)W?Q?4\$L#!!0 (Z \$5*Q*VL4(MHP(/'8' 9 >&PO=VJR:W- H965T#X\$>X09(5QA&G\;ZPZ;4A#W%AX >_JLM:6\54P\$4OENE\XIPY M)(.E71?26FR^0*)IB*OMDOV318SR\16FE1- F3,H&2\ M.GI@Y;!/333 ; M@M\EA*|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|@>O@.L>F"0")\$8!\ 7&/9+JC53L9T\& ;? 8%=?M^61J' M4T67\|E-|:(GU ML&+4#2,[84+

/J\J027F0;^V9W339-8ZAN.AG7 ?U-->]*7OY(MV@Y(^% M_CPWTY&V#Y7-;A7+^,+V%UEC %- OX^JT+,7RD^|3F3,W^8,3#OMTQ0MFA>)/ M)AN4RL0\$F"+(U.:3S8COQ0M\|JE"K\IID>&>.T?H^=^N\Y1)\JC8-&UJ_RVO M\HL=1]W7LFR_578->SW6\^RW;O+J&\$S&QV#R*&XJ=PPFDR,PV7VU;|W#3490 M_L93\Z09=0L+48\;M_-]I- IQAHY4PPM8MCN"KX9Y P:6\S+JW5KC MNXU7R/XZP7T7X5@;|4K\$9LIOM: ^<-&\$GBWVTL#S"P7<.>8!Q)\$@R\6037:|PCJQ/#Q\ _V%,214GB1P#S.X@B#(&G\$4 M-8?20\$3;8T.P6BP^0"X99K>J9\;G2 /UO MJ=26;D.:6C10\JS@9QX\5QV:VT\+^~MTD0CA;N=I+S\.)XS@G\X9\;%^|.O.\ MT/J9; NI\A.:|>YC&+UKR@J\|>< 57EMH4U,&I6<5V8SC-[9IS5\@X\?6M M<4&%BJZO=F--3>R?;>9\$UI\8\7P)/BKW5^O3LF+L&(AI""_1U%]+ 'E\$ "J"%\$ M(=YX/HIZ\$;%K_?I5& &FE;RQHR6%1T_RYJT=X'HQ-)<"^+IA)7H-WVFG5DEN2RL4M\8#/\$, SP(i@!X2ZVP%=_4< OWU%T_>I#G M".1Y, @, (&8,R4D^7Z\J5)O"86B">A\7B"0%P\$@ ^P#YI W6?2,3G\2PVMT+ M #8 L/M?)=C%QT*5TK%3;JPA8\$T4TP4G<[KEK9AA*DDZ=DD=-P9P=[HHA*MZ M-Q\;U\HG6E;&9))T;.)LB+GALP-S6\$ "0VZJ+V_%:UR? \$7-)TK%,9F*E\!2E MU1R',5U6 5R1*51L)MH9QVR2=*P3M\("VG)=@/DE"" ,50*6QC8E9)0FC%+X;D ME\;>DML\B/FE"2U4_95\5T^S"9")T87-(0)*CA:24=,T\;WCQC\JB0ELSYUOF8F\|2\$/II84)\K2V+3=W5Q\0L M(9>U.P\X3OPHYEA%LK"+G";*2^ICXE9*MF(0 SE,R<9L\JDO>MM#|13LU 6 MPD)_K\SV.? 4QT9VT\$!8Z.\$/RRWN&62@+8:&#F'YYS +9;6%XMV&=,Z7,,G* M'^ 1%MH9E6QJ2/73K)W\@VKVNBREO.(V1_5-TWRWO[W;F\ ^ U\+ P04 M" .@ U92XJ@ "W,!\ !P%0 &@ 'AL+UJR96QS+W=O'VC<(B?%\$7W2#/\ M*G'BC-J-'D7>? KDR"]>F\J6U\U\B\U>9YC\]G5F"28Y9=W%A9^R\]&|J.UQH\UDVR>&T,IWAL,;&#F(XOA\ D\$2/V@.0?/X M00L(6L0/6D+0,G\0'H)6\8\$+2. [2\H\$W\(\$I1QE1\T@1K\5H3C\JS0KT9M2;%>C- MDY\MI7HSZLT\&;4FQ7HS:@W*)";46\6H#>CWJQ/T;J68'>C'JS KT%118% M>@OJ+0KT%M1%;.@MD\,2\7H+ZBT*];46\ZIMP^/TOFQY\G&_)=>C?=>/V MP_Y<_)!#3A;.&#=_P)02P,\$ % @ #H -6=|A)QN2 0 ^14 !, !; M0V\N=&5N=%\J4>7IE&ULS9C;L(P\$(1?)^@)ML MB\$426\AV9UPH_4BD8@*G4NL1+OSHR\TG?(Y'UKR\$6;NFK<-"ZJ- X^>N:RD M6KI&VK"3J%M+7UXM0MF9+;4"V)B-!JS3#>>&C_TK48\FSQ3(5>5CUXVX;-3 MNIG&EBH71T^|PM9K&DMC*15");9NLE N SW#DGH\&I\JKK0DCAC2>;N)\U ME>Q\$! W./MPP\9\|.O\|.IL\|P5,ZM-BY,S-+E=H>1M-U#\$X3(>M5_Q*-CD+|Z M?-1..Z?|3.IPO9_+KMY_-8MU\ _Q\QD?|2_ ,(4\RI" Y;D\RW(+D&(DN /) M<0^2XP\$D\Q^A\;\$A*D=1*D=A*D>|*D>A*D?|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end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {} ;Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e.nodeName!='TABLE'){var ref=((window)? w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e.e.style.display='block';Show.LastAR=e;Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerHTML=p+a.innerHTML.substring(1)}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */.report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }.report table.authRefData a { display: block; font-weight: bold; }.report table.authRefData p { margin-top: 0px; }.report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }.report table.authRefData .hide a: hover { background-color: #2F4497; }.report table.authRefData .body { height: 150px; overflow: auto; width: 400px; }.report table.authRefData table{ font-size: 1em; } /* Report Styles */.pl a. visited { color: black; text-decoration: none; } /* table */.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; }.report hr { border: 1px solid #acf; }.report th { background-color: #acf; color: black; font-weight: bold; text-align: center; }.report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; }.report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; } /* word-wrap: break-word; */.report td.pl a a { cursor: pointer; display: block; width: 200px; overflow: hidden; }.report td.pl div.a { width: 200px; }.report td.pl

a: hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /*
Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .rou { background-color: #def; }
.report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report
.rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles
for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align:
right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text
types */ .report .text { text-align: left; white-space: normal; } .report .text.big { margin-bottom: 1em; width: 17em; } .report .text
.more { display: none; } .report .text.note { font-style: italic; font-weight: bold; } .report .text.small { width: 10em; } .report sup {
font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html
125 181 1 false 26 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet
<http://www.moleculin.com/20240630/role/statement-document-and-entity-information-document-and-entity-information-cover-1>
false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet
<http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited> Condensed
Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet
[http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-](http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals)
parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false
R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet
<http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss>
unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false
R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet
<http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited> Condensed
Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated
Statements of Stockholders' Equity (Unaudited) Sheet [http://www.moleculin.com/20240630/role/statement-condensed-](http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited)
consolidated-statements-of-stockholders-equity-unaudited Condensed Consolidated Statements of Stockholders' Equity
(Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Business Sheet
<http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business> Note 1 - Nature of Business Notes 7 false false
R8.htm 007 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and
Liquidity Sheet [http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-](http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity)
significant-accounting-policies-and-liquidity- Note 2 - Basis of Presentation, Principles of Consolidation, and Significant
Accounting Policies and Liquidity Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Accrued Expenses and Other Current
Liabilities Sheet <http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities> Note 3
- Accrued Expenses and Other Current Liabilities Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Warrants Sheet
<http://www.moleculin.com/20240630/role/statement-note-4-warrants> Note 4 - Warrants Notes 10 false false R11.htm 010 -
Disclosure - Note 5 - Equity Sheet <http://www.moleculin.com/20240630/role/statement-note-5-equity> Note 5 - Equity Notes 11 false
false R12.htm 011 - Disclosure - Note 6 - Income Taxes Sheet [http://www.moleculin.com/20240630/role/statement-note-6-income-](http://www.moleculin.com/20240630/role/statement-note-6-income-taxes)
taxes Note 6 - Income Taxes Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Commitments and Contingencies Sheet
<http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies> Note 7 - Commitments and
Contingencies Notes 13 false false R14.htm 995445 - Disclosure - Insider Trading Arrangements Sheet
<http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements> Insider Trading Arrangements Notes 14 false false R15.htm 995459 -
Disclosure - Significant Accounting Policies (Policies) Sheet [http://www.moleculin.com/20240630/role/statement-significant-](http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies)
accounting-policies-policies Significant Accounting Policies (Policies) Policies
[http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-](http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity)
accounting-policies-and-liquidity- 15 false false R16.htm 995460 - Disclosure - Note 2 - Basis of Presentation, Principles of
Consolidation, and Significant Accounting Policies and Liquidity (Tables) Sheet
[http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-](http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables)
accounting-policies-and-liquidity-tables Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting
Policies and Liquidity (Tables) Tables [http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-](http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity)
of-consolidation-and-significant-accounting-policies-and-liquidity- 16 false false R17.htm 995461 - Disclosure - Note 3 - Accrued
Expenses and Other Current Liabilities (Tables) Sheet [http://www.moleculin.com/20240630/role/statement-note-3-accrued-](http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-tables)
expenses-and-other-current-liabilities-tables Note 3 - Accrued Expenses and Other Current Liabilities (Tables) Tables
<http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities> 17 false false R18.htm
995462 - Disclosure - Note 4 - Warrants (Tables) Sheet <http://www.moleculin.com/20240630/role/statement-note-4-warrants-tables>
Note 4 - Warrants (Tables) Tables <http://www.moleculin.com/20240630/role/statement-note-4-warrants> 18 false false R19.htm
995463 - Disclosure - Note 5 - Equity (Tables) Sheet <http://www.moleculin.com/20240630/role/statement-note-5-equity-tables> Note
5 - Equity (Tables) Tables <http://www.moleculin.com/20240630/role/statement-note-5-equity> 19 false false R20.htm 995464 -
Disclosure - Note 7 - Commitments and Contingencies (Tables) Sheet [http://www.moleculin.com/20240630/role/statement-note-7-](http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-tables)
commitments-and-contingencies-tables Note 7 - Commitments and Contingencies (Tables) Tables
<http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies> 20 false false R21.htm 995465 -
Disclosure - Note 1 - Nature of Business (Details Textual) Sheet [http://www.moleculin.com/20240630/role/statement-note-1-](http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual)
nature-of-business-details-textual Note 1 - Nature of Business (Details Textual) Details
<http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business> 21 false false R22.htm 995466 - Disclosure - Note 2
- Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity (Details Textual) Sheet
[http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-](http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual)
accounting-policies-and-liquidity-details-textual Note 2 - Basis of Presentation, Principles of Consolidation, and Significant
Accounting Policies and Liquidity (Details Textual) Details [http://www.moleculin.com/20240630/role/statement-note-2-basis-of-](http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables)
presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables 22 false false R23.htm 995467 -
Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity -
Prepaid Expenses and Other Current Assets (Details) Sheet [http://www.moleculin.com/20240630/role/statement-note-2-basis-of-](http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details)
presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-
assets-details Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity -
Prepaid Expenses and Other Current Assets (Details) Details 23 false false R24.htm 995468 - Disclosure - Note 2 - Basis of
Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Schedule of Fair Value
Measurements, Recurring and Nonrecurring (Details) Sheet [http://www.moleculin.com/20240630/role/statement-note-2-basis-of-](http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details)
presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-
recurring-and-nonrecurring-details Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting
Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) Details 24 false false
R25.htm 995469 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities (Details Textual) Sheet
<http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual> Note 3 -
Accrued Expenses and Other Current Liabilities (Details Textual) Details [http://www.moleculin.com/20240630/role/statement-](http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-tables)
note-3-accrued-expenses-and-other-current-liabilities-tables 25 false false R26.htm 995470 - Disclosure - Note 3 - Accrued
Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) Sheet
[http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-](http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details)
other-current-liabilities-details Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current
Liabilities (Details) Details 26 false false R27.htm 995471 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities -
Accrued Expenses and Other Current Liabilities (Details) (Parentheticals) Sheet
[http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-](http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and)

other-current-liabilities-details-parentheticals Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) (Parentheticals) Details 27 false false R28.htm 995472 - Disclosure - Note 4 - Warrants (Details Textual) Sheet <http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual> Note 4 - Warrants (Details Textual) Details <http://www.moleculin.com/20240630/role/statement-note-4-warrants-tables> 28 false false R29.htm 995473 - Disclosure - Note 4 - Warrants - Assumptions Used (Details) Sheet <http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details> Note 4 - Warrants - Assumptions Used (Details) Details 29 false false R30.htm 995474 - Disclosure - Note 4 - Warrants - Warrant Activity (Details) Sheet <http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details> Note 4 - Warrants - Warrant Activity (Details) Details 30 false false R31.htm 995475 - Disclosure - Note 5 - Equity (Details Textual) Sheet <http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual> Note 5 - Equity (Details Textual) Details <http://www.moleculin.com/20240630/role/statement-note-5-equity-tables> 31 false false R32.htm 995476 - Disclosure - Note 5 - Equity - Stock based Compensation (Details) Sheet <http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details> Note 5 - Equity - Stock based Compensation (Details) Details 32 false false R33.htm 995477 - Disclosure - Note 6 - Income Taxes (Details Textual) Sheet <http://www.moleculin.com/20240630/role/statement-note-6-income-taxes-details-textual> Note 6 - Income Taxes (Details Textual) Details <http://www.moleculin.com/20240630/role/statement-note-6-income-taxes> 33 false false R34.htm 995478 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) Sheet <http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-tables> 34 false false R35.htm 995479 - Disclosure - Note 7 - Commitments and Contingencies - Lease Cost (Details) Sheet <http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details> Note 7 - Commitments and Contingencies - Lease Cost (Details) Details 35 false false All Reports Book All Reports mbrx-20240630.xsd mbrx-20240630_cal.xml mbrx-20240630_def.xml mbrx-20240630_lab.xml mbrx-20240630_pre.xml mbrx20240630_10q.htm moleculinnewlogoresized.jpg <http://fasb.org/us-gaap/2024> <http://xbrl.sec.gov/dei/2024> <http://xbrl.sec.gov/ecd/2024> true true JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mbrx20240630_10q.htm": { "nsprefix": "mbrx", "nsuri": "http://www.moleculin.com/20240630", "dts": { "schema": { "local": ["mbrx-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["mbrx-20240630_cal.xml"] }, "definitionLink": { "local": ["mbrx-20240630_def.xml"] }, "labelLink": { "local": ["mbrx-20240630_lab.xml"] }, "presentationLink": { "local": ["mbrx-20240630_pre.xml"] }, "inline": { "local": ["mbrx20240630_10q.htm"] } }, "keyStandard": 148, "keyCustom": 33, "axisStandard": 13, "axisCustom": 0, "memberStandard": 17, "memberCustom": 9, "hidden": { "total": 40, "http://fasb.org/us-gaap/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4, "http://xbrl.sec.gov/dei/2024": 6, "http://www.moleculin.com/20240630": 1 }, "contextCount": 125, "entityCount": 1, "segmentCount": 26, "elementCount": 277, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 413, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.moleculin.com/20240630/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "R2": { "role": "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "R3": { "role": "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null, "R4": { "role": "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "R5": { "role": "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "R6": { "role": "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "longName": "005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"] } } }

[, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "unique": true } }, "R7": { "role": "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "longName": "006 - Disclosure - Note 1 - Nature of Business", "shortName": "Note 1 - Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "longName": "007 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity", "shortName": "Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities", "longName": "008 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities", "shortName": "Note 3 - Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.moleculin.com/20240630/role/statement-note-4-warrants", "longName": "009 - Disclosure - Note 4 - Warrants", "shortName": "Note 4 - Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "mbrx:WarrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "mbrx:WarrantsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.moleculin.com/20240630/role/statement-note-5-equity", "longName": "010 - Disclosure - Note 5 - Equity", "shortName": "Note 5 - Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes", "longName": "011 - Disclosure - Note 6 - Income Taxes", "shortName": "Note 6 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "longName": "012 - Disclosure - Note 7 - Commitments and Contingencies", "shortName": "Note 7 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies", "longName": "995459 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "mbrx:ReverseStockSplitPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "mbrx:ReverseStockSplitPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables", "longName": "995460 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity (Tables)", "shortName": "Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["mbrx:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["mbrx:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first":

true, "unique": true } }, "R17": { "role": "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-tables", "longName": "995461 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Note 3 - Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.moleculin.com/20240630/role/statement-note-4-warrants-tables", "longName": "995462 - Disclosure - Note 4 - Warrants (Tables)", "shortName": "Note 4 - Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "mbrx:ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["mbrx:WarrantsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "mbrx:ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["mbrx:WarrantsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.moleculin.com/20240630/role/statement-note-5-equity-tables", "longName": "995463 - Disclosure - Note 5 - Equity (Tables)", "shortName": "Note 5 - Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-tables", "longName": "995464 - Disclosure - Note 7 - Commitments and Contingencies (Tables)", "shortName": "Note 7 - Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual", "longName": "995465 - Disclosure - Note 1 - Nature of Business (Details Textual)", "shortName": "Note 1 - Nature of Business (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "i_2023-05-05", "name": "mbrx:NASDAQComplianceMinimumClosingBidPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:NatureOfOperations", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-05-05", "name": "mbrx:NASDAQComplianceMinimumClosingBidPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:NatureOfOperations", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual", "longName": "995466 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity (Details Textual)", "shortName": "Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details", "longName": "995467 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "mbrx:PrepaidSponsoredResearchCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "mbrx:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "mbrx:PrepaidSponsoredResearchCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "mbrx:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "longName": "995468 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)", "shortName": "Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "i_2024-03-31_FairValueByLiabilityClassAxis-WarrantLiabilityLongTermMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-03-31_FairValueByLiabilityClassAxis-WarrantLiabilityLongTermMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "ix:continuation", "us-

gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "R25": { "role": "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual", "longName": "995469 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities (Details Textual)", "shortName": "Note 3 - Accrued Expenses and Other Current Liabilities (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "unique": true }, "R26": { "role": "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details", "longName": "995470 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "R27": { "role": "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals", "longName": "995471 - Disclosure - Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) (Parentheticals)", "shortName": "Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "longName": "995472 - Disclosure - Note 4 - Warrants (Details Textual)", "shortName": "Note 4 - Warrants (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-03-31_ClassOfWarrantOrRightAxis-EquityClassifiedWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "mbrx:WarrantsDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "unique": true }, "R29": { "role": "http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details", "longName": "995473 - Disclosure - Note 4 - Warrants - Assumptions Used (Details)", "shortName": "Note 4 - Warrants - Assumptions Used (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i_2024-06-30_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "tbody", "table", "mbrx:ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "mbrx:WarrantsDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "tbody", "table", "mbrx:ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "mbrx:WarrantsDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "R30": { "role": "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details", "longName": "995474 - Disclosure - Note 4 - Warrants - Warrant Activity (Details)", "shortName": "Note 4 - Warrants - Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "i_2023-12-31_ClassOfWarrantOrRightAxis-LiabilityClassifiedWarrantsMember", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "mbrx:ScheduleOfWarrantActivityTableTextBlock", "mbrx:WarrantsDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-06-30_ClassOfWarrantOrRightAxis-LiabilityClassifiedWarrantsMember", "name": "mbrx:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "mbrx:ScheduleOfWarrantActivityTableTextBlock", "mbrx:WarrantsDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "unique": true }, "R31": { "role": "http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual", "longName": "995475 - Disclosure - Note 5 - Equity (Details Textual)", "shortName": "Note 5 - Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "d_2024-01-01_2024-03-31", "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-03-31", "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "R32": { "role": "http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details", "longName": "995476 - Disclosure - Note 5 - Equity - Stock based Compensation (Details)", "shortName": "Note 5 - Equity - Stock based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"] }, "reportCount": 1, "baseRef": "mbrx20240630_10q.htm",

"unique": true } }, "R33": { "role": "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes-details-textual", "longName": "995477 - Disclosure - Note 6 - Income Taxes (Details Textual)", "shortName": "Note 6 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual", "longName": "995478 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)", "shortName": "Note 7 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "i_2023-09-30", "name": "mbrx:OperatingLeaseMonthlyRentPayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-09-30", "name": "mbrx:OperatingLeaseMonthlyRentPayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details", "longName": "995479 - Disclosure - Note 7 - Commitments and Contingencies - Lease Cost (Details)", "shortName": "Note 7 - Commitments and Contingencies - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-04-01_2024-06-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mbrx20240630_10q.htm", "first": true, "unique": true } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": ["r201"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "Accounts payable", "terseLabel": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r27", "r432"] }, "mbrx_AccruedLegalRegulatoryProfessionalAndOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "AccruedLegalRegulatoryProfessionalAndOtherCurrent", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued legal, regulatory, professional and other", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for legal, regulatory, professional and other costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details"], "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parenteticals"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r29"] }, "mbrx_AccruedResearchAndDevelopmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "AccruedResearchAndDevelopmentCurrent", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued research and development", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r9", "r12", "r231", "r234", "r278", "r316", "r317", "r460", "r461", "r462", "r465", "r466", "r467", "r468"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in

excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r37"] }, "us-gaap.AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r326", "r465", "r466", "r467", "r468", "r515", "r537"] }, "us-gaap.AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r23", "r24", "r194"] }, "us-gaap.AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap.AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r198", "r199"] }, "dei.AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "mbrx.AnimalLifeSciencesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "AnimalLifeSciencesIncMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "Animal Life Sciences, Inc [Member]", "documentation": "Represents Animal Life Sciences, Inc." } } }, "auth_ref": [] }, "us-gaap.AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap.AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r122"] }, "us-gaap.AociBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociBeforeTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap.StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, attributable to parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners)." } } }, "auth_ref": [] }, "us-gaap.AssetAcquisitionContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals"], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current." } } }, "auth_ref": ["r514"] }, "us-gaap.Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap.Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r56", "r63", "r78", "r96", "r125", "r127", "r133", "r134", "r142", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r226", "r228", "r256", "r296", "r352", "r404", "r405", "r432", "r444", "r481", "r482", "r526"] }, "us-gaap.AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap.Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap.AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r75", "r79", "r96", "r142", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r226", "r228", "r256", "r432", "r481", "r482", "r526"] }, "us-gaap.AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap.BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap.Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap.Cash", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r65", "r299", "r327", "r347", "r432", "r444", "r457"] }, "us-gaap.CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap.AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [

"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r14", "r77", "r395"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r15"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodStartLabel": "Cash and cash equivalents, - beginning of period", "periodEndLabel": "Cash and cash equivalents, - end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r14", "r46", "r93"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r46"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r21"] }, "mbrx_ClassOfWarrantOrRightCancelledDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "ClassOfWarrantOrRightCancelledDuringPeriod", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "mbrx_ClassOfWarrantOrRightCancelledDuringPeriod", "negatedLabel": "Expired warrants (in shares)", "documentation": "The number of warrants or rights cancelled during period." } } }, "auth_ref": [] }, "mbrx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "Expired warrants (in dollars per share)", "documentation": "Exercise price per share of warrants or rights cancelled during period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "periodStartLabel": "Balance, warrant exercise price (in dollars per share)", "periodEndLabel": "Balance, warrant exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r183"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r183"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "mbrx_ClassOfWarrantOrRightVestedAndExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "ClassOfWarrantOrRightVestedAndExercisable", "presentation": [

"http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual",
"http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": {
"label": "Exercisable (in shares)", "terseLabel": "Class of Warrant or Right, Vested and Exercisable (in shares)", "documentation":
"Number of warrants or rights vested and exercisable." } } }, "auth_ref": [] },
"mbrx_ClassOfWarrantOrRightVestedAndExercisableExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://www.moleculin.com/20240630", "localname": "ClassOfWarrantOrRightVestedAndExercisableExercisePrice", "presentation":
["http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": {
"label": "Exercisable, warrant exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of
warrants or rights vested and exercisable." } } }, "auth_ref": [] },
"mbrx_ClassOfWarrantOrRightVestedAndExercisableWeightedAverageRemainingContractualLife": { "xbrltype":
"durationItemType", "nsuri": "http://www.moleculin.com/20240630", "localname":
"ClassOfWarrantOrRightVestedAndExercisableWeightedAverageRemainingContractualLife", "presentation": [
"http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": {
"label": "Exercisable, weighted average remaining contractual life (Year)", "documentation": "The weighted average remaining
contractual life of warrants or rights vested and exercisable." } } }, "auth_ref": [] },
"mbrx_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri":
"http://www.moleculin.com/20240630", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife",
"presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-
us": { "role": { "label": "Balance, weighted average remaining contractual life (Year)", "documentation": "The weighted average
remaining contractual life of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr":
"credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-
period-unaudited"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 7)", "documentation":
"Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply
arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential
losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under
contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future
events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r33", "r57", "r298", "r338"] }, "us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies"], "lang": { "en-us": { "role": {
"label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and
contingencies." } } }, "auth_ref": ["r51", "r152", "r153", "r391", "r478", "r480"] },
"mbrx_CommonStockIssuedForLicenceRightsUnderLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.moleculin.com/20240630", "localname": "CommonStockIssuedForLicenceRightsUnderLicenseAgreement", "crdr":
"debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-
unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } },
"presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-
unaudited"], "lang": { "en-us": { "role": { "label": "License rights expense settled in stock", "documentation": "The amount of
common stock issued for license rights under license agreement." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"],
"lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of
the issuer." } } }, "auth_ref": ["r434", "r435", "r436", "r438", "r439", "r440", "r441", "r465", "r466", "r468", "r515", "r536", "r537"
] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-
parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, par or stated value per share (in dollars per share)",
"documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r36"] }, "us-
gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesAuthorized", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-
consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock,
shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's
charter and bylaws." } } }, "auth_ref": ["r36", "r339"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-
parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total
number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued,
repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may
be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the
treasury." } } }, "auth_ref": ["r36"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-
parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation":
"Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } },
"auth_ref": ["r10", "r36", "r339", "r358", "r537", "r538"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": {
"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {
"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang":
{ "en-us": { "role": { "label": "Common stock, \$0.001 par value; 100,000,000 shares authorized; 2,560,785 and 2,227,516 shares
issued and outstanding at June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value
of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes
treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other
disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r36", "r301", "r432"] }, "us-
gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-
condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-
statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-
gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase
(decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income,
attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } },
"auth_ref": ["r13", "r82", "r84", "r89", "r291", "r308", "r309"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [
"http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": {
"label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles

it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r25", "r400"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r100", "r101", "r167", "r172", "r282", "r288", "r295", "r397", "r399"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 }, "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r6", "r125", "r130", "r134", "r404", "r405"] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Warrant liability - long-term", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r80"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities", "http://www.moleculin.com/20240630/role/statement-note-4-warrants", "http://www.moleculin.com/20240630/role/statement-note-5-equity", "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r448"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r449"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-

unaudited"], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic and diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r90", "r107", "r108", "r109", "r110", "r111", "r112", "r116", "r117", "r119", "r120", "r121", "r124", "r222", "r225", "r238", "r239", "r292", "r310", "r401"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r16", "r17", "r123"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r257"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-6-income-taxes-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r205", "r416"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details"], "lang": { "en-us": { "role": { "label": "Accrued payroll and bonuses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r29"] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r446"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20240630/role/statement-document-and-entity-information", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-

liabilities-accrued-expenses-and-other-current-liabilities-details", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-tables", "http://www.moleculin.com/20240630/role/statement-note-4-warrants", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-tables", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details", "http://www.moleculin.com/20240630/role/statement-note-5-equity", "http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual", "http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details", "http://www.moleculin.com/20240630/role/statement-note-5-equity-tables", "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes", "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes-details-textual", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-tables", "http://www.moleculin.com/20240630/role/statement-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r446"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r446"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r452"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r446"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r446"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r446"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r446"] }, "mbxr_EquityClassifiedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "EquityClassifiedWarrantsMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "Equity Classified Warrants [Member]", "documentation": "Represents equity classified warrants." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r10", "r73", "r85", "r86", "r87", "r102", "r103", "r104", "r106", "r111", "r113", "r115", "r126", "r143", "r144", "r148", "r184", "r211", "r212", "r219", "r220", "r221", "r223", "r224", "r225", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r278", "r307", "r316", "r317", "r318", "r326", "r378"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": ["r139", "r140", "r141", "r218", "r453", "r454", "r455", "r510", "r511", "r512", "r513"] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EquityMethodInvestmentOwnershipPercentage", "terseLabel": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": ["r139"] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [

"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited",
 "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability", "negatedLabel": "Gain from change in fair value of warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r6"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables"], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": ["r417", "r516", "r517", "r521"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r168", "r186", "r187", "r188", "r189", "r190", "r191", "r240", "r242", "r243", "r244", "r245", "r252", "r253", "r255", "r283", "r284", "r285", "r408", "r409", "r411", "r412", "r413", "r417", "r419"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r246", "r247", "r248", "r249", "r250", "r251", "r254"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r241", "r242", "r243", "r245", "r417", "r519", "r522"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r168", "r186", "r191", "r242", "r253", "r283", "r411", "r412", "r413", "r417"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r168", "r186", "r191", "r242", "r243", "r253", "r284", "r408", "r409", "r411", "r412", "r413", "r417"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r168", "r186", "r187", "r188", "r189", "r190", "r191", "r242", "r243", "r244", "r245", "r253", "r285", "r408", "r409", "r411", "r412", "r413", "r417", "r419"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r246", "r247", "r248", "r249", "r250", "r251", "r254"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r241", "r242", "r243", "r245", "r417", "r519", "r522"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Change in fair value - net", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r247", "r254"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r246", "r254"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r168", "r186", "r187", "r188", "r189", "r190", "r191", "r240", "r242", "r243", "r244", "r245", "r252", "r253", "r255", "r283", "r284", "r285", "r408", "r409", "r411", "r412", "r413", "r417", "r419"] }, "us-

gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r417", "r516", "r517", "r518", "r519", "r520", "r522"] }, "us-gaap_FairValueOffFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOffFinancialInstrumentsPolicy", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r8"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r43", "r362"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r43"] }, "mbrx_GoingConcernPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "GoingConcernPolicyPolicyTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Going Concern Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for going concern." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": ["r145", "r146", "r147"] }, "mbrx_HoustonPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "HoustonPharmaceuticalsIncMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Houston Pharmaceuticals, Inc [Member]", "documentation": "Represents Houston Pharmaceuticals, Inc." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r149", "r150", "r151", "r247", "r251", "r254", "r313", "r315", "r363", "r394", "r418", "r535"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r150", "r151", "r247", "r251", "r254", "r313", "r315", "r363", "r394", "r418", "r535"] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-6-income-taxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r97", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r213", "r215", "r216", "r217", "r325", "r416"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-6-income-taxes-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "terseLabel": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r64", "r71", "r114", "r115", "r125", "r131", "r134", "r204", "r205", "r214", "r311", "r416"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses and other current liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-

unaudited"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedTerseLabel": "Prepaid expenses and other current assets", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r5"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r450"] }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Intangible assets", "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets." } } }, "auth_ref": ["r477"] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Interest income, net", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r404", "r463", "r471"] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r270", "r423"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-tables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r524"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20240630/role/statement-document-and-entity-information", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-tables", "http://www.moleculin.com/20240630/role/statement-note-4-warrants", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-tables", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details", "http://www.moleculin.com/20240630/role/statement-note-5-equity", "http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual", "http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details", "http://www.moleculin.com/20240630/role/statement-note-5-equity-tables", "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes", "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes-details-textual", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-tables", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LegalFees", "terseLabel": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": ["r456"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r11", "r28", "r29", "r30", "r31", "r32", "r33", "r34", "r96", "r142", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r227", "r228", "r229", "r256", "r337", "r402", "r444", "r481", "r526", "r527"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": [

"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r41", "r58", "r303", "r432", "r464", "r475", "r523"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r30", "r76", "r96", "r142", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r227", "r228", "r229", "r256", "r432", "r481", "r526", "r527"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Fair value of warrant liability", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r242", "r516"] }, "mbrx_LiabilityClassifiedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "LiabilityClassifiedWarrantsMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "Liability Classified Warrants [Member]", "documentation": "Represents liability classified warrants." } } }, "auth_ref": [] }, "mbrx_LicenseAgreementsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "LicenseAgreementsExpense", "crdr": "debit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "mbrx_LicenseAgreementsExpense", "terseLabel": "License Agreements Expense", "documentation": "The amount of expense for licensing agreements." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "mbrx_MDAndersonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "MDAndersonMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "MD Anderson [Member]", "documentation": "Represents MD Anderson." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r154", "r155", "r156", "r157", "r193", "r200", "r245", "r289", "r312", "r314", "r321", "r329", "r330", "r384", "r385", "r386", "r387", "r388", "r392", "r393", "r406", "r410", "r414", "r419", "r420", "r421", "r422", "r433", "r483", "r528", "r529", "r530", "r531", "r532", "r533"] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r518", "r519", "r520"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r419", "r518", "r519", "r520"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details"], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r518", "r519", "r520"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r243", "r244", "r245", "r419"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r243", "r244", "r245", "r419"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r154", "r155", "r156", "r157", "r193", "r200", "r245", "r289", "r312", "r314", "r321", "r329", "r330", "r384", "r385", "r386", "r387", "r388", "r392", "r393", "r406", "r410", "r414", "r419", "r420", "r421", "r433", "r483", "r528", "r529", "r530", "r531", "r532", "r533"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r451"] }, "mbrx_NASDAQComplianceExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "NASDAQComplianceExtensionPeriod", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "mbrx_NASDAQComplianceExtensionPeriod", "terseLabel": "NASDAQ Compliance, Extension Period (Day)", "documentation": "Information pertaining to the extension period granted." } } }, "auth_ref": [] }, "mbrx_NASDAQComplianceMinimumClosingBidPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "NASDAQComplianceMinimumClosingBidPricePerShare", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "mbrx_NASDAQComplianceMinimumClosingBidPricePerShare", "terseLabel": "NASDAQ Compliance, Minimum Closing Bid Price Per Share (in dollars per share)", "documentation": "Information pertaining to Nasdaq Global minimum bid price requirement." } } }, "auth_ref": [] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or

services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r66", "r72"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r92"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r92"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r46", "r47", "r48"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r42", "r48", "r59", "r74", "r81", "r83", "r87", "r96", "r105", "r107", "r108", "r109", "r110", "r111", "r114", "r115", "r118", "r142", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r222", "r225", "r239", "r256", "r306", "r360", "r376", "r377", "r442", "r481"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r451"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r451"] }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual"], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]", "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": ["r276", "r277", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431"] }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonmonetaryTransactionTypeDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual",

"http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual"], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Domain]", "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": ["r276", "r277", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Other income:" } } }, "auth_ref": [] }, "us-gaap_NontradeReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NontradeReceivablesCurrent", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Non-trade receivables", "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r458"] }, "mbrx_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "mbrx_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "mbrx_NumberOfCoreDrugTechnologies": { "xbrltype": "integerItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "NumberOfCoreDrugTechnologies", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "mbrx_NumberOfCoreDrugTechnologies", "terseLabel": "Number of Core Drug Technologies", "documentation": "The number of core drug technologies." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r405", "r470"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r62", "r403", "r469", "r471", "r472", "r473", "r474"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r271", "r423"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details"], "lang": { "en-us": { "role": { "label": "Operating lease liability - current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r267"] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": ["r268"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Operating lease liability - long-term, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r267"] }, "mbrx_OperatingLeaseMonthlyRentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "OperatingLeaseMonthlyRentPayment", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "mbrx_OperatingLeaseMonthlyRentPayment", "terseLabel": "Operating Lease, Monthly Rent Payment", "documentation": "Represents the amount of monthly rent payment on an operating lease." } } }, "auth_ref": [] }, "mbrx_OperatingLeaseNoncashExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630",

"localname": "OperatingLeaseNoncashExpenseNet", "crdr": "debit", "calculation": {
"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": {
"en-us": { "role": { "label": "Operating lease, net", "documentation": "The amount of noncash expense for operating lease, net." } }
}, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeasePayments", "terseLabel": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } },
"auth_ref": ["r269", "r274"] }, "mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "OperatingLeaseRentExpenseAnnualIncreaseInRentPercent", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "mbrx_OperatingLeaseRentExpenseAnnualIncreaseInRentPercent", "terseLabel": "Operating Lease, Rent Expense, Annual Increase In Rent, Percent", "documentation": "Represents percentage of annual increase in rent for operating lease rent expense." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r266"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation", "label": "Cumulative translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": ["r4", "r9", "r55"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r44"] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Payment of tax liability for vested restricted stock units", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r91"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of fixed assets", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r45"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity", "http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity", "http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PREFERREDStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r35", "r170"] }, "us-gaap_PREFERREDStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r35", "r339"] }, "us-gaap_PREFERREDStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "PreferredStockSharesIssued", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r35", "r170"] }, "us-gaap_PREFERREDSTOCKSHARESOUTSTANDING": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r35", "r339", "r358", "r537", "r538"] }, "us-gaap_PREFERREDSTOCKVALUE": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Preferred stock, \$0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r35", "r300", "r432"] }, "us-gaap_PREPAIDEXPENSEANDOTHERASSETSCURRENT": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r459"] }, "mbrx_PREPAIDEXPENSESANDOTHERCURRENTASSETSPOICYTEXTBLOCK": { "xbrltype": "textBlockItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Policy Text Block]", "documentation": "Disclosure of the accounting policy for prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_PREPAIDINSURANCE": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 }, "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r396", "r407", "r476"] }, "mbrx_PREPAIDSPONSOREDRESEARCHCURRENT": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "PrepaidSponsoredResearchCurrent", "crdr": "debit", "calculation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 }, "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Prepaid sponsored research", "documentation": "The amount of prepaid sponsored research classified as current." } } }, "auth_ref": [] }, "us-gaap_PROCEEDSFROMISSUANCEOFCOMMONSTOCK": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from sale of common stock, net of issuance costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r3"] }, "us-gaap_PROPERTYPLANTANDEQUIPMENTNET": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Furniture and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r7", "r275", "r294", "r305", "r432"] }, "srt_RANGEAXIS": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r154", "r155", "r156", "r157", "r185", "r193", "r195", "r196", "r197", "r200", "r245", "r286", "r287", "r289", "r312", "r314", "r321", "r329", "r330", "r384", "r385", "r386", "r387", "r388", "r392", "r393", "r406", "r410", "r414", "r419", "r420", "r421", "r422", "r433", "r436", "r479", "r483", "r519", "r529", "r530", "r531", "r532", "r533"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r154", "r155", "r156", "r157", "r185", "r193", "r195", "r196", "r197", "r200", "r245", "r286", "r287", "r289", "r312", "r314", "r321", "r329", "r330", "r384", "r385", "r386", "r387", "r388", "r392", "r393", "r406", "r410", "r414", "r419", "r420", "r421", "r422", "r433", "r436", "r479", "r483", "r519", "r529", "r530", "r531", "r532", "r533"] }, "us-gaap_RELATEDPARTYDOMAIN": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party

includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r138", "r192", "r279", "r280", "r297", "r304", "r332", "r333", "r334", "r335", "r336", "r357", "r359", "r383"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r98", "r99", "r279", "r280", "r281", "r282", "r297", "r304", "r332", "r333", "r334", "r335", "r336", "r357", "r359", "r383"] }, "mbrx_RelatedPartyReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "RelatedPartyReceivables", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Related party receivables", "documentation": "The amount of related party receivables." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r26", "r279"] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r138", "r192", "r279", "r280", "r297", "r304", "r332", "r333", "r334", "r335", "r336", "r357", "r359", "r383", "r525"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r100", "r101", "r167", "r172", "r282", "r288", "r295", "r398", "r399"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r202", "r394", "r404", "r534"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r38", "r53", "r302", "r319", "r320", "r324", "r340", "r432"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r73", "r102", "r103", "r104", "r106", "r111", "r113", "r115", "r143", "r144", "r148", "r211", "r212", "r219", "r220", "r221", "r223", "r224", "r225", "r230", "r232", "r233", "r235", "r237", "r264", "r265", "r316", "r318", "r326", "r537"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r60", "r61", "r88", "r96", "r125", "r128", "r129", "r132", "r134", "r135", "r136", "r137", "r142", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r256", "r293", "r404", "r481"] }, "mbrx_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "ReverseStockSplitMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual"], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "Related to the reverse stock split." } } }, "auth_ref": [] }, "mbrx_ReverseStockSplitPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.moleculin.com/20240630",

"localname": "ReverseStockSplitPolicyTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Policy Text Block]", "documentation": "Disclosure of the company's policy regarding reverse stock splits." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r451"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r451"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual"], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r139", "r140", "r141", "r218", "r453", "r454", "r455", "r510", "r511", "r512", "r513"] }, "mbxr_ScheduleOfWarrantActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "ScheduleOfWarrantActivityTableTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Warrant Activity [Table Text Block]", "documentation": "The tabular disclosure for warrant activity." } } }, "auth_ref": [] }, "mbxr_ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Warrants or Rights, Assumptions Used [Table Text Block]", "documentation": "The tabular disclosure for assumptions used for warrants or rights." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r445"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r447"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r415"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r22"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures (in shares)", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r491"] }, "mbxr_SharebasedPaymentArrangementExpensedAmountTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "SharebasedPaymentArrangementExpensedAmountTableTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity-tables"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [] }, "mbxr_SharebasedPaymentArrangementNonvestedAwardCostNotYetRecognizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "SharebasedPaymentArrangementNonvestedAwardCostNotYetRecognizedAmount", "crdr": "debit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "mbxr_SharebasedPaymentArrangementNonvestedAwardCostNotYetRecognizedAmount", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"],

"lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "mbrx_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Policy Text Block]", "documentation": "Disclosure of significant accounting policies of the reporting entity." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r49", "r94"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r36", "r39", "r40", "r73", "r85", "r86", "r87", "r102", "r103", "r104", "r106", "r111", "r113", "r115", "r126", "r143", "r144", "r148", "r184", "r211", "r212", "r219", "r220", "r221", "r223", "r224", "r225", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r278", "r307", "r316", "r317", "r318", "r326", "r378"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-tables", "http://www.moleculin.com/20240630/role/statement-note-4-warrants", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-tables", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details", "http://www.moleculin.com/20240630/role/statement-note-5-equity", "http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual", "http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details", "http://www.moleculin.com/20240630/role/statement-note-5-equity-tables", "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes", "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes-details-textual", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-tables", "http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r102", "r103", "r104", "r126", "r265", "r290", "r322", "r328", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r342", "r343", "r344", "r345", "r346", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r359", "r361", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r378", "r437"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-details-textual", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-tables",

"http://www.moleculin.com/20240630/role/statement-note-4-warrants", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual", "http://www.moleculin.com/20240630/role/statement-note-5-equity", "http://www.moleculin.com/20240630/role/statement-note-5-equity-stock-based-compensation-details", "http://www.moleculin.com/20240630/role/statement-note-6-income-taxes", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-tables", "http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r102", "r103", "r104", "r126", "r138", "r265", "r290", "r322", "r328", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r342", "r343", "r344", "r345", "r346", "r348", "r349", "r350", "r351", "r353", "r354", "r355", "r356", "r357", "r359", "r361", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r378", "r437"] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices", "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "mbrx_StockIssuedDuringPeriodSharesLicenseRights": { "xbrltype": "sharesItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "StockIssuedDuringPeriodSharesLicenseRights", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for license rights (in shares)", "documentation": "The number of shares of stock issued during the period for license rights." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with Consulting Agreements (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r35", "r36", "r53", "r323", "r378", "r389"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) (in shares)", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r10", "r35", "r36", "r53"] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Reverse stock split (in shares)", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r10"] }, "mbrx_StockIssuedDuringPeriodSharesWarrantExercises": { "xbrltype": "sharesItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "StockIssuedDuringPeriodSharesWarrantExercises", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Warrants exercised (in shares)", "documentation": "The number of shares of stock issued during the period for warrant exercises." } } }, "auth_ref": [] }, "mbrx_StockIssuedDuringPeriodValueLicenseRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "StockIssuedDuringPeriodValueLicenseRights", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued for license rights", "documentation": "The amount of stock issued during the period for license rights." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with Consulting Agreements", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r10", "r35", "r36", "r53", "r326", "r378", "r389", "r443"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability)", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r10", "r53"] }, "mbrx_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "The cost of reduction in shares during the period as a result of a reverse stock split." } } }, "auth_ref": [] }, "mbrx_StockIssuedDuringPeriodValueWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "StockIssuedDuringPeriodValueWarrantExercises", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "Warrants exercised", "documentation": "The amount of stock issued during the period for warrant exercises." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r36", "r39", "r40", "r50", "r341", "r358", "r379", "r380", "r432", "r444", "r464", "r475", "r523", "r537"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [

"http://www.moleculin.com/20240630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Stockholders' equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r52", "r95", "r169", "r171", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r236", "r381", "r382", "r390"] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r54"] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SubleaseIncome", "terseLabel": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": ["r273", "r423"] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20240630/role/statement-note-3-accrued-expenses-and-other-current-liabilities-tables", "http://www.moleculin.com/20240630/role/statement-note-4-warrants-tables", "http://www.moleculin.com/20240630/role/statement-note-5-equity-tables", "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "mbrx_The2015StockPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "The2015StockPlanMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-5-equity", "http://www.moleculin.com/20240630/role/statement-note-5-equity-details-textual"], "lang": { "en-us": { "role": { "label": "The 2015 Stock Plan [Member]", "documentation": "Represents the 2015 stock plan." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.moleculin.com/20240630/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.moleculin.com/20240630/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r18", "r19", "r20", "r67", "r68", "r69", "r70"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "parentTag": "http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-note-7-commitments-and-contingencies-lease-cost-details"], "lang": { "en-us": { "role": { "label": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r272", "r423"] }, "mbrx_VendorPrepaymentsAndDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "VendorPrepaymentsAndDeposits", "crdr": "debit", "calculation": { "parentTag": "http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details"], "lang": { "en-us": { "role": { "label": "Vendor prepayments and deposits", "documentation": "Amount of consideration and deposits paid in advance to vendors." } } }, "auth_ref": [] }, "mbrx_WarrantLiabilityLongTermMember": { "xbrltype": "domainItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "WarrantLiabilityLongTermMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Warrant Liability Long Term [Member]", "documentation": "Information pertaining the long term warrant liability." } } }, "auth_ref": [] }, "mbrx_WarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "WarrantLiabilityMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details"], "lang": { "en-us": { "role": { "label": "Warrant Liability [Member]", "documentation": "Represents warrant liability." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-assumptions-used-details"], "lang": { "en-us": { "role": { "label": "Warrants, assumptions", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": ["r518", "r519", "r520"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r518", "r519", "r520"] }, "mbrx_WarrantsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "WarrantsDisclosureTextBlock", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants"], "lang": { "en-us": { "role": { "label": "Warrants Disclosure [Text Block]", "documentation": "The entire disclosure for warrants." } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": ["http://www.moleculin.com/20240630/role/statement-note-4-warrants-warrant-activity-details"], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]" } } }, "auth_ref": ["r245", "r287", "r392", "r393", "r419", "r528", "r530", "r533"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.moleculin.com/20240630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding, basic and

(in shares) ", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r116", "r121"] } }, "mbrx_statement-statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-prepaid-expenses-and-other-current-assets-details", "lang": { "en-us": { "role": { "label": "Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Prepaid Expenses and Other Current Assets (Details)" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "lang": { "en-us": { "role": { "label": "Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-2-basis-of-presentation-principles-of-consolidation-and-significant-accounting-policies-and-liquidity-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Basis of Presentation, Principles of Consolidation, and Significant Accounting Policies and Liquidity" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 3 - Accrued Expenses and Other Current Liabilities (Details)" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-3-accrued-expenses-and-other-current-liabilities-accrued-expenses-and-other-current-liabilities-details-parentheticals", "lang": { "en-us": { "role": { "label": "Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) (Parentheticals)" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-3-accrued-expenses-and-other-current-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-3-accrued-expenses-and-other-current-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-4-warrants-assumptions-used-details": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-4-warrants-assumptions-used-details", "lang": { "en-us": { "role": { "label": "Note 4 - Warrants - Assumptions Used (Details)" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-4-warrants-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-4-warrants-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Warrants" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-4-warrants-warrant-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-4-warrants-warrant-activity-details", "lang": { "en-us": { "role": { "label": "Note 4 - Warrants - Warrant Activity (Details)" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-5-equity-stock-based-compensation-details": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-5-equity-stock-based-compensation-details", "lang": { "en-us": { "role": { "label": "Note 5 - Equity - Stock based Compensation (Details)" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-5-equity-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-5-equity-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Equity" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-7-commitments-and-contingencies-lease-cost-details": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-7-commitments-and-contingencies-lease-cost-details", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies - Lease Cost (Details)" } } }, "auth_ref": [] }, "mbrx_statement-statement-note-7-commitments-and-contingencies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-note-7-commitments-and-contingencies-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies" } } }, "auth_ref": [] }, "mbrx_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.moleculin.com/20240630", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c) (3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" } } }

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } ZIP 56 0001437749-24-026367-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-026367-xbrl.zip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|9MR CWN,8T'/%^3.@:5G+6Q*XB26(,1 MJJ]U+&PDM2VP'W&=T;(\$0&YT!#\$V6[:%|1X# J@,ZOY5E'(U!-9#<CDO)\$JT M]GBJ]78+MGW7UMNXO"HO!2VZ5 D\&I\1V3MO;MAYRSVUPVA?-T0^C-8'IHCUA=B7X=30#5BQ M]JRY4K86 MT* @TE>6^+O!)%|@[(V\$JFZ\$4*#|. +?FJRO,SWW:0MHD\$.NI4XYIV@L M)"?QFEY(V8E*/8HZJGY,AR_A4""R*K8'^(-BSXG+?<K>4\$[>2L.]>7=& M-F:#D8@)L-QJY:..6P0[+0@]Q=S\$4T0AQ@&A11N0L7K*K647SSX[*U"!# M=&YI24N(JV!>6^GRQ+7UQ7848=>Q_ S:<@>H,VB)]8(D'B)?<H,Q?<"/I!>B1V! M.VVY? QUX6[7?9<*@5]+ ZV-DZ_OU;!PNNKV"0A*Z J^S3X!G#/'"#QN@'N MYS*BEY!FZ;5\$L[?F0=>=4YH[.55-7J""H,Q?<";EBU\$Q;A^UTXH=C68P! M]J496[;MW1)\$C(8@O2E\$1PLOO)]6L'JN[=HNK4JYO:ZWB?|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||[4K M@5)FWA3639]/ 9O/&+<R MM".NLT85_.BLB42,8L>VX.^Q (<*I^Y=1M@/# 7K@D?<@6)YAZO=>JNB>W0 MM/DV+IZ*1TG[+ET C_IG1#9+>"SP0;<6E%R15\$"133.591"@I+-UC/ROHV\ MO7=7[%SX_J8AE&:0G\6#EW#8T,B]FTX52E'C'CN;M^\$LK6! #1*347Z9W*L

M=>[>4L7VP Q20H=^:\$.^X,%E+K5"8"U,@%&*Z-&*J00E^6 MLMQFP+4+R784P>^# 6%O.10.:;0"O%\$C,HH;)(M9@<6?0?R40!QM
M&H4[8Z[RP(KDX2)]Z.L#~JT: 9RR*AOP: %X J-74 K&H(7;X)]CS9!Z? ?>\$!=O&N!^+CSZ.C+HT+3<
MPH6:9>"55X7N+EQ)6)VHMR2 R^E&D&MZ38WS**=+/(3;X/L:W'+P+9N:)(MR&"Q">G2| CP"N"J=|2L|
[E=VX55(^F^3;Q7P"^-B\$-B\$.C).T14_)"/+P M=T6^~MU3] SVQW+0J';30'S7@Z9PC1?/D%|=|_1X3+Z%E1\$^+E#3GUMAPJC
M./:GWE@W3V!/# 3I+4^F]G\$&L?F"0"o---+&%3:+X%70/?\$U/FE_/ LFXFLN M87((+D.;jVX[>FHPV]CCG2!RT<2",JIP>A'X#;
)U0EOQJ!M.M.B?UV*BQH)Q.\V%YV6]+2A1IILQ4H'8R,@/4BOH!=K6)+RO[Y#?'79NXA];! M9BM;TWTW&"/R<
*=IB"CS15VIR%K\$VB,TX#^ET,KJV2IE?C4N4K U5]XB^4U9AWGST7 M0]+AC'K@|I>Y.;.C#>FW0^Z")
W]O2%411*Y2T6+@/"9]=RFBG,YBV3^QBV6G%FDSA;F0EWX:29&PPSD1GQ1;W2+&_B7F;9T6UR-0 M?
LV,8.*BOKNX4RD%MO]LNG"?([A"2[\$|>-9K_L/ M^J'(4NWITV^V4K9**E9,[E>2)S&3C|??_EMH0T2]-N7-1^PHDZ_A>FTZ^\$G M.?
|'4\$L#!#0 (Z #5DI7;I%7 4 .@9 - 97A2-CU9;7/..!#<W/R?*>N368P8\$B |C9#".GEVH84R+U|N!M&>M.EEQ93N!^ M_:UL0PA)
[CIS24FO99!|KU;[K%;]KD;ZHCWNR\$E?G_O15E>K;EGJ"Q'I(1'M60\$N4M.U333W-I+ # DT)3 M@=R:D%9_KUO)
(.NNJ)>0Z"?7|@|MMIR1B?-F&5Y12J3LSM\$S\$SNDU M3&1\$1\$XL048N04(5'SJ0S4087|0-3C76'8B)[S,Q;T.5":B6'28ZX*4JD:H-
M)-6R8S2([X-J007X>@OK|BI#BHB;J'&O] LUY"@Z4+;A+.Y:"LV#S4B01)N M\$G>ZE;B_JP#H?
UIKH0)D#QOPL,+ONOWI(F0NTU"OE9UNQ>U_>67^2!/-@N4. MS>&A&U*"@Q'DJG9Z=EP,#L;GV%Y61Z.3B?
P6R|0YV<%ER6I^5A&;C8:~7 M4S^JEG:HT6 *@Y/QQ6QTDQ,M#+,FVH#QJ' ^FMKC7]/^H/! M<&9&:M5J]5MT|L-SH3)NR+/P7#-=
@ZI/Q)0IMR9SSI:..DB?|5JKW5V"!>J:Q:U0+FIJRQ. M_6SPM%MX>+0:1RVG*-F[:C9K&E^"D5%K\$NY8];!;(7V0 7R0G'HIQ[Q]
MS"26D; \$9|(KP[|1|=7+5JU6|0QE%!.QS)Z#,"B(6).0M^#2>J32&DBB+V)D9NHA4\$*E&"7P@WAOFY#.XC>:(2 M#\$-& Q2.8)I=41@'
?.0 T49286:I4R\NT175F:#2A|C*4J)T* E;\$1^L5J9 MY)LU\$5_&&E>UR;YB,E%0P\$R)<+J\$@:~B(F"\$HX3W7XVP:")RRFX
M4OE4|2QT\$HJR7M3J]7,2\$V_U7"A|S7P=&M#J#P4.0^<4VB O3"U_L?<~>Q>U
MXK|RAO8(7ZFC99QQ&29_2VB]G\$6|>:T_P.>T,KYL<6&W)?S4 |.:M44/CBHW< ME\$:)~55WJ-4;#(0D*;5XZ/3_HH^.[PWX+#,Y\$?=
(P7FP,.80+3-.L+RBH:"#.5-E8T,8Y?L.\$< 06K'&, M< R+),9(2\$K9K|)(CBH1X\$^RT2;RH5<~< C1L9499C)5H\$|S>W_Q^!W7(G
M3@.#?X);V(9!D?OZIK9*PU)4K=34ZRWDY.AW(HWVT@L@J<<7A0OGK\$Z-M.?(|L4^~N'&X9M&S
MZM9#V=656LMHO>@|2S_:!N;5PLYI,|6'F#@2R1GF@KF|CYVA^|I7U1^,LQ+J>25+;WP=2SK/9FRTK.O\$ "A.3CQBT;/LT.?JF=^|V?
T*:[U|HABU1C#W1'<.[?+SE^~MR#Z>C;OS'N'C=&+MZ>SR18M#&PEK^|233<&%V/_M+S_95RSPJJ43&O5M BV1N>OP%02P,\$%
@_#H-6;<#!=~W10-M-QH T IE>+V-S8T,#N:1M|5G_<|HV%/^Y^2O>N;[*!\$)JLNUM:TK4<=V#129^G]_W];JSG M2<^~
0E!|JW3Q1_.DV7#J99QU|4@SLZI)A#\$1"JJNU:F([ME]8I1
M3N:T:T5"SHFV0ZIH)G@%@2":|J16M.\$IK'@M,N%U3MP*P6DZXMP"4HODWPY MUW9\$YBQ9MN"%QTSHSI3-J8)+>@-
C,2>|&"Q!|EP"126+I'04^POVH;JD^H. MI"0,&9^UP6\$,_M_\$O MG)1K.*#10MLD83/>3FBD\$>@%|U7?:<2MI|!^S|JTU!4'D#|JLH8-
D|C@NWO ML(B9SS34:<6'6_%{7Y^9#YG2+>QKN41P|6B&5R\$|,|Y>G%_TO>G%|!)&5^!) ME7EPCSQ56W|5G13|99@,^CE?U?
JQ4|HC1|X\$0+A;#HX>R(B6@OFE=, \$MX3E;?QI QN1?>I>#B3W|?>W@= #Z4S-31&"X8;I&_1, ME7EPCSQ56W|5G13|99@,^CE?U?
T>@61.|;&@ LI#&H)+("2:V-I/\$A\$TK>~% MU=J,%#&_56|UMP:ONU;-L8"%72NA83YY7G-J^&E4FXU6]BD=M)TCAM6|TW&
M*~2=\$FJ|LUG KI PF"!28O/*,##.5*B_6_AA+9IA!321%| M&Z,0T1H"F2C!&|&)QGU@5\$;Y*112"ZHQHQ<,TYXP\$@ "PRAB
4H/=S.;K3@M MY0C^\$JU9&AV5,(5DE!&N0008[A(Z!^0)L9XP@EG"~X_63|0I,_H> +&5+9M=!. IHDJVR|>58I"=;/X9O M6*AC
^K(M,)|A;|<~&2%R>;/#IYA|2+7|=~&T%Y)UNQHD>94ABC3+?S MM X'H^NVN"KS36@;_&J+Z%_PP^_!X|DO6AUCQ:;%(8QC
^FM,9)3EE[V\$FV:~2F/X)3~-D@2M|5_.218XD:(GJ%*~MHD\$=PP9/G6)GDA M5984?B-2*G,-M9@RD_-
[|]'8'?;=73G:\$*V^!ELTRY9O&: 9|\$?|ZDR^AH M!R+!;O-YE'JPB<9H9TH=MV(6)\$S\$LR?F"JG=\$Z7NAJ94|P8G,W+ 'WVRSXPIH
M%3,|:K1_2^W<~WF#L701 UAV?F7:MN/11=?:&UF&|.7431I|U_@D2WL_@1#
M>8R!0NF\$82R8^8=8&9KOT2>1^5&N,>ZYP#C%XU14Y9J|X&H|V34LR/(:KH M+K#IN"/&+Z/\$KZ6<;T|IW|2X|PLL3C6|IO
KJGDPPX3,C|_, 4#S> /A7Q| MA1R,)-IIRC3|MPHY3;>2|(.#-KS&5\$J|J|ETV?R|_JOTQR6<|A8-8WPK) MDI/Q\$F5>?#L|[-
,TQ>RDL2 R|=VZU00!7|ZYJ8B) I|B:2K%-3-72UH|>-EC M];#L%3V3>^X*JYQPW^BCS+)|F8J+C?_M'9 \$A14U'-
D|5W=;|JLX\$G|_X/X'G5^N|U2Q MG33M)FBZ<).V%R|)?7&ZN_>TH"7:)|E:FO*24C_OK;X;ZL"1+-BTSCSKS2R|+
M,YP9SH_&5|B/O|_.|6L>RHD|_E9JW00:5F4.[|+^/BL|6@|P;GEY_~WC/VS|&54D("ZUO#)NIN\$W*7BPI|2ZJ?/MU>6;76.
M3K0_60KQ|VY=~=Y?&=W7K*|1|J|Z>.C=\$^E,2%38H\$>7|](C/6) AFI^WV MPV#P,|!V|~2C;J_ 8D\$+X\$;R-/Q^YT|<-NPDD=
MMUP\$|B)H#R<~N9)H|XY|+3I8T"Y9\$./VDB&|!/?20L0?1FS/SJ3"D'P")? M8_R/V|'#+"E;XCS<1@|J?,>%YP=#
[KNR(+C>0G0DE6J)3>G6U@>|Y/-:2FY#CQ7I2 M2V++4HD+J&WJ|5*%F K6%N8J/91E>=)?-918"#R:(RUAP"%V7,_N3-#5LCFE M5U?
U'9T+R77=K=183X?5.425,JLXU6|9Q_&KL@TMC58U4Q,>:4Z@AXZ8"V MB7EIG|87F)R0*B)R\$*H ?G;!H2@3)I|KX6F;QF R7PS@;C
L|)25M #M'F M=(QUB\$Y\$|H3(<6%8.L&9O_N^J ?AW |44^I>3HEP4,[R^L]J \$Z,BH"15S/YM6I@ (NCHK(59MITD1|J|9@ "5Q"LB @
MG^&(H.X&=&E=S|)>Q,|92TG>S2V>NOF,1;UQQ@&:11>:6A1KETM^Y1P,(X M;|I-
,T'7M0E8)%0&M3R%#=#P|@<6@2(8,/5!%ANWZ3J@N"=A|@A8|&3C6!13 M):5E(=^/VTN_-B/24;_I5,%\$Q;G+HHI*IW#^U.ET+-
NZB&5E+WO*IO->:27U5=Z63|20?ZUAU(|A)HS@OC3=+I#Y,0>>?|~-1%6 M*M04L-[5@=0Y;&1|18WV%-VHPQ|YX^)
[|E42)O^&6+O:0T0+9=N"DW"== T MR*CV3^N+TFV"/_0L|P-J=VU.@E!0|.(PE(Q3N5%J5=VH*12|QJ-XJ-20=F01 !M/VY
|I59^HT2BD|_ M|JY 97#):22> R&DHL#?6.X;\$E-4NP#|4 I_S_X HVQ(OW|& MC+?P*|%#36J9.JZJK&DP-
|3|J|898_=@017.5&+/*,7V\$KA8A3\$T<8;1/_ *S M#V6.2\$LVCY\$A|QBNJFV,SK4%FL+9324XPRR]|%RED?8D54@#YC@I9235X-5?H
ME0/FG?U A("AM3D4,DV92_7N^ORK"3BTTOH"W#~ I. M3H|?^2_,N|LR|?)U6M?+|A.K1:0H6<@KFQ567/P?
%>66RMPK3>W"~F37C06 MUZW|3,&VKER#"Q|B|:O/?=0*E..ID"RV")|YXB15X|(K937YB&V,MH;1"SY30 6RR|J|/@!0 %3<|(6UH3
M\$2GQOCLR4:WR^!>0N&|)~#3C|Q?5D_VE/GIL-L|MVW \$C_A93MD|U|JK>~;S08T5, CK|M<=ZJPK|G.PS9Q<M#Q|;|V-/-T 4MXU-
SPF5%1MT M??D>5^9C>C?E#M%??>)*VOT^D8<,JMH"=EE)"M?7.>J+;|/"60RQL/"RN:-PB&A|X^OZ^Q"OYMLEI@&QKCR#"E?
M=XK64/ MF;5-YB?"= _J,Z ME3\$^AUH|!#(^N^SU>^+FB8^+=TC\$:[8NGOO!5.!|J|3K<5^0MVI|J*SJX/LB95507+3B#"F8#F%_2>
M>OX,RN/R6,%VW-&N6&T1E&2SUX[A\$IOX_B\$O2|N&7C27".>5YU+T(<=,S
M.H,K,6HMCOK>E!,8WN+|GUYI,AD08%PX/>US6VR+Z9=|. 7;|J_C "Y4!M=6\$\$QDJCHDLMKF|X3N_JA|JM7?5J|V|_ *XU:ORO%)
W7LJR>C>4@P<@%N< M_CRA5&6|K&D&J-NMCY,\$X|S#DSTS&JL D_?/7+)=2PFS|U1=7 &J(9|H8 M^0/_S8ZZ(VEO+^CB3^VOR_V,
<|I+A^53^K+^J)S3D_-R\$>CJM-S+|/&_42^L MH-D@)|@8XF|3U<:5-T>J2P|JZKRG)PG,^55E)U8ALY9L^C2R"JY>|7J* F*M
M^J^D#7";FZ!!N9E&0M&3<8?_VOQG XO ^3Q)0X-(QVB!>2R|5D+^FR2NN2|?^5 MB-0A;_0HBP%/QB|S VI?+XS@?ZHH>Q7?H|
[Z22^XWPR4UO<|_#ZZA>PS| MXTOT3T!@N.IJF=5D99BTBT|>0WXQ?;?GGB|AR'UFKLI+^W%:6672JX756HK M@8>+5W?
^5|;|D:|J|3,>WJ+EGHC8W6I6|<+ (V:RS+59=:V2HH=LJ<7LZRV M^T/Y4O;-[0DQO?T?G?N"7HAP?>="<?>ZS.B8DM64Y3WP;&
SjF8M,3|5 MFH_50N|U%|@3|^D62KD*9OG;|_U;96NPL8;R"_,G|03|@VM,+,K&E\$3""#).3=QX<11(95 M/VZ8096SX2W%_X,U=+)
!*R(|)%5S|N1#*|H%|%-.@:|J02CX#2U?SDG?O MU*\$0"Y;IDS?60!FO5|K,ZZ?X|JFFP=KLC>D K\$;4JU1QUM)#.!.**IX'W-X4
MOQ>LZ(C+&0019#RW\$=K^@|J\$N+CG#WGX?VD |<4?<_ Q#B=[EBCK88%|E7 MS3|CG7]|%FGQ\$6A_NUN1#"KFZ_?
9_4OE8!FO545/>35T'8X7W"=JFTV=BL"@=M3X^J|U8= M:J=(5RVJ|1?VG&88J|_N|O2=UF\$6* _I)KXV=[!-I)1Q|*2J|?>7Z? DC9V
MIT 6^*A 1<^LT|J.H F"%"FDWQY;ZWR*NZ|(C:7YU^DQ3=|H-L|3:/|_JN| MNV6--K;6)|'7QUAS3PG|_#J02P @_#H -61)AL6C8"
#FD |4 M !M8G)X+3(P,C0P-C,P7V-A;"YX;6SM76U3VS@0_GXS|QJRN<|F ?K*0#OA M|8:9M&1X?;NMH|@RT566V?NL=E>/5E+8
M_WB7T,X,"TDX.^AN;_6|'?M=71YV= M_LZKH\NV-X-@@_|E+ ?>_K'&\$G< 268-!|NA.EIGN|WNWM|=;=6- M+FYZ
M_ W^;FIABWZX|^G;7R&Z_? ^~9^>B|JR3A >NMW| M|FEX&4YP@@"M\$5"K8LD>|)</'(0*6)&2@B=0@G|*5B(!?
I2L+T3|&YOW24Q)E|] 3 DEN&(E)B.!!* QY MRA1X3#~#J9! (RU#R3|B8B:ZT=/8D"?#?%3.:WN9I@821\$%H;)"56,HBP
M0H1*~M!.1\$X/N|F8W\$7+&!HO_SY:Z^0|RF\$C20)-+M+75BB"CTD|G")|S M=<U/_J/'S"R!|Q2&3)|!|
(8E(<50:ZO?|JE|I|Z<:@P"1Q> \$HEP/\$F MBL:89@^Q;9(I1W444L
*Y|2E(^X1@BW3/Z1U.DCTIXP:;%6G=HR4"!A_N|3)NAN0DB^F_E4*4 I^"XB2-1W> M^!5NN.H3J;D1D3SB2<+9I>+ACS,I4QR=
Q+I=^@V\$C"A#~@L.\$D56B@-E-FK;Z2&3L|:SOIG;B@16.G1^L| (M|(|#^35PF#-V2AA02TCP@U"165DOU7^_# C.V Q2UP;X2A|@
|Y|,M047@M M..#N.\$N.6)9 F%65QFT5*2|GY\$64*WZ|KX2-9EPJED2L.?+^1+X\$*(^ FZM MP|V,DVSZN%:P7_%"! 1 8'
EGLNEF'5|_5F&+;_7WV.O7.FRQO_F)? 4?+WIERWP MM|YW>@D|M@7YSGN0-8L?ML#|+;IUV0R3;|Z>?
P43E!41UIA@L^G2+|G;_U1 M;^;1P!.>#7A+:Q5||WJ/3^|30A6?4G|IYE(^~9N6L3S:8;CK14K2|G^;G@ M6<>#>@-G("L|#XC^!9F2&
PH|!-EV8C1XLT<_-I|K;|=O8_/J|,L*9:P>G/8| M|L)3M/A?W>)EI?YEW1DTRDZ^4&W0**&,0*8%D|YP^:~F920'Z|,*Q@I,G=? MU#
(YXOA<4'49.F+^M@^UK>\$X|<DPQ05Z MQK)-H^!|"K"1(1&&^|VGG+~&)YO#(2#2N1-N*.15XU3I4LD5^Z&2G?RMZ.#> MRLM!_R
|E)FELP3(N-T&3^PQ3;LI Y3"LVACA<,<L+4PECV|Z129G/"< ME.=|=|VL(-:B"S|_-
|:W0U0@>GXIN9;.;KXJT|B|X?'5D2R05|,.GOEG/Z7BS M<<<K0J|S|@Q|,1SM2|TODV7Y1SM.RA^4W_&Y%-XV91"@=;.|S7IZ&^IM6L
M5J#;*YV.\$=4K9(<8'W?W>?~VI*RD|8**WYGE;+HHUT=50\$?;2R7W|NO%S8 MZ41F=9|1|>KE|FZUCZ#P>40'9G#IT=H2A2BU?
M@|1NZQ<-~VT?REMX/P6B<6>_~PD+JH%3S:K5+F|6%I3QQ>L|_IX@

M6"@UKXQ>ZW8MHCE\$;Y,C:YF%!62@C:NOJ8HQF#\$J#+J|ETB^?+74I@?^UF \$ M+5Y^MFGB>/%(<)P=(((\$ _6,"=)D|J1LLSW&,0E)\$+1[AFZ/OJF.#,W&@O8* M697?&M2 I 14D:OC^9J]_P.^73=A424+>^88='8\$6137NQ;+ :7J%DLZ%3?+T@0 M/9!7J5LHYV?Q:U7-0J*!"L%K%L&I%3+!)I?D/ T^JL12I|U!+ P04 M^ .@_U9!;CY974H #C7P, %0 &UBXKIF>BK,^C6- G22+>)G9E|Z*!)5A6T644V0.OK7 M+T#6I2H"/3/ DSO>ILB)IRS^J?7Q=V|>OR)Q MP\$:(SWY|_>76F|JR>7%R|? L53/P|JB,7DU|"] VWO _|G? SEOSSO(XE)XJ;RU?>JS?O?CE^? 2 WIU9>|DU=OW|S|WGOSDW?| MSO/^ ^I> (QK_ (O|S|W/R2@|_1_ S/7U _/TW3YR|'1X^/C=T_ W2?0=2V9J;|^ \ M>7>T+OUZ55P^#=-A=W"|X^*AYNB|TT_ OLO+^O_ |||J|^=- 44+|^"HI&C^@ M|>GR-IB3A> 16/9((&7A|I|>- WC) C_-N|S2PBME?"P7M|RF9^|X|?>N^/O MGGCX603ZJU=%U_E)D+> (W)#I|J4_O|Q<^/8%C=,CD^Z.5F6_- "@2(NJ9D^+|4PX2QC,CKH^9"A6SAT|A;D,4|26J^5|I&ZX+2 M!8GE3/&*UJ655=%,V^+.17M)D- T3;_/_&FA)K6NJPC|G4SZ^T>2>_;\$ \$EDL5|N2M6|I%-FY("45 IC&512_%GZO24MCN0!6RD*>4B\$U@ MM52MQ8E8\$|)\$%DX3X)RPD|>^4/>Y2FBQ|);* S_Z- &3 MLS@%1^O3+**HAU*>;H:1<6[KTE^67@N?N,E8E:6M2:G|".8E EK0EXS43^DSTOW2IV^6K"|N2|J%6?>=<(>:&2 M:F55%|JEF(IRWNLK2W&U! MXS^E\$5ZI>|D+M:Q8 <6+Y1ZZT M5>R7<0!2|3DRQ74?#D^89E8|)ZU6PVHE@79A4|H:RE|J(\$S|5=KB49H7?)). MI;TA,|K%;A*GG_V%NFO+BW4NW>V<1%'5Y"XKU+UD"S^*/F1<*(=HU6U6D M0ZEN29 EHA..W|]? T;34ME<5L2#5V5,P|^_94:PANF(=2B=,7ZEEWCXO|EE4 M(E;IL20DR:~OWXB:N6?|ER|BG(2 ODZ3; -OY72OSWQ,\$|;0 MP5611R55U@^H\$F\$RME@J_5_ ,/V|N(Y; T_O=U:7ZA<86|ZI58_J3%5 M44XO_/J:D|EB1Z< (JXA)+5?|O+ U|E,O(V6/V,9C5D/L :|V|BQ2;3NT# M0GN^B^AX=AC0!|3WAT|(%6Q/>?TZX= D|/(Z&% MI^6 _O^A^1HM.O1%|^~VVM.,1J.6&(/BPZJ5J|R*4%Q8- 1(#^Q|4^CX-Q< M M P6)3JV4!4Z90C/@T%RB%#46(3Y%1A)|,|>%37_3N M6:A)CD|S@9/34(Q8M1<(*0;%B%63T7!#4A8-1< :0R%AE5? 4020"%BU5C4 M?"H4&3YE1<^~07^A4U T%.184%#Z=I)HNA&+ #IYN8!L5MD?|E: ^H>,>?OK1ZN M^5@L|\$W13?)?G\$4TE 4&S&WC)W#GE9|&660OQJ M3E)AKD8;X-5^<3IYK96#.QU*WLDQ^Q=>B#\$D9>KS^WS9R;@W_ UE(1B)4K|^ M92OAZH?? =A:0:S^Y2G+|_ SJ1QFY)DF^INQ^J-F7XB*)7&2I7.6T#_ %*A\$ MHJK1+X(+SC.XI|^|JRN.Y.K#;I(I5#->B&2(6VK#.I#"KW",NX-2 5>H=AW:" M5%?H7?|J:0^L917|)|51_5|2|X17%^Q^WK)#C?I^+IBOZV^"BOYW87P(P_ M|YO19I;E3ZY^80RQ0%(+SN/< -XO^<13U' M^)^EA-#9*@3B|=T37QMG*5.S>=(T07X-YV+U?NB\$V%#|;F*7\$ _9B|T2XK&I M=[_ %%;|7RN;L.)+!4KA_*)C|HL>#E/YRV^3F" |Z|).R6U 21R(=24_/KV8 MT2LYH,5;\$J&R\$L=2;\$@+";_J@6|^~KBIQ^V98&TU9|5S MH(95!) S|>A|>K4D1F+FA7 M7A8+>)86D? O*266#;^G?C;BL1C8W= MMK?@0#1Y|O=)6.O>7>?B|UPL0>- _J|,2/YH&TLMG|F<")S. MXOP4M,R1\$ 3RP#>-9|Y2E!** L_+1%3LFZ%,G6#(?-@5RAZ7T@I:125O^%BO|>Z|ROFE M|5!#F; H/7VNH&T60#FM^C#ABQ K1L-6>)AOEZ7JE.VVV#14!8539\$3Z. M|&\$#SH@)EH)JZ4 8\$3K:|WGX78>|O8|W/BH&K^5A6X4PY96UL@X1CFFV|JR" M^% C^!K^UW3^U|0Q_ZQS..|D^2#Z*_1(L1H6C !+YR397^434?^>BMU?R&W(MQM1MWAZOTDQ^QY",F2%I|+98S7M^|3_+|6U2C+3+|6@2.LF5^&D|VU7F=4| MF55NIFY>XL@; (P0W)|G7*_J1#%7J@L.1=Y>;*|XF@9,77|WN3=,2OYA^?>= M)QK2PKP!YTAVCF3G2\$8^L,&\$90M8|"]_U;KK'^HK4?.%%' 'XX|J>^B_8^J MG%#"."875">=6E<6C=6?6|J^@G,GVE|J1OJ^*(|Y|JW\$ 5T-#6,+J|J&".N&2Q:8,KD Q:T:=GD/74U78ETE-W0V3S5V=67Y M|J77^4F-Q;+H%<?T_ "=DC=<@-9>?P3IC@)L.C.N, (M|F58#<4^EO3^&6DQ5^RGN/Y(N@H3=EOYH|7TKYFYTG MY1OTI-S-R=LWQ^~^+2|8C/U9|4/0EG6EIEC="=*#B3E=-D5YDU^H^R@MAE|/= M\$MF_6Z\$#.<6LGK- (Z#"|L\$H^B|VNV@J;N|Y|SFCBG20M.D|^%GL&6V,&Z1M2| M&SHC1=' S\$ O0F4SUQMWSKWAW!O.O='M2:=Z^HAU?|0R^H^YR/- !X1N+^_P_L#5[6K*10\$YM^K:K"_ _|XRGK+XU>N^XG^T|@64H#%/J)GH 16:4&X3Z>36%K13,-GJLH75PXX|A^>R),D)%G^* UR: MO(C:Z8IW+>\$.661+>,74XFLX3D".^,|ITD|9XQX&F5T|Q9+M:BU|LGH6PTV| M>HTX\$|S=<&R^M7=&.<^<(^X-XMP@5G-- :.I4IUDAOP02UP=HUYLLQ8.HT&F|) MO<^'(0^8^*F|>ZS-S)\$\$\$3540-^,9L**P.LX!5^*.XJT77W2WL^' 9',1^*,#3Q M>-BD^*JR#Z|_ : <=3%NT0CW4\$|K1#|@_?"1B9\$A)FQ DCB_#/RY^*_ VLA5P MI18\$O\$|(TJ^A^*CG^YGHU550\$|Y)R@\$B-VBF!1^B4L \$D/KM"">|J|FX@*AU MZO=Q|76.517>|NH^5N7_ ('M^7DWWI^|8J04JVZ5;?#Z7^H/X/QFH^~^1^4H6 MP3^J:YE\$VLEZ# 0#J&(5PYF? Q&*H|&N2W 13DL^& M917+NT^2K^V7D:GI. M8U|H17YT\$80G)^VV T^!QZBN550?&0L?:22S"%W\$|_J+Q.,=_&|O_6|JS= MCE6TG|GCSO^5L%CL^R |WP_V|LV8 <8|JDL9^C|JBM^2.A0#@=SLGI_,B^# MVB8|DD>J:Q75%RY6U3.>TH7H8-5^*2|T>^"(3-&LQ\$6(# (C&=J|6Y6H?D;JU: M^PYOSZZT2M%A! BNS/&JW:LL3|2VD#8QS>T25ZU#AENZ0^*OD %MZ!\$#HOX> M&6|P@:|\$AXIM(F,A#|)#|C0UW^X Z'^B QJ |B\$/%/R|^W0XT P?^,^#P# M)Q|4|<^F8=7RTT+!8E6R:KA H)"Q^EG- ^TV(S+R4Y)007NI^"MLZBT3PL7O MN78H|J|B-BXCD|^*=C7!"QE59R#++!-1L82^POKU4FD,FIHX|4,T>|=3^T/G M@DW&^S2_P.F!A^*H0GC^?<Q% 2U(C HGR1^?5^-18^/+|6?^8^AMP15M4|W;W(T5 CH^% 8|C) M^P^~L^-1^7G+^#^=- AS,29A%)&=%|Y)#@S10 M|P:<=>L\$V>=..O\$62?..AFO=5)W7|2N='_O/:Y2%-93IY7U|2G^%2(X%7C, M^*K#JD.5F_JTR<\$Z^E#Z(JV@UESI5NQ^6KW+TK^FG MG#OEW^GG3CEWRKE3SL>GG+>W0PZ(+|JBOTUBW1=890NM9(HK:|NP0K0#."OD6 MK1 9|G003A0SH VCV#=#MRJ3CU3|9U|J|U|I|H| MU7ZLJG|TK6Z1UM;-3DXTV0>N^!+>7^VF6\$^D,|C|CXGMP+L96ZM^*(9" MR,S?? \$2@&FS2I#KEV\$GP|JP^6056N|G,5WXT2B=DEMA&4|T6>J!1100:C/ MD|O3R3|F)|EU!)W0 M^*POXH# ("FNA#=\$S^:&NIB6|N\$Q?>?XJBC:W M "H2YI|E|-LGDLY9>!\$_)X2HLV2^ZLP-+G;3V!:(?^67#X4+>|)*<15|)!N MHSF|M|>7BGGU& (O9,*=+L58\$XF|_IC^8C>O;O0VDU|J^QA77P5AE MIN8Q^E>LW0D^LE3\$)FHHF|^MO# I+W-^|B|6|5=&N^1TT;*>3@VVL C>&0(| M\$.G\$H|V|UAI|7M,7 T1K+WL^Y%LV|0#|=K+FU #KY%; *TEST|NMXTL=*M M\$|YV;D1NQB#W^N8+J=V^+? CN^RBPJ>U8GHBM^64HR^V|4C& V>7L^8@R M,8+Q=(M-YJLF\$3^;M|+ 5%HL2M\$47%#B B EQ9R|JH^V)70# MF , FG/N17@)O_ :?I=IU4@POA5|27|BR1S|?>9M=<;2T MOKI@:_ +N^&|XA^?>)QINT|P|Q|S89VXUQ6^('\$B MG -- ;L95|LJO|FZ>::|9&.L5|D%@8L(D?S=)\$I)N\$ZEJ3Z|":O1 M@FBZ)\$"p67^C43@1DS&4|Y|_9NF_27I# C;+Z9_K|\$|E -ILURYM%N4O(F&. MX(-\$)EWL4^FU/LJG%|!HQE5MGO8M&S<:|B2RO+|2Z|EVP UAHN@5^*P5^|5 MPDGR6U .DP6KSL,TJM_U.N(N&W\$SHEO+4GXX7E?;!|YJWVWQ-7621AN#BD M|V ^E:H8J3L?^HXD^X7DT&K.B6&%0*[6 5B-#7=P|AI# ME0@=3PSY,JR&X8^2|7VF6,L7,U#L;5_."C&N&6#=-Z|^J&G|N|O| M(L1C6V=@|W":N%&^>CJGAEV^/5")% [|MKV28>)\$9HMEGGB7JF+3|3G69(OHQ?Q,DOEQAV(+4VJW-HS4^/*O>+) ME>JO+!):240KCG49U>T5U0WEOY|GA^P(BSP1^LB-V F-H^4WT^N^BCLJ^XKW M+KN6Q:RN,%3Y7?|':XRXVA|*4@L51..T.H|^AEL8JU^5,"", 3-?>@=' MR&F4;C3DFVIDL4HK!A4C YTY(Z'^S^ON-^(-8,9K0\$+590#M-M^V%\$<,P;K^H MJ!TV:"^T,U0|QBHZ9K 9XB|J|@UVX+C+!12;,+S^AON5FG>9Z|Y\$|4JOAF:~J M9NP16C|') (LU9A9+<4;L|D|>OCE^G^N>QWYL?K8E+ZD54>2?/U^5ODJ1U%9 MD5YDU#I RPMAE|J-? YVQIE,A.,6^YVV1=2%C^I81|%-PC|? 6_TH+|Q,8KE;ESEGR4BE#^G:9ZW3#Z|JH(NR,O5BP6)+V:"JFGA*;|^*H%W;1=1|%9G;!*E5X&4S<^1U15:_KH M^*1%_S,#^PN5XZ|>N,/ S@>?J_ QCL_VD1504?IM #97\$49Z&DP:RZ^*@9X9 MZ|@5;|;#9G9|)#0,JEM:E6|SZH_6#1_-J|5?>|NTKDC_Z(DB^YK^7XK< M&4&NY(S\$0?_LJS5;MZ;J-Q+OZ=YCUKT5|65_9QE/67MP3.6%^Y^L2" CIKDZ MT Q8I07A+FD@5|+>+^"Y(^.E-U)"#RK8@SJ?322R3WC--)ZJ3 NOWZ2>OR0^>M|Y_Q^J^Q^YSS<"ZLJ|428.M\$|KXLEWK+^|)(!6B&1R(?7,3YZX4^"!+9K)W. MKWHDZ;? |D&0IL^LI(ARKBG5_0599DDP|WG.L^TBI5 MR5E:R#GQ.K|T0JL\$4;Z!B:H#=:@,6<M|>_RSE&_J>Y|3KG^IMXR(5S|GE/GX@|:|W09 MD?R1V(DXBVA8|-4+J>SF\$Z%BB8:|H- XA)CU^N^*4CFY^M\$|(^,AO|(\$='T MTJ>A1XIO7#QFZ9PD7I EB93&YYQLDTRO>P7(A2- '88)\$T1_&|_&^3VKXLQ M<[N48R|AX8T8G6^UFY|_J_? 56:4&XW?7ZA@2\$|DA5=[^#(\$;\$_.KF|PL MR<?5^F_T#D#D)DGX02_2|RUOUA|6^G7BAY2G>|J_KR^W5MNBG&WT9G#^|FT M?|(530_H&8?B^YBG@G- (U^Q\$Z|BCI|RP=M^#|C J0^GG7+>^236H|G2,S#G M%&R?&9COR5 ^&Z@;^JJB#=\$5!5+!|^J),M9(1^J|XL&@QJE M1^3PYC)A|B4RY;&|^B^*O&[-X^P-FMU2|T;^FJ^JB=Y^P#ZQMT8^WN)+^D_GV> MZN^2%1G^U<9+S.XY27)KHLCK1(0V M\$XA:N3^S/J>UQT^H?>U9A0O|76,S@9=V?H+ZY?JFN-!A.Y;_9.F|X-1QU|. MNY=C=#,\$/PH|EXS+L-DH\$Q^*17SF) [|H\$5E;VWK_(J7^~^#E;-7-5B^E ZOD&^_>^&| MZ9@8;|CQ|T/W^&MEW4;>\$1K^2AE^_W86|CZK=^!4C|RM|3^X4)':BYTQ_% MOE75X|^5!% #SW0_P\$=V_-3 +8UWB^>^D#;^,^@7|?^R28D|Y&L3M@KOA#+2 M#;MZH8L.P3Y)NE2I,>P>? 0V&4F8^78AC)|!+2V|7|VW/5470F\$W;M2%GK00 M_&\$GM^QCJ);F6\$0+? T XM@|YD+M!YQ_ \$Z&C8J>UAY@CK8SP;1XO6!ARU+9 MB_/M|9@+T?T&0W0GQ<#)7W!#9EDDFWJ^3MB4<*G8^-Z (3FU^GM1MH#L#|S ME1|B\$M8!6^8WWE7^#IGE2I<=>^9VNNH/4%>6MYOA2RR.)FOU0A, IPO1ZO M|JZ;7UHLH|I#N3I|:~BN>L;~R^B^N@N|FX1GPL3Z=X- FV^B|A;HK_E6W>A MRSV >XC8<(T#(V^X^,3& @1^Q M7^YBZ^2QZ: <7RW\$H?;_ASOT/XH|@>J)|_/_O6G\$^KF7Q7X64E\$|\$G1O_ HK M^O26I^3N|&_0^7|!%"@L6WZ8L^~V")\$2^8VL254I37%@OV=(| M=B+D%+OJ Q7S|)L+J47G2.WR5U3Z3.LK_G^V1 MT0<_D+^A3PT\$^NW26^EW7DUWN_@J|F|>=?BF?D|+;E? 1J^DJ%K^R)+VNCE44AW-M4ER7QJ|J M9XU/^ERO?S1|=HL)(^75GC^M=M|3^TE385+K=WGS|GK&|_ (^2C^J|FIV;|4G M:9FZ=\$YC7ZA6N^J2 I5Y TCQ63|YXV(F^EL^&F95HS3=AO^T^|7|8/LAI| M=TT^2/&U|J|UK-HZA7TK,|S|F@:0XFOON|=LW^:;_ \$UD- S#;G8S>JSN&5^Q M^*G?LSG^2L=IS%DEKZLIPEMW_(1_ \$|AF|L7(<-G6V2|F>L^%>QR:|,102(H:9 M&#OI|W4D=&UA3\$CS85GBRZK? @.5L+2P@).3G^5M(=YN|(O|JNN.#4|&"UK; M|F0R^A&-A=NM4=FN^ K%|GA(C>^H4HUY2T^W%^/8A XI>EI|)(W.I@5TU M_%MKV^Y^*)=+^;^*2I9O|)"R|4\$D/ U3^,HH^\$F?^C6^_ L0MRMQ_DWKJ<_R0R MWHJ\$DPA_ "Z4?PI2 M^2:~C@C|TO))>Y2@(|VKY6:U|!AT8|)(J)%S^-V(-8+>69^_/2K:"&^%SP,= M-MUP/7,-#/MA^H W=;A66;C|G0;_6PPMJ@8Q-

I'M^C60FSNM4V.W?0P,.[# M9HA9GFWs>^JQI;L_ ^Y1:S=<|W\$I 8M6@D)JR>4" 4;J'C;|WKJZ?|V 0CM*W^4> ^XY\$P
MEE1S,6^NXM,-#PI3M)0>2+FFPB14|DP(X/L=J|&Y%#"ZRS7?|1^=NAWP95L|H M0A73U_ :P'4EV; (WEA&:HJ19&5FF*HAJ!T*4?
P|A|)#74|<HT01,5\$ VJ?TH M+<#;16"/+P#;S) #LWBT -,7D(7)NN+|9BH-Z|Y\$, _AD-Q.4=B-Z|7|PAM;TPLF8T ME'&
|JF*B:HKF(J/-'!G5V+T^B?(7D;#|WE7|:7RSRIBN,BHE;6O5M7RMD8Q% MW2|W|JURTU%3N8
:&!!HHR5|0G6&CZ)74U1Y&U|K@B%)'H!@008Y MZ3CW: U+TJ;327%1^;T?2?>PQ^>\$!-P+|J. 7j;?,G<0MWN9N^X^|VZO):IS
M4CDGE#Y*H8YV5E^I.RXII@ M;5F|YQ"* #=[66|FZ8F?|,|TGN5W" E0&6UG8=C080TQE+ /&0C,0|55ZJ M"ZAA< %J9=- ^
D4QRSEY*Q'QI?B9YN12ZU,Q98RW;.IS^>4;0%S.TN JI MR*CUd;|PD6|-K.,<#^"J5C&5I.'=\$UV9J-> ^A&+NY8-9)FD"3_ +Z>EJL;75
M^L^BW|'0:2'8E1L7=45^LGPd.>8WQS|J%QJP/5Z1%.J?SZ_&)) 2%1U+&* MXEHT0T0GA17;EZ:D;8EWDm6+U22 !
JB=QK4M(Q(D55:G:4(4L4RB9SZ-;A M^KX^8|>|.0|, M<6|D |^)G21%J962/W\$|K|/" 9KK&>B.Q\$&AMH3F@&S#|BFY|-\$-K1'6AVQ-
K#USDVZ 9+C!|C&YF0JU?F(|W08) M\$/RE';5G'-#MCF;X| \$!Z#9%,W"F46 (IZ(17+,H,72;|!E:4|(&W3YI|K>*
MBT"W79K|,PO.0!|WORG /38M+D18";R^)*&|V/L:|^HS_KZVN+ 8?7B@GS, M7"">O;PGITA>=DD#*6AQ(J3ZI;L9#,QKMY|K0?
02U3TIZTM|Q*56=-"=X+D& M4; >KU94|Q*EBFKDXXR80<+L4:9"RUNH6.16|P1K3U;1|16&_ @*VPU:VT|K|196:Z?
T,6|Q8|K|K4"U7\$!HV,) M&%6969_8_Y(W=9)-V,75& MA9'8L!4,2'.5N.9P+J^+!E7|@|FXV3&%N"./K*ZQ0Z.C*?6V5#F#ARK9E>X2
M,-B'8;5L-'2\$+/A+&KA|T|&S8) 0\$P4=#PO_A/5|D;V=-|<-JG.'&UW,7+G M|SH.ZM\$;X^A6G;JA2LB7&P-8AH8EPIB|!E|U1@?"
<(&|/?*08 U*9%:0) MKPK\$BR7|2S^L%K"3L*2* ?_0\$0. (T4/U")& MCX*?7C>X_UR&C'5|5T Q @^"+
|Z"940KQH&RG+NOJG^65%WWY3Q-W)|0|V9RRN"SN)LD0|6V2Q/JTP- M@QU-LZW6YQ|30M612,,M2V%;_ \$&9ZL938#;Q=2/>"+N/^
Z|VXJ8F0N|I5TS/3/3.|H;K>GWG MLKTN= .255Q,T"ID<8LR3-' |RS4^?3^?SRXNOB%E%>5)E+&<
M_N6;G'WS+ _|W_ ;G_ 'R|_ +VS=O?G;SYX|GINY.3?_YSEN9_P'^=Q^5E' D|E+|^9=O MEE6U_N'UZZ)?OW[|= %]DW[+BX?7;-
V>O6Y;?U,WAU^?3JNW0;?S=: ECV_1@ MZ* 01-03|_ _K7XM6U:IGT-^:'GK_ |T^7G>\$E7T4F: T5BP*5,?
RC%EYYTQ6,40RX(N^OME1; '3?#?X^O X_3W@|4|J|HU7|;X; M9;I:9_2;UY,QO:;%RI/(N664^X=U@OOG*BHJ%)|@?#FP9_SM619E=S
^M(TS M%V'4,LX'OUK&^8L;YH_J>WABT".D12\$|L,6EWR3W5#&'! J IXM0C0#SR? M*LK|HUIJMF.S>&<2J_ OBZ02.IC>_?_ =&H G?
_ VSB7>='0.2KB\$=S\$J%JJCQD 4=;4|KT7| M5B9\$9L:4DX3@2.ROR1ZK /YEHV@LHO)>S&!3GCQ\$T?HU!-!KFE5E|XW@*L%1
M|J1= ^QBEQ<1|M|J'7BX|ISM6'_HNN")1"\$3+&Y:E|?,>=Z'ZG*;\$0S77 =(M\$(\$%8002XD\$ZB,R(1(5|J?^|XWN=O.?S_?
O_ |J|5N,5ADRBNRZT*P7;#GK' M6F!/_ L:661F'7*.V#EG. ^HD|EB=L<;+FR|2_ ME^K%NDCY/N-JK?
B)\$ZWD: "7RMRA1FDA/R'J865LU-9TIG#<=>0 M Q, C,6A'6A4;|T|RD|X> "BNF4Y|6|6\$679|AKB|JL|C%=[Y]|X,/L|G06E<(^ M-
#-"5&CC90B?AYY'4-^4>8|7 5.Z6E\$0KV 4@M:@\$30@5FV0",Y!0480\$8D"12 MAQ&#F(|)X @T67H1B&H*Z.F=^=? (V*@NNNJ -
\$V=OJT7 MQ800_QT7^K_4<(|(G*M)/BJH1^CHBL6^Z"|JH,S6"Z6F60/1A>F.L|SEP?
MI-0C8BT5L4<9:Y""W|1|F_N2XX^Q^K#X_ :51/X?+-GB(4CQC&4%_ F.I@7# MN6FX18)(+(|NT7|XB=EJE5;BVBBT83YQ,
O1|;\$>UC.2*!>-!> |8J^*VZWUZMN1_49+F.I:Y+Y+&* *P|&4BSBB/OZ/YG-I|,872" M/T8P-
|Y'26QJ|JYC+OB>7#AF0P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%? M&C3V|CB;4GZ#Y0TMQ\$51+|J1,LQ=261T9W37C->)AT|\$ M D<77Z9+?
X8DZD2!>K>D;|J^NHS>%E%';VE,TT<1U#9| MXQ_O@|2FZH'='^#YB0!-BBWL(.|2@|C,G&(3A>19%I5E^YI|7=RF#|0J9UI6 M-
&|SD^TB-,2H|?3|/;&.%&J#<3YB;P%15ZE.2GA |N|O|J='.(|06 #SA!- M2QTKB,|H1B1.XA; N..V>N-B'7;.|XA|1"@ +|1K@E -
VB%N#P,=|H;|K! M01U1M 21YIN#"||55|CCIQC&M8AHX 0Y7PYHQ<8(X.OLJ_ 2 2FR*-IQTDO2,Y M/55V/H|8F:MMUHM>BA9
PI" "8LRZ*B)&LNNH0H=BB))Q()Y8_|ZYG2<(M9_ACDZ?5KT9H|S.UL00?6"AOXOQZ#='7*^ V_|>E6V ZUVR,%OG)-. #DVXKMGO?
91!T3Q^>-.3XD\$@BQ&^ -48DWJ)\$,HX3>?57&A663A|G=, #G M4#8A1?^1PC95">49>9=C.4=, ^7SP-\$\$MF@MI< ;,FV4T.=|
B+>LQJ>|JP=[M6|OIO5"|9&C71|?.7IXZTRG|/PD2@N^9|O=-WJ8D=>|7(I'S(JQ UV)!H M@=;+|3L6|3.|U0:0C0;=O8D6W,54?
RBWL0?P;1G0|JZA|J8KNV+Z?|FVR*N MGZ;KX^& ^8&IX'1(N>KIAA?BAJ|HKT?B,R0|XQ&7^LNM.&P %[3_]J_F>Y?KH/3-J
MT:AQKQUFXV=2;?%>/T>.8W,Q/C99K4|M|YIERPD:G\$,8ZT(LF784:SQY)I5
M=2RS\$-3I(J5)\$WZG=GC1|H2K8C4RN&L>;Q\$@6PRV,8EHAQ@|YK|&J-&LI-X M.|5&+PE2\$DJ7L1B.JKZ>K&S;)2W
|0DI+3N>W7@<^P|@>V?GVES&D5H|MVS..?&;+Z-C. U_8DAB.DO MKP\$XVRY9EM"BE A"H(X|O.).JQ9|
[_ +7/+ENH5%.U7H^&B|P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%? M&C3V|CB;4GZ#Y0TMQ\$51+|J1,LQ=261T9W37C->)AT|\$ M D<77Z9+?
X8DZD2!>K>D;|J^NHS>%E%';VE,TT<1U#9| MXQ_O@|2FZH'='^#YB0!-BBWL(.|2@|C,G&(3A>19%I5E^YI|7=RF#|0J9UI6 M-
&|SD^TB-,2H|?3|/;&.%&J#<3YB;P%15ZE.2GA |N|O|J='.(|06 #SA!- M2QTKB,|H1B1.XA; N..V>N-B'7;.|XA|1"@ +|1K@E -
VB%N#P,=|H;|K! M01U1M 21YIN#"||55|CCIQC&M8AHX 0Y7PYHQ<8(X.OLJ_ 2 2FR*-IQTDO2,Y M/55V/H|8F:MMUHM>BA9
PI" "8LRZ*B)&LNNH0H=BB))Q()Y8_|ZYG2<(M9_ACDZ?5KT9H|S.UL00?6"AOXOQZ#='7*^ V_|>E6V ZUVR,%OG)-. #DVXKMGO?
91!T3Q^>-.3XD\$@BQ&^ -48DWJ)\$,HX3>?57&A663A|G=, #G M4#8A1?^1PC95">49>9=C.4=, ^7SP-\$\$MF@MI< ;,FV4T.=|
B+>LQJ>|JP=[M6|OIO5"|9&C71|?.7IXZTRG|/PD2@N^9|O=-WJ8D=>|7(I'S(JQ UV)!H M@=;+|3L6|3.|U0:0C0;=O8D6W,54?
RBWL0?P;1G0|JZA|J8KNV+Z?|FVR*N MGZ;KX^& ^8&IX'1(N>KIAA?BAJ|HKT?B,R0|XQ&7^LNM.&P %[3_]J_F>Y?KH/3-J
MT:AQKQUFXV=2;?%>/T>.8W,Q/C99K4|M|YIERPD:G\$,8ZT(LF784:SQY)I5
M=2RS\$-3I(J5)\$WZG=GC1|H2K8C4RN&L>;Q\$@6PRV,8EHAQ@|YK|&J-&LI-X M.|5&+PE2\$DJ7L1B.JKZ>K&S;)2W
|0DI+3N>W7@<^P|@>V?GVES&D5H|MVS..?&;+Z-C. U_8DAB.DO MKP\$XVRY9EM"BE A"H(X|O.).JQ9|
[_ +7/+ENH5%.U7H^&B|P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%? M&C3V|CB;4GZ#Y0TMQ\$51+|J1,LQ=261T9W37C->)AT|\$ M D<77Z9+?
X8DZD2!>K>D;|J^NHS>%E%';VE,TT<1U#9| MXQ_O@|2FZH'='^#YB0!-BBWL(.|2@|C,G&(3A>19%I5E^YI|7=RF#|0J9UI6 M-
&|SD^TB-,2H|?3|/;&.%&J#<3YB;P%15ZE.2GA |N|O|J='.(|06 #SA!- M2QTKB,|H1B1.XA; N..V>N-B'7;.|XA|1"@ +|1K@E -
VB%N#P,=|H;|K! M01U1M 21YIN#"||55|CCIQC&M8AHX 0Y7PYHQ<8(X.OLJ_ 2 2FR*-IQTDO2,Y M/55V/H|8F:MMUHM>BA9
PI" "8LRZ*B)&LNNH0H=BB))Q()Y8_|ZYG2<(M9_ACDZ?5KT9H|S.UL00?6"AOXOQZ#='7*^ V_|>E6V ZUVR,%OG)-. #DVXKMGO?
91!T3Q^>-.3XD\$@BQ&^ -48DWJ)\$,HX3>?57&A663A|G=, #G M4#8A1?^1PC95">49>9=C.4=, ^7SP-\$\$MF@MI< ;,FV4T.=|
B+>LQJ>|JP=[M6|OIO5"|9&C71|?.7IXZTRG|/PD2@N^9|O=-WJ8D=>|7(I'S(JQ UV)!H M@=;+|3L6|3.|U0:0C0;=O8D6W,54?
RBWL0?P;1G0|JZA|J8KNV+Z?|FVR*N MGZ;KX^& ^8&IX'1(N>KIAA?BAJ|HKT?B,R0|XQ&7^LNM.&P %[3_]J_F>Y?KH/3-J
MT:AQKQUFXV=2;?%>/T>.8W,Q/C99K4|M|YIERPD:G\$,8ZT(LF784:SQY)I5
M=2RS\$-3I(J5)\$WZG=GC1|H2K8C4RN&L>;Q\$@6PRV,8EHAQ@|YK|&J-&LI-X M.|5&+PE2\$DJ7L1B.JKZ>K&S;)2W
|0DI+3N>W7@<^P|@>V?GVES&D5H|MVS..?&;+Z-C. U_8DAB.DO MKP\$XVRY9EM"BE A"H(X|O.).JQ9|
[_ +7/+ENH5%.U7H^&B|P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%? M&C3V|CB;4GZ#Y0TMQ\$51+|J1,LQ=261T9W37C->)AT|\$ M D<77Z9+?
X8DZD2!>K>D;|J^NHS>%E%';VE,TT<1U#9| MXQ_O@|2FZH'='^#YB0!-BBWL(.|2@|C,G&(3A>19%I5E^YI|7=RF#|0J9UI6 M-
&|SD^TB-,2H|?3|/;&.%&J#<3YB;P%15ZE.2GA |N|O|J='.(|06 #SA!- M2QTKB,|H1B1.XA; N..V>N-B'7;.|XA|1"@ +|1K@E -
VB%N#P,=|H;|K! M01U1M 21YIN#"||55|CCIQC&M8AHX 0Y7PYHQ<8(X.OLJ_ 2 2FR*-IQTDO2,Y M/55V/H|8F:MMUHM>BA9
PI" "8LRZ*B)&LNNH0H=BB))Q()Y8_|ZYG2<(M9_ACDZ?5KT9H|S.UL00?6"AOXOQZ#='7*^ V_|>E6V ZUVR,%OG)-. #DVXKMGO?
91!T3Q^>-.3XD\$@BQ&^ -48DWJ)\$,HX3>?57&A663A|G=, #G M4#8A1?^1PC95">49>9=C.4=, ^7SP-\$\$MF@MI< ;,FV4T.=|
B+>LQJ>|JP=[M6|OIO5"|9&C71|?.7IXZTRG|/PD2@N^9|O=-WJ8D=>|7(I'S(JQ UV)!H M@=;+|3L6|3.|U0:0C0;=O8D6W,54?
RBWL0?P;1G0|JZA|J8KNV+Z?|FVR*N MGZ;KX^& ^8&IX'1(N>KIAA?BAJ|HKT?B,R0|XQ&7^LNM.&P %[3_]J_F>Y?KH/3-J
MT:AQKQUFXV=2;?%>/T>.8W,Q/C99K4|M|YIERPD:G\$,8ZT(LF784:SQY)I5
M=2RS\$-3I(J5)\$WZG=GC1|H2K8C4RN&L>;Q\$@6PRV,8EHAQ@|YK|&J-&LI-X M.|5&+PE2\$DJ7L1B.JKZ>K&S;)2W
|0DI+3N>W7@<^P|@>V?GVES&D5H|MVS..?&;+Z-C. U_8DAB.DO MKP\$XVRY9EM"BE A"H(X|O.).JQ9|
[_ +7/+ENH5%.U7H^&B|P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%? M&C3V|CB;4GZ#Y0TMQ\$51+|J1,LQ=261T9W37C->)AT|\$ M D<77Z9+?
X8DZD2!>K>D;|J^NHS>%E%';VE,TT<1U#9| MXQ_O@|2FZH'='^#YB0!-BBWL(.|2@|C,G&(3A>19%I5E^YI|7=RF#|0J9UI6 M-
&|SD^TB-,2H|?3|/;&.%&J#<3YB;P%15ZE.2GA |N|O|J='.(|06 #SA!- M2QTKB,|H1B1.XA; N..V>N-B'7;.|XA|1"@ +|1K@E -
VB%N#P,=|H;|K! M01U1M 21YIN#"||55|CCIQC&M8AHX 0Y7PYHQ<8(X.OLJ_ 2 2FR*-IQTDO2,Y M/55V/H|8F:MMUHM>BA9
PI" "8LRZ*B)&LNNH0H=BB))Q()Y8_|ZYG2<(M9_ACDZ?5KT9H|S.UL00?6"AOXOQZ#='7*^ V_|>E6V ZUVR,%OG)-. #DVXKMGO?
91!T3Q^>-.3XD\$@BQ&^ -48DWJ)\$,HX3>?57&A663A|G=, #G M4#8A1?^1PC95">49>9=C.4=, ^7SP-\$\$MF@MI< ;,FV4T.=|
B+>LQJ>|JP=[M6|OIO5"|9&C71|?.7IXZTRG|/PD2@N^9|O=-WJ8D=>|7(I'S(JQ UV)!H M@=;+|3L6|3.|U0:0C0;=O8D6W,54?
RBWL0?P;1G0|JZA|J8KNV+Z?|FVR*N MGZ;KX^& ^8&IX'1(N>KIAA?BAJ|HKT?B,R0|XQ&7^LNM.&P %[3_]J_F>Y?KH/3-J
MT:AQKQUFXV=2;?%>/T>.8W,Q/C99K4|M|YIERPD:G\$,8ZT(LF784:SQY)I5
M=2RS\$-3I(J5)\$WZG=GC1|H2K8C4RN&L>;Q\$@6PRV,8EHAQ@|YK|&J-&LI-X M.|5&+PE2\$DJ7L1B.JKZ>K&S;)2W
|0DI+3N>W7@<^P|@>V?GVES&D5H|MVS..?&;+Z-C. U_8DAB.DO MKP\$XVRY9EM"BE A"H(X|O.).JQ9|
[_ +7/+ENH5%.U7H^&B|P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%? M&C3V|CB;4GZ#Y0TMQ\$51+|J1,LQ=261T9W37C->)AT|\$ M D<77Z9+?
X8DZD2!>K>D;|J^NHS>%E%';VE,TT<1U#9| MXQ_O@|2FZH'='^#YB0!-BBWL(.|2@|C,G&(3A>19%I5E^YI|7=RF#|0J9UI6 M-
&|SD^TB-,2H|?3|/;&.%&J#<3YB;P%15ZE.2GA |N|O|J='.(|06 #SA!- M2QTKB,|H1B1.XA; N..V>N-B'7;.|XA|1"@ +|1K@E -
VB%N#P,=|H;|K! M01U1M 21YIN#"||55|CCIQC&M8AHX 0Y7PYHQ<8(X.OLJ_ 2 2FR*-IQTDO2,Y M/55V/H|8F:MMUHM>BA9
PI" "8LRZ*B)&LNNH0H=BB))Q()Y8_|ZYG2<(M9_ACDZ?5KT9H|S.UL00?6"AOXOQZ#='7*^ V_|>E6V ZUVR,%OG)-. #DVXKMGO?
91!T3Q^>-.3XD\$@BQ&^ -48DWJ)\$,HX3>?57&A663A|G=, #G M4#8A1?^1PC95">49>9=C.4=, ^7SP-\$\$MF@MI< ;,FV4T.=|
B+>LQJ>|JP=[M6|OIO5"|9&C71|?.7IXZTRG|/PD2@N^9|O=-WJ8D=>|7(I'S(JQ UV)!H M@=;+|3L6|3.|U0:0C0;=O8D6W,54?
RBWL0?P;1G0|JZA|J8KNV+Z?|FVR*N MGZ;KX^& ^8&IX'1(N>KIAA?BAJ|HKT?B,R0|XQ&7^LNM.&P %[3_]J_F>Y?KH/3-J
MT:AQKQUFXV=2;?%>/T>.8W,Q/C99K4|M|YIERPD:G\$,8ZT(LF784:SQY)I5
M=2RS\$-3I(J5)\$WZG=GC1|H2K8C4RN&L>;Q\$@6PRV,8EHAQ@|YK|&J-&LI-X M.|5&+PE2\$DJ7L1B.JKZ>K&S;)2W
|0DI+3N>W7@<^P|@>V?GVES&D5H|MVS..?&;+Z-C. U_8DAB.DO MKP\$XVRY9EM"BE A"H(X|O.).JQ9|
[_ +7/+ENH5%.U7H^&B|P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%? M&C3V|CB;4GZ#Y0TMQ\$51+|J1,LQ=261T9W37C->)AT|\$ M D<77Z9+?
X8DZD2!>K>D;|J^NHS>%E%';VE,TT<1U#9| MXQ_O@|2FZH'='^#YB0!-BBWL(.|2@|C,G&(3A>19%I5E^YI|7=RF#|0J9UI6 M-
&|SD^TB-,2H|?3|/;&.%&J#<3YB;P%15ZE.2GA |N|O|J='.(|06 #SA!- M2QTKB,|H1B1.XA; N..V>N-B'7;.|XA|1"@ +|1K@E -
VB%N#P,=|H;|K! M01U1M 21YIN#"||55|CCIQC&M8AHX 0Y7PYHQ<8(X.OLJ_ 2 2FR*-IQTDO2,Y M/55V/H|8F:MMUHM>BA9
PI" "8LRZ*B)&LNNH0H=BB))Q()Y8_|ZYG2<(M9_ACDZ?5KT9H|S.UL00?6"AOXOQZ#='7*^ V_|>E6V ZUVR,%OG)-. #DVXKMGO?
91!T3Q^>-.3XD\$@BQ&^ -48DWJ)\$,HX3>?57&A663A|G=, #G M4#8A1?^1PC95">49>9=C.4=, ^7SP-\$\$MF@MI< ;,FV4T.=|
B+>LQJ>|JP=[M6|OIO5"|9&C71|?.7IXZTRG|/PD2@N^9|O=-WJ8D=>|7(I'S(JQ UV)!H M@=;+|3L6|3.|U0:0C0;=O8D6W,54?
RBWL0?P;1G0|JZA|J8KNV+Z?|FVR*N MGZ;KX^& ^8&IX'1(N>KIAA?BAJ|HKT?B,R0|XQ&7^LNM.&P %[3_]J_F>Y?KH/3-J
MT:AQKQUFXV=2;?%>/T>.8W,Q/C99K4|M|YIERPD:G\$,8ZT(LF784:SQY)I5
M=2RS\$-3I(J5)\$WZG=GC1|H2K8C4RN&L>;Q\$@6PRV,8EHAQ@|YK|&J-&LI-X M.|5&+PE2\$DJ7L1B.JKZ>K&S;)2W
|0DI+3N>W7@<^P|@>V?GVES&D5H|MVS..?&;+Z-C. U_8DAB.DO MKP\$XVRY9EM"BE A"H(X|O.).JQ9|
[_ +7/+ENH5%.U7H^&B|P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%? M&C3V|CB;4GZ#Y0TMQ\$51+|J1,LQ=261T9W37C->)AT|\$ M D<77Z9+?
X8DZD2!>K>D;|J^NHS>%E%';VE,TT<1U#9| MXQ_O@|2FZH'='^#YB0!-BBWL(.|2@|C,G&(3A>19%I5E^YI|7=RF#|0J9UI6 M-
&|SD^TB-,2H|?3|/;&.%&J#<3YB;P%15ZE.2GA |N|O|J='.(|06 #SA!- M2QTKB,|H1B1.XA; N..V>N-B'7;.|XA|1"@ +|1K@E -
VB%N#P,=|H;|K! M01U1M 21YIN#"||55|CCIQC&M8AHX 0Y7PYHQ<8(X.OLJ_ 2 2FR*-IQTDO2,Y M/55V/H|8F:MMUHM>BA9
PI" "8LRZ*B)&LNNH0H=BB))Q()Y8_|ZYG2<(M9_ACDZ?5KT9H|S.UL00?6"AOXOQZ#='7*^ V_|>E6V ZUVR,%OG)-. #DVXKMGO?
91!T3Q^>-.3XD\$@BQ&^ -48DWJ)\$,HX3>?57&A663A|G=, #G M4#8A1?^1PC95">49>9=C.4=, ^7SP-\$\$MF@MI< ;,FV4T.=|
B+>LQJ>|JP=[M6|OIO5"|9&C71|?.7IXZTRG|/PD2@N^9|O=-WJ8D=>|7(I'S(JQ UV)!H M@=;+|3L6|3.|U0:0C0;=O8D6W,54?
RBWL0?P;1G0|JZA|J8KNV+Z?|FVR*N MGZ;KX^& ^8&IX'1(N>KIAA?BAJ|HKT?B,R0|XQ&7^LNM.&P %[3_]J_F>Y?KH/3-J
MT:AQKQUFXV=2;?%>/T>.8W,Q/C99K4|M|YIERPD:G\$,8ZT(LF784:SQY)I5
M=2RS\$-3I(J5)\$WZG=GC1|H2K8C4RN&L>;Q\$@6PRV,8EHAQ@|YK|&J-&LI-X M.|5&+PE2\$DJ7L1B.JKZ>K&S;)2W
|0DI+3N>W7@<^P|@>V?GVES&D5H|MVS..?&;+Z-C. U_8DAB.DO MKP\$XVRY9EM"BE A"H(X|O.).JQ9|
[_ +7/+ENH5%.U7H^&B|P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%? M&C3V|CB;4GZ#Y0TMQ\$51+|J1,LQ=261T9W37C->)AT|\$ M D<77Z9+?
X8DZD2!>K>D;|J^NHS>%E%';VE,TT<1U#9| MXQ_O@|2FZH'='^#YB0!-BBWL(.|2@|C,G&(3A>19%I5E^YI|7=RF#|0J9UI6 M-
&|SD^TB-,2H|?3|/;&.%&J#<3YB;P%15ZE.2GA |N|O|J='.(|06 #SA!- M2QTKB,|H1B1.XA; N..V>N-B'7;.|XA|1"@ +|1K@E -
VB%N#P,=|H;|K! M01U1M 21YIN#"||55|CCIQC&M8AHX 0Y7PYHQ<8(X.OLJ_ 2 2FR*-IQTDO2,Y M/55V/H|8F:MMUHM>BA9
PI" "8LRZ*B)&LNNH0H=BB))Q()Y8_|ZYG2<(M9_ACDZ?5KT9H|S.UL00?6"AOXOQZ#='7*^ V_|>E6V ZUVR,%OG)-. #DVXKMGO?
91!T3Q^>-.3XD\$@BQ&^ -48DWJ)\$,HX3>?57&A663A|G=, #G M4#8A1?^1PC95">49>9=C.4=, ^7SP-\$\$MF@MI< ;,FV4T.=|
B+>LQJ>|JP=[M6|OIO5"|9&C71|?.7IXZTRG|/PD2@N^9|O=-WJ8D=>|7(I'S(JQ UV)!H M@=;+|3L6|3.|U0:0C0;=O8D6W,54?
RBWL0?P;1G0|JZA|J8KNV+Z?|FVR*N MGZ;KX^& ^8&IX'1(N>KIAA?BAJ|HKT?B,R0|XQ&7^LNM.&P %[3_]J_F>Y?KH/3-J
MT:AQKQUFXV=2;?%>/T>.8W,Q/C99K4|M|YIERPD:G\$,8ZT(LF784:SQY)I5
M=2RS\$-3I(J5)\$WZG=GC1|H2K8C4RN&L>;Q\$@6PRV,8EHAQ@|YK|&J-&LI-X M.|5&+PE2\$DJ7L1B.JKZ>K&S;)2W
|0DI+3N>W7@<^P|@>V?GVES&D5H|MVS..?&;+Z-C. U_8DAB.DO MKP\$XVRY9EM"BE A"H(X|O.).JQ9|
[_ +7/+ENH5%.U7H^&B|P(|)N#X|JF#*+??|7U?7C-LE;;,="QJ'=1F%L41H&ZC(M/%'^_ H2_8>0,6+?!OZ5(D_4" H="&UM85TK"U!9/X
5S|!4H7R%|XH9'V, M65FAA#Y^>*|Q(=H'(/,?_J\$E#CWY;549X'\$Q9XLMQOV*192\$Q5|N4HZMT" MXZVQ":CZ1_7!H*4BZU0_7W<-
|C)#FCECC_E|617|F#FO&)ON|+)+,WI0MB%

MYR80V/LA%2XAVKR3S9I3(:~I4+3H**F:MR0S2(1V9\$G&C\$6(3L(QW'+Z|R@5 M25D^T6H)<3R
*2!J 37GVVJ9KF|H9PK,0^J"U"C&,">G|IP?*E;V|AAJ|N MLT7(2XD-D>B0+3XSTF)\$=,?KRG'5X W99&H?
X3N505(MR,&=OV|=4ZF6UE>@ MHRK5\$E@U\$U.1 5(MDS?+,VB-?)AZB ?!#E8#+#XZ@9(QNX?U#6C-E!) S9L
MB'(VI)T=#^8901^Z;,Z%W##YQ|68O@XUF|@ZHLG0-JD+N4[2:X%^R, MY\.#@"L; F)8OE&3DFG3QQM_2+?
WN^BI|JL9J3W.Z2%6F@9'62%Y1C.I+!5" MQQSWUF,"-HE;,*I-U5:R*L:2IC<"F,P@SIYG-/!&60;JH=C2:A,>F*WRVC
M(#QNG5%8/A7ASU|F M)J8^PMX733ZO.6 O<|&\$5\$1N(T:0W!N!<3:ZDZ\$F,;^"XYGA^*^|+7P4V((4 M--F(|H- |O|R5)!*JB3*-
B0SU*P|MDHA-|B|I. ""<%&LXR"ZOCV?&@ ME1"PI1M;2C39H?7S2V>JTS\$Y|>"|CC:G?;OKY,QAF45E>+WX13GG5=7&;
M/BRK#T^TB-.2WA0IO'K5/Y;UK^6IRJ@X92RLX1\$#TUN^=PQRJ+3M?JB V+\$" M,U"M:O!0XU;
A^+"\$C|B\$.RT*=M&)7G%M;>\$95E4E*\$S24UNQ, 5E\$;HDB;O M94'T&?E:4XHVJ)%D+^KQ02A@7-'%!!U>F_TD"CUE=D;
GQH"E9K2|3JU."%4*.'3;R%+FO9JR0MT0=6H|Q5|AH 3Z,KC=5 M644YQ,29|A/-YN,UAD^J)+:P<.:AC%I;G95SPXJ0I^0JD%
[RM2DJ4|5(JU M1EA-4'|^/@5@GR 8DX)*(H85A5<;|BY7GRF|:0KOQ1EH0@_|[:2(1S4>U
M*4CUH0>5L IH6MO)&BEC5TI+3.C.W+Y:\$@NUF|36J.3%(B-, "9(L&OH|YE| M|>\$SFLIJ|JW41.|->-[3N#>)R5QQV./3CVZ32I-
M6;@.HW| 4/T)7'OIY,W M+O^1YAR1;XG|V25YBG\$NE7I8Y-66,'SFKV0.V|D=-?[H080*>B'02"L),N MK1F2@/X\$*CBAP0-
L09<<#8|/MH#!%:VN%W?14W|QSI?P7WL#8T7V9 3|!#N/ MNRB2C&,7)M37XH(Q=ZO@|T83E405M:3S\$ 9NP8?P=D'@L+ UF_VHZJ,
(NE*K MNPO)AF;NE>T@G>-N\$;Y=<;U|V>NF0A|JP&^U.X|@7%'87C|EW TM>W,R,XF MT=)?:&\$F6|F_5G=AC51L|
[88\$M(Y94;|>J]. ^57C@1' KF:(SFPV=9JN M(BS-V(U-H|'W+?@Q2|LA CYQ=6A3"\$)%QL6?R?Z:DP6?
&7F\$J9+38%F9 6|Z%GQM04G42|X@V4>JM!H? M (Z42.TXOB1&"Q"SHR=@B| D!#0RCJNC_76XQ&R4\$H\$0?S+2D|;D
MS(!.COACS@\$G/QC%NW|NRE_1_#"SCC.,PDUP A ||L_31CHX1PM,0|HKK M|
<9\$)A|J3HL3R&#Z:C,NKKYF<3|J|J|O/X+AIM%I^@R:S,\$D+ U3QHTJLZ
MTA+BX\$U2^E82NQG#EA:N')@YV=E"YDTH,F7|GB@A'OC5&F|F.7M29JR--% M&D.5K0/6RT@#A_>=EB07JY./3USW
MV#0~^TP"N>, T3ARJ\$P3 MXSWPZ25%(WOSKE"C@'LZ#DCA-/FV8\$W4JCDEZ,LPQ|4L>4\$CQ96Y|V<\$-W2'<6Z+A2LP M
MSS^VE&!LC@|>34KR&72_VCO|G/7N^66?D^>:D'Q#47"2P@&+>+Q|'9|@V7 M@TVCL3<6_ :FDUXL/996NHDKY+
K?",ERNX.Y9BT.#1BKA7=T^?6@+=,CF#<^ MN:)?PQ\$6:*R|_X5Z(SG-U*VP_ +@_GB^3+L'@#\$&7008AT|<8VT^+S93CYJE
MF3:9"FS=>J.YP|/L?DOXI6?<|>H68|G;5O..O:IWM_|3<7VU>7VI@N M*+^*)48,IJD+R7,CH|MFNQ|;\$7.>
@|(P)%4=GJVJ;@ OTN|@0L-ODPEG7C.4 M:810,IZ?>KLU?UOFUQES|\$.O,2,AVZN'I+E0:7CVD91|E?>15PW?*6|5#.C."ZF)Q\$C
!R(2#!N=-@-?7;HR\$V)Y.Z)^CHH4 ADO(P1'>8*6|S@COL.)" M1-'88A,'HH.'6#1T*QY2TLN/&.(##RGCS1C:U\$042,,PJ G^AUB%O)
|V|!\$ M0<1 =) XC@ (DR5@\$^CJV,%1'N+2/V1?|? 2J'5=H*+X|&8WGP<:Y5+@B8" M=C O1S5EF1&Y_*?
M'3M>U0VG)N|U=N^V\$|K/70.T|,MY: -X.Q4H<"O0\$R<' M+2<+DW9\$WZ)\$W-Z.09 9,M,CQ-|%< E"YA M|G@&ZATJ-
\$*#6,&1G;^FM| A1<B0=IX,|X_|@1L/A#M49@I2A&6VP_J%6 M|O,YJ<KB:A|R'J\$?|<98+6A/QL|Y34'749H,9XS6|89GO<'A?
1GAQ# MV.8MSFTWC^J=>7+&G;ZD?88IDLTR&)OR@|EJJ83|NH>|8|!# PO(| M#G|P4-?MAHVR&QG>>53=%C|I|(\$ @|
GNC;A&9::NJRWNB^>|!#^|?V|-X*G MX)N_<06#)O5C/H8H MP?Q<%M6GHOSY-R59RVD6_/OA%-B<1AL4W|K=1^9|1M\$#=OID?
UA18L'3LL? M" :U6IY)6BM|/|6Z(|=U1/9WH#FTC@I(8>Z?P|B|S))KK5\$|^ 'C8'?G M*2F#>%= :8)XRW'9@;H\$V|&=\$
%IU+A|RK*LO>;,LUIV?B.=+>05V1O.T M^P5,T@ -M.G|R<@T:>.6#Y8TR|8.A;Y&>|"H#.:+^0!D8,'2T.F1Y@CN-P- M/
WH=);^L?/Q0#|K0OW+J|)=<?>F^|3|!T6J;|9|Z7G|&IC@J.OXF+F>R8 MC+6+S-
^CCDZZ8)D+^@Q6#M,M@M#LXN TT3XV^B=)#M-[9PB8L@P)X@ M?12'QRY=U0=#
[&|*;G8"H.EHL3@4#ELI|"0*K43G'R|7CM|WF<-4LM4G)J7 MY|5/'90/YT555M43|Q:J|HLD7,_@*:;V/K%#;I7L3?(V:\$?SZ'!0D 9H
M0)^#0S(>N|TH:;#QLOZ."N">4,@0&H,T)\$5?F9F MXPXTXV|8CKA^ X9KV(*@02VP#7C T>8SAR.M4@-97,5E9@J.%|J|H6TZS=\$B
MM7|83|*U25320B<2?" I.T)B9DHW;>E.A+C10!UXNFOOH+41&IOD*Q?B?F1U.1JR H.ONX 5I#%#V|J(2H|M|
ME&Q1)OVN!8F26 KJC/4^(\$L\$18SXSC\$.7AB+M|A#E=4G|"?F(35F)/YW M;XDHVY2E-U\$:*71GT7KM(HR@>5)5-
(\$YD'S,I+^EOZQ288/?<1J E">2\$5V"#79A|YVNM6:@%="J!WD5/%PF? MB"@B'0B,Q V,M\$?
KH(IQ/QFA'#K91|VOF",RLR8=&ZO,1QZ\$647>4*? @J5 M6X(4|? 7E|WQ?-U8)%0BP|(-J1514%-IDTBITQ2Q|)\$#>Z|4B0:'VJ&9HG=
MX3QQQ9|9HF\$3C@Y1DNN3Q_3W_KDU79|E4J5L9M*?I|J9GZU-8WMO,L&@U\$(D^& M|J%?3HW?>^|4XX?PSU^76|Z->7DFN|JV'DX-
WEMUGUEOU9#8;>8,[E=Z MH \$B)|@N|7|F|JL9F2/>@7OVWQ^%M2IKM"|LUO_HW4#|WQ:ZP1|&%),C9& M|T?>7DN?HDQ?
[3G3N0V|4B?Y|JJP M(^19MSN80X0Q(5S|1@C(|*CB5+K/DX23KZS_N4QS>JH4|0-MT7* 9TQ/AT - MAKHA#U&5&)|,O/:X7'|,XDI+E-
VP4AA+Y_ =PEXU5SY8F7:=* MF@\$07A-6M5B0!@U^M6(!I9,J0O)ZZT2>N-JW^AZ<.RHLG|D1;10YWIY7IQ M4-H(=J8P9RH,9!
<:@3+>LVR|)(8@-/2*+>VD&Q|QFY|X1D| B|@/).H9|Y M<OKF_KO3>5^<%:N|2CYFT7X-JVV MAAPZ.*9K3AP\$;N|J87D6"&|*#OT\$P! . ?
BRI?P2U&1/7"NNXJ|C Z_DVJC:=Y-3D3O4|^3+25H?XRM,OY(G9=BT3|;R82C M>R^"&|ETDGLXG|66W|JIG\$|;2<>#YU101|J0'5
3SFA)LW XA%5XW\$,YU,? MF_0<4\$K*^5#;UA91=G_3==G+&|Y@TUGJJZ|PSJ6WN7P F'3@|6 6^G|Q| M.OP S?RI-
70A)4,F|L&V6&6E;TSG">9H13)6EF|(V#%7DQ.%B3IA6185LH-H M&<9;P"S(BL/N22>|.Y+FX*|ICF|:AD4C2?>IOVAO4MG01X,"XT"
(253RHB M|TFH0|X8UN&&TJ_P"/LU:FA3WS"MW;#;UA1;O-BF P7#C9;GWA@R? MJB(#PKP?|#@P1GBKHA\$?8(N)WT)
M5-2D^+>C(PA_#;HG+Y,6-22WW_&V67Z7XW|T-|];^#X12_|IA(|J^C=5XBAO&(&8RT4%).FB\$BCC4(30# MT7+BF_YN-
@WO|Q|PS(1HQ8U"7,&0 :O M/<@()JF0-E1(L&T,Y4S|)GZHBST&<+*8M*V9M44*H:T)X;MD6<)W MP8=.;."RKJVVCC?
>=KK^I87A5Y+IH (9(1(Y(I=-8B7|=3I>|WEASKQ;Q"#.. MM\$;RGV)4UPQ7!/V H;|M<8<=45I /ST.=X29-1J|7=;:[3@RLB&Y2F3WP
M V %G38@Y|*NQ@2\$75.?HH-,;RFG|G4EKS|^J>97NL M|P=<7=&<A--55&T*SH&C'E|JADAAI-Y3P|N 1 3!4"C4E
M|9@.2;R) 2TJQ|HXNE??Z(>*<=B+0S<@7 M96|DM"QE=<M#U|; MTBP19KMU|P81*KH:1L7|50|P-NC(2ABVPOP1*))Y\$(M|PH
EN*6J;|I0 MG9\$K2=4.RL&E>WM(N9L)2>^RBP\$8FQE<Y#T^TB-R0:>@^V/>>4S@>(KZ M+ FM(2;&|Q5NIX-|I|A;4A+)>9/
@W;J2,9%;&8(93TJ(>R:Z,&#&6 APD4 M_|')JQ!|:01 HVMUJQYH@_ ^U:0?'+>J9|X89<6#>GFSQI)QQNPP-8 M/-WZ ?
D_WK#*|X^YX<^Z7%@O.GOUQ9J(XPYU@->|M77HRJ1#%U=S)GII69B#C8M. M+M%HG*OZO* \$;(-I7:G9|= :!H2^043Y8
IX=4,+HME|HNHQ\$1PRR_H >17" M=DJBZ^<8>6VNI@"5R.YA.RAO4-ZTV|[E2'U7_P=3T70\$#EG5(^E60|JXZR M\$)'UF\$=9DK#J3?
2UKVF@7A=W\$^>^RW+>U?'56J|U/_U^#CIHVA4+>4\$B? MCEGM(N*U)|E;DOYRI+ SJM0*20K|ARJB^TT6?>
L|,NI08P/4Z&Y3(%LAIA'B M4CN1HYG-M?F'7&<#6/95E#CIE,ZO/ EYQ_*M.DJJW9%AB119,5*M3\$T9|Z M%A*J:|@\$T"
(=O&9DBQG906VV3>\$Y:TIJARG'.7\$|F>55)G&<#&16|/T M;|&WL^V'Q1T@=(X<0#9G\$HE;+EM|:9PX/T_/C+L\$.|YKZP ?ZCPP#A#?
Y;L' M=M<-J+;^XG&\$^|= \$TBP38A|_SC6|3C4H\$HO'Q8VY3*&+7&.L13B4+>+6K0*51 S!#8NA@&H'S956;=&TZ8\$A>8!6
VJ.HO1(-6D/-Y'E*:/+ ^M;\$Y3%WE=9R9_F\$.R4\$A\$TU>C="1IDT|@V%0 *0T@X|/O@X6(ALJ< #Y)%@QZ) M6OQ^"!-
"8G<1F=N5.OKY#NF\$*#|VIV|'(2A?84ZC.&|<9RV\$>7W1KEH1W M(8E&-QW-3%8,>?
57&A6|RC+L,ICF.75(67|>DW7^39IPS1Z>/L7&[ZOP_ _\ M;7(C/?*\$+|JUUE^%).ZR\$5JJ/?= (\$ZTUI1E?F|TNUJB8BL|TPP18 #XG M
B'217HG1=],^FVJS60XBQJY&=\$H@J99YHOC6.,P7"ST9@?+K#|7%CK-L^ (MY|AKE> _M|!^C^|PTF3I|Z;\$W3^M-
>XYE:Z_XABG&9LIWR54Z'R&#&.*39 M2(I^#3^A0C\$|.KN(MVR!|_/PZ?2YC8BO&.637G?^T/I?ISUF#PR-ZR7;Z! "QGO [FPV2/:ERE
@0.Y(AF9F) M+8:))3"QJH-+&@VMM268,1V/OS>3W_/|I|=;/'8Q3D=3#N)"5SL YLT<8X25 M|106N%;M%#;Q=8EH,'MN-54-
;_JJJLCB^%M;W>2#|SY# 3JV(WZW9#|M^Q MX7WMV#\$.|'04 MPJ5G%-T&B="J"EC8Z'N|EX-BD|R/RO? KCV|_ (E0C8DZ
MVH+;.:3:PU UJA HO-:1UH|^O@VP1+>V<4P'A6)Y-I,Y3+1F3;771D=\$_>3|N4(N2\$9"Q_*E&G|T=<9XNN1F2AG;B\$%OG M=
[79;+CEA.C#O1%|L4+>+F|DLS6|R?;QK_ML'R|.4,4?S(I'F.D.RJRC-:=*4 M+9W?"\$V(O#WG"|2.%4)4?
V.Z)#M,0#.C3,0)"=3I4B+946#>4@2#2R< MMF:|<6#BH(AG\$(P,HF+&|3C7G#*1>ER>Q|V|)"I4#>=&9GXF,-2U9B&#I/
MW'L TSQA48 H_">+<7N69GVQYCM,?LDJ?Q761"5MRD@1>ZSX20Q^&L3L7 MW":9MQLD|J)V|D8\$1LG5|FC) 6C'R*'
/9RMQ5G,F,3>+A| 7XW11K3 MGQF_WJC-5*B^R\$N%#@S76ZV#!%8S(C @VP1T31N.;IPF*TF1>;ZS9U<<J MITV=UC;?
X%FT3JLH&ZJ%:3@ DDGU 3D/T%Q"%\$(LMCFE(P@,8L|'3J/G&B M-!%KPJ83VN_3IH|/@'4O@7!^ 78| 8*^ 6/?^MU-12;
^%Q\$164VH?>1!EI M6+P Y(D#K%V^H8_Z4AR-J|3D7V;EG_ 6% N"RL*2)NHXH|J6WC UC2W=2 M BAP@ P!;\$B#%#@|CDN/TUB:
65.EJ|(^D.TYV.J ;:_.%J1?1V< RA@ MQ+75&\$K/;+>J:T@Y^K?WQ_Y.(MS#% 2<D4R_WP^_S_>(N7J.) \$AZ?> MYF7*^E,
F'1!Q9(,#^TGG&08!_X'|MSPFP@0/9(C\$C+1JUTS=Y=1Z-%6/R M,3NXB7|!B)0UT7.V#5W*1OHV)=R#:SK7.Y?8 [B@T'1%RHKEY&
(^W@|/ MW6(+K5_/J|^B=C_D03HZON=2(T^B;*DAC L2Z2(>*5D>9|S27|)&)K.EL^H M3WQSKS:K,WX^IXFP%/(-(2(X=
(XLO1%LG&#&D(<(<.,H33X|_, 8SG%7 M8T5JM C'J|;:<|QDO.(:;\$I8ED5%"0>%C*':?B3;)HCM\$_(J*I/H^3'C-US M-7E5\$^J>\$V@M"%2
J4E>Y8|@P-3ZHC"0#"S!@|'FCJ|.UBN#E92M<&H M|)MC.3_ESDD#%|^!-|WIR4%)G7D\$T'65',"T'K3?>
#)LIF/R98LS^9ISF2V=4.HJM890M#859123|>W1|^J. L&I1&|<3K_J>VW MFVIRE<JW#;=&K8|GVZ.>??WY7/MTVI;BN(1OTZ-
U_?|VXB19H M&08XY1*). "T4_T++/UZ0*,Q+,2I9>"-LP7%|FV8!_U-P|'"X>/3=(XW?,JF_M>5.)+B,)ND:S-_R_WZ|/7|QSR?
X6%:S9=Q%9ON-R?_#Q_?O>--WC.P<+5&: M|S&)BO(2L|L&|+|X?V)LS4BV++E@G)406F1H|NO;Y5WV&&Q&XK3|N_9 ^=.*
M*0_RU6"WKJ;8665(<1I=BW9#4\$)B5XPSVF@ M&PVC^/IN3N?Q0B7-/I_E)(II<)^_#%AKX|Y"6=).^+|>PGO4/+K6^SBIZ\$

MJQ#)UN+IB)YC)H)AL)C\$J,;JTE-D66<=TRC,/D?%&:G:7S"/EX=98JF M/5)YLM:BZMU7*,D/F- HS5D*ML:HY/+ "\$;E7DL#-)X ST(VS=)YF[R0F7- MS5)]&X=E?Ji:FJ RDK;Q%- (VLX ??HPBQ'6?)TC58DRR44"EH:H/\$V"U. *M^-=3\$BEJ:H)*J|H993N/>Z3FM-Q0)W|.JFRZ @^?G4+&J(F6F1EUX6)[S\$Q (ZJ4)F1Y9995 M*RI;? "M28T'GOU#W-,3BB? R<> 4G"Y1-F="")*1AWS|/NVZIVV_#Q/:: (S0Q70)IB|5&T|Y> M"S0/D|65|XCKY"AHT2=-A,(/Y**UVQ1DQZIND%1D3\$A"VXN|5YK1J2..9GG8!UDD602%9C+)?W|Y_ M^X8JF2&V|91|;RZ4-4IAL;?O3.*V\$E EACP(X&K|@X(BAH^JQSRT| MN|B.*HI")##+\$"R1#VY(1!*/ HOBBHQN@B\$6/P/>+A|S'MH M&@<9<, (Y8N^@ (L4K@H'+@QY6\$6N#@+QBE|5Q*(ADO\$ M*?M6DM@'EXA35BT@20HN&: ? L6G&?5P@CIBT|B0N#<@<6,E*01P63ABN;JS M/ B<<2?/=5,-GX6T- >|73@|N1B24|):8%RS,ST+>OJ8XZ|O;-0H<@>:> E".7I MH%*WS:2|S4)Z5T|P@>S; %Q5A*\$DIYN /%X L,?./U*LRF60G4-^AIBZ-? 9H4^8)D^)|H5G,BZF&7@W-*"SCU+UO;I5QV\$6GBU\$> MKC9;<9-)H=?9(E _J0'K9)T/Z011=[.OWJ: 'L9Y>1F8RGLF82OB!2OQM|)0*3CPO)OP>; M&* _XP(>0\$|6 725=DX9:I&,-I: <<|JB(2&Y;0@'PUR53)W%?9;?*S,O|:4" M ?F2VO)QIM+ 4LGH%&8A|+IZ-E9J 1F99B;?7&##0PTU(D XD^!^1P5&0 MAGF1H8#,@KM7Z0G2J)R"\$-1 2='N'O|N?5PG^ES|F*5ZR06>H9L(HS1B MDS^~OJ*~_ S0YAT0=^JG;-4 *|H|N| Q&O\$KZU|U0JQ2G NEIFB M:7N8AV;Y#L3?>CVK|WQ| OQQ^E?|=-;KXAM=?Y%Y|HJHCLHP_ |#8N M\$C2=(1/\$/ZN(S)HYU- 5P1B&Y\$TSY9LA6QUNV""YFX_ ^IO!RC=-/+63I/Q 9,V|T.LT\$#YJURW= M;C| X8,!.M:S*U*!KU-P#,2YX%Z/60)CB>0= M?)8 !),A%X'O>K%@KMG/OLDV"V=X3|RD|F@\$,LT29#(G8X,P'67H-LOAXQB@0 MYO%S8 DCKPHQ|),TGL1+G)9WF_ (+!4X?5 _S<5ZTJ->IKE"M^W=42/=LIZP+ M\$A@=T&,(('\$@!=?"?@40"?\$3#6D3CV=B8;+V-|J|6IL5V61)\$#K.XC.)Q0&JYG,%X9- |@;+M94D)#N|PVR@8Y9H|E*;# MFPRM*M*/1|S4.)JC1&D=9+P3T*GSB| ^FD4KN+9|5BF^R4J|W.GYZ7G?6EN2K< M|Y^7C#=:;7X.+5;KE""S_ 5>A9E@*5(WMS;O-|D;FB-WAV C7Y^VGTBB3|H M#^!1;H|J|>Y3;H|P>Y>Y>*QJLQ@2^A|HB)36>T'17ZTZ/#A/7|OZ:&RTZ MZ:\$Y*337IX=L <+|/G@,(U|F6Q>DH_ :B@4:0*|@* M2%VT'0-7L-Q)X|Z|>).>JZ@!0314X#*J:R|'JWN9A(|JG^WQXX.)AE+0.+M M GUX? 2INIP^"5,QK"50.5ZG>OP<6((%N|((G:O-5- ;%"HQ3UJF_D(1;\$S\$|L M=+)|YLB)LXYH97|SU56-1C?N|P\$D#R|Y .FP :3:78 _JAM79*V>L6V@208 MAT@/P.:T*X+P0) '@1J?'VQF@5E A7X(<'E2.,C#1V\$?_ 6=32\$),@HJ3GP M.-&PH(WQ|<Q^C^@#\$59XK*J27572\$3ZUU0&NE?D0(7>+@7F:S0<;K M_X^? W^=CK^>QJ,QXW0G/!KCT1B/QN@PK|0?22M3;>SB;:%9^=M|7JF0VDT9 M.ZX'F4P IW? L8H##F_XRIR;+BCZ'XWY:D;|QW<<,Y#&#-DA,%U&\$%V RBN)* M9.R|7^>RPQJU#16)*O^99/8G)BNU'9TDXKZ%4W+@#- \$V;UMMFL>9 4L;+&J\$4+E*|@+|LXTDQ|7I M%<.HC=S^|-C#0)>+J|(ZG5_%NM@)0-?1/NS906#;|,HJ&F&9D^:R87K- BOA#V9B+&\$ZL M+8M|J57_>+&V|JRI P*O,K0*k?;PNDK>|47A|>?"#4113 ,DMANF B;U*D0"* MH7TZ(};8@U :I/^'9"J|0T7F1VV>AB/!MEL':\$K4CF4'ML-A|J|N.G+^).)|V"X1T86UI|#6=YI921\$9?F) 90!>C>)R& M61CDY"W'V6Y@4:#K;YF|P6YB9V,MGA1'PH|77%=? M"(D?<,*+Y)XSPS.=8UY7H-R=7_ ^64K(RG|9X1VO@%,/9L M8 ;'I9OQ4>YOZ';K^JCBCJ* "D;#Z;WN=-7J:Y2K;Y3M*",B5Y#|J2<%|&E /"#2|H14|Q=),=LWEIYP=&'X(|I60&9;|LO8S|P6S16"2H? M1;L>1GD-D@I+Y6T2S;|U&=?0TDGE1D,2(O M<'B'YRS3_ 85A9S?)I>LW4LRWA*=AI?DC3;_ "QQN1('5TFGOQ?Y\$+P#(7B0 M#@W@^S>@T|5C80/<07Q|7A2?EZOCV"-N|BSOP_ ('++|K<"<\$V2?HR55W1+7<+ M^C9B+6 ^~ E.RP0|V@- JY?;+.'?/X@J9)UMNELNF|W\$+|=JB\$HGIA%0JM@! M55I^! ^THF'F'+ H@6*BP25J3.LN#Y?1|A/R^PKRA3R?L;J);4Q#A_!>;!G;?^J M^@J3*?W|U2NZQ)USZ(I=/L&L|7.9U06BQ7Y0W\$W|JCZT8!XO:Z|(""%\$P+D MVRJFD_?JO%G\$<K|@ M _T81,|%W|I4Q)*O"- E)T%3|UN|!)(FG|_0G7J|V.K| MD^Q!!JNBM>>PO(I!&BYVGT22WO4%;G, &:=T#4Y>3F9*/8|(T\$H?L):=QAEF,1U MA"FZ-"NN B3O"V92*9;('C|W)Q?7A" &WN^X-O*Q^A6^+9+PEVSL;M|O# M234);U .P1=5_ 7L@M2"Z|5T=DPR=) (5|UL4+5*2D+F@.1^L?;6UA/ _XX+<+U7U&^(/%Y>H|HCM|EN\$2U;Q^!0^_J|T/Z>& M|!-48J4",FL6T*Z&,UN&KI;,Z4/*M&F15VQIB/C6/!?!\$N#^ELI.79)T25*V M:AHAB,PC0KTSW|D>3_2MH+'+3G-W)4UW M,5?D) (H;G KSSBD18A8@,6C72QP<.+I M"O" P\$,HU+<+5+D^!|=#NG MRUO'3A^CI&|J?<96=;Z#%=7,8E| ^J)VWU5\$&_#:=R=B6XE>|J|: +?|(\$E5? M\$B;0UY(=A(OF?7%Z|AQZ:Y/EM2J7*._^1KDZ3|J62CYM|OY6;O.(X6 'D/@ M0|HB|/4Q?/* K>- G:" Y8N^YCRG|F|&J#6V;?%TAOIRD|QLT+U/;14R(VEO2 MJ6MNN#Z0HWFP^DR@JED7")F5|IB-B\$6;F|ICD-IAR8?Y^Z+3A_D|P@E|F- ^' M^67X\$<2^ (XU,*5O,YD|T"W-/A^@X|(!VL?>JJP3>A4^<5/YN-(Y43"JMK&UJ\$EI2UR\$F4 J MU0VMT2L-DHL;6J- W|Z"AGY|VGTBBGOH#^! "5^1#5N"15|3Q01N9A=U@S2P MG<(5*GAL:9KMRMH|\$N0"Y3@* M\$|T+S>T2.6AXI =./:ABY)UN|J|^% |T9*(FF8;)71>+&52)&|O5GJ*47Y)|JK MP|3SY>EX<|LUCVE2"?!.|YJ5=0^*7AK-YK9=|J|#S"YXZD0D8@Y=0>C|&| # M^'6|N|J|NK4VIK,M&G%J| ^R/NK\$(L+3\$7<=CVI!| @ 4 |L(ZHWD|""O M,L|)"3SK>|UP1G=KGA^ZBK@!|FLH\$,PY=\$8Y'R0:- DEF2A|0@Z|D MXQ'802.P@|U3|A6|/ #|KJFW0&>D^_ |3|\$D_ :ON4!G:IOAV|XI'|10@G M6% _C%Y00:'C=F.2; (84RU5YLB|*ALDIJKN>>|477/55%!=?.^9&6J\$ M\$J|Y:A1K_H| "6F2ETI^GJR+G>W3\$|A_N54BO5X|WM,I;?G_1A*V(218<6.\$ M5E^K7YUC^N=9AM|YRDP<9B|: C'8GN=&&<^XN=^Q* >N" **VOL7(-W1** _|@B&WD1>|(%#;./8 MG70Z2-RRL?,-#|3|C\$A7Y- %F@8 Z"V,/ALKNG|A@&30?7>@ (P%)T#N+|@V'C&I MA0|75,D73QATJL@0#^U= W8M!+|^!|A, &MY\$|UC,DP%XP6'|LZN,NQ|:3> M+M""|T>?RL(F5T78BH_>R5L!:>?7XZR_#10QF);.8 M0.|9FLC-L.2?>61|BU>_ VZL4EO6|'K)>WT|+U^&2:=JUKM2_S1J->"8J4- M<\$YI@>*3(F.6??65JVE2_9W-D1N4W>-(-6+Q>;Q|K&B0A|AK1/, <""B;54L& MxA>1D&R<,Y|G4;,0|;UQP%CK@/"KK%O- 2F)S|KVA49J|\$HL>?C2A1\$I=@ M-J450?BC?/(&9P=W<*\$;T^L 3^YU;JX=X-\$^@|/#| 1X |T:J 3@Z9QHP,| M8|@OO&0AE|A#@%/6" 5Y^~BZ>B|J,)-A11V*?#QX^*+K7&VT|D,1,S&|WFI M9K?A(T|J|JRY6+YB|M;X#F,U| :&| 2DKBE:WU^~C.*T0R+0A:"UAY"|4U M/)KJT>C>Q<|>| "0TW8&;TP&B1,UM\$ L.RX|!;+\$.?|+52DIVI2QB7|K M#Z;AZ"9=FE8D>A^G5Q_G|Z2@.4FO%F&V#"-45*6YV+02IR<"NW1 W 6.^+HW MF6>H5"=:?YV|M&VG912^GDR8+F:42+ (W16T<=4@%I+XL)?5S?=%|G3-WKB& MF.J(5/7I)|. ^?|E_RUIA)FG*1,'4.>./SM.2)1%(*)AXW3I7"IN4SGFMU^A M;5KP@L2>57- ^K_Q|:V*+&J\$.|/W-3VU2W6COD;=XY?*L59CD4M?W|@2\$&- M\$GXQW147HC2Q6MS0&KVVW69C2,'JMW_+V-SJ|=|P-P(ABA %|DQUJZ>GW2>2 M5'W| 3SXY4(2:<^>7.Y!W'D2M?FBD4|Z|J|##=H%|L @9L) MKDA)?GF*VLP>.^ +F4P - WGL8H#CWDUM,EBW\$_ #J3=%&^"2X IU M763M?)?G8%XAYAH+/49\$S W& ;A'5""KU9HY@'SN)-#BNGO%P+|7S%,^8=<8&"J. (|18KY:Q8JS(S-LD M^~*| "Q_P^'3;T*L1Q@'HMJ1Z3?(&R("JR4NXAI2BG#IBGL N'1"WNSY>HPCA>V|RUY8E433M M@)C? F|J2K&2^VM@G:7R"5H3B09@>N'V?|5T&|KMW1356'HS&<2Z9WY;%=K1 M|O|)N|@|J*N2LI;URJ><@E/2L'*&0'T## |Y.D|I04SU2)1=\$W4S,=7 >\$" M0-1RM,NCCY^Z'S_UQQQ&@4Q;DH08%M+R(IS3\$ "DL)#<7G MEB74\$|D(Y%)R2 M*@C4LN;:AZ25.#^?X|0,|G#9@0"

&2Z5V1Z7>'B H=W99&<'Y+.. MA75V-7KT0|JTSM'O.% L?1/Z|J|_ M_(:#; 2%|7%|*,|73PIFQ)^GIV&6LF;*U;?O|P? I3Z,2,15P6|(I5L3"E|PJ^ MJW)K)+=|@Y\$;W|AJE*>=G7)+XPFF'|D9 JX@77R M&1\$^ (V+X&1\$=@P,^3>)|PTB0T|172R5|GH/ D:\$Z=S,PX=P|*68DT*314ZCJZ M(B|JUXH|V=N=*QDN'J62W?5T1F8N3J|M5X0"7OC|03?GLJ@Z.#ZBH-TVM M+56(PA5%ZE94M;\$05Y+TNA55;=#%0:UJL_#+\$CA<4283>?-C2>_T>?.@G\$X= M*+6_G7Q5E6;PRP? 8N*KD1|3#|OTSYS4S;Q|W5;1R3;/A+;WY?*>IZI3 MM;) ^%K*^/W*HG4E6>K0P>5|L=)LW2|@V3)7)7&LKK|DTZ5|3I"25)RI?<(WF M1<*">KK*R Q16E;QW15ZSD\$SIT7B0|AC8G|KCW@QMXBLRBMVE32#^O69;&UX M4H%RI^U,=5-1|(VN/I,COSU"V=YL 4ZVSI,GA- ;GUSM1N|J604E M2;ERK: TND2 PM3^F:1^_C_ 'IJ7,^26;+5G)JJ@B^Q/ K@EQXQ.MF>8S8S M/C|J|HSPA8,O,A|DW|^6*.+FC><; <'1HW^~KCJ,TIC =_17@>_ #1)5I|(P> M'+UA#|G%L7+^/RT M_BGU9B63ED|3PYV3DVFVHOFJ\$+9U+Z09NZ5CSQA|J| MZ6.T"- ,YNF;|V.ELAH2SRRP1ENYV/T;.,HBJ3|KV|P25IF8:3Y8DR_ \$_0TDQ M<9VN9J,I4"GLUTA3|,^YE:;|I)S? O|Y1YG.UGG*RM"9V,>4SZ;#T|JNM@N-I:(!?A"N=AHK|Z|>PS- +VVG|7+WL M%J0_6V&'69-U%N2ZNORN|2E@#Z I2T03N QX1HQWO_./Z|C4\$=O?E&PYN6B|/ MV(&8O?TV9@M2K0LEK -7M^0V?2.1'18DX<[5&D6DNK|'G=|@AW+AH#R4^1%|)=)W9"= (@&C MOXW90N">=N)K'D|TQ;|I6VT'C+WOHF85<2.1;1;=:JY&W'7<;|5.|/PLTS M2%RQ%LM LVRC YC&6|JHIEH'7Z@'NP: (^BU@OO|VB/#F:5|4"JS3,T73&V M^I-M|R<\$^MOHG-)QNX=YP! ITVCNIQ|HIV|= _4/((E,>:ARMWK1,NBL.ME* MH;RTC(W'%;J|P:O@>|>RK|7>:O|&AW3(OS'Y_NQ_-V?_VY^GW?UD50R'K2/3 M&?>47E\$,Z.%JG9W4G5= X 9&IL? \$4<")J1MQWU:U%;6^1>4LI6-7UB0S= M6*0^02EKG;9CR^+&M;1U9WH1_24HV4/_ ^U1|J- MNOI3-.VIM'56:>+OOC4JF-8T'YV+A-? \$R.2_ %X|2+?HT,A=65|JOK<;VF M|2V)EU?G|=M?9R1#>)Y6MZ1%NU>AL|JVH_)543NUVA|JUB;?%?%WH3.0F- AK#07.##A2?'QG|TIP;|D4% 9%"04%. _03JG#5(9_#TY5Q1# MS2YI9^"ZHC1:|M""2%TYVZ\$EH1|/(XA/5Q+5DHLS*DDF&:B\$<-6KDPO8"JL M'NKK618KF'OH 4=WLU2;B\$H'|G)EWC42E'YLS|JG MK9,I,\$V5PXT-),(>A MOQ3+\$C77X+D",36Q1TU T|J|_ KZ'8>L^@,%F(;?=\$-G@3L4#T#H1H*M L3IU |.?:.1 FDUU+DLW?Q1|;|STJ3^~L,K|?GI=EF=QJP|HJ'TY&9D^>3C M?DN.)2&E6P=QFI47#QWSHWA)@N*3(F, [<#797I&EV;MA5FAK|D|2419AB|XR M^T.G9MC|_ |X&C|B9;&L_0+Y_ U3Q7112E7=|JZINN'9 M4&N,@=IG9J|12JCF:>|405I3A+1)VYD|M56W--9|87|/[^37VL|/>QS|_L M> Z3K)_2(QW>5&9JD)|JG6|+54?K;-U|3W58W.DVI*_8 3=VOHU/>X4136# M07=G;|IT7?73=>L-5.*P&,.=QX(PTL)5>DHY?|A|_KF20@-2E"4CABH#\$ M&B-QB,?.O'O)E< 28TJ|5D0,M|HG&N27|@T,L;^W4V>|!FH"HSAA(^U2^I@ MR2^Z#GQ_N|08|:4+8CFWYM2*K./85@^KE,TT|:R@^4)N) (VZF4).P_E)G M+=V1V=&R+|S2TI&K1/M<J)O*|DYUHQ6871*^W M.^IL?RK<^>7X0H,<0.)#F M"(Z#.>Z.:EN:~3TN18^UZ)- KH7^QN,S+MS|N-#9&\$BC= @5|:FC^#&-=>PQ M|YH9*|T"0IOGH M|J&M W6EA.:W&TW

M^JS(MZT:VVPH%LV,4'. 73+OAE:=NC1,HU"-S/(C=5OM L&ZT6%A G@CY& MN;C:H#;*34S2TC3%*^9A;" [D3_/ROCZ/:G1TS!_++1_.DJ="D,36.^+*16 M-S\$65%W,1RXSD.5M (F79D^8/EINRS)Y2Y8N(D=+^9I9,&50_D:2@-U#ETY MW H6C3[V]YUHS2+.CZN\OZ_7F;KS,"W)I@J T6673%]/S/N:@@/Z4_M7&Y+TX9,WHR4@>=7#%KJ.2B&0MRQ<#1\$Y)6T+X V=,DZSQ M[!IX)3LJ]@8#S:YQ+D9=:.U#TVQ5K!\#O2XQ""AAVQS36\$8L\Z4>NV+CZ E)-V_*3-'3U3JL+-30(Z><'2S\$P=QX&O;@ 9D5AW# M7Q.J.9K?W:W&O!N^R>_ "K,<+PPU^~RWJ*S3FGM^AY4V)5-2L"1YS0ZCZ[S4MW M+ G1][W!/?472EZY0"-OO*!=? PCG^>0<0?H8YF)Q)S>\$@%YY:IS M\ K0JC5?|BE;ZVJ0=LJF=Z5JUR@B\|0<19;R;JUMXL2;5 V,XHMM941QD5+ M408=I- =Y2=L:I;H*ZKJ(K3GK6UC)[2#8+DZ8YXGGJ<57A@JW;(UFO)B6LP3 M2./R5U+YI=OIL:ED?T6R|@|G*T5&JQFQBMN<9,U- ILC7%IQZAI >^TLE2AL M3J E(H2OEBTJN701U,>?DX"=DVB0!*_1UY^4\$)TJ[\$F,E^BA?"36()W.P^K M&C'- P%&^#I!,/L(L+C"Q3@IJR],YH4A9KH_X\|3- MFE"Y:.)|J1%;,H(XOB|DPVAJT#-('9W\$B,TY04 0IU;C 9X\$^7@/!3B5P%U M.C)TR2AM>>?V*;4!-) \$7YS:K)A*2.7/[4]-54B%YKAR!A-OGZ|-GHVV,#=U0 UQZ+EO|{#>,T<.&-VA%HE<4-E|&H?8\$VZ==P\$6G| /48<9K&@X0B M5-E*,<,%H6_W#%HPR>FGVI\$Y9?<-7@9SL M2M\|!8;.Y'1'I: "9*=-.>?/OMGOBHX? AS5ZSS|DX9E2|8F|ON:7+>+U|>@2(A M5-S0IX@ZD\$5GYAA G*5&@C;N9/DTJNZ@. MZYQ>2*6AV&CZBYE;N60"=\$VFR%2\$^*;K)_S_>B+_>7_5!+P04 ". M@ U9CUV\I3K: !(E L %&UBCIMY.UP\$9?AV|{#FJY? 9M9ZAZ,+OP+J5=JY_6FDK8*#SZY P)Q;N1 M)I-LZB|1KU6;|2410 2WZUYXQ&=3&)=?9_96X(|(*-F|+CK>./>#V_%?N!| M#GV9,9K=8|@<<|YYIF9\$R1GCNV.:?G| [-LE.K*Y'I=;V1DXP7O!.#RQ| MQ-&"MY|5-T2+X=JMM)9A" ^1 SF7B+VQSFW@2)QG(DUJ;QZPU\Z2.;@J| M|C^BWNDE 2%YT:R,-.V*S3BU_V\$B;E\$;JF+Y|6#|J.%|J| M<91/?CY|- F)HV@(|0-!&^"V.E;54/VF&CVN^XP!O&R?W M+;@;ZZ|K'; 9&CQD;QK@^OG|4|L46<.)ATG1DN:|5N>,Z^S_&:| "YH^IP>: M^GL0*.9%54>)I(OWXC/@>(G4'WM(JYPI1A\$#%=P^QMN"(RFUAE(Y_Q_R>4!5_M_9S|{#R&?/<,SZ3FN9|!H?RCUOXY HGP^YO? 88_J/K4:~4@NQ0'7R/'9/'67 M@IR;SN>:I(.3T&%H+O(O.LW2;WWTFMQE|QI)Y^L),U^I=OO/Y:N; M M I)7>X(.5HC&O_U;|0!_QTRB9J_/_@YZ^OG9UL?%)<8F4|D@QK6=,Z+ZGOV) MC0=0=89J1L6J1|A06|).%MM;XZ-,SQ&?G? OWS;^_1D#*E+;ND;>;"JL4O M5@F|7"4N=8R^~)UK)>>4^4|CY5SC KQF00KFZX(U.%-UJV1?&|7Z&'0. M_VCH.K5 9L-G>. (6:00<4S/H?.*VX\$G5%?#RI(:%8*K|(-.S*POF M?7P|<^&HY@U,|OOO=%PA|F LPFIJR8^=UX%|G+2|)TKG|W&L&_ETZX&^&"Y* M.^|6|LSKU=13Y|)|#|D^&+9'M4&5W%C:4"H9Y=V,.AX6&?W)ZE(|=A-XT^5(6WYNNDG9N F/ J6A MT|VZ|Z. F#E9|_Q_KQ73O6GT4_~T_5J.GD5Y_.1DD+-(-2;:GLUG6K&4 4S M^P B71S>PT,Z0@X4K#:P0B6*#F1=H)W9TC-5*N48C#L\$;?G>P/; 3FEU16\$ MNPJB O^L.);|6J.K79@8&TUV1&J?U,PVBA|AQOU;XG<: U^GJG>VA'H|95T "2 M&H:*"ITD_S|701D| ^MKRTQ4(|95DEX: |>^MK@HV7C6D|61D>3%7Q7.75?F ML-WZ&J*B5-.80U+,C",SIV)C:~3;)_ 5JY|2|X@C6D| MJ#;P;--^F3* 5AE"<|6N=Z: (F5FUC8E5VYA9C.@H@K4|G(W8MYIZ^61OC"S M+C-SFCN*)%,|F.|F|2/"U-UW;O^OU0"2YWSH/Q,O|Z|X9;N_K+1Q<1WC?Z M|M7V(^YWBKV?E-P^RQ3|HHHOIZH,ZQ\$Y|&%M!@9(9ESG3?&8/-CZQV!?. ^ MVVZV\$M8DR=.PR+;^L31|2_4|ZOW\$;5<^H5:M&X|A1:A4,(D5#5K|9880;/\ M(SA)'H&R,R-H-9:BJ+FW6|E@AIGJX^ MC- ,DSC|C|>|J(D6\$1A'WO@)8JW7>27YEME=U,TP3;>|F,. ^39.B=|J.TZ(|02LY0D U M_>S!-ZE2?VXXK,FIU(7OF ERYK*|^@183DZ9P.6|H3& M12V(7Q^|NV#6|=L8^_ZUXAK#D4E9.'GZI>R|: L_ |IRE|{|\$?+1S--%S|6S ME 4|@V^&CM|!UW8(ZRE- 3%2ZN/D|)JB= 0%Y<"G^JA\$+Y07?0#=#W/(P|JGD|Z M&Q/N^&7\$|IM%*M09W,N|&'5!>WPQH@!><3%FQABX7THUQF:0&; > MX* (^Z 5W7B?0?IU"KWE25ZVDQ\$,_L_BY?4LH>E&E?3:M\$PB|HKC>.^7P?>> M'-O^*D_S|58A?MF:A*,E9+-33/JW#1SGYMIOT? YYB;M0;Q;HRH@W3|Q)A MEXVU&6"2"C+HL=\$PB;|WA|LUHF.|\$MMH0Q|4J3|SKA8 M/5TWT\$A7S7O5T&^L"W5D>*JY%PNW<&S|M(@/U%,B^I7JF|AYH&|6+WD0>W3 MLO4TS1_ZS"UWYPVH@|<=.L\$Y"ISN> |&2|<=9^L6=\$Q^2 C&_ =50#1=6,+/*Z MZOS*BRP%Z0\$OOA3 ! |7<4G|O4'"7%AOE,.VW/S>&5'LV|0>86|P9*FN^O#B2W7UH|9;J|L%|JJO%@|*0HKT E2S/.)H4T=L(S6QE M\$;6HW<:G5EYD*4@/>|&E #ZHY9;"NRB;YE 4;8\$A;W,C2'5 MGLUO5,@K06&Q9+JRXQLHE1#=G+9I#1IU\$;%32QN"=2"C8Q07N\$A*0WININ M;V_U:HLEB4#7GRI9|S4S|=A|A316|'GBU|\$*61W M\$&T\$7P,2I^I3-|>"JH|IOTKL|C|COU|C;P MKK?>J>I,9CEZE\$%_HXT"RL|K-Z- /S6#U<><5*,M&71H1/?<|Y6KV0I3!%|J=4;X9Z;1K<\$LS:E MD;,>IM'(Q0CR,M/8)M6&\$OUX:UN@KH+P=*(%IO&D5J\$KX,'EE!|& @3BE9-/ MA,=U+!R-X 9SQK0Q"TO,=A>TWFGI. KHNNN=<+Q-R7A? M(WUVP51^Y08V8')E,E1+O|D:.QF#\$0(JOL671|QH6.^48C|40|YZ4FRP6 M#&RB9Z<:X2:|I#3U<"40M@B\$|3FM9XO|2R|LER,4<|)BBK0\$@C;Y0A;*GD= ML(%KU7#8H;!? QM),J=DP#7\$EM <7Y>?>(>|_|J|QJBQ>?%?_0OUGH/PPH M?";RA,M=-|Q#_NEW,A9."E"U4Z>FKE(R=+VO+F=H#?-).^&VR6/T75CC7S/93>4671*2"? :L&|)B|K=H)SQ;BDKYVAKX:DK|W2 M5T/2UR'35U/2UV;IJRG|:V? I*SBQ0!*Q&.93M"0|DIY^;VT5PZ:OJ2|)NT5 M25^;HR|IKTA|I|=+7?| |73#R|J|V|Z=+O%B.5%"KV0^5LUC"(CYAFS5|-- %=,W^@SW3|{#U MP*KUJ\$=|P&+&3P #ZKU(GYD6;+O+SF'GC?DR:*F'WMV|QIW"8835SG'K|'9 MVPU^L"\$8J>|21MEA|)VJW8|1(%8D-RH1C K@1AMRA4MN5"(8%<-MJT;W3N& M1O|I@R88#8SL/2-*|);.|M:T1+P;.|?*< |!R 'BOYSPYSGFUKY+A\$#G MV;|. @|J|-8_||\$| U_K.=V3'0_9MKM\$S#;|R7 V#9L#T|,DM|E);K-M#4=R MfyWD- AN"#00#W_5%|W.>3!>!AZ#0CQ2CTNFBZ=*FAV|I!\$IL'2@1W,"NZ: MO-C>Z6.^E+R&DOEPD|BU)420V%) MX'|3=;*XT9K _PY^NFI-X\$B!+ZG %* 9* HE?75S^E,6;GR!;|J|HKZY;OR M4N4MIX94H;B =M0D%&J00NF"NT,9J1* M4QJ59EJQN)1;6|MZ6N|CE MVI4D8I^F.HJ4YT\$JN>5%QK?<7277?|C6@G'5,DU+U_|.N|U;Z,N M%OEX;ZI6>); WTX VZD|J;6GV*-|JJO-&NBQ5-L F5|(|=4;>6K&0|QTR\$QF0E M&W(EUU_1)0J5;2VDH8DQ|RLGBM'5.Y5MD"M2 A|'EM.6'ZA+L0AT'J2@3BSS; M(WSD:F|.U\$PQOL,P3"4(M@."4EFJ\$@1;XP3E,5TE"+&;9DR|90Z:N?1C|* MA6T|D** 7P*HXYKEY26,4\$B|>."GJ>[?Q@JNES)? =&SY4KNB|(L M5W)7=YL,E"M?_?- _U;M^H#1#5;. ^9VBJZ8*|4<|ESE+ZGP%AR3@/0^I* M7)0&%Z62X1(71<%%|30"B8O2X&+C^L7G8^|/S*&N|3L:=0F^U 59WU7C=> MS|G_\$(9/_A/SO3|D_1. |%K|>41<;VS"40;AU;6^_C3,|=D03S#Y+KFE M;^3|J'K6+U7"KE2)_ WI?V+/NL9_Z9E2'WF?AJKS8EAG^!|5U--X|4Z,VG? M^UOYYTU_5LG H?U?*\$JYME9:|A|U^~|7V;.:IE?G&|>3-HGV(*^9Z;%)B M|D%3I#EN9^/59B(\$OPT>81KM/;)B/\$2|B4R8J)15&TG@|Y>|SX_G_ ^X07FZ MNB2/3|VGJ|?Q||+YV.%63^=N^+1UA^O+GX|W#S=7#V2WNTEN?|_B|JZMU^O MR,7=|~|WCX|W=[71R11KW=ZA;];C>7 R'TE MKN|>O1/P|LV|KUA_2C5@J7MN8CDV2AQ4B^L#4NH<:/'G;|O MK|63>K-1.5?JM7|P|C_Y3E9-JED:I;(K+<(|T0&_A ZNGC<D2:60|7@7& M!+|PPF#EJAV|FS;YK-JFK;W;+&O/N\$;):WTSKYE#SGS^?_~%|>+IZ^Y0 MGIU?>P1.Y/#S^Z-T^D:<| E3Y!^1'E":Y>R!^X/^D=Q=DZ??KDB\$8\$-B M|5T|X6VEVVP53JW7MD.| 25_!3-*N"PD("IOASO|^SI^RY/8^MPIL.5VA Z M-,?" U71U7|M3U:E1: 4%;57._Y;E#3K58*/3|+L?F.^4B|Z:E&BD;8>> MVH(>6G|IX>FA=_MXPu" 'P3AA7;4\$3?L8=|N.Y(M8+.L-? H5+,=%F|^ (SXZ MUTS#H|(|>R'GGYO|F|0=@E;(YY=|CX6M|@7|G|HN&C;D&L#|%; +)@=9_-Y MVA4S//|9_NCJ="". IE2:W8Z|=9%L4&#N9 ;%FFQ2W8#(%|!=D8OA#51#(> MVB;5?%@PB|Z9|HL-- @G,@G|TG|\$+;/F.MOB|8WA98)"\$ _W|E|>H:8Y470>% M|<=<6_P\$|JP721TS=#|P;H,M1_%EJ"8:&EB7K#N|J|M.X:VC3")5\$7%M P M/P*!(%)J#:@>@Y>:O|^&X=5AWG "QBI17.P"MUF%D;K->S|7GV|,1,W/2 M^3F_:0 09-'G6JEMEN|WWX#K? KNX)5|N|IZN+GZKDIO;BZ.0UWX^J M 8JAPP M>0|NDO-E0A^NWE7- 8TP>^OA@NBA:/J"YQ1UCVVF(81'#.;A'QD260L@.;+VR=SIJ3+CXQGV=A)S#1.(IGZ5>C<=@4_*2^WPCG M- |S*K#G5;6YU:ZZ2C+>N)=<0IF7;.'S|Q6P|FUQW870|YN^~|8KZPF.(M3#|;|?0C)@8=YP7U3+^R|Y_W T>L-<<^<.|8| C8P* L735TD=JKY_QDC|II9=<(|E?-IUXOB677V>J7@ WOE(N1|+::)'B2<^ #?\$|)(MWS\$| P9V|X- ML'HTZ6D>WL;\$|Z+>75@7?3D4(VR55:(A&74N.0#0*V?UQ?&Q|W8&/<*,A4 M|_J-JWW-S7>2^PB_ |\$8P|Z.G:/EJE/% [|C*P|YN@J|S04HWUV=W-J5|WJ3|=R8I1210 MU5N;A'DK&P9U/ JW9R"-2PVK/#0|W_!_ '\$S'-M" 6N.'05A.R8W2*V8 PXB M^U+U5)Y-. 87XR3M&ON/XZ^&JX|>#%#DZUZ&T\$="-&#X^UUIT#G|?R OHE|X@N'L\$+)|D2G?8-B^5|;T5 M96>C_FE>YJAMY5/PV- (YG8M?!Y|AX3C^Y#)PV+Y?2>?XU JD26259P6N MN'OW;BRHU|H9DT:PFV_U|+C+N4)7T?3-NY|7|= M9MSJ\$V|+|XS<[*|JYB =:Y+)|L9WQ|!KS|7F,H#7Q4(8,J-9IY?PV28#| MTYKF,XW5G42|MV17|U0|QKH6KV?PVZ_LIQ?|E|G3;G?N%H&(9E#2K)F=@T-/ MBM;|82 M=LZ W85MF6-L_V IE'7L&|P-BHAKX;+@&RIEH:A81 *FV+#[LBU|1 SI:7./)H?'@.B0.6|VR^E=Z05G16 M2=7.45+|RQV=C;7HANU 4Z;J_1E>9/TY(ZYM&GLX,5@>6(OB O9/L@K05;1 M VF"J9%YY,LW|XSA|A/DV2,V/7S>IJ:4=V#V? H%3Z:C_ _TX'C|);OF 4?<? M90(07DKMEHQ3-) :@;\$|L8+H5|JRYO+Q;3S|ORA7B7X_|?->C^GOO.H M17#B8HEEF>|B.,Q""V,+:VN42A|RS!&I|'0=)6,5(>|J9/R= J1_6Z@NHL MJ\$V)>|8RTNF*:[V#R2US%TQP/, |P5E^M1N7|^Y> M^ESDNK67,8G4|V7TEY@ M(R +3G_QLC=; X?1*OD.U@|UR+=0%UM-H=JB.? 4-_%B M|1^> 2A@|ON6+H3W3WWV_QLH(9%7JX=7NAM-EF#<44VT8_(=P|WV-V.9 O MT|40\$V66@F|9? \$794Q6P)S3J)KNKY6;V^MX;1C+|9JTFQ6EP\$?B@B.ECH% M0,10T^J<-ZKM\$Z7;H3YFT&OQ8PS|LPBMQKGY2|{#ASW1,5\$|TO-?8.* (PHO) M'!55FB+).X#U|OCF &OE NN7WY/MK11&45@Y80^VZZ>|4)&=8DTD0EK^47_M_!S0KSGV&|~^?0--1'+_J?;|TJT|U|KVI>|J| |O MM=[UT|7#&5'-W7L!MSN#|/-;~%3V1^6@;:.'*+22G.OL/?C>-|>|6Y7AV M9GZ|3)X9MD|KSLO3W<4WP_HS? +|JNN"-3|0EA6\$AQI?9LVLC59YH54|F@A-; M&#.+3U#-0|PS3M^|55U#-6;>387M2&Q"N^2M0_34Z)6D9=*R1"X5Q&26RE M.HV+ |_(E+R&16\$6,CV' 0WU6?|;8@&=TK|'15_(%|VJ#;HDM+FI3Q*+"_LPJ|{<"2|25WSC"8@LIA.14?)\JUS#+3+_6NUKE+>CZ3O;CZ

M*Y7:NE=?Z'0YK.AHN=9:B07Q1-'4XA112Z\PS+ #DY ^FA U>|K5/3 E!L:S M(4C000?P1&Y8TIRB?" +7->|VXN;WC<"6N"? =P_<>JSS'TUR=G>^L8"7,76J@ M8 _#_YSI7?<+.FXGC*^A&.12%ZE!M&BZ=9'('RQ|5A M+;/:ZS8&Q|9YY(\R55UPV\ZA WC58G\$|.C|)%HHC+ZHYN. 4L|=B-0'| MNU%'U8^YQ5A.#/P>T\$4)?PF66@/E,%9 EL|.)EM? 4HV7PF|JR=T#R\NPP|":3 M*:&W'W'IW(\I5-_RA1^.=?+=Q-PR?49Y?,P?'^PC=I,4X;TD0+P/QA>H.KDW|+1_HXML(>UV(MT0DRR<&!+A=;|0_N(D1%X=&B+%)'^?_M2#@N@^_M|=&E7)\$|A|ET| M9?3|7;74%T:60|CDTG UGQ|#@/R_9ZGFW#680)G0,1(C3U99QZHZY03:ON^Z?Q?AD-L^5TMN%LZYH2>)S2+R9G<2W|/'|C?'^_<_EI'W#S|W0#)BZ8STBM<_M,(O2.ZF|?J8I=)|MGTOR UZ_-P_|Y&V8R=*|U-D#_"XCBI=VKD11%O:Z>) MM_4'!N =Z&L*>X|JQ|CWWK\$UJB/%|B-|J1B9E0U0JU>F|BGDWEA%&/&.>|+WO MGGZ|>H@&O/1;>42H+U+Q ,W&'RZ_*Z3K7A)Q,&V2B/>#B'?=.7M) M^RJ&1I;1V.^&19?&2N\$9JCV M*0C82.QD'RE43(BDSOV@SO9.4V?|F#W;BWEA|| |R|)U7M'V\$&Y%R M-(M:F:DA\$BM|,C6|GT0Y%ORO\$;8;U@_9^A+|O,4J-S,SOV*AFPSGKW<3?#6 M72UYLPH|JHA|++X&#S:8N=%-H>1M1XD\$4N!?'8B5N6*+DES4(5IMI=BJ746T-M-YFER*9Z,5.1*|'9\$HD5M%D.M7>A,VO M7/U)"- :<83%QDZR#K%;:S|9J3R|=|JM48,W31KM=)<?%S^>1916<5S=.\$F@M M29D5JU|/'@^3SEH3CTN=J@ZE;F=5|Y|JH;T^>^E- ,5|'0JVZ<+DDYPR825G_N330PDWM M>4**",D4G0"YI\$40:;|@)4W).NHMX|K-TXVQCL 1T:DO|,,MLN#GZ46A3T"L M3|QF9NO1<|VH(E)*L;G5MTS5-BU#E|KTEH3I*8T|+HZ0Q\$GI1&74=)"9)2;YE ML|KLB62D)T | C68R05<|N-L7\$1P0#Y;70K^~AA_H7|JQ|UK<8Y= 1H\$W M8/K|DMKN)|!|P0?_M"0^S^/%X61%'80AN|4551V>X8CU+QW^N)LO5|RY4Q|C+O^)|AP95@I,QFDN. MOI@O6TUJXWY6)78""X:M-M'0NSIC1J365+;|C5)K5=KN^7;25 M1|JDN7?_W2D>B%*WT<89.9|66R6ZJ? %5*DRBH#5U,=)DQC/GLS@>WK|?'W MTE|TX5U>R FZ6>6.@_T51PWP|!)8VR4U8H8)GE#J-ZNGIB10Z\$M|YX/NDGE72 M;1+?'72N|8"8V|1E4YA;(/RCG/(<MM3S8V*M|JSY21ZDF2E^M9"|"E*SB(P)" M4IK53E/9("4ES\$;|J|HG,&EDY<*Y|-N3.J.S28:|!"8':%- <^PXL|JB|R@~"- M-,*|KR|Q|J%=&,V)#S6S-P#|I9E?K|1\$@;WQO@BP%K>_M_|V'62N|=IT_S#H- J507S.=O+&^U7@Q,+BROCVCOJ*Z=E;E/HOK54!L-Y9F M^M^MB#K|:MOQFFF5475Zi*ZU3R^?U\$W\$E6/K_GB#M U5X<0F""|S|.J+N4@K-G| MFN|*(5|&S&2#|J&OZ43/IT.|)?\$X.! |_H_7,X/I)^JR.#TA+7N>_ZC@|'1'8R1Y? 70B1PWH;2*1DB%IN"YG;^)A#Y M+H)OAOILF)|JQM'#3MDIYU/H@ZRW*PB-ZO(S2KK;U8Q)Q0G=ZS(M|@=*ZG|_MD3U- @_Y%Y+K0YQE(59?0^|M'6@4|FSO|@H>|Y.JV=(|S<<@|E|FC=30G1E3BC(M&5VMKHP|8&3.SY=N!\$EHB:5D<|+;_QZWOA.YLP&@9V(X;HN|^@J4KY(5.->"MZLS9\$WFCNE5M%N\$WE!&FM#M/-B;/#F? Q2=S5D)N)-6N=EJ;W*NRX#&W@NEYEGR#E8#WM@F;(|SWK^S3S%O5+ZAB00>O-*('KDWIT2K53WS+9 MEZ89B>TUL9UY7_UFL-VJGK.WG)E?&BMgrQC,TJ^TEK/@_0.T)-&0V0306T_MLTD31#J4N^R"^^U,>T*SA"6|XYE3MM?%;_M0T&! <|(+|+|S3.WAT#8T5B|<B|!|@0=M31,P?UP:WN4=#|N:V(|@'L_00(= MU6F|U&KE/K+&2VDTF;^+A,J%UG,CL;C,Q#4"|@I6AZ_^^LVA\$FQN|GKU>N_0/@4K%+L=%4E?TO#T|H*##7-?VH7E="UL?^=|2 M(|J8O|H32?6:9LKF6A@BKM?K^&?J278L(LA|WQO8#DR87DW7=#METYV45YVD M?.ZTM4<:;#QN37PLKM?>.=ZK7_4L>>- D78=K#&HVRV|K3M=6UWV|@==#H M5H+B@M@STO34K5\$D;K?XQHA|�%+GH|0^XJX1-738|G6|0,BVCJR|44|+R-B@N>_6B<- WN8=EN MK N^!:"S|H&:|J63^JRE-Y^D|)7IQH.+^E_GM*&+)|JR|I%;1V3VPWL|V@T=SBA?3>^;DQP? JJ89%|2O5L:"@0QEQQPZQ^|JH73|M;4"#W M50X=+LHSIV46@/F G;Y%C.)K";<|B:%\$F'WDTH>KH@MZL|Z=(%TG2&3.(M- KYTEKR\$;59?1J?>*)W%IVHG|POX9J|PDQL<R?25^D87.79C,7BZKLK6_ZMP|7R;/4_-2|R-S>1B%Q.H.6? \$F7%+U|/^-?>U@E+G6_J=)|UGGA%3_CQ\$M.#36QXET518BX^4\$E7#N(JC3'GR|(|>+MG(VAT++C*MITQW8?Y^&J&I5J: MP2PAN;VIQT5V>_I.8+E",8*WG_-JGME&C_U^L)|M"6N,%)EERKL=5/ONWYZ M""|8I7#1&1)I1/P^|H|)O^>8;|&=Z5L;-4UR_7VQ_>;2QVSDZ30^6<5RZ|;|Z>|BFV|J&;A&^|(-M5&\$B#0MWBM:>36|S<7;.F@Y? 2CZK9_@R-P).&(EAO&:9>IX6#(|'2?>\$|"="|,?|=MJO^*O+&_*J#;KDQM*.PK-QBAO.1@C^ MW""|D6(X%3.|1;#J7RN8Z0,|3^A#X7=WI&KA|X=0:@SH\$L3.'!Z<^PN;0_M0"QZ08Q9<"N>_4|RG,B'?N- |JC|RA)004JW<|C%YW@-UF*|8UR&^W=^&I6_M_Z^5D^4*10|J6_KELQLK0WR6Z8I_F8.=CL,QU&NX-">0"ML+OS;ST!MZ?D M.UP=N.0*4^V^NR4^~|J|AN?@K>A+!E&1Z(F3D#PL2#X;|HL'2&Y|2|Z7#Z\$U M)*E16CHU"TI\$4AL|3ZVFA);#EN2;TEL|1BVRLJW9O3(7-(+CDRX65I-WXN_M%_Q|7Z@K|3RHQ5A\$X;<(>T795Y_TTF10'_MJ3| |GHYK%FZM'_B|M|K%&E."5X"TM>+O)G%>1G%>"MM^S@;=3.;|B>|Z-H|T;MV9#NR=F;#>VL|..N.TYWR9^T=+W\$;HN6>% M.#64/8'R=F;\$>V(JL|5R7P2;>7BS-IJC%5\$ARNDY?J6F;|^&K*9LL_MFU^LD4LXC|ZS|Q)VM^Q16ZK_7.5^0=0=87URN00^P>H) (Z;S5PB;SGC&'?|_M5D|/3R6.2|MDV7#ML3B57Y^+)|910D,B<38"7K;Y/D_MLJO218:DTAF%X1_E=#0Y|<*>2727QN%A|*,Y&1TK&8?A- @GA?|H|749|ZDJ_MIW..R2@_|_Y'DL9?D,2=19"5C, #_R:"F|^IXE>>PE>|D+ZCCT,K#K;.@1K-MKJR,9,F1U|TYB2W9# + |2|_E)|VL|YQUMNWQ1)F|F|Y|0AW&W-R6C)9B3E_M">%MVTL2PCL"X?<('ELADQ^\$^Z|32,QO^L8GLXD,W8R!"#V|<|EF%8!H|2 M6Q=WWH_ZQ&#HD,609#NR=F;\$>V4XYV|LPM2#_JAH6=Q-J|5ZH02_JH9#_M7E739^=30ZF. R|@H|\$^&Z;AC:47L|1FBM|666K.A&O8?'B6O?T_CNQX6_M|CK_XMC8_TCH_K2+9T_4%9T24|WDJ^25G4I;A3038GFAC99- C0G91&MZEW<M+)|JK2KMTKO^RHDL^NIV4|_JJW&C@.Z4+G8I4|9S|C16B45ER=;2LH8|3D!D MRWUK6W8|&K%>=8,RQ8+|^BF)XG8>1R#N!;4|4)^C'(B2&|G<23B1D#<*>U*_M0UDA)5%|DL?9B)M1*!;@ZI<_B*2V,6X 8PYU00,S_0^>#>Q2:E3JQHM_7YB_MK"7*K|JL|39>8O225/1E5?_H4_32JIPWMMWPXBZ0722|Q>ID3 MGU_)\$ML40,0KYZVZ|!>+R6BESGA_Y5LO@WJ8YW37;T)F-J>U|@ _|WB\$ER22"7.2DA*YF\$N9)+N|HMOVUE;DEPDN0ARF9,FL9)%F""NY=*N_-M4RE=)+F4DUSFY&.L9!#F2BY*LWK;+5E&4HZV<& X/YO6Y/MR'9D.(-=V@V;D#U;&D1HY5U|#8L62Z8?H>U:6K|3"U^SF)J@M=MK?? 4>40<36OY5ZIC@0H|O>_<A,">6MN_N;V;JOM^G>V&2*5Q+;EG#0ET_MYF3(+G2|)%DL^S;-ZR5*^)?E(A^D,R? YR@JTF2ST&0SYQNSYYU[R906X=WC3>J|5SVFB_M2I5GV)1YN8=.0RL7YMH>#2G5;J=;;1)0U)&BH3#;U<#FRKJG;JY=I- M*G&HX&EHY0ID6Y5#K=JTB\$7T;|:6@'HYW|X*6|8&AT|Y<^1|7?>=*)&'TC:H_3GOFOMES\$C>22?YE^<^JW_LGS3+;,&_QD <#&R*\$#.KG&*V7|%>39IK(=V8YL1|8C_MVRE'.|)*F%|JH7|L.A5\$2S7<<:FECXCFJY9HJ^FJ^X%64)22|HTEIZ9G.(Jf (MZH;D)T|3|T+/U|@K7)R69@|=SUG|3W>|MA-SS;9Y|3WTVZ9-J MKI)KLM:BW&YV^+;=H5EMA|J9LZ^DMUB>STIR3K3R4GEIKN(V_G""#?75V2 MJH#VDI\$S.QWX)&E/TI2D095H+RFL|,Q5;"M">R4|83<-|4F>^&H3^F+&(WX(MAK/95;B.84-IHJ|UH_|,O?|7J;=, M7LIF1703/T9@KU\$|3_WFXI%2HFJ8+J5:8Y@JL|X|>+MG(JAT/&%_QT_?Z)B_M19Z^8;F69J@F|_TNH&_"/2J|RQU-S!_M#_%-U 8_W7|_7ID&6+W^R2;|OCH|M^>@A7&&4;HC,DTDC@_HB^8-"O.79;Z%"8NJ51TR3W7V|_?%_8_M1K^U'Z|M:FIA?@2MD58(|_ |L<-1CX|0<7+?^WI5^_)PU?N|JUKM^NGHX(ZKY_MH|)=@ (NA=|^BL8%_)(#@9|&!.Y""O^6G.OL?C?CBA&W*L=)_|_J?9*;X|+E M;|=|>Q??#O/L_W=;<\$F"A-I6*9AT=J5;6M-QB4\$;SKB5+)|P\$^<^I-G:Y48_MWM_\$1|C @@UTP?"UPR>F+X>FOCE7.3U\$_.(M8O?)I:3?|)IGF%|/TZ=|&9C=|H9|_101+X8P\$U096>6^"JD#="UR|!MGT19=N/(-FP|!A M\$#.;+23P|R2-|J5|5T|>V.O#&4GW=@&DIO/7"!#SS^F%R\$|+>62,D_MHLXG4!WG!\$SK\$>R>E<9_OBD4J?|_I.U*U|*OGL*_8;+3+ (%7DV(DVFW@&^A_M_T;B839WP9#@ZD^C?MDNT;%N(<*>D|H"\$9|L3|&>|@JE&<2=9KLM5\$!&6XFTTPQ<\$+G^?Z_M!O=IP-5- 7FE5B8_3,2H2&PQFHXY|Q9;"8LH?G(P5;TELPCR18;R=S|K@9X_M24=S@;+G&<'PJA#S);_9MPKLBD=,UMU&QO% JYX^5U=^&Q2L5VBX%UGD_M%G#MN3|8_36J_D(P;PCJ6J3P-RBXX@|HL(MB9M\$S|^K#VK\$5J;_*6R7- M5@FZBVE%ZTN:X*1"JE|JEC4C"7=;ZR=%|A?0KBI<DX9HE0"9OCLO&._M-M"VF|PX|H^U;|MARV|A_8NO^P=H(^/1>;K2|N91? |X|WKMOJ2QIXG|_M?W|Z;2B-3V4B|)_K;GLXG5.V)Y7PV0!.ETBF3F>7Y=^*6SH7_15ZH2A_^JKA_MD%? 5J|E^<9OJ_*KE\$=-0GPW3|,92,FTM|@4DG7>UH&M8X'_B^D|B)?2?>U-M7CL6U|PJ|_*\$PDH_E<-I9AZU=#;*\$S; |ZQ6^<9OJ_*XOH+HR|FA2,X'I&9J60_MV;):=X3'KS)U\$1|B@M|:F%TJSZHU?OV\$S?D'D8!_YIR)>+>D-G M4XALEOF1);5HBL\$X5;_Y7_X|K4?);MOTW|3\$J|Z-|A(170_M_Y>JMMB+=^;=JNAN_M1GAN3AO.J|>2EG-3CC1RP!%2?4|T(+ ES|HBOAD|U+^,? (8*PSI|4(DK"W^&M&M63DR^V""98|X7AN&N|51%;L_ZI>X&M^U%DTXIE&|*_76JCI/KSUL+KOF- P&C^T_ZVHV^HNF_V(W|J04WO7%FDL>_M53KNU3&KK21D|H2_?_AH..UN*|TVPY7J6?@571VOL%))D&%^2PL9)(8^Z M)OLGA^*X8Z6/NN-2M+3=T<|G+&=B%_-(H#3+^+|+)%CM^PUS^N0\$;IXE_MOPK\$Z(X^H^T,AR04KQ=|B3R|S?A 33RV|E^4M_-97B#@6UB_MAZYM|)>"8(VR"/2(-=P@)|NDW10^U+V9^2;IK;VY=G;Y3JON\$T57|NK;9* M1W)Q\$HVX\$7#>7U01RG<=7=#5,F4OD5|7LAB|LCM";|U#="Z\$>"YZT?^DLF;_M>|+W)<- |LD_F7&_5(<32'E|MF\$08;|(FKPD8R\$UXX|CQ|_S^*AM;29?XVD_M2C0Y|1BN-RCDY|PMT0;+Y?C-SG|&8W E8BQ&\$.8/434ZDQ7C">2U1.0E98WD_M%+|^("6MRKG277_G1B858RGR|S0W;3VS|JK?IQ|S&NF|QHO|JH^J;HX008_M9'(3- TZR#_0OWW%>7%|B|85GNK|V|CPHP?7O^E=B|1|@Z>|L9!#XYVJR_U^A_M%QQO|P|?B^RY_J1S^XGTH KH|_.8>NS6Y8UTT>RB3(+SD|RV+W8J1=|^G8=A^W_M)"7R48;2;DQV367OF_MJES(2?9250S./91CQKA^1M|_ HUEMMPLLO)'92.1719DMQ*0W2@ELIN5_M|U;SJK3*Y(74;I5Y1|F%TFV|Q&6TF3:%_W_6>33A/AWTK")>;W<^&;">P_MB;H5-!/= %|XNT\$|2^V2_KW9J"l%>@29>A1>0B?GVU|S&_+M^R59RK|Y|M;-5_XI44C|M7#7Z|SU7B@AS|?YKTEW57B"/A&\$;H)F|,?| MDF|_JGS9-8MT>;|H;&C5(6GRDE*B:9@|JC5&*|_R/7B|9R/Z=*QRJN;G_MIL|AOG^0VZ;T#>XP*%)CXKL=079)Z#;Q|UT/_80OC+

(*T1D2:230C;(0&/1KCOT6:DU3MS1JFN3^Z^V/PO; MTR.G2:9RKD@-J(,@1J@.08Y^C\$0:H?W0:J7M2V5IW7:[WKIZN,Z*^k8
M#;@:JEH6C0W\$QE0/HL-)A\$A5/Y49-IV;T37&K_U-TM=-L/X,VJ-=V2J)*)&&91H6K3V;M09G7"ZPIB.JKTH�+>GSQ;J3P_B8F
MP@#V*^_RM<^,GYB^&JN1A-GJ_M;IM4A;P\$Y(LIK%;5,F-1LV%NS6+Z-1%R+OH@S;633"FGAXH/CCLJ3P_MSB?>QI6%G^
62,&MN^"D090H>|,7FH=Q 7JZ"X?I1Q^6ZNL&S\$SAK2<0 M B=-.IJ (#0QK!;P,J,\$*A1^=T>J%GIG3-JD9,H1Y|@%%<3+>2JKK",ZY
M1Y2IO1>?2?X=K)5<6YF? W;?@|S\$=GB_X\$Y50Z_=6.1"1F=;LJ5W_.5GVBY)+V#(4ZQQ)RN1:ER;63ID"%AH@_PL@WIPJD
MFK:%%@?#>N^6(G690K,UBJ35,4-L.K&6.TJWON=ZJH6\$52;+U5,GRJW<7N,Q
MWXU;JH6M(HX;9ADL8EBV5;@>;R3F;ZX(Q(<6,)(I0)"/KM3O6D+4&Y>ZJ@J[M4
MW2+A&#W41:F>U%LEV,|L(9D3)+O9&>7\$|<+;|9@USHWQ|:"T*^Y2-AM;=WKG)XL9)M;ZM\$@X|%,TL\$K\$0U|2>KM3."A#9ED4YC-
X;+|2P'V3'6/7M>W\$H3P"7CH?IZ-Y*+F)GP0^"CB@J70@.KRPN|<-<\$#(-=I9|9^,,";|M/KAG-M#;YJ4PI
+JN3R,K6)>YW3J2RQX\$ETITZL6EE&=V@4A6*Y&<%Y*7"PR4AAWG-MZ#F1X)9Z1|HJ
(NEDGUG@2EV@M'D<1;I8'B@,PZ7"K^*.3,RHDTZ3O&A^4\$|-MA3M-Q(J\$9QYQO3-{3S}=JG(JPB30KJ@Y.PK<M@Z>9?&*DV5-
6MD4-RT|+--+O%31(%|+6+U6X@749*GIU&F|33BZ|U9RR-M0C=JB|;O9MFG)H,W"H\$T97&\$R0+?U-UI-M+@'G%=U:0-<=>|
(";;NBO4BP;A^L^423L_N3#ANXAQLC7I@==>9K+SM\$L3H4
M<%Q)OTD";5{7;*.)L^CSQ(R4(SL|+|=1FXQB1%2RTUF\$I@NT'B|G+&ER-M39\$>@00.=K#
(L>=>HEFLR%Q%10^-2GK+4E=@WH|4R7"TZ6Z<#TF%G/79P-MC-M."V2)+E\$3U?T;|MA-
SS;9Y|>O3MDWVOPFN7=&9)+T+|=WE\$W3-|JZ1M=-HUH+YZ+9+;S9VX-N|>2-W)Q7Z(?85Y^I*P61E;KJHS#>79HB-T!T58W
M7=19TL3F:4*F&<7-L-JN.MH@.)RJE?EPJO*IQ5O+.%QQRVU72:CSOJDZ2/D=-M8-54E&J|670RX3Z;
<1LZF&|J,YW8#>DSMRA+;G2/JTJG8Y<^\$;^J|Z3-M|K2VL_)D#&SFXM^*M?|@-|4K=6F8>TGS/(MKC+=7.7ZHZH#1KOG\$OI.
M'-30>."HJ3F|KM4((=ZOI("J7I=ID|A|V(|"FCFB-7H^1|>)M3WTGJ\$^&R9PX(-2RU9N'C)G)^&O&PI-MSXX*X;
<>Z|V|C|Z2JZYMIT-SW>R-|4;K73:I:5)|FF2T4;_<80;3WEN9;
MQ)4(O-J<>|J9T832Q*.E6J<_IQKQQH|RF"21M#FZC70Y*V6PP7Q+).H)CSI;A-MS?GKI/38"70>/&^D\$M,OX+AS22N'W'1)-
UTH7^I+;VL+1UH"IP|4ZRTC!,M|8QV;9\$.A+Y(222W;./%LD(||323S|'IXI)F,C96^Z'24+O=-GBE6-M2@@=9M/E)Q<
N|IR3+2H.HPFRX'+4+T>3IG97\$SO8S#F+U;A"IDNLP@X5-MDQQ"<L|VL>ER2)|<(O6'^<#9CJ+LX>&3|3JP
X|VU\$!0+8%X;E5QVRV-E M\$+5F|B@IK)J4-99;C|T|(JGRVQ_P(6P|BKY#-/Y"-M|(%&6+OLF4XU-MSQZA^9)H|=W!%B6?
DA&4'-CR"Y1|2QD)TVP>2VY=N-M.74"JEE)DP|(T4=LSO,SV2;W;=U>8A24\$E9^E\$4CHL-RZM,AJZ\$4*=
M5Q9F8)O09Y>+Z.&LKU-*J4@B|+T0Y)G\$>39S4R>X0K*KD|V05LCC5!MUZ;@5I2"ZY)X)?N!-\$NI-W&?-
HM2L'M5#L|HMJ&7>;P^=G6Q-P62,&X?OR-M^5@W7OFG49(+>)OY2Y5|G*G&I8_0-3?K*NBKZA|C*2-A5(GTLD1;S%H
M&F8.R1-PMQX&C5;,>SPNSM2M2"|J|JP'W#>L*25J8G0@|-6\$B%SOW68|-M2Z>6%KE^>Q%)J|6QR6<;B+541XCEG?)
|XL|L=Y"Y3Y-MU&|.5B#;G^F^SKJ^H8*JROA21O)H-T@F-63EF05U^26X_-D.UP8NN0+P-MZK-3U-
D<-|:TE8\$X+*+>83SMET=-.9LBD7-S(1V>5(ACO-/R|SKRT-6-M9JKDP36D?7:XB-Y)KVCH-WN.AQ2-XERM1VF
MOBJWCCA!#G&Y)'5N;4)*JC,6;H0=F@VVP)AB4"E4;7*5"UGE>J4AK,HI-MZ0V|RCVYWON|W|,|H#)+4;BXA4|KGR>|R\$|V27-
^*H1F2V;=R5D@E<OB-MJ82'4LD'+|KT40)@OP'P9-C)J-XW^\$1^BVMO)EW6LB;S\$S<_SUVY%QTIL
M+8E8S(B#P)O:4W);9;A0H%#R|T,NK6=NNVO2+|S^V9XAS<82|G92=TJ@I-MC5I3>?TV"J7;K9J6VPB&-9SNS#)9PQYI'7D#;D=
(OUP;C|)(S&^@42M)09+A<H\$F@N6Q^@6>WFL+|;@K)H4Y,(FVW,J,R)G?=>5ZVMP2+E?#)60
M7,XGVJGY9)G2FF|G2CURS|Y;A^;|6&JW:@J7:4LN"H)">#9;<8I%CHC*M^8WK^NA2(8?L,&R0%Q<,)F>-"V5J3D>|H
J6E1'UQ*"V1K:LFI^8)|"(-MTI-.FK6ZHHHF@,?FYOP9."CB|B7-H.)F?DL@=#:0=LO-|ZH5^N-DW(4-MWB|("^^>)(-|J5
-9)R5GXYCY+/|WIBSD3J'OX&(?=%#ORL!>UV63E0B6-M622M|57'@X#BH5/|2=*A02M30687D90!AJIT.=OY"(#=#G(-DDC8TZQ?
+!OW0'!K3Y8!+<C^Q-M;UBDB)DT^6AB'1AJWJ-NOG);#+U9<68SB-J2QU:|JRI%+97#52PW-RUK
M|YZP0@A|I5)>8Z)G=XW+H4E16\$R|J0%6;-K|9&79HK1>P|XN@>T5YHF-MH^Y3-8;YCY-IDKN(AP@@=,(-4-CSY2YQ7D
1WD\$|,GKJT+9PO48);W9W:3"F9>V;FCBY,O8&L)&%9GTXXNW>S.\$)2-MP3%M<9J.M:OL2FD?
R4(SL|I|=MSFX|'0|9Q%2RTUQ\$GJ8+&AX@9Y1)'<7G.U@
MO6-/42W79"XAHH>I>XUQ%0NQKT=J9/A3+|2.1Z2:GKOLX&WQW!);SERB5"N-MZ-N8IP|=VPZ%GE-XCD,M;?R\$W(OWN6?I3Q>-
G&;PR|ZS^|>VPVYXGF;|M^<S,XR?|7H77>+NB,TEZ.PAZRR<8FMT|VE|TMZATEXNVV6S.*\$DTI5.=%NL-M'IP|<6W
P9"ZDXOJ\$|GLP|W'4U8*(DOK+VD5X"M)2V"|5#7^@&@K7=19TL3F-M:4*F&<6.*ONN.MH@.*>LF2F\$|W-MZ-
G7'1JHPWZQ*SAXW9;F;EN.LM:UV96,=-J!-MO-"BZ-8SHWA|9ZNU8F>K=-N=-@F8|1XD8Y46P@L1G'2(|_%"K-/@R467^>)3<
MN&103CH".W9ZCP@V&I73Tf7=|L((JQ3%NAH6XL2B'E\$S4;8?+=77G-M)-T)B|>DUJ|SOEN'NK6K=-59UAI?LNE2X7|.0#X_=QZL.
|YQ9A0EKQ7+M6CF64"Y9T^6-|Q(^&IO+NDL;2?K;_@_""O/!";5FO1@2%-(FF7JYFRX' MGN?
LI5ZJ6-IV4)7(W70Z(SJF8/05QJ7OL3&A2)U4TTEGYWF|I\$#D;MM(L.*P<^H8&\$|A^AQR0>+>GC;99X&YKL;4);?
O392Q|A|;GOA/34)|-M\$YCH^G##C<#F;9?IL^K(<0?NRQWIOJZ"Q-|IV^M3P?>|>ZM3;9-*XJG*MWG092*1G|+?
VONK97H8C=VC^P;^)|A8EH33J>0S;.4DKA|QT232M=-%UJ2VM-MK"=1^K:K.=O>Z?24:P3&B6J&+8KBW20>!CD9S(6HO3Z-|).
>;WDDQFP-M=R?;M67J;^F;+@X/E\$-MW-L;)=1=PA@UAR\$S)94/ZUH|);>|G;^KOJE+@JRSJD#C/\$>>+9'8N/O|RH,J|("R
M|S;R@H(803X)*-D|D|IE|8R|J(R1280J-7\$HMR*;JY;R|J(R0RW&^1-M|U|GGR(3|W@NZ?V6JZGT|B2))>|XFI-
(N>69H6<(-T<-8^Y;ME#3K19|%.KNNS3WBF#-6HML^D-T^L|SYHUS(I0)AQ9ML)CC@?/GK:KW79G-MV|QQONU12EGX4A>/B3P
K\$Z&V-D*H>W7(|GHHBS|D/19|'VV;|G&I&+7+4-ME@*U)/V0|)O3-|=|TXR4^SV#D^&?|N|H;|)"<#ZM%.W?D^2Z%>2ZD%H|
MV>5KR0Z*EE^V%|V09%L\$V9|)JNB#L6N5QLGV50@8Q6L|HWEV/G9UL%GS!ML-|I0E8-
U|YIU&2|-N7J3|^4N4.YRIQJ6/T|TWRZKHJ^H@?|(RC4@M2)|J)-M46\$M/E)*5-W+D:K6&.:06+8;_=-L|)
(-7)L5XU47N@EFHIAFI"WX0<<(^M|/4"R\$;U47^#2=F560-QQ-(7)|>G-E)%%Q#GB|HM^>@A?&4;MHC,DTD@0)XF^8-"O?>
9;*&\$9NJ51TR3W7V|_7%-8QJ|K1#4%DY^2\$>8#>V.7H-MQT\$8*;KO?VJ?7FXZOU>ZUT_73V<\$=5|4|=NP*#.16C0W\$QE0/HL-I#H1
M8|JISOZ@W|W\$GL2MRG'2C|JVF3SCN'1YS/23W<4WP-HS;\$;WW)&ICG%/@E&MINW9|88%Q&LZ4@83'4#|JGH3|
S\$S&|OXF)+^&C&H&X=|3%|51U-M6;=>M3<_IHAG|A^5|R?D7G@2V7*J#|S|J>5HT+&X9|DUSP(V%JR;GMEM,+W/
MS<>PBB@Y;Y58AG>BB^<6%YZ#>2MNFU3S-1ODBP&WM4&5@19|6*(8B^OR-M;
<"90:W&H7<.587YSKDSJ&6|FZAJQ|I^6*JO&|CCT6W/BL>.\$?DUZ<0SK64-M6W|(#6FSV0R8RB'R&5J!%C6UBU"%NUW_-L1=5A"
L"-62-CM)M=L|HJ|&MC:@X1500V^F0?J|C|34_*\$=0O1CCG5%|5U@?JX;3-YDR3;964S=-/AC-M2LE-/MGS9-1-
|.*|UC1&EQRB@M;J.&:<>X4="^!XG.\$M;R|0-0J9@O-MVJA-^O|EAGU2A|);2YRLF6*EKA9#6ZJT>DKMN\$;U-M;CJN^%%6#@?
R16-MEO\$S-K87(LZ^&\$.RR+O%V^X1-69"%C;SU^A7NA9#10870;15GZ|Q*8|6Z-M|J);&4Z42?E|J14W|)=S79&-
H<|H(HL0|KYNV-.2;NM^N\$80|K-R;R|'M?G&4F#8|P1(ZH8;15?VU@Z+;9X@U-1|H|@%OIY^A^ES>NFS:P0#%Y,1-M5-4&2!|O-M
P,^#-17"G-IBX8(ZA"G)AC"\$\$\$^H_-Z+2UQ?TX"@^KX)\$X\$S:E(-&UR#|VE-MB|ZG|+>%<^0|0LTJX<<N/XSAO-
188#7PO2#^J+9K-|3H(^AJD,+|LMT|X-M=.@|H|A|OR0|TT|<4%F;R-P2@E^1Y|1\$7\$<4&|0#|T79T|V-|H|W9-M?
|O8\$UB'|LT6|>2^3?G\$SUHS#R@WGQQD?DFZ=P8<&LZ03E^H-8-|Y;O1A.W@TCJQ+Q-M2%63OL;^KQ<^W?
|RHC^<RY.S97OV";5-R0"7G|C|I@>AF8MJF(7-M"IF-P#K6|R4X_*U\$S2.N/63L%SB#2X-6\$GXUV8S+XJ453Q|W\$H\$;5#MV
M#1#U5LT=H0K@P'7^<^!|WLV-ST<@>@U3">|-R4-&CW68=K2*&SA10*;P-MM>BF\$-G(8C|B.OH\$|/32-/8L-
-"G)U6WZ4*@4TP(@6^|=A8=D9*P0^MX>&W#&Q|.LV|)M|QRC61ZZ\$J"?MN_A\$BV"^^,P=#\$|U<%W')%)5-\$\$
MQNEE'0>?H6XJ@F-\$OR7,5J^IA-QH70^P1-^C@XI"/OHR104/G74K-)"_M=7^<9Q@2YPP9%|P.H|=WA7##V*^G8^!8HP!;PHD
J^V**K|;BLO-OND";(A)8>2A>D-%)2BBKV>A-M/Y|J4|H&H^7G^@WD0^_J\$S=U=9"6.Q1G"FR((5#0:P,?MY@?U?>
8<_ZQO|I^&G;1%V&2L5P|^@9&\$D4UJ\$>45ID0P?|F|F|WB<|>J|MJZM-\$9^FJ\$LT?<#0?>3?
0#Q|GU%21%-O#4#/#|@|*|P:4&'.34^B=T-M>M!%0UCBM:S;#N?L|>SH>|/-J^733YB|O8-Q-MO8GT|HUTT8>|QL
MX(V+M#9AOZ0-2W173=4(C)6WX/QXI7*Y=-<.GYWW|JO>XV70J@UT%V!
M=K-SAB^@0S|57PS|J%\$J<5;V;=>M5G29\$;H1REK%||RG386R.*XZP*L/R-MF<EF3#!*^M8,%ON/ZJ,T!%Q27OH\$HQO5J|
\$XFT#1*=OM-E;#K^KXN\$M|WOH(-D-OP=J<=<_H-IDVJ?JH3U03F/T|BS=-5A*8%;(|O_05Y|:4+A1%M1\$G@,^AJ>\$K3
L)@|7CB.^X\$*Q7|+0PM8:T786:B;0I5G-9;UEKKVFC5%MJ=4;0IRW;HWN0@*_M/(0EKB1>8K<6;2C=\$UNA_-!<^
++\$>O+>2VZ);SH-M8F|O38|8)-F:739RK2\$8V6:L|J?P%D%(DN%#;IG|5AC);UMU4\$XDDO@/HG-MHYM&*.LP_0XH9TX:1T<-
)JZVB.WD_-BPI(U:PTE^O'6MH"XJ:X?A%)VY6)S-MA;|I5&B<|'\$*F?M+B>.^Z/OH'1?J>@&48)&LQ%'+U|NAQ!<4|>CZDP1
ML+FFCHC"FW|;S5>K0WEL>J"|NUVF09OYH@WLP2*/BG,U|,(-HOB,H8H\$F M-S.+@0G&\$ZYWR26=3'5>4CDS\$=-M?
H6'3'0=4&|>T#N;"R04PT5T4|>NU+D;X->+I0&B-L_V60JGM&+A|3+F-MV9KM\$G;N|A|@7CZ|8V6D18V0-
\$2/PIE9GTP|Q"BJ87TMS1@Q+UT_-MDB##;C(7Q60BF%K)9X*;Q%0Q)SV(%|V\$RFZ%W3;="5P8,179
2ITL-"SG\$D;FV|HN.\$J9RPKO.EJ>|I^XZPK05H&0:FHNA;5-0#7-MZ%IFUA7WG""F|DR.3R77)*R1@090-GI6'PH5IQ'U\$K6);HGQ;
MGMQU8W%V@C|B(BAD1.Z1-BV5|P|J\$F/UF-|0L65^VFE\$7:1ZK#-|C3-K&H8C-1-MB#ZHQ:*28|Q/1Y|@+EQ|

CF*/OI:ZJW-Y%QCDF/C,FHN!*5T*0C=3\((X+%MYO-"*88F\-'W?>%=>.SJ71NHU@N344,09CAM*QZO+C\|R=|(2C-2+N)8D
M<+4V1>T?|+T+)BRV"*/C;CBH(GDZ@FU|?+6%#QE,JS\$5T=XDT7F2F+4GJ%N%;#U?<N;...?8 M/QXLB91|CZ895/PV".P.7FT&&A2?
1&14MBMG<V3>2Z2&2%UGS;F3^#27\$VYH,M,K(8EC%,#EYJ4^@-.M;_>15M6YY6C|Q|>XJA32B8.3-Y7&-
#:9K"K4PN89#,2|M4@G(Y.'8.M)3XR'1^L B%\$>E5-JW&4)/PL'"Z2|HKJ) M-%Q?'|<8*9S.H4@_Q|LDPIP\$;6Z%PO^F3SI(8/N>-M>
(F21.X6S)N8F2\$G@C8|T^2|4O2%//.B65RF>A.K*JHN4.,80L>\$T(Y1HY(-MCSEI^|LAON,P(RPT4=01J.T:2PQY0TN|4%-
&E(1LOPS7\$,A4N+)(J&?1-9 M>=&\$-NLL%QC|5N@?Q-35%&FCG;9(AN)H^+-.|2%YQT&|9+T) 8MAVKC+MC|NA79?;3C|(
T.G495(FBE|92PHJ]"9^ABAC7C%-W;7\$0&2C:C;P"Y5 M+4J?OFC+G9|L22"8#; M:BZ3H7%&DVR.L88HD.C'FA_LJG-61>W\$P*
MW47+UE'GR;1+XC"N\2Z;@1L#-170HD496WQ8DD?N'8\|+>?+F900EL(OW>*M\$79+PPBAF\A.PHY&"'-<1Z(&RRD;=,,#=#B&6+
#A4_Z0P_*!!ELKNNNOYP.MQ#4;%KM6A7N6V9G"F2|KL9FO=J^C|' M|<78 '^.,0EF78-R|D^WPG|;&"6.^ZT>|/TA% M-S+*
(S#5PCF8A#FJ#1A M_CXFF@#7=2FZ#UCD&f-.@/VK;2_%O)@;R_2W33=T,(DTXF RV8|V'8E&'B-MRB7|2B+&#&+0F+
(|CK8_@ZTRCYRPV6|X9^!9Z;|)G885(F!G0X%#XOXZ% =M|B|_#DXN*AAOLO(=CZ\$BC&+|P0\$|)0J('W|+71EV6RKZYK:P9#
M^_0\$9FJ8-(BTQWI#;|L;49P&#&@,#Q|X;BCAF<|+^170|;JQ^L8-1|HM M9N0_X6;:1. #71LPD|.@M%HF3.1L;U&2Q;>8YQ
APL*"\$Q2U4U^8H|/|"\$(" MG+,+09=LW|.J-U%+9("CF,-.4)5)KH1&^&X-!;Z\$04AJ&8<{|4NZX4WR M)|4XA7+;Q 4*U-(8;P*E3GC!
H)0H4)&YVVISZ8|8;|VL<.:7:P%1.1(9|MQIU|KZKIQZ;=,B"~3%P4CC#JY(WU<%M2P)<+^14XYOHT)P%(,^"B9612?8 M&Q8(P-
"2ICD8|PP9?..ZGMH1^1TXPC|1^,4VHP)"I9;+B&@X;9JQJ+K;M.L5%=-3A&FW0QTA1A7D5%K9<96/=-,ALKK|ZA39VO-
)&E0P;+J2MSFA^XER51^TJNUL%7V|;?#-/L62P-R5|G;E|?^#8EM5Y P6);-|)LX-WACL\$QX7/(MAQ"YT2<|f_G_R<=6;(51/GT76#
MV*)AU0*M*!f.5;HY|~9)76|HC6FP5BR\$P%4FH9^&W1&@<@&B7WRBUTVTK.AF7)UBB0NV-LJG M\$4A%Q98;8"16F?|9XK+*JQ+X;-
NWIKH#TL<6D;-1^81)E1B|RTV@CDS6UVA-M|J|QT)<4AFB!@5*Q835YI)@?#HVE<)=YCVE/E@.WD)(!D6R/%W?G4G.+X+P
MU09@fFZA4<=>#D>"\$Y|;MD+3<14&2<0H&?7%#B1&3T*B\$SK4\$0*7V%;5%UM\$
M5%E;=*\$F&N"W@HA2*!XA#J?|012944S#9")2M(<;,P SP&U%"FQ|? M(L4%N*+ #W8B|LR7,H<\$FHGZD;,&=+|+
Y;8CRN;2^";,MQ&1-1\$=+C;QGUD2-MYB151NSF&E;7L.D1PYR^C;|7>-B"0.@|N^|E=|PV79|GN|XNHSE@E/-79 M?
Q&^.@N|KA8+B,M|W+BCLCRQH.RPV%Z;MB?>)/F%|V;A|IK3I*KK30E5J2+MF\$<*)5^R#D-)SM)7W*U2U1WJH?>6=+KZZT(L?>
3%;FP^A>DS@")H2RHA.MA;|V#&*)P\$R+Q&+>8-*Z5.QXR8&FEC&E(AW#|4#S1@)Y99MTG*Y_@&|&3-7
MY0K+UJUG7;8+;#;+PIPK|;2KA9ED,40Q\$C74U|C0@&N|2+*|P\$5V_SS=I M,P41B-^P%0;WD(5;,(D>-Y=N#|98PLF54\$?
35,UBP4|&2K>;&TL#1)TLRUAM@ET)00Y=X-JW5_.SP">%LE@=98|M|G/'3+1)P#;@FE\$,,MR)P6*X.5^4-QP M)9&DVRON<
|3.%%(3(C)YGX,6N|/3?0|<.B"8\$@P8<0SX.-1%|A00P4MK,0\$S.-8 M9&9-
:CU%WR+;4E,=AS3,N:GOF;@7DA%Q=Y8FJ;=#Q(*.1:STNR845"*"E MPW*W&
(A8%&)&2R&QD>#M8\$4;=#OEGM:WT;10XL+/P79LG7,EYW>.:4WPCW-M6@.O'=G44B|)'U#-.|D|)QB5UB8?.(=P<%
M^@LP18+YR9(2&2YLA74F)<)'T';O,GC5Q=C-T;RX7;0Q0NF)GP%-;W;C|+|MSV.F;HPM,QN&/50-7&8&8ELX%<@S_|Z2,+1^?V;G!
M0|XW^4Q|26*UQ;5.MGH7Q2(C%+&@+BT+IV)Y2G;@835KHP7#B7A4A(N|N&*Q6\$%40.&B\$2MGODPXP;,-
=#W)_-136K4T+/1\$X5&GAH?X"*Q^4P/V7CU|@ M"(S|)98B301FCX,SRI0(+D4G7667SLT/' 4DAF4P7,&+<8+S|QU@&D/O.
MX.^0<1>^&V+V1%#&>_VM=M+TJ8Y|>(@|V4AC|F|-%|^&^U'^XS;NM(AYO&M^XNE+E\$WX\$EU/'&@;QLSN;Y1K'="T+;
<;D*2LJ+R:8|J3!D8U8=,J-M)VY6UC88UGBJJJ^H.O1E=1;P;=P9J)A)7-M%>9'T+E4T7CTPD>"WR(^;S?
%&S@B4SW443P0P\$|5.DEK7C|G|3MS@YKCA;4C.MO4Y6VY;+;Y9LO-U7OB>L9^D|';MT;=T%UNJ|SO-B4#?ML%3K-
<4,L4S66/UHJOSNN,V+I+MX)M(=>5|fF6@MGHG_@CEGMC2)YA;M-O-M*83;&69+0\$X^Y;DA8I;S-.9H=D|0R+/R5KHH0BS9-
-22360>#12\$|L1T@{|MF5:4PZ.5DV1:47;-5F8|;I&9\$#514J5)\$ (OWW>W:9Q/PSP@090T;JW|33+! M@I0|W^f'
X.;J1H#KDIR 2&P%#69Z|.M.TX66@+PD=C*OSJ;0IL-J M4|1<0^N(3|>LF@XF'5<|0W8IQA(Z|@R_C'4.;ZU|E;EM0;UBY?>
#AXM#C>#S|AJ0H(3KD<?7L|H_KEL M3M\$8RL>#?!OP0Y3W,OE3>*JPD>U9#F6YD,@(7.90Q|?QJ6|KSZ)4Z1\$4W>8|MD1TI2|Z'\$S-
Q)=f6AS44W;(|-1HL M#QR+|+U@?SP9V;|)S9R(<#D7|P)8^7RL^!6OD99=R(M^L7E5=3P@.949GQ3
M=%B,6D6L+4UO8:B83.9|8B;9W-(A<|*+;"L7W08QP3SY5|QNX> M|=QNL0-G^IBM|?T\$;1>+|,|ABOX;|HKTD>;|J3-M&;#
(#J@^@15X7K&J MIK=X7UV649KM)-AM|E_V(3(\$?^C|3%+W%'|Y)*|H(KKK/_GV|A1B?B|J M/'A>9-4;TM6F2N|'6-
BU<|%)#KK)RV1AFB6PZB<(B)|@QF;9/LO(F^X8|+RJR44OYAS M,(416WCE@)IZNFPIN95OJU@R2U;ZQTP;0Q?&F0NLF1|S57E;
(KN|/|<+UW M^E;A5J\$M(&PX1(Q;L^*^<|f\$M(R)L)YX7Z4(1UAO?V|<4#;=&G|L>S-M|E|G|S-MTE|F)6^GK2^Q-H-P&LN;-
=SQ;D#>+;8F+D+7Q6+T-/>7+T)E=H2^QGB;D40IP.'WT'?T|+O?;,"<#&6RI|>FSFS233H;U81(X?2_R9GSO| MV7,B??F-
LDK+E;FV\$SL4NM'&K/BKX^?"*BY|'W(|#(SY+&)O0D!*VW^R%R MG'(1fX=AHYK^Z6Q?>
M'C'7V0.#|PI|H5D;0A"5|3)/O9VS18)B\$;%EY6X-MGHLV%X|D^-/LG"O51JV\$LMHE0&I^*^1-97;BETE>VA%K65-EH
M.NG@0%0,*<1BA|f8S'2LM)IEI&).R.T.LK&JD,D9D.V3V6R|J\$|QJ&|/JL3* M/ZFE8^<(OKO|XNCF"!8M<*62V3M/-3"8.7|?R;+V+%U\$-
V;Q-UJ2^M&XC+& M92N30;|7+9;Tf;9+;%S;ULU\$&3E1\$WT\$C9/DDGCG8N9RIZ|!67K^3|9S041 M%*6D;G+
{<#R)*M5D\$LLNZ7\$|31OYD|;Y'FSC>@{|>T21U)+1GUT^|W0B;1-MR60F"7S<(SPB7"*KA;05|I
4|CT447;8F/_VWNO|<1+1%WX_G^*6%E=/(9-MDD4C6UF=-S%EJC2=,BTH|Y^V7#ME\$-?GHA8;#00XY3Y4K"V=5C%PCJ\$SA;!
|KZRSO9N7DY*0OH;UGM1KR14Q5QPM-MG,&Q"XX;F|G 4Y9KF-%)*|OZ)\$M13T.^IZI-WVU|B=|M>-+&K;_Z)(
MWW;CLVKIK&HO%Y?>H^H^U+CAf|O&V\$XW&4;f#JM4Y+MM;M2-K5#4|2T#WB6-M&B+#2|VBX;_RLPAX;1%#
M(2A@VT|WG>E(TXB"1+&JY_EA%2NB\$1V(\$4TY_-+|LULO2;Z=;RLD4?Y^O-MI9-^9<^6/N;R#KGQ&)-4DT0<*DNCI?)C^Q\$X-1
M(U(2|R1CMM-J+8D&K,D|f8D6&)7=|BN@^Z^5C0C;|Z7<^*B96)V#P;L.M^97|'8;-JFYG5%GLVF<|f\$;3|*+
@7@C3T3SQ4EY3|;SA05GFYN_E\$'5?P1SU@/LGZU_5L#%R M#%X(X-H"U?<L;MX;\$9PMH&1%K9^T*^0V;D@Z=D30=[V5T%I^K=8#;
MGQ5*R"=WYD1Q@M+M%ZQIDK)D,ERM R^D33%Q@/L-NWL#VJJ M^+<|Q,<;|;#1A|BG*7,J.1\$|>HVV|G=2J"A;Q9N6?
Z71HHR&^6(Q&%(M+|f@6>Z%BY3262^V7.6((G^4CN/|^<^&O^X|M0
MDSB",=)N")J?"VN5^OUS|WJ0?/XHGIRWCRNGGYN79|4+QM'X>?1X)W;ZZ-MU0|_1
<\$V3H_-UPV&M5+F^WUX+1^46VW81D7|9|C|L|+QN>W@5E2U&ME M'28YQ(N7D;L0;J|);B%,1"%&'M+XCB4SB5|WC*;
|4SF|50#B84N|45).5RFT\$>SI<2^J;01PFCM/_X^A3 M5E?F+#+,WJ^NRD)6=,,5)YW;?&1_OYTVE\$T|;E|0-
XPIFK|@;G^1-M%UKLS&+9%<71Z8O&.).^#<|NYM^E5?V|+U|H|@>/_CR=8E M6V^?>
K;=4R+V&K9LE6Y=L7;+UUM@ZKPAP|6S=>J|ML0&|T78AB| M\$|Y8F&|Z|/6+0G759Z55|2HRK|>G1
|J)P<;>@J|*R6+D1N/%X2K%&D&4/8 M-6>CY.9WSLUY0-8M|(M6|;7GG;8G|!A,Q9V85(|;#S-WC5=5-/2,BYGR(-E;F#|Q*;
MT|/_HH|A123|?Z_KI8+H77-\$Y|N|X6I3|JBU)|^U11Y)F\$|F0\$)*Z|L29S1-M?
&|S|J4Z\$Z)3NA9G_/YG5K@O+N95TZ\$%|0|Y@M9PNAXSUC=JCY)TNU|_RO@ MV72PY|+^J^+9I40Q)V3Y^RZGM1\$A=RWWL3A?
3O>E4|ZZOD0|QQ05<.(4*M|GL2?'Y-(T^Z;E4=|XQ2J5L|E-1<|0(C)-BXN3R^9%NWIV<7A6/6A2'E<_YZWJA?1Y?'
MY^WfV>?%I^6IF;-#CO!M9I/5^H_G9*;X>U9ZIC+H&S3-MB2|>6"6/TN|OD+(Y>Z.*DI@Y|!%LCAT^LX;MB<T75MQ|%"EQV+
<|)K7|CR-M5GY+C3C52|KK;W%0K;<6OT|;D|FE;=#R?Q-@;^5VRXU+|^L5RRQGE5N#)<M+3^O/8GC51D0B;
|3|1^K16|>|5SWIDJ5D9W7=|YD"WO+|^" F2|??CX5|XL7 M!%=&CRLGCG2CYJB8C
M4+GC0=G|UA7|N'2S.4W>;/ZS7-5PIKLNZ|K0KZ3#R2^?3@_W|U3;L@_1-MO8>6MP%CHGV4|{KH|?'I?&OF
HMH|2)XO4M.2&8|?E-9?|3QVU|;32'B-MUCL|F7U84W|X1^?+6>Q-.CW2?YD>Z&V6D6PFP5J5QV"B&)M@-6TT*+Z3-FT%
MP?;=#69E)|A8M)WD%3<55YX5+^I>L)SG(L3CR|9SKP?|UOKX3OH|/;<7W&MN-M!-\$Z;CIW6)BFV%(G_@80&V K>Y<2R;
M3^XAJWG|7GRP8\$F-CSHC3|B-(AN|8K^BW;H?V6P|XX/O|K5|TH\$|JX-X5KP/L57|;@_97EIZLZ?43 M)U^6P-
RST#JX1^@HT;4^&M3%60B6EF1K5|TDAKUCU1|BW9|T|DGN|;M^9X3@>CTB|V%DA@C\$K#NRQWN^MM
#H902^3|<Z|+W^&OD.XLK;|JCP;3R=@|;HH<|H1T^A85T,M6|?>M;=>G|;1?2X?LL@|4;^FTE';00|NH&D-C_L|L-
P|1|WVHEY7C'A"P@O MS7T@&6#;Q#1F,G=|@Z6\$EU2K('4LN*2-DP5V984(F5FK9'D(ZW;1HL;ANM-M75&(4OI(0*/
2LKPXOGI"OO="OIN#&#V4C)|P=;75;^6|KH1P0Q_L='5NR^?M;?F"N0F.@SUJ83|&(^2S2D_@+EBD;_GB_J08E%KA%9-
K(4UKMA9USZBR)B-ME%F09\$*C@RY*K4V5Z9-R4(2#SB5K^C64="K)BI8,9M;JP;7GK=#|VLFHF4N#!);|D1V?
9K0.1^JR(4^MU;4>H4_OQ|F9?_JMI^U;L;+MDZ2H^GLIG/_YF; MS6-RPI&S9-IV4W|M.RF77;3WE W|0D|MI?&O @/M\$8_-
^3H_V>L6FQ^YP M9PQQY?|/T\$|_IG-MU|K%#J.ICQ)4C3,6UJ-JKWG<.&V=M\$;5WJ;LI5F)3*U; M^*K-8K9BTC1NH5%6/FHJ|593&?
XASG#;VE%?KM^5NO^9/|UYL_U3N-;K@CAA M-FE0B?XNR\$DTVO>RK1V+NP\$K|_?
X8;D%3GRMCO.C7E|16|f>2R6^%2=G-G?//PF|1K8>O|_=@M,M?8?M&#;?M#@_L X|G1@&:2JM)E%EK;DS>R|>5TO+ZS."3*26AT_-
+OH#QQM%>2|=MC&NF+IEPB^=^|X(X/Y^KLCBZ|DED;V(R)Z;CT|T0V?16G+!>S#f>W^A
MV#8\$Y=L0_%>@2N|!\$DMK"U|A@VWE|0|B0V3Z-3FD2D|@_8|_6=U@/2J M_-JN=9Z6RA=ZL4=I^VIC3FV
+M@;YH5DX_=DM;O^77P)%/MAH/L,\$&8>CYPXH8^%Y7|I@V9CA)O^!54;AF71T2DK|;|@L=W^Q_>7>KH M|J-7
Z|3%X4&I^|X@T4U|*1%MHFLAT17\$;RV@2|%)7\$|D+Y|^2&.Q-3NI-;M55|?E6I431R.URIBK|f2?&A?
|_R22JC719(=S6)P9\$EDJR2RUK+H-43>:N MOP+SMO0-UN;I&#>5-|S|S|&#;3#|<+BCLK|8Z KO?J;RN33D"15;/_@_C-/1 M-JR

7Q!^J: H0+!J?S%,V.IT>|3@4=K*7J=DEMX; 4^Y,=D9^@=/M?&-!VV7H_YT|2H|>B+&R!9,5=U-|%"A".8K6SG"L,%K|.69W
65U"9Z#M>9:|IT%3=J|E|I1U4?S|G M-(H. 22); AWGKU/4LZ8N_SP_4^!C|CX"&NB TIP5\$ \$D(4I2#(=DA|DT ZJP M9F8##TG#
|E@((C@N>Y0810|)^J76RU|G/Z/79K|/%E< 11G=H|T A MB@<0#1!^A#HJ|ZOD 2| "G<U-|P^JP4%VXVN^UAY@ CZAW
TQ5=P*!%/- M&CX6BN.K|QX+|/@.KQ,;MLMUWXCL,E381P1!/ YP1%..>W|@WNF,;KU3-7&A MFE|8XAG?
S#2++3U\$G|V|\$,PH)IS^R7GFWVLETM%|02GAM|1*6+TJM.9(81 M3H6V>PB+20_Q8Z=E>.S^_6=1BE^S4|}5
RNO>BP9A@|C@)A3S4=<&X2H6 MD76K&W "(R;4.G.R8YB|J- D&|GR%"|49:X6">1;
<4@YV7,8=JY\$5%\$S\$UBAV^XUX#0=3LN=7PK|JR5LH;5RJJ|TPRWJ|ATM^82R=72 MTM;3(481IQMK%3PRJ0^?|O--
|4T|D2_73_A@E3/(X- FM^<=>4T_A|,R_0K%;\$.M^6AO@O)^ ^XD|<)&O| #OX3SOE+^?0^GS0&R/^ ^QQP_-"S8?C0.+GX7C8-D
M;NNM|5ILOMTFMNWHX;\$|K=J<."Z"&@??:%71C^@<3=NN5EZ2))JVR_A>I.TZ MK(UG_-Y8;
(!>^@3>ITAIY5TIZ&C|F|Q8IK=K)\$B+E8^;5321,IZ^5BB1L04, MGMP|WZPX|1%.KQ2""OY^3_M@|RM^C8G;WT"|U243.OS^59%R?
%L;|P|?Z8H&6T6L;M^I8H;=1/-N.Y:H62 M)64\$;RXI<)&Y=|{#"^)|OTCG6(ID)6=6\$|2QYTT_ |ND|O%XP^ZZ>T|YGICC. MRP!
<13.M6Q8ON\$T. 6J|KV|R|J0F4Q&RD@#4CHF0=C_3|&25S.XZFTJF|Y.MK.75UQ5^A.Q4?&X|};&S-7?
GV^|3NI88VM^QBM+X>;5B=3SA(4?0;D2D3LYE MH^Y?S8|_JA2^,HO/2A)X^R10G%JMXM887/C4%D^4A|_E)#5/RZH5J|""?
M;M4)O7Z.L.FW6=U|8WMLFY|PT5G|A9R@|><|MM6YS EQ7>L>V29XKM^ (^B@M^"F^| ^E3L82;2D^N "F7-
W%->HL^&PHX|@B|I6Z;&TX)0PY2OR\$-%.E\$2 M5EQ|E|Y|U)1S^LDFU^&W^05T0P?QH@|THQGF1)#24U)-0@|F7?X.HU;,\$-)
M0:3(<+9,(3L3-BHMI@6+60K^5_-1|>ULBQ^1"K|O<|JZP2W&EKH P5-/AR|+^&3JO|M+V8H| M+^W^3.3&:(- 2AZQRZ2-
I/^I?_33@<<6AS8?>|Z8/9I1L|_|8HF^|B^/&)MEBB1A&R1YODCV^Y7;4TJG\$@JV3@-E\$&L4)O) L MA=J67/W6=EW|RT^B|5T^F4>^
|#5EE_-4ZD>5TY-QC)EB./<)>NZ^7C|5 MS;G)2U|8FJ-?)B^4W%\$H|B&0/L^DA=.#|K>,DKZ| # 7,7UL<;922C;,Q1L\$C&R;1F!
7,8%>|DS0::ZU&R21E^&-|H8P| MVEXJO^2W^P1A%PCO|=!:-;F-Q6)=Z5C|JLQ%/+N1><+8Q3>V.RA=V\$ M|8JN8?OBV7-B^8"D/-
_F8.\$7.^QE@9|Y;1KX.\$%%|CK9!P.Q;H<4-UX%-:0F MCU;5GXW ^G#U-U|&L:L\$D5R!?!FN:0|<2=|PU^A^_G(ZYR
)L)K&JTX4=5<8G|J3MM%|SATG8>^*AB^LW^|T(VR|)\$M2V2^|8|H|6L M^PQ2G|G?F/!:(A?%)Q^M^QKJQZK|O=JS+3C9G^/-
//KP^93N+S_ALY^JJ^V|+^_P^21KXM=007_-="H,1_M_S;U;^9T^EW5V13FWKS6&>J8E^H/N8JL_ |TH\$M=.%Z<4^I@6TSC8FZ7N2S
M8|]^F=N^E9SL2V2^<99AX(6+^#H2)+STL>92FLG1|BZ|}\$%|;1^*>4X9"QRZ8? MNO0??
\$/_L^>I.5^DN022M(-3QJ51KU^PPDDA'S|AF3A_Q-2S^|TX|0BR9_M^#^+O&^??AR-
Y|ARQW^9FY,^N|J5H;3U1S^B_J5/H(7^="Y)G.LB7^HN^L^M^YU+D_9%M^B;K37.7S^X|H\$7F9F-15|,OFF>G%%;Q^_76IH3YF2|&3O6W^";
M;8:TFT='E59,|#;9H#\$\$+9CJ@XG+|Z8365)W;+^L9J|V\$Y>|7R^|J8^=J.XL MNN5+Y@V|;M7W7N^O1K_#;B=Q|^O-
U^O9L^!I#RGC:HWLV,=DM&D^ME%GFT5/_M|^">86;R^U^#R?_?B_(Z|J|7U<-W%^U_5MN7CQ?W/PQ#>3&&@;X|_UD_/P^E-.B^*T
ANGYR|P^@C(4/P+VHS;_1,2,3HQ|^&|YMN&|/KB3|J25V&V|_8B_-V5B^*HCY;SR49BK-;V|;|(7|U^*MSI?^E-,4\$3
MS^O(9_AAC8/|LV#N4|_B|ADHP|JV|0|-8XB.E.EG<N.NMLJ3&7/^+^T3_U^M.6683"&_FU BT|^H;
<#6HE&J3_X0T2_K=H^FBH^|(3&D>|YUM^#&8<+OX^|MD24\$)OR:6(R^#^+|K|TLG6\$%+;^Y;+19_QJN)?BGO^1R2J8(12)^#M;L;M=-
I>16P&/6+^+G/YW|_"OX&^T^5L|_S3P_8ST@RRM4>JG4(A),1,8_M^Y^KQR-.4_BZ|V7HC?3IG.P#QAY-WDT@FI6?R&+B&?
%SVG9;OD^EYL0^7\$K/_M<|B#O@|_0|KW_Y,Q|_&W2G^*DJRFU6NOSGK=*S_PQJS%|;#G^#;6QLQ:X8+
M7#&#A=QPY6UZEFD>?^5==D+STO1?X^2_D7%G^_4|@KX3,ZS?459R^YM M^?_9L.RI.L/UN&F3B\$+;@>G;TF/|
W^0>9@XZNVV_-88&=OB-9?+M^*YX M.V6|%^%_YH.W|Y;T1R^INE^|}|>+8+5(&^7%+5@C1L^>R0|M=6|793F|_MM?
FON^*W@R^2TV,)|^J^;SCG15Z)TOCBH9+HS-QGU_-^+^S^|2MY|+4>5D_M^JUYK8D;,07|^">9|I-0\$|CE4CG+232-"9
MUOMJ;HT6/+_3^6#N7G5^J^V^C@P6^*AT^1L;ZC0QONW^D76F^8\$DN2:2_T|KQ_M06N^A3|A8\$?,<^0A|
(S@,3^>|J7H45STS)ZHPO%Z(FW>0JG3,5?+<1=IUFNL MU(6:(%+8>^/447,69EI^F%N^H+V5|PYX,XKL1/_|0M^JT):9@+^V|KCQ.\$7Z
MIT\$;7DE1=-P1|(GB&GYR,"GUN9SHWQDDG0Z3|T_R(M+1N>^CT_H#-.R4V2-MA|,UT)!NB><-CS0K0-DSC=RVW0>7NMJ2E|H|^O
M^#(QI=D(V|H^E>1XNSCJG_O=32|H|D(O!95%#A-ZO1|Z|X_-^F4D1=4^6_M\$D^YA6TR^Y;N4L_WIBKG^ZN\$|G^>9^H^J-
FP^+WS|KOL5U=KJL_4|ET M^O(*1^S|^=K9^A|_R@4U1^*T0AD A) L%&'\$7>IU|?SW=M.\$Q;_1N952ZVJ^M MT(O)^E_|.IDA;
WP,Q^07PTF#_YT(<24YZT7(|_IDW^*J23=V24!9?^K#_M-#?8+W|A|>1L^>)|_S^E1;KQOX&+S?^C^G|W3M=U^E3.6+
<>B%)_H4H+N&\$9_M|ZE.H_Z^J^KT\$-_Y3=HJ_R_@+^/K+OM|_1>TT?%|C6|^A2>V=ZZWH_L7L_T MNZDI7SVB|!77+1002^AJP;*P
4E>=>TJ#;5^&BHJ)1#|0V5%|H|_RMD3_56ZTC<@ MCLBW^K9K|Z%O8\$QK4PBP)5#;|(04@ON^?2^8AL>X
MOCKKMFNU,R>MXG1K2^MOS1VRKQY|^_OZ^#^V2NK|TXE^2C|54|2_TMH|C_M@K16+JF_-2?
E^204VJVR|_1_W^"RA(TOJSZ7^H_GJ^">|^@_RP%>V3OV%|YBQ_M|_I7@:2LM|I<+^DLW2|_9+=6_2_YHU4%
N==NYI3Q4^QZ|JWNS2|@/0Y3PBE_M^*GT1A|DM|&WQ>_X+P;^R>_2JOUF=15Z|@^63D5MR5,E1;^H|^!-=W#_M8G-
4LYD^&ER5,E1Z^&H9EX|XX(N9|SYZFAW=%3A;_VYX4^5;DC);(,@@\$|);&H71|(U^O=^<18I7JNZ_MHM9/SUOZ?
SL;N4D7>2|&;#383W/A#1_3(CZ2?K|;<((W#)|#6\$&|6| MIH5^#KZO_L^|)|J2C;H|)^S4BSI+ 80A(QY,6|JF%&WKV0X|?R@>|^T^?2M
MB|\$(%N#/+%G%=.?CU:R?>6^X&^%A|(4E^NO_P|ZY^JP^/<8(+00@*=RZ|T_M29-/F|4:'S'-IDR9^>W0;35FW\$+D0FO_#^#DA^Y
EEMV^MR|5|Z(CPQ^*|MP|TI<^SP|UCQH^ZPVR|38^E_M33-)>H)"(H&9:C?;E18F;2&N&)&Q917@^BFP)3Z1H3Q^&XCR%3_JM
M^HX1(3HB)|818^7T6!83ZHHK+^((NN^#^HDF0;G^*2DQ/_B9+CR_-^&#;H=Z8C_M^8UN^#^*L1?
W(H^70XX4K2M\$Y^C831Q^+F(0^V\$4 GBKB7;2\$Y8_-^|3R/RO MR^U^G0^V2)7_-^C^U)O7?ZG@> H|BHWG+>E14M^IMA=88>(I?
+W^TZ:S^K^M/E_L|TWZ0R1=Z<=>/_=9_-KQ48:|^2#BFQHQ%HH)):%+H2%=V;4:2S9L-M^8IY^+N#)V@>K(%>Y307_4Q81;&?
HK/9MD^_1D_3R2,T^"1;(AN!"N;=""X_M,SG;|.Z@Z/W^:4L1EZU_?Z;(BQ|N46X^A^Z?|^|H?/_S_|HKR_M@>|^7TJ>JN0C+^--
U)5L5=V^50N^*AC:8|FB^KL^|_J-D+RF)20|C<;Q_MQR!7|HFT&\$^0WSYMATI6^;^S;VT^MLAUJX&|^P>^>OR^A_V#_1N29UH;Z_M?
#NP);_7H|HJ TO^FS4|:5|_MM0Z^84_->J(R7|T7QFN0^ZVV7M%>^629U? MGB(_>Y8VF2^DS5\$SWY^X^68^CP^?^0L6-
E0|^#KJW|GO^UBF^709_14|^_M|K|HG4T;_5R&3(8C|T)?3(AP^&?&A^%&ZSV|^+>I+;W^<W-V^A|Y;J&;?5_MFW\$^2|0_+|J|)
BV|5PN2^J|&O;I@5_6L4,@^VK")@J8616,XL;|/|_#7O_M0IC_J0X;L;DSLE-F>J= SP6F;W= PTHGD^RL"?|3|MB>^_2IH=);I3|+0\$R
MP8R^O+G^V7Y>TT=;QJLF0;<5FN|^+Q(|H<=>^39DG?&\$_59&?1-7%|&LJ5_M3|1^T_|_"+8=\$"\$(4+^+)<14;
(?_UX4CA|P|^*QZ&2^S|JVW8(3S;H5^_M7(+J\$)=XH|6<^GELB|>FJ8=(KD7O?H_ONT0Y+Q;2AHI#0^5!
MS^QI;#)=J|1#|0V|J^3E4^<K28B^W^5;890_Q^2|R>7|R_1ZGP7T|^@JL>^<6F^Y_-?^20\$VOB8X_NK90^Y^XG)61+I_MJLET/C3Z39^I=K
C2C(M)G.IQN-(3|W@Z\$7TFFA2?3^?#=-T2F1X4DT|^M_Q+9GU?^7V.RT=LVZM^O&N?1G|CLTP6\$)|_7J|%"@^R40+3OA/3G
TLO2;|D_M_3=^O.AFF^|^|^?&ILIS^A2?OOD^_GQ|^?C_AOO^FDV|=X^4%(X6_1,2|I_M^F.ILOH@|^=*BX-B=HH@5K?)PNL
NK|M<^BEKI8ERQ0L@RP^K_O>K^4Y^M+5^RP/988!5PW;_&.EFFGVFWL|Q|U63)|Y;BGPW\$ _R\$^J(U(C14_R-WPVE)P_M8|^E&2\$6&
(P).E;"^8^0P,ZFP04W/^WB\$P>5UN|^H|\$0HW;J=\$5H1T^P_M4(T;+>IFP3|DKD^Z9M1;5|YD8=#L&|3X>+^V|9#@^AF+P4&1)?
P5HUY_VPP_M|+WOA^T^O|^_)-3%PY&T|ENQ|E\$ENYW_1C|37|J|F\$^%\$%16^?R@Y^Y(^=K;+|^#|S@1CQ^:DH?P4|HG28710>
MEL^2J|YH00P^&J_D.2L|;(81-(29Q_5V244TXT%VS,MY7@^64M!(L1L?HL^CB_M^Z648F@5+ MQVDQ_0<28C?
R0|0N)L%\$0RGRK48Y=5(BZ_Y11@O:KKLKRO/ M6S1\$K^V\$^\$H0GHNW>^&F=OB0_2^*@:%9_O|-(H(88BNK&#K4P(|G\$H%L/U
|MV3Q>3X6PA^>S^&#A<+N4VK.9GF07|SB=EKR^|J^K\$5|5|2P_PU^V^MR8> M1@<3B^>^18B0_<KL+XZ.X83AM^3&Z^Z=)^#
&H-O^HG91.D^?UB@>N2|H_M^O\$T4^DUYI(RA,(-^B)KNJ|;QNS8A+^*^)(OC4)6|_|.DROUR7|Q.L
M6);_6B+>4JL\$N93MLK(>V|OW3!;69<=YUX>O2_Q|HOD=Y9_04M0Y>_UY%R&O_MRRAJ|^J|A0#F3C_6P2|2|#\$2VL8L2|!QT?<
H>P2E-D8_>?F^ERTL0=) Q9_M%;PWMFI2K7TMCJZV^Q6P;J);^Y>83R!7&;L4|+UTZ^>6_U)7RKJ59LTY^<^F
M2Y>|Z.^X_OOS#^ND2)|LY+@GV06Y7L6T^O#DIRM^A|<;=HA<%(1W)IB|^_6_MJ7G%);_W^|5;|01C^<C4N2S&L
LU(BYD^&QSO1L&M)|X^A7UYB43CEL\$Q5MV_M_2|MVPUOM^D0^3?|J|2BC_5:NH94UNFA2|J@#6J|^T="^+Q7QFP>3_*_ZQE
M5Z;^>^_Jv8^>^_JCG^X8Y;MB;5J|T|7R^7R^VW>^|JSO<^JON&^_*|^M\$S|^#7&=6M?
(L^I1TYA0&^|3QFGWD;^#VV|JLV59|S"?_WE?X47^A|8_-#-M0>9%>LP5,E)VJ\$<9U2^O^*SCGJ|=D\$,EWY;+(T?|AB?
PPNE>QE(PP>>3#0U MS|J937_DYX|ZANB5_NEL_O(I_G%;7B1M^#3&6QJ|=DMBG_&A^XHD_5CM+61 MUN1;|^T?|NRR_A|^?<
_O^YO?Q^A^>^PJ4_4 MD<+SL%?S^KNKQXMKT;R_Z_8|^_UQJ^G@U#Q2H&KB+^|UGDAEQTU=SY;6;Z@ MVZ|A#
>RMB>HL3KBW36^&^JKN^<K M7BB|S+^|771_1,(*Y)SCQ^V&0|I^4^W W,7_4N)|_>^%&F+XFC5_M/ZW0FCP/NV5362T^COT|H-
G=)|L^DV;W|JW|^N6ST;\$=,QRBG_-FG-CU^#ZG_M|^R^*UYX|&+^NV3J|D|J9N=15O_R;^ZCM\$4MH|6|NAHG@:SR;=5EN1+Z|^PPD&19_M//
Q;2P<^J&XDFCK@G)\$M%:(U@18(&.1//6Q;+P8J0^7PQTJ98|XW@^#IN:3>DGI^_MA78_4CKH#>7G_%_1B3^W^<@_OB&U2|^24|/
W|\$G|W^<K^NH3(&.)|(PM)Y;AX^OW;8G8H|QA|B|F\$^#2<U_*XAJX64>^_MV>^B/^#78>|KK3F(3Q5@+1FK=^U+5;RBT5K6QR|;6^>?
GNJ853@P_M|^N;^!PB/C|6;#S:0)<4_GD5^<(9T^DG_-SV|ZOS|N4#^_V;=OO^_M5SQ)\$WQW|Q3/8_"JQNQ1&5C/
S_V=-8AP4%5ZBB^2(LI98)|^|);^&^?V7C MB@>^VO1#&^_1_MLD|Q^Q^>^E80V^F=3G|X#Z_G7^"K^74Y+>^|D|+MC%\$|
M_FBT4D59400^T%#69(8)+P0E|9<4O+P_X4K_-?DZZ(-2G_Z|BD^5|KSAUR^M^<4_IRRTAC&|7C@KJ|2X^N>=;^/!1+^7,13
^FX5T80^SE9BNJ\$P|_IF&Q)3Q4RZTXBL|QD|B1_M5^<K=-7;^2/OG|\$W\$<8H_8D>HQD;^/_=HDH^|G8#^+2_P_#6>B(-H_X|8(
M+^_O<68;P=4ML\$=@OOH_M&\$R_U,^JRIQ)8=S;^%+NZXCK2GYH_HU5:2B6=W_K9J-7Z8>YA|OS,A4,^PD_MHA;YGI^!&A;P_<

ETOJ2FHL-MJ7\$%U,CYF:D(O^K55^0^>BAN^Q,%"40L&\$%MZ+.EQ.=+1L.1?>?<>05WN
M^7\$A/Q/0082)CTBT)(&\$Q+828(M^Q^Q)YSM^QDT.L@\\UY4.IV]@3M9A)T(M%#677'">@K4:T%:+ #\\UW;F(?(
DN^A1^89)U^E+8U(T?&\$S3,Z\\13?_ET^M^X=5\\2VE.TL@\\T\\HS4Z7.O.&39@_M)\\WZH^XC7J]>F;@R^#8X7>Z.\\13LFW?C/H!
M1>X^871#\\2M&.^2NB26TI&&#\\[TI@,/7^+D\\[GRXIXD>A]8^7I4V2_(1?^MN^Q!>LGTW^P^I^R^?U0Q
W@V^6@^"FJ\\A]FQX;&-5^D6BK\\96!\\ZPL)6\$41^M/S_-8<@_1\$_UEQ\\@^B4C%#=#;0<3HW2AT^N&
MOC1^-IF)\\YS9N>S\\4>\\#%0W^M)AGSWB6^M^?L.T._"G-GNLYWA.5TD%\\LE=-MO^C9GH'^R13D\\I^!\\D-@E)6JHA>_J-D1A
10%XI%\$^Y43<_H@_!^PL^#W^_M]6^P\\X=9BELYUL3B7J%PW.\\5;6UC_!\$60_U<\\HT>^*H^K\$67NJK74Q2_M4_!<?%?XEMDS""5^W#
(\\?2S^06L/>@^ATHOZY.Y."91,RH^*O=5)K^G>_H^M](<.E)B^%FSI/QN>?FOB\\|MV1E\\7\$@^VJU^C\\8Q!^#NA@DV^*ZIUAT\\T2IQ>\$9-
M5Y^#51F9C>U6LC,"F=BW0X5>K^HVZ2ET:D#_J@F/3:WMND9_")8>\\JC\\T1T) MY^WP+F)%7A%G_E
^YO:L^C6U8EHB+L_#1+8EOLCHE^S;MAMAK7W_99X_KQ0Y_,?LD)K6\\|\\(3\\9^M3\\#0Q1&!.V40+QU>\\I.D\\|TH\\|QCX!&'5MV^M@9
4I^F9\$S^N^X\$S.(5(209D.\$/D\\|FTGVL&EC\$+ILX_R1?^TR83>AT0#5,3@_M2^G3Y1^HB^0!@3D2^@9CA6OZJ3V?_!>\$HH@>#?
O%\$98J^_N9T8!A<2R^@S5^6%*_,D;\\IWOFT+L5-6AE>\\)B70RT.M[2#4-4)=#Y4Y.6+*L2IY9Q^XVO-8L^YUG\\[*
\\N8J\$=R>B1."YXXK87>M\\|M-MTZ;K^0T_7.Q055&-3ESJ^HVQ#0C:PNI\\)L#_. "%8!#. #OH9;^O%#"#(+,9\\1
M1\\J18+.K:8F1=J@SQ;V:EU09,9QG7F,+B_.\$P+M3L\$ED^\$T%XTN?+1M6Q^#CT%;V(ADB;MJJ_28\$7I>OGH_9C8R+4.,1G5
M0UL770#3MSMCQR8<G9^_!^JAI?&__!^N+W^#/=KA9,JJXG.^\$-7%KQ/U;\\(MY=?R7HSO^5GRX^D>_\\JQX.,<.UTD>3G4W_/?
\\0@0\$0\\?\\;T:2#Y1GDW8X%R9>_F&E2\\&%7SN@_MRV\$=9\$H.^\$-RT1+_,=)T21Q^G=E=434DFVKKWU;3Y^"_T;_%#75JF38Q&Y%>
M6@HJ&F1\\^8QBY\$@^9S0/L7=\\|T=_N4J_RI__N^V\\!&%FCH/>4.SUI44C@3#VC0!=MEGT^*/2E\$40^5R8_,0-?/KD>\\VJE>+>"
\\0=6,NL\\|X:0TRBZM1\\KNR&/&/7% M^D^_#\\[K\$P>E__N\\I9H\\|*\\|@=_%MBH^PQ7>E&N^#BFQFY+5_!/#&G)9=U(7@U1
MH^*7F+ZV.,,_!#1/WS@^2@NWE7;4P<_?P2V)\\|H2_@)_!X+&9(VPT1X=M2^+D^_\\|J|B(E9(Z^24-1%TI%)"O19^K'
<1(H^"!%#@+_H\\H8^0V\\|TR;QG^A(MOPH1&^_.L4-7%NO2GMW^@^T8(1-61-4:H?Q^_!L\$;Z_!Q9J<_VW3QXF! M
H(M9F+&"PXRQ0R-5^MU8#%.&H;(WIC).L)UBAAA\$D93_!@_UCO\$X^PY=)
M\\(>WZ+_!)1HHOE18L5ATJ;VWG>>I0GCDVVC(J>49_!_2Q_V^";M22I@5V8\$V6A@K.(5QE^YJ_!4FEKZF;(<
<_DH0T\$7YR&5(ZF;#&21R_!B^M^CQBI,=#34(_5\\&H4LCP^#K5DI_A_&V^P.DH^QTX^HU4FEBB0.C^2@_!^FA=
M@AKA=8+XB3A7E,R8GG0^+\\+891FJ^*1;M1)F_V/H>(^E;@>LR)3_!<2P+^*8;M&VA73.&FP39V?
#\\|Z&6K@QPGE^LZ@W5^&9_5R9_2%+B)_!N^N^714_!%_MJ>@+EHS5BF%@-
+5\$6)8ZJK0M4%#&J^*=O_!+)"PZ^+_ZN/8O=D^_!F<^*97-5\\&+0,_R_!4R^#X_MQV;8&-2_!_K^M^|E/^#Y))
0C(_X3^9XLZB58_!>^6PD(_XG"C58=O" _@4^O1JDEB^FV8 MW(1Z7=Z0^_15>ZR>83;8V^N\$#P.P4/0_!4 _V9OF0\$R^2EW=D))_!
>_IAHBS^MB#^_!T^7^,UHRP3_05A^9SRKZ4DFKJ_!F%NP_!(6GU_E_"9WU^E__HJ6(LP2S%Z>X=^_7_!2GJA_!0@_!^LM<
M^#X\\N^8G^4Q_H\\R_J2KY0_!H^1BVX2@>7,N>>W)ES3_!R_!\$_!Q,G(PPS+C^Y%43
MUK6E;3L^Y\\Y(CQT3=FB_!L^TBX5=TM,%3W^X^T^_!2_P^T@^UD^_!^HHZJ?^M^QG9_!5ZFX_!EA5AOKZT^VBY4X0.\$_WIRAF^_!4_!
!08TJY;TO@^KY!4G)S(Q MN+_!7K)_!N_!)=_!#R50Q^*TR9X^@A>)2ZBEWMN.PX0@>ZFA>#_!(<#>-RE6Y^*M6H7&M_!@FH_0^-CF
4GOV^\$YCP_!DD)+A@_!J(^K;^>_!@^*^R+JF-W9_!CYK6F?MDV>C4FO8_!B^YRN_E\$5J=W^#Z9__!T(E3_!FP7,R&5&31P)E.3_!_PRL6\$67.R
M.O^#ZE3B1^4L>P^YV_9.Q+SP,5PX0=LC_!B7CJ5JQ(_!B^*^<_!P_!D+W=_!WSM^7%
M_!TQ^<^Z7S^38^C7V=^R?2.DVOV0\$JG(PVN)O.EV42_!G&SRO.D_!D^W^D^T3=JS^M.LXE9JPT0S,_!21<4M^>>;NQCB?
F9YH_!X)=XV_!5IR_!^ZGQ6T^*+IEHM\$^MXAK\$;3MZ@A>)HXL^FS,PWL36_!KE?>_!V_!3.D@VXU^*(ANMT(_!/^S^K6.W#Z9-M+VQ;SZ
IE_!V4W9/Z.\$>5M3^H-37HO_2.DT^W^*Q0?25K_!^*QH_!L^D&QXIVM_!MCR_!P^M@6_!ZFKOXO8__!B^/8P8__!PZ/Q0#J_!T,U;GJH+C-
32J\$E8ZP^NH8_!N_!T-39.M,#1@P)&V3RJ(9_!@0ZDMWVC>L^B^#^_!^+79?@?_!MZJ8S>;7KPA/ZY?
OTI=J(EAC8SUZH_9B8E9(0_!SL^DN2G??2_!Y_!JHEL)Y&E^M^>__!5P.D^*RYD@_!^.. "NK_!^V_!G^ZQW^MJQ0^_!0,U2_!6<>@MX/GL64-
NSCN^M^M7>_!JSPNR>O>_ _9_VO_!W;7_!H_!7U>+_!BWSKZJR^N8J_!X(SX(_!_!HPYZ_!HF.M0258)P9-8^M@^F_!4L^_!KP=QFU(\$T+
<7=+7_!J-NH66R_98J_!OCU<^""XX1_M@JDQ\$OJ8L_!H._!H__!XV6&2@;W9=_!FPM_!K^X+S/S6H=C_!_!Y^JHG&__!^2^,B3_M?
+N(_!7.8PL^SL1LD^+_!1=8TQ9<DB_?X/HM+^HXF^H%9U3_!SU;_!M+L5S,\$>1O1N_!P>^C\$%CX4LX^3ZNA-T^ZN^3HN0?
!!V_!3ZU;#V#QS^Y2P>A_MTK^B^%\$S8@^8OP&3RMBP^BHWRCQ53N6Z_9_Q^D_!^EP8_!^J7083-JJHK;D8EG)M>U?
550C_!8M^_!_!6XK_!P_!_!OXY9Z80V3__!R_!F8_!>_!^79D_!W^1^*D_!7&333.C7)MR>7+^8S?T_!6#;6_!4ETG7MV^T^YQO-
)%EF1^_!U_!D^7X_!J_!@W(_!@51+V2XP^M;J;MQW2,_!71^*V+_!M^/_<49_MMZGX=N1^Q_!^?UBI?
61/M(D(=)^*0K2L/&L^K^#5U\$DC7CQ@:0NO_B4-PB)MHBB^M^ID_>>FETM4JFZ5G.%UM0^O51K0_!Q,G%S3#>;=,3^O?
EJ>X^_!D_!AV;8G;9_MU#>0%J_!EK^G_!J32XR@E+%;U4)K_!1^;1^_4L2GKBS^5T^85H3_!<9%@TK_!JQ_!K^M^7BLX6A\$-
,RAHG^+BK^#JDC@>7,U@H_!5G1VXT1MCV+B\$O>_!_!6YI\$8%B^*3V_M^97W_!SR??J_!U>2JW_Z#;_!2_!S^_!J^#G_!Y1^#FDY^CQ=#58
%DC^_!T(E^C)U_!G_M6^79NG2W9^IHY;W0>0_HYTB_!F_!XZ^R#_!BM9CVC@+^BM_F4^5=O_!8WOKK^H2B^M_!G_!A_!R^Y^J4Z7AOMI=,=#
!DS3HQ0FA!C<#^""LKW4+;RAG16_!4<;L)E8B^_V5>(U^M^!^!@0U,8QE7TVCVZ;L0OLT=C_!P^M^"-M&H=P^FMJ_!QSZ0&(_!69B,P73H_!3
MR::9LY1_!HC\$FE48^X)DEJA6F@N)CF_!PL\$Y\$Z4_!5=R-38FU&.C1MK1A1Z^W,M&^O^TR?P-BD^XJF_!EB/5:
<_S@+>R>)U_7F<W44_!HNP@G?GIT?^H5BGOB^M_!4FYB_!@QE^E44__!4_!&H^#&+_!J_Z;I9W03^V^A9Q#G^_!I(_!@^VVBH^XFT9M^
MHBV)-B;0^O_!8I9H+RD^\$@=PDD^A^#F6_!+L^P7O^).7>^/PXBY^6(B(_!^VH/L^MT=Y+TX_!L^B4K^*D_!H_!Q_!^?
V%VJ;5S%L(YKVV+;QY;H>_!_!4NQ>_!S73\$<_!O^A^M?
BIVA__!(K;^*2_!HD^R_!4_!V2<__!5T9>>__!3=_!^23U__!UOL^CU.43;__!);6;3VJRZ>CC@;>_!_!H_!K.5JB3PE^MV4MZ+^E_!J2_2>^Q
"&E7Y4U2_!GI>L7=SWMX^3W7324=J@0#^*_!I_!U9@NSQ__!^<46;JZ_!4Y^Y^3_!TYFN+^G;)%^CB90_F&>34L^*Y75C^M?
4Y6GU4_!49^_!V^D^#V_!D)_!^+12.B&^9E^Y^E^A86^@BZ=Y3^Z)MT68^SMX_#^MT:R/PQ_!G2)8V<__!S[X3YV_!9OV@_!HJM\$^_A^AX?
!T!H<_.OY8<_!@_!H_!1ED^MZY&SG:=W2=C^?J__!(Y08N>^/0)H^4M;_&(_!N^U>^/?>QOV^+^?_!6_!^>5RR<M=G^K^W^A-_!L^+X^@W%_!1YS^R
1^2Z_!4AT>D_!^:(J^E6-H)QTI2^X9^T^_!_!<M^!5^H)Y_!_!G\$0G^Y_!9_!_!(_!TFUN^PL^69_!_!H^W_!^_!JOGF-FZ^9L<<^<^%=-,C
MB3O18U9PZ__!DUWUP4W)H^X^SS+<_!@D^2_!X393^7MLHGW_!%RZ?28MD_!J_!1G0;M5_!3_!TJ_!V^*Y6&KPW?
20;HYGCBZ+AV^/8_!J7CD^_!U^/O_!_!3>;H=N3.6Z(O<6^M^Z;E_!3WY;_!5RT_!F76F_#0M4S;IGNO^U7A>^*C3>L_O_!C8C^F<1Q(O9;1S_!N
MGTB;0^*U^LSCL^#S._!_!_!ZT^?_!O15\$XJR\$@6<^L_!IO6,K42MK<_!@^XRR_3UH;9_!J^12/E_!^OXHB\$%6_MJ_!2G6Q1G5
FQ(_!DX^IBMA^_!J=\$/E(_!L^*Y32F3F_!D)+OWGJ^T9J;_4DQ^M^N^J0RFGP4R_!F,I^E0^&TN6+_!B^W4>I0>__!^N^A^WXYQB_!AA\$(*^*+^%
MX(_!28WQY^J^!J8_!D)=S&L;H&X^S^#((S0D6-B?P&BD^\$/_O6/1A6WH;_!V3^_MJSNV^_1>X_S6#^1Y;0S%L4;Q1(2+?M^N6B^/_E_>Q>W
=C%6_!44;EO3^P&@3^MS^d^J@_!Z5^T^&__!#/?2\$JKMM9%&H^+&1@3_!AJJ^*8I^EWHEFJ8&#MS(AZ%TZA3AG-N)(^*O_!-G+C)DB??
Y_!+?_!%?7^D+G^!>S4>XN_!J_!HAWPPAQ^M^E.I^O@_!_!)ESS^OZT_!2N^O562)9Y9U&5;<^+&FJ7EH_BPC;9&5^2W4?QX=-
MJC7@;_!T+2N^_!G2N(W4;H^&^&D_!8(NO>G_!J^C@=L+_!4F94JG6;L^U9_?S2^_#^W^PHBR__!DKXN9%&Q_XDH6^M+57^G(D&R^U8_!4Q(_!
!PK!T;+;J3;_!)MY_!|=J91R\$;K^*51WQ=#&TR)(+LC^MAW7>D2^_!^5_C^ON@H\$6S_N5,W_!MUFNKXH@_!R^W70RCOF0US6^_!)Z:5F299D2=
MH5^JXY65KZ_8E\$VR@K^%CYW9324AC5TJ>_G6C2<^_!GH;A#KDL^Z>3^Y&M^Q_!UE7CW%UV\$QOV_!AI^RH41^?__!^*S;
CE^B@S(B/K^+O^AN1^&I8W-B+/-#(_!@R^#^MURJGA^J@JCRTH8R5%CL^_!H;A>0N2YE_!T_0AD,ODN+WPT+Q@5R;S/=YS5^!M4-
9PL;C\$VR_!^?^7UEC2Y2_!2HIRZ8@^W25;6=-9X1LGC^5_!TU/20T^*M9^?<
Z?;0R=-7_!GC+KF))ERND8BK5K)5S_!5^*9K^?RC7;%KHLTA^#%"33M^*^M(FDNY;P8+O1^WS\$1N(5LIE_!5_4L@3VA?R_!V^M^L28T?
2K_51G/%_!^V__!(%6Q#?>A%665:XJ0HS3)2W/0;A?MLB2>B^N1GP_!VB^MG)_!L1=J\$C1SD^7,X
D>Q^QXR;95K+=9&WXL(KEJ^C^Z;85A@^16^RQXV4K5Q>O(_!>BX^7?2_M1Q&^&EQXN3N;_!CN^;AXY@8_!IN.9#_!6P)UUS^"
^JEN.^5+A_K3V(_!^J1K8+F^MF3X\$>@GSE^UO^_!U@>^%NUONGJLD^W^JY_#\$^JKL(32PR1^#O)ZGS1Q_#GCS^M-U#571N/M^N^6FY;
K;_H_!J7GFC43D_!^#0:C1_!O_!B_!J\$CK8INH@3^M^O=EN^1BB^P;P9>_O@_!3D^U^_!V6S90>D_!YB?>=FD_!YK_!@&DC>Z%FP_S3U_3?>
=J>P&^M3^FRBAQ4#^I_6?W;Y9H@/=MR1AY7_!9\$7@1Y^N^GIU^A&E^N^*78^T^0;=D^?#^R7(O9@Y=JJE3^UHVO6#^J9^M_!C^T^*
ZXR^*6?^3;6)_!F_!O^M4.KALY79RXG_!0<5U^S^X0_H@9^*L>2Q@_!J^M28_1KX#)C1+KX;&M_!P(O_!NH^P^_!H^X2M^M,WLNNF;#^#R_!D^!7
B0EVM74LV,4H=TD3Q)S4)2/IZC_!N>U5\$5@^_!J^V_#D^M^_!H^_87/^8&_!8_!D^F^2_WB^8X%=IRL%0;9(3O^L_V;)^>?>?Y/_Q>TX_!N^A^6
MEFW025EH_!H1(_!U&4_!A7A7D2^_Y^>_!@9Q_!J2INTM^#D4>_!#7^<0F^DP^SH
MUA_!@<(_!NX_!ZIPY="U(^CV)_O+&H^"DE^_!_92;_!5_U_!JK=SPE^N_!_!_!T4^8AB2_!2DO@%98^@2BST_!X3\$=TLV^EZ^C#QO_9^MIZ\$_!
L7P_#I^M_!JRB%#JQ5AV<3ZV\$C>@JOMNER6M&8;_BR0L&Q^*I_#QLQ<MZH_!B^Q^H@V_!P9ZU)_!\$7^#;MP=V6_!L^REFZQTM;
(T:6>JEWYHE^O^T\$6FG4^M^5Z^32+W_!B)HC9_!J2NFS_0T_!Z27&_!P^PVL5#),%Q@^&B5W33.F3_!=-1KNS;MU_7T;N;M_!8=BH
MBR&58^&E8MR(_!E+AAD>R5V;_!9A36G>VVO@J^2_!T?>C>2^4Y^M7^?QU2&2QF_8_!4
YU<_!PT_!W11L,FW^QAD=XJG5L34B@&9&52JW15^J8>M4E9S%?Q_!T^_!W^?H^*8QX=9C_!J0BO^TLE6.2^<%7TEX,WF&I1#?
TETF^*U<;M%_!^FJ(FV^_!L_!K&WEUFO>A?>01O;QI9B^*5P;_!D_!Y6_!^_!G^XZ)O5\$E0^4%.P+^*MCJ8-
C(T%#WRN@Z4Q=HZEYKPKX;D.;>!U^VMIA=A^F9_!^60;1IG9<2<MZZ&MV&+0643\$^_!Q^VW^!I^N\$^P_!3^C^Q_!
M_2B@)_!\$!5_7J_!|=L02W^R__!W^M<^*MAO)G;4+QXY^3%?ZD^!7M@X_!FA4MT_ZE)2D^R_!G/

M98;.C^9A&4J3%R.KY"U+J9%: /|RH>^1+3K.F==YX?MA{D2B R(330>&J MFZ|<-KG YJFFY=GR*ITY:YI#ID&K.#3-2^11X,9V.L* NV#514J#S(I"H;4) MK3ZS*2!#IKO N54*L.U|<(<5WORGL75^<-BYNRQ?GAR?H-K',TU_*H)S%_-MB3"#/-XAF@)%(2A;/FTE^/!2 24R),L9+EIJ4 MISIVG I#E X#S!W-U.A.1\$(AR<-!# 1.("9@<B8Y6DFDGF3J6PH8!#9!T\$ M28(UQ^X*FCDK2NIAM'C+ZJH J2R5AL\$%^(N> J?>FMI<";D|HXO";199*P?Q:0C8<15;#3&RE&| EQMU1NC MR?R!#;\$%O=WS7/-+!+3#)JD"(#5JGTGX<52L^>A68@ T")P 3!BQ#<5 M%JDLE7"K;I-5,J#<#-0:BF0I9HN"I65[NMNJ];#DI2\$)Z#^DE,&>4DK)LEA M<| (H@|F%HL;_3P=I 2^G;D0>#>^G(YIS\$);P=0/Q>=395\$+K\$U,6R!8 "c^9M&@)8\$9M@+E(6MJZ!5;+/7XW-M&9Q@0X/^#J3-? 63VT@<1J&B80*V<7KQ70^P&NB24@ "5MALLVGU|)Q1ND% M@DXRIC|>-L'9W7EFK4-D71Z)B!S+^0T+)>0^ 1A6EA\$G17\$;R#;8+CW0@<N M\$5F8*K>_Z=%?V|1>=3J.P0TG&YUL|TRV&|33+B/7U->.D7BS)M'Z3!D|<PT2G M,0_1J8QV5^X8>>CUUPD*LR&(D4G#P\$Z@P/R#T>S;|J5V_CIG 3795W&AX,M?2!\$K0^J8K_JO_N%2 N!5X WH#T!8#1>XCF% |@7W14|'5!D4G*6FO5*\$S\$O MKQLV1C%H>N|>M1>GJPO^|&-8W"=)4B=UD6:98LLA^+X(U|T;BA))S=()Q6 M23@EX902IR2<JRMQ)N"K5<4>0 4K3878#YM+=@M?0=T(WK7SM=ZT@J0QCQJ7 MQPDS^X(X|SWH=;?YL^_&DNV/- :9T0)=)BN*8V\$E<B/E/Y|H+O^-R|T-);|R MF*80N GB|6J|=|7I/U76#@B5(P8=CKNJ;OWZ8;0MA).(*073 M29T;RCZB6\$J5N7DY0|_2"N(73/ZFT#0;UB2U/ VZ? FGE|VBH8=2!D26 M,*1^I;IP1J5V)RT3GF5IFV+N9J5^M%IP9BK\$&? Q3D|_X+14K(48<2LNU<^A M<7GZ11AQ"Z=-6&DT3PMV^F6L;@FSZEP.2\$FA-.\$ M)O^H(=;Y-Y9455JU;X1W*XV3PUU@WY+|=I7 #AH|H1)*MM-FLT*R=TPRA Q323VWBC|H)M,G|PW9N.U>@OC?O\$ "U1?2!>OG&3M|!<_3WJ-MT)PY M|!2M'- |<R6-6|"/O|B@GOW&|K3SZPA\$J|VJ4+2=A@G+ZDEBVV-W|J6995 MEL.4PY3#E.4PY1EE476VK|B3TH*=G 3%VS0TC5L7V C96!J\$+XV+|=+9! MK>N'92QD6J9QHW)T6K1:FT*+5CM;MAJ3F-)JNL%N,#)W93>JEW2YPTTJXS(|YV15VNC(0E>;TS|CJHE^15DM?; MR.OX9"=*,%;S|Y?#;-MX#F+2_J_*4Z(O6%FG^F>|=5%J- MK<:6QGBX13TMWW3FZCNEMS>T=EHG|H|RK:2U3=!:HU4Y.=WJ MU=P-/CF<-Z00XVX U|=^Y)N9_C+!M:3%4_F3R)6B!2>*>#% MF=^&4?RAQ;150^V-Y,4XOS MI*F%N&|8E1KNEIC4^D+LW?>Z|^<GN|K&|;Q"S:EG^B=-"E|^#8+T8 I(P/M? K;0:TQ|H\$; (RC00WU|UNUTWE_SJNN7J+|U?1/P?72;);)9-2|LV2+ M@Q)S3E!7@R&\$@3|R=80U(\$U=35!;@50#+#;Q!7_D=4/Q -JM>9R>V0^M^AU|PW=(2S),4DM;EG(8#YPB>|>O^SH"2?9IEO,DBZD/>@F+/-LUEV.|#7"2PYWA_?D@Q7KUWF80(P, MN0BKZ9%\$FOA\$BOKC(H"SN C@\$HL?M=% ^H(H ON@B V>\$/,BDB<8>L>->M|ZM=)YP2^BQ/O%&|7AA#H WJ)|CJ08P\$3C^OR+#!W-);)BB@U RB5VR>);3 MU8(79@S\$63J(SR%W<&*02LQ^<452(2X)V%,X(^|R!<OMX#9|QXB"/D7^RP MEWJX(H(O@<W@PS^?DF00N>LZ4JJBV^7AR@;.%L+PI@R9|Y#3|M JVZ3T\$ MCQ&V|B;S5V2K+>*)2?IA/).JZ.) (T0*7H- CAH<X\$)HC3R"C1 M@H3\$&#*1%C;P\$SJR A LGA3(R)F\$;0\$QW+=,P1,C%@"4.P MJS* W|>> M%H=JV- 5JL+|OY.B./K^,F MF^6D|CBWYM;STOYW46HL|1^C5G;?SNM;WF M1?+W P=?" M%H#Q%8")O)?*V|KHFNN5C2W1S2G*_J6Q?;* %K:GEV.D#;NOGK1?&| TH 53IH# M5AT/B F|,1*)_|,|T+4E04@-HI-TR_H=;N^M|Y^DNV-;L\$1\$7>_WGRJGCI&?C+JH%W^| (G\$)QK(2)?<|<=|Y.Y.8!SO+|%=79E;420D;V,3DXI5.O /M=? H/_&XL4UAJ|>GO^W_|3Q R'_L5K^AC|=G7VSW6SR^90<QX"=+!L39&2U MXX";&|^|_B 5/QBB|ZHEG|<^4X8< |<HC0#W(K0Q19@/#Y8 3#)LY^MO))LID?B;DAJ|=;NQ56!PFB^HL-%HM%-A*HNS-C8&-S MFWL9@"HSL:=9Q-W@C2? G"OJS6Y(S@30Q^MZCN.ID@G<@HD6)@EBH|C0| MO_HU(|1D;|L@ (Z0YMP<VD04V"%H^> P^_FW JH0?|OL_WW)(Q|@;+; M^|>^>|PD/ECL7_!@5KQ0|F=;U7>*^?2#VTF"P2C5A UT+HER0K;7/5Q3/U M^2+X?TN #_#%9LT_/AS 5H+6B++5%/(<714= (<Z;15#G)>Y@BCL_Y Y3 MO<@<L;R=R;GU@H5L2Y838?1J\$2+!K=|>8XK|L26+LB-U504SIZATM/ MH?7JB|1=4@F4M1P.XL&B+2%W V6;|X6DF1?OSJDIGE"PTFG/4+^PU M;L6;%JXP\$|H0H (X6+02^M4'5C;10M0F'!3&2D4<;3GNY- M3)-5.7+|=HEL FY,VF5:R+VUXRV&J2<_G|QNJ|L)0^Q=-Y1GJ,UP4K^4E M9UA@_VHK5M>.\$E|F.OS;%M|_!U7<U=|B&VBAMYGYEYNKI>KU-MS91U/NJ M&IN5ZLLW72KWKS(8Z7;4)J6@8;H%<J-YSR| MEXP5Y&08<>X+^_8LU3JQTM@9V0J="||ITL)QPJ^IBDA3?06_R_!#>+>3Y|761H02@U^ST_/WT|5?|X+FM5LK M#ZU1PHX.PZTK'E.Y(&22%;GC\$C_V3YWM|=FX&04R.8BZ7=NTL;8(Y%P MPHHDS(UU#>?C^|K-M5@K+X#X2|^9,B- *=BIX.B3M0^;5+29A1/PH= M8|CB<>|+K.G@ ?^#K&P,8+E^Q^FA^@^4MO 28FNT'N|B3A/VV';SM60\$=^|B M|F61WE4\$.*YIQ2I2_2 TEL?Z^IQ^4_NN0.YNMU|C.E;8_ DPL3JYCX%LU MFLQ48^E)&B'^4I=H@8SJVIR^FSR+953*\$C64Z JD!%L3? |M| (RZ;_GO M4T|I6(^H3NZ8|Q^LW^RX3^I8Z0 @CIA.DWXX EUDH)I);S#P8)9O5\$;_M2#@JN# |UBO|B3YQJE@M3X3;1A@<@6UL R+68ECB|425\$.2011ST1P# M2?|>|) #B%B2+^|L4|BA6K;A7>(2>|MZBT*10\$((R;|#+^ |\$K*;0|Z UU4U M:2Z*_Z414=|@ZHUPN<\$D1860L0TUZ%|X" X(K(4^KY20A\$U3@;? 9)"B(G5;+J#CRAH5*J^469S*LG\$;%ZN1%7.H^|/+^/U M|^_8P\$Z+%,59X(XF6P#20ZA83Q)JTA&(;)P3%:=&A5\$3U+_B';J^F#6 M1#O>5F>H^6WX&7BY3\$ \$4C|4VX2#;R&+;)\$D=F^_YS=X.5MJPW84U5>E9 MI&DIQOS)- QPH;|EBFL^OH#M;E8P*H\$#>H)"U"=J#|PI&LD|;A2V5AIK^4 M;+>+>0|0|H9G1DJF)H=6! DNC"%*#&+F%Q.0.9%<4>EK7A,7+!+R@(%Y M2%;2)1%GV3^|T|_#21H|60K-8Z)SATH)*B\$|P&7H /QH7(^!^3X5N:4_25& |U#|IZXE@ (DL'?_E|92)9D@!N0;CU)9|1R MA);1D=(EK^/9|APETF^R76D1O G(-!#D"R%8|P_8+P4/9X>@66IX,Z/CZ M^&*3F4^/(! (BZA4;Z";9%#|L>6M6PPS""Z3DYXBR;0^|J=I7IA3'_M\$@S01'(&-BD)Q|U;3^BH+&V52"?#6\$?2?39-?+/#A&#P)0;X07FP(!+KS6 M+5Y0G "F8U&M4C5M;Q^ZL.U|I(Z8W^3\$W5;#12A=><|0Y15|8JC\$6 MKG?C3L>"<*>^>FKX91!|VUKG;9#_Y1J5- H;J@<MHSE#KH>K;96T7^NO<MM.F8A/>@50+B|KQ|YUE#@N^M2124^6I28A"MH\$5>?QX9|8IDKJ6;(2UU42Y3B*|L;N|2?SAI- HX_M|N(A&8!@O#;'@8VZ<+|N%AJ#_0SG9L^XK)|XY#;Q|>B-C8|B(>*_R15W MZ0|I^G%U51%78-&)8|W@MNM&5\$^J#086EIP| |<155B;DS"U#@L

PQO.:G>YWW(UA06/2ILJH.:7F:YU=2VM>T=G M5W?A.CHV/C\$CFLA<6EY9)KH_6UHF MW=V270D_8_0IA98?IO_~^|~|F|
MF%E965C9_1B8@|~X#|/RB9U|HC)4OVN|H'3ZE&<0A>?OFNHIE36LV*(.3B M-|0E+*.^(\$O|0^UO9O|9L>C_%.|_\$_L?7EC
/(@7)6;&SL+;_5B*#\$P@#K\$=8
M.,)^Y&^P_P..O|Y|IS_O|@3'^>9&%A8^S<\$%V7H3M):vX%XCI(&)HNE>2;T_=36NC#HMCLH&#/N^>K14V.#I
MH3H4%G"W(L#UMMQHSNU|HG^R#XH3|M:(0V#JUB?XSQ_"L5|Q9K_14;W5 M\$&UCS)HG&^@X5^&1=T;H"W^M325|*0*|&Y
>G8P6|_8EL?A_17%VN_16; M|J*O\$.BG83JTW@6Q>1.MR2|(CWI_FU|)=403-FD.#1.M"31*~^|<1<.(08ZZH
MIE7BQWR\$S*2@60+^3)Q;E|P(NSH_CQF;&D_9U% MQ&8(ED34\$8=4S(QVEJL#%HO+@_V_).DF_5=4SA|'5E+5X;,,4IT_OXR>4
MO%6.YFMK2137P%&5ZK;V;TIA.C59ZKW/_G73.>73%Y4W&B2#)'UY|~X5.JP MOSPR|LXR5;Z@46AI*~@F;&D(("
<-21^BT4|'^&BM7AH2#R'(E*C=,7H-A M6"AA1(M6>,716/77GCNZ3RQG%7N&Q^0TXS_8H|YG7T)|S5TPIU7I7U)9N%)
MGI***=Y(Q5QELWLR9_/*^F5A?U@H*~.#!F_L_P:0^L\$U R^0|A|@R8"WHZC
MD,ZI8D|V"U>YVDZ\$#WP12=2X;8LTYLN&8O|H|U)5%AFN8FK:A:T<'6#T8 M0HXD%R_X;W@/H5PD#0Q8;8N_KU+O-D
U'PUZFJY|_G|F>_H)V5R57|(G MR2 M-6*>HJ1S6D|X+V5T1R#M#.4L0=D_1,OT=:82K-E>7+C|;G'AF?84M|QG@
MCN%&WH=BC4G>C)|4_P1\$9X*00Q|_:=R-W?JZNQ(M6U-|>G@1YY1|M7|JU.3P)(0@:T#B;I5.PK&NJA0;|I:29F++G8E0&/_W M+
W\$-8'B0)'B_&M27Q8"C2W"Q'1H/19K5.%)'Z'R5#P95|+|HAI'9|P;:=91T;S.C\$>M=?XEO|T(T4'8;.*OZJ6@.)\$=WZ-M*?%PE%XT_%
M6'UA|Y|Y)29EB|U'CB1+D'P'_LR+7|J.QLXXS066I5,WS|>Y13;R|JL34FT MOO2D_T2+Y)Y<6 M(.33R%+2MIXZ,>|V*Q2@-|
QK(TK(5:4|)6_W#=#|R?E?P-M)|@O|J1E;^5;@A<~+|)LT>|M(8)AT0|H|O-P>P9|XX>".F+=_H_30;R;6>YR0J|@7%|)OPOX=|GL'.)ZC5
M%*|1|HMG|AGIE2?_DFJDI_177;Q\$;5D8*DIGLSLG?@_OL#(W:\$W;HVM3
M#CN8Y_ZQT+;MQ%IZAKI=B'V)KJ9JO:Y=1>KJ_09|2LZ7>>\$789LG+\$52 MOCJD^WZ6=)XDLQK|4W'_4VI_8#?;1|+;~^WD%-
^X*HRZ>1@Y"1/3|1@JZ MT09R>>O33X MZE.O)2+^10\$5WFOY4M+Q*QR"2IS"IL\$ZE|YK_"O_2 IP(A)9IUGNO<)UL2|Y|VIZF
1>)E6U+4JD_~|H) M.HR9;1?BPR9O57F@9|VC*+|D=\$G02W2_INE;_9C;1*IR>_KP3;?IMP"X:C MAD>_"@6?X|M9|+?M6,<,,O?)5-I@-
<5TL0)'8_1BXCH|4CHN1(.%@A& M@?"+|F6=03|Z15M9DO>L'E4X;N_8*WFT%;RH&S_11<(9|)2#A5|H4@ M^#T
R#|137%T8%G^9=+*LL_#;XDGOM:W|_3#7>_3U|JA'GHY9\$DS(,M>P7 M5L<(&5A;V2;_75DZ+116YI@_N;6;M#I_0DG&3OR6.C3|_59?
^B&J#(,+W/Y7_U_E#~#0FW|&\$;-USS9YM?)OZDZY1Q)Y MRDDKYIVSNEY>D8KC>3^LV2P).7&S@|=|H|1XXAY^<QV>N2>Y;KC44.\$I
B M*AS9"5 M>HU/3*~&I%Z&\$|Q)|=F"1P_R.9|L77\$S_"T^<(NJ>2)";YK|CTKO'8OHE6)_M3_78Y57|>?KX+;
|HP3|82;5E@|H?T-WOY"3OGR'A-M&|R'3TGBQARZ< MN=NO%E>M|FJ|_Z4^);_&TRYMV&@MPYGM8&98<_NU472Q1%BZ-
K^>K)KW@M MY|DV7N)XK#7Z6'IM CK\$;_>|YS"9D|@A#P6(CP7\$<7SKR;1%#9=@C B55&+8AK?_18|O;+GY)|2#*6';C|LTX
M:4>\$_Z&P652KBUMTWX+5-W;8R*L0B0AK"9_T@|P-@ZCUSI\$*ZH;O|61 MXS5W7HYC(CUW^|;R2|8&WKNLYKQ@|T-
5^<"6|DBSR|C|YXAFXT>G+;_1K9 M(C_K_B|I0<3M;_&|6PCE G6|=@B92D?/7_4B)4^%|&?)D@K;T=5H+)<_20\$ MC8|3ZGPF-
V"9**B2SECZ631_U2_DG<+~|R|L_EB\$=\$4S;\$?6?N|?&#&?VP|P7=,S_M_7&\$KL%9|B|YPW*6&;<6A|Z;Z-K M&J)-
L_/=>4_1S6ME#@G|9A8&+S\$|"/@_O8;R1AMUM+M_2_|JUY%|W>_J MNC^C> M2"92%AQ^>5<+?Z_*Y;:=C=G-3|
_XY=;B;L3S/N>4E5G1^_JUGQ2Z71X" MNWU(94896U|Y%OE#IU|=TV2DFG:U^|HMK&+~+|HCVQ9H|920@|@U'7O_'L_# MSR|XDZ??
P.9#_U<#H;R;IES#_O_M#1|E.AR:BVZYKH93&|NE IPSOZ|9LK"1&2#GKMAN%R;B;_M+CGEEA+%2|AHN|\$&H
/S|0LBC2"=J4^U(SL4O"@=2\$Y|L_OZ&8\$ZXBL14)EU M^Z^@N_GYBSI9ZKCI(HW9SL1PZ,"|E=R_RVO7OZY5|H;Z5GD%8S&U|*1.8
4TA6;1R:A^K7;+~97VR#|C6|H28;8WY=E%E M9|BM^75|A^Y;+IA0)2HM#%XTU|72'MQ|HR|VKJS(\$I2V\$2"+NX9A#5<\$E
MZY|@U9>B;=>|S?L_15M\$D>B|L3\$.#|K?Z8V|H_HK93Y_V_XM M9K0T^|UXT0>O1C"C<7D=WK_1^1HCP+PIE>(1^U4;R0?
W%F^=EAN>_1LR"O/_MYNN7MJ&.RA=O<S-2F1W3)&%_#Q2>+~#ZRU=BX\$Q|_JL2^67\$FN2U>H<9LD?
M*K190D7|Z8;GRWE<\$|&\$_9|R_1G22LK|<^>|>#>1_870Y|T_P.2?|H-E MJA|FDVES;1%PK1-
IG;|UOW%=_JR_ZJGV&8G^E63UFJ&=J<#J.PZ4>=Y1Y1^UG MP?>4^ZH/N_38RO34RJ#&U#P=*\$Q|)\$3F+JNA_U=9AU3-
4\$SYSLC6BTN MK3K%*J3^V=H|G.C47W|.#%|/J7#1>4 MNR+&US|U^OMYVWW<GWS541*THE2.P63YGUM/_S%'UW2"
MGL/>4=%+M896|U&QH5VW&_W5S+K.GW_@|;11W49YQX=4S|O)L)_"X8S=I M(@->18K/4^GZ_/6JRZBO ")#5S7A+;HZY)-
_N;I3M|*0P|SY7^6#C#EP>J#)_M7(14|58|8V&9N*U6B)"^NE6%|ZC|8?D|9DU&FY3C|G3.5W2?Z*|L|~^D|D58?
HKLFL6B\$P2AE2|_K3/S52&MG-M)P?>_3T#F8M\$6FE4D8P+;_>M>5+^>*7V\$;MZ_4JBB;M*X6G
_47M#_*P2N^7U#N^NOD:=E/7\$??J_YO?H^1#3\$S28<M^UG&XS4JNFDZ@_C|J=;#E.E"X6A^YMXQ^O.OYO975%&?
(YH;U|@U%1|B_Z6I_M4(Y9D(%_9"9KGFY4AGBL8<_E@BS6ST/?9+Y4);RMN&_X*C T=%=)/V MO1S-J_&RS_K_ZKAA->
'9W|H;M|>4@<=F.O1<0|C*5>LWV24;AJKX%WVN4)_MD+L6+YS9&&.X\$6P60GX1*^Z/LSL;ZY-0K|43RY|KOL6VCOEZ_XMJ&A(O-0
M-F&1-|<^#@_I+^G_L1|FQ_GU^%ZFI)BHIE*)8|L+<2X"?B=&L_0|S_U=I#O MYMQ|N^YIX#3N|6VY|K7AY^GC1QD2ZMKC-
1-1A|ORG6|W M(&+I"SYV>/*8=X08|/(<?IO^GDI_SQNMNM#D9E?EP=8VGNM;R62ACBFC6 MA+C|O_#DW7.15%9FFU"K5%V|
|KX|9F16_W#R_J5B4W|NB_1BZ2(FH^02C7(0#>^Y2\$<Z.F8'68 M&+S#E)F6D>IW>2FISBVQ477|G2+D@C*PI0FR1TLD#D-
_2FRV#S5Z2-V>H MC;_VU_1FL;|I M6/\$|ZX7NV9WYM5_~CC*ECV9O_F.7703(M/_27X8;+/7&NFUDGQO7^_00Y^67
MBL|Y)Y0V|DLBG_1V|L_E2*172|<%_KU;O&K4;:=/N8O77GYDQ==FL+;JZ_MQUA%0B(H.Q(3|R|70P85FC|92U;H|&JN?
GU2^|L_ECS5'MX?@%0D6O^&M0^76NVGC=:=A48Y'N6S3EL_3G?^3_~AM^F_HOLXLB^@OPIO47;EG;NIT9_V
MPI0K&LP\$J37Y%<_89|1^6UN^1@/WBHU=GD;+&YADAB.G4_CPIKUDEUX MAB*~089XT;CN88Q;<^8 N&|O(Z|'8|UCTKTLL5
8|N|E_~AL?D|FX>ZB(EV M<4SH4L;RKM*%Q|>9>WAI+07>?L\$ORCV>6TB&RQ%|DAI%9RDGQIP2&F.C MX"3YF-1^U)^S>2ZN-
=X|CAC|I2P+@IM^WK8"|= \$ VM+8_1^C|P-ON172^ M=0MND|O;7G+4Y9D;X#1;544OZJD+8MF|ZIOD="+DG6'+|/"PU*EQN)T+&B-
M@&"&4^U|UM|9AL+|W"G|H^NQW_XUHC|ORE|U^CD.BU<#W5P M=|UYH1*~"8SDBFQ&.34R(18BH#;_>A?
O*_DH?|82%|D;W4+&ND>^Q^&L M67YKYX#0NIB&M_YB_2;_<E9@1?&UW@30U)C|7I_*U?V_C^|Y"G_N^UKHK
M_66=:=DW&^&_GF2\$|U8>1@V4&_LFU=:=YUZYU_P.Y|P|(DZ1S|2H_?Q#?Y> MW18Q\$2^IG_~S-
=;|YWQ>|0S|_RWCE9P0HN=:=0ZMBJ@Y5PLU|*N1(MR^\$ MB3BI9_?JD#9EQ4C:9-*>O=LK4^%+RBF;3Z-R9
N465|C)K"Y|F(A4=Y.C| M6B5+@?C_#W5R"8=SWB+ZSW<^HFE1(%_<"+S6%D-B%VY25%VLBO+&K>BZ
M4M=W7=FV|8^L4|+XNC|8:8#C8E9D?XTP^X";>(#ZH4M'1)AXZR+ MK\$B|B_5MG\$@56^_18X&T+QOJ+T|1\$U^B
P*O54(CDCK1_U COH2P#TN|)6=HH SA M_6IAU^&NZ59^~^QXBQ_%;1&1^M00.SQ=B_V^M">9F1%C21Y@T|\$/ M^YK4F2A)#
E=:=.BT&?)IR>|R1%>_S5>C 4S|OC/K2_&OEX^+ZQQ=&G>#/*NCYLUC.#VT76K'08<6HDI|HPVX8+S0%|/2^DH90W2_~KGQ-
MN&<3<-Z6*0IXW*5GB\$|V8|;R29_4UR756%0B2|+8+9|R^D1+1NAH@/ETA@_MC.C8FY|H9YNW7\$K&Z;_>Z_*Q.GEA8^?
#";S>^45"DR5_~T^OL^1M|H|<=>M3 M<2|_U_FX=U7R9K|YK^G|+7CYF|T+Y)|YEL4/2H*Z6XQQ=YYL+>A3%|978RF M_4K_1YKOCIT
|WFO3Y;O6(;_9W?>|A<8O3CC^O3%\$LU|F|C_TALO_?DU+(-M'D21O5'3R;(3M|^2=MN_~(R*+7(M29|VGB*H3B;8
QS3&3UW_2|;_CGIOQC@^7_F8%\$XQ;8GP8=L>_RWAMD M^L=5_*4D+|LM;2/S&>)<&V_~(\$6;,,/12";H#Q;=#J|_IV=9>);_6W
M|70K_?8KQH&WB;|G>R2=M^)|H|5\$E2>?=-DW.25>NO_~\$_/3*W;U;VH_+(5
M3.6\$JG4;_LBMV^9=|TVS#@&OW|_#^_1Y*7U=ZN2V@W>N7E/1+JD^E(3;9OPYUY M&L<"|T1^87Y886>=>UUA_~S;R/M=^JMNUA=K'"
<#P*_ME1WP1"1AS.8#0|MY=PHL;QN_UO)4 MJQ)<5V"JOYC/13X|K|CECC|Z*WO_~T+S9B4Q0\$|L|V9+N_?R1N9*XR9&8(
MR.FE>_Y=SSPX_3HS=8@N(CX#T8*W)RQSDHO.GEC|KH|E=2^6FU|_4 M6|S@N"D)T%*QF+YX|0HXU&ROKT+|RW|J
|RV8Z;JLBPkd613|F>_F+X;MGXKV/3AJ&/QS.E>>R6;|Q2+=7^OCS6A;%NQCEF==H"SGZ?;U)&6R|L%_8;H M;(R#5C.C|14?
A|K|DBXH;N_)G?+|=J^|W?>6;#Y\$Q;BA|A/5N*(|Q_>U MBN-O;O7D&TUGU_O88F<^%UG9R*QJ|>UZ;,\$*91T<2F?_2?@A|D|_9|/_
M|1+|U+|_0|4 QO(Z_#5F";_@#&@&_T_~M O_!E>^V-S8T;#N_1M4\$|L_A0#%_@_#H_62%7<&0E" F3_M T(-L.O_&5X7S8W-
COP;2YH=&UO2P\$"%_4_~M@_U9^5VZ15P%#HD0_#0_&)&_97A?C%V-S8T;#N_1M4\$|L_A0#%_@_#H_6(B|TN_#0_0)L!\$ M(-
|LAL&UB^D4\$|L_A0#%_@_#H_6|AL6C8" #FD_14(|8D&UB^T#(T_#8S_M_1K86(N>&U4\$|L_A0#%_@_#H_654_+|SR*P4|H#
14 M(-|@Y@&UB;_M_12?_0|M;VOE8W5L;6YN97=L;V=O XML_57_mbrx20240630_10q_~htm.xml IDEA_XBRL_DOCUMENT
0001659617 2024-01-01 2024-06-30 0001659617 2024-08-01 0001659617 2024-06-30 0001659617 2023-12-31 0001659617 2024-
04-01 2024-06-30 0001659617 2023-04-01 2023-06-30 0001659617 2023-01-01 2023-06-30 0001659617 2022-12-31 0001659617
2023-06-30 0001659617 us-gaap:CommonStockMember 2023-12-31 0001659617 us-gaap:AdditionalPaidInCapitalMember 2023-
12-31 0001659617 us-gaap:RetainedEarningsMember 2023-12-31 0001659617 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001659617 us-gaap:CommonStockMember 2024-01-01 2024-
03-31 0001659617 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001659617 us-
gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001659617 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-01-01 2024-03-31 0001659617 2024-01-01 2024-03-31 0001659617 us-gaap:CommonStockMember 2024-03-31 0001659617
us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001659617 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-
06-30 0001659617 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001659617 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001659617 us-gaap:CommonStockMember 2024-

06-30-0001659617-us-gaap:AdditionalPaidInCapitalMember 2024-06-30-0001659617-us-gaap:RetainedEarningsMember 2024-06-30-0001659617-us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30-0001659617-us-gaap:CommonStockMember 2022-12-31-0001659617-us-gaap:AdditionalPaidInCapitalMember 2022-12-31-0001659617-us-gaap:RetainedEarningsMember 2022-12-31-0001659617-us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31-0001659617-us-gaap:CommonStockMember 2023-01-01-2023-03-31-0001659617-us-gaap:AdditionalPaidInCapitalMember 2023-01-01-2023-03-31-0001659617-us-gaap:RetainedEarningsMember 2023-01-01-2023-03-31-0001659617-us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01-2023-03-31-0001659617-us-gaap:CommonStockMember 2023-03-31-0001659617-us-gaap:AdditionalPaidInCapitalMember 2023-03-31-0001659617-us-gaap:RetainedEarningsMember 2023-03-31-0001659617-us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31-0001659617-2023-03-31-0001659617-us-gaap:CommonStockMember 2023-04-01-2023-06-30-0001659617-us-gaap:AdditionalPaidInCapitalMember 2023-04-01-2023-06-30-0001659617-us-gaap:RetainedEarningsMember 2023-04-01-2023-06-30-0001659617-us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01-2023-06-30-0001659617-us-gaap:CommonStockMember 2023-06-30-0001659617-us-gaap:AdditionalPaidInCapitalMember 2023-06-30-0001659617-us-gaap:RetainedEarningsMember 2023-06-30-0001659617-us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30-0001659617-mbrx:AnimalLifeSciencesIncMember 2024-06-30-0001659617-2023-05-05-0001659617-2023-11-02-2024-04-29-0001659617-mbrx:ReverseStockSplitMember 2024-03-21-2024-03-21-0001659617-mbrx:ReverseStockSplitMember 2024-03-22-2024-03-22-0001659617-2022-01-01-2022-12-31-0001659617-us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01-2024-06-30-0001659617-us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01-2023-06-30-0001659617-us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01-2024-06-30-0001659617-us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01-2023-06-30-0001659617-mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30-0001659617-us-gaap:FairValueInputsLevel1Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30-0001659617-us-gaap:FairValueInputsLevel2Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30-0001659617-us-gaap:FairValueInputsLevel3Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30-0001659617-mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31-0001659617-us-gaap:FairValueInputsLevel1Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31-0001659617-us-gaap:FairValueInputsLevel2Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31-0001659617-us-gaap:FairValueInputsLevel3Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31-0001659617-mbrx:WarrantLiabilityLongTermMember 2024-03-31-0001659617-mbrx:WarrantLiabilityLongTermMember 2024-04-01-2024-06-30-0001659617-mbrx:WarrantLiabilityLongTermMember 2024-06-30-0001659617-mbrx:WarrantLiabilityLongTermMember 2023-12-31-0001659617-mbrx:WarrantLiabilityLongTermMember 2024-01-01-2024-06-30-0001659617-us-gaap:RelatedPartyMember 2024-06-30-0001659617-us-gaap:RelatedPartyMember 2023-12-31-0001659617-srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30-0001659617-srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30-0001659617-srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31-0001659617-srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31-0001659617-srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30-0001659617-srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30-0001659617-srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31-0001659617-srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31-0001659617-srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30-0001659617-srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30-0001659617-srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31-0001659617-srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31-0001659617-mbrx:LiabilityClassifiedWarrantsMember 2023-12-31-0001659617-srt:MinimumMember mbrx:LiabilityClassifiedWarrantsMember 2023-12-31-0001659617-srt:MaximumMember mbrx:LiabilityClassifiedWarrantsMember 2023-12-31-0001659617-srt:WeightedAverageMember mbrx:LiabilityClassifiedWarrantsMember 2023-12-31-0001659617-mbrx:LiabilityClassifiedWarrantsMember 2023-01-01-2023-12-31-0001659617-mbrx:LiabilityClassifiedWarrantsMember 2024-01-01-2024-06-30-0001659617-srt:MinimumMember mbrx:LiabilityClassifiedWarrantsMember 2024-01-01-2024-06-30-0001659617-srt:MaximumMember mbrx:LiabilityClassifiedWarrantsMember 2024-01-01-2024-06-30-0001659617-srt:WeightedAverageMember mbrx:LiabilityClassifiedWarrantsMember 2024-01-01-2024-06-30-0001659617-mbrx:LiabilityClassifiedWarrantsMember 2024-06-30-0001659617-srt:MinimumMember mbrx:LiabilityClassifiedWarrantsMember 2024-06-30-0001659617-srt:MaximumMember mbrx:LiabilityClassifiedWarrantsMember 2024-06-30-0001659617-srt:WeightedAverageMember mbrx:LiabilityClassifiedWarrantsMember 2024-06-30-0001659617-mbrx:EquityClassifiedWarrantsMember 2024-03-31-0001659617-mbrx:EquityClassifiedWarrantsMember 2024-06-30-0001659617-mbrx:EquityClassifiedWarrantsMember 2023-12-31-0001659617-mbrx:EquityClassifiedWarrantsMember 2024-04-01-2024-06-30-0001659617-mbrx:EquityClassifiedWarrantsMember 2023-04-01-2023-06-30-0001659617-mbrx:EquityClassifiedWarrantsMember 2024-01-01-2024-06-30-0001659617-mbrx:EquityClassifiedWarrantsMember 2023-01-01-2023-06-30-0001659617-mbrx:The2015StockPlanMember 2023-05-31-2023-05-31-0001659617-mbrx:The2015StockPlanMember 2022-05-31-2022-05-31-0001659617-mbrx:The2015StockPlanMember 2023-05-31-0001659617-mbrx:The2015StockPlanMember 2024-06-30-0001659617-us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01-2024-06-30-0001659617-us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01-2023-06-30-0001659617-us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01-2024-06-30-0001659617-us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01-2023-06-30-0001659617-mbrx:The2015StockPlanMember 2024-05-08-2024-05-08-0001659617-2023-09-30-0001659617-2023-09-01-2023-09-30-0001659617-mbrx:MDAndersonMember 2024-04-01-2024-06-30-0001659617-mbrx:MDAndersonMember 2023-04-01-2023-06-30-0001659617-mbrx:MDAndersonMember 2024-01-01-2024-06-30-0001659617-mbrx:MDAndersonMember 2023-01-01-2023-06-30-0001659617-mbrx:HoustonPharmaceuticalsIncMember 2024-04-01-2024-06-30-0001659617-mbrx:HoustonPharmaceuticalsIncMember 2023-04-01-2023-06-30-0001659617-mbrx:HoustonPharmaceuticalsIncMember 2024-01-01-2024-06-30-0001659617-mbrx:HoustonPharmaceuticalsIncMember 2023-01-01-2023-06-30-shares thunderdome:Item iso4217:USD iso4217:USD shares pure utr:D utr:Y 0001659617 Moleculin Biotech, Inc. false -12-31 Q2 2024 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 100000000 100000000 2560785 2560785 2227516 2227516 3 1 P10Y 0 0 0 0 12000 38000 59000 117000 false false false 10-Q true 2024-06-30 false 001-37758 DE 47-4671997 5300 Memorial Drive, Suite 950 Houston TX 77007 713 300-5160 Yes Yes true Non-accelerated Filer false false Common Stock par value \$0.001 per share MBRX NASDAQ 2561527 10845000 23550000 2886000 2723000 13731000 26273000 221000 272000 11148000 11148000 475000 524000 25575000 38217000 2833000 2498000 2913000 4317000 5746000 6815000 420000 474000 1704000 4855000 7870000 12144000 0 0 3000 33000 158605000 157653000 -10000 -9000 -140893000 -131604000 17705000 26073000 25575000 38217000 0 0 0 4090000 3888000 8342000 9576000 2064000 2492000 4457000 5129000 31000 31000 63000 61000 6185000 6411000 12862000 14766000 -6185000 -6411000 -12862000 -14766000 -1696000 -36000 -3151000 -75000 11000 9000 22000 17000 159000 390000 400000 783000 -4319000 -5976000 -9289000 -13891000 -1.7 -3.02 -3.71 -7.13 2543244 1979258 2504709 1948135 -4319000 -5976000 -9289000 -13891000 8000 -1000 -1000 -5000 -4311000 -5977000 -9290000 -13896000 -9289000 -13891000 63000 61000 946000 1012000 0 772000 -3151000 -75000 108000 104000 163000 757000 335000 2041000 -1515000 -410000 -12666000 -11143000 13000 15000 -13000 -15000 25000 21000 0 211000 -25000 190000 -1000 -5000 -12705000 -10973000 23550000 43145000 10845000 32172000 2227516 33000 157653000 -131604000 -9000 26073000 6834 0 37000 0 0 37000 77186 -31000 31000 0 0 0 0 456000 0 0 456000 0 0 -4970000 0 -4970000 0 0 0 -9000 -9000 2311536 229506 1000 0 0 0 1000 19743 0 -25000 0 0 -25000 0 453000 0 0 453000 0 0 -4319000 0 -4319000 0 0 0 8000 8000 2560785 3000 158605000 -140893000 -10000 17705000 1908522 29000 153985000

-101835000 12000 52191000 10026 0 141000 0 0 141000 54808 1000 771000 0 0 772000 0 499000 0 0 499000 0 0 -7915000 0 -7915000 0 0 0 -4000 -4000 1973356 30000 155396000 -109750000 8000 45684000 5013 69000 69000 7588 0 -21000 0 0 -21000 0 513000 0 0 513000 0 0 -5976000 0 -5976000 0 0 0 -1000 -1000 1985957 30000 155957000 -115726000 7000 40268000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><em style="font: inherit;">1. Nature of Business </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p><p style="font-family:'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><em style="font: inherit;">The terms "MBI" or "the Company", "we", "our" and "us" are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in <em style="font: inherit;">July 2015,with clinical programs for hard-to-treat cancers and viruses. The Company has three core technologies, each of which have had <em style="font: inherit;">one or more drugs successfully complete a Phase <em style="font: inherit;">1 clinical trial, based substantially on discoveries made at and licensed from MD Anderson Cancer Center (MD Anderson) in Houston, Texas. The Company has <em style="font: inherit;">two wholly owned subsidiaries, Moleculin Australia Pty. Ltd., which was set up to perform certain preclinical development and Moleculin Amsterdam B.V., which acts as its legal representative for clinical trials in Europe. The Company utilizes its own internal resources and funds to conduct some of these trials and also has trials being conducted via physician-sponsored trials. The physician-sponsored trials utilize primarily external funds, such as grant funds, which are <em style="font: inherit;">not presented in these financial statements. The Company does <em style="font: inherit;">not have manufacturing facilities, and all manufacturing activities are contracted out to <em style="font: inherit;">third parties. Additionally, the Company does <em style="font: inherit;">not have a sales organization. The Company's overall strategy is to seek potential outlicensing or outsourcing opportunities with development/commercialization strategic partners who are better suited for the marketing, sales and distribution of its drugs, if approved.</p><p style="font-family:'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"></p><p style="font-family:'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;">2019,the Company sublicensed its technologies to Animal Life Sciences, Inc. (ALI), to enable research and commercialization for non-human use and share development data. As part of this agreement, ALI issued to the Company a 10% equity interest in ALI.</p><p style="font-family:'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"></p><p style="font-family:'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;">May 5, 2023,the Company received a letter from the Nasdaq Capital Market (Nasdaq) notifying the Company that for the prior <em style="font: inherit;">30 consecutive business days the bid price for the Company's common stock had closed below the minimum \$1.00 per share requirement for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule <em style="font: inherit;">5550(a)(<em style="font: inherit;">2)(Bid Price Rule). The deficiency letter did <em style="font: inherit;">not result in the immediate delisting of the Company's common stock from the Nasdaq. In accordance with Nasdaq Listing Rule <em style="font: inherit;">5810(c)(<em style="font: inherit;">3)(A), the Company was provided an initial period of <em style="font: inherit;">180 calendar days, until <em style="font: inherit;">November 1, 2023,to regain compliance with the Bid Price Rule. On <em style="font: inherit;">November 2,<em style="font: inherit;">2023,the Company received a 180-calendar day extension, until <em style="font: inherit;">April 29, 2024,from the Nasdaq to regain compliance with Bid Price Rule. On <em style="font: inherit;">March 5, 2024,the Board of Directors approved a reverse <em style="font: inherit;">1 for 15 reverse stock split effective <em style="font: inherit;">11:59 P.M. (Eastern time) on <em style="font: inherit;">March 21, 2024,with trading to commence on a split-adjusted basis on <em style="font: inherit;">March 22, 2024.On <em style="font: inherit;">April 8, 2024,the Company received a letter from Nasdaq notifying the Company that it had regained compliance with Bid Price Rule <em style="font: inherit;">5550(a)(<em style="font: inherit;">2) as a result of the closing bid price of the Company's common stock being at \$1.00 per share or greater for the <em style="font: inherit;">10 consecutive business days from <em style="font: inherit;">March 22, 2024through <em style="font: inherit;">April 5, 2024.Accordingly, the Company is in compliance with the Bid Price Rule and Nasdaq considers the matter closed.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><em style="font: inherit;">2.Basis of presentation, principles of consolidation, and significant accounting policies and liquidity</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><em style="font: inherit;">Reverse Stock Split On <em style="font: inherit;">March 22, 2024,the Company completed a reverse stock split of all the issued and outstanding shares of the Company's common stock at a ratio of <em style="font: inherit;">1 to 15. The accompanying consolidated financial statements and notes to the consolidated financial statements gives retroactive effect to the reverse stock split for all periods presented. Certain amounts previously reported include rounding up of fractional shares as a result of the reverse stock split.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><em style="font: inherit;">Basis of Presentation – Condensed Consolidated Financial Information The accompanying condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for financial information, and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC) with respect to Form <em style="font: inherit;">10-Q and Article <em style="font: inherit;">8 of Regulation S <em style="font: inherit;">X. Accordingly, they do <em style="font: inherit;">not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements furnished reflect all normal adjustments, which are, in the opinion of management, necessary for a fair statement of results for the interim periods presented. Interim results are <em style="font: inherit;">not necessarily indicative of the results for the full year. These condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of <em style="font: inherit;">December 31, 2023 and for the year then ended, including the notes thereto contained in the Form <em style="font: inherit;">10-K filed with the SEC on <em style="font: inherit;">March 22, 2024.</p><p style="font-family:'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"></p><p style="font-family:'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><em style="font: inherit;">Principles of Consolidation - The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. All material long-lived assets of the Company reside in the U.S.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><em style="font: inherit;">Significant Accounting Policies - The Company's significant accounting policies are described in Note <em style="font: inherit;">2,<i>Basis of Presentation, principles of consolidation and significant accounting policies</i>, to the consolidated financial statements included in the Company's Annual Report on Form <em style="font: inherit;">10-K for the year ended <em style="font: inherit;">December 31, 2023.

There have been six months ended June 30, 2024. The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.

Intangible Assets – The company evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. Due to the sustained decline in the Company's stock price, the Company engaged a third-party valuation firm to complete a quantitative assessment of in-process research and development (IPR&D) asset as of June 30, 2024. We performed our impairment test by comparing the carrying value of the IPR&D asset to its estimated fair value, which was determined by the income approach, using a discounted cash flow model. Based on our quantitative assessment, the carrying value of the IPR&D asset did not exceed its estimated fair value, noting no impairment.

Going Concern and Liquidity – These condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations. As of June 30, 2024, the Company had an accumulated deficit of \$140.9 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of \$10.8 million as of June 30, 2024 is not sufficient to fund its planned operations for a period of at least one year from when these consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company intends to seek additional funding through one or more of the following: a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. There can be no assurance that such events or a combination thereof can be achieved.

In March 2022, the Company received a subpoena from the SEC requesting information and documents, including materials related to certain individuals (none of which are the Company's officers or directors) and entities, and materials related to the development of and statements regarding the Company's drug candidate for the treatment of COVID-19. The Company has received, and expects to continue to receive, periodic further requests from the SEC staff with respect to this matter. The Company is not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that it has made, the Company believes in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to the Company states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. The Company cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. The company expensed approximately \$0.1 million and \$0.4 million in related general and administrative fees and expenses for the three months ended June 30, 2024 and 2023 and \$10.8 million and \$0.9 million on for the six months ended June 30, 2024 and 2023, respectively. The Company is in the process of filing a claim with its insurance carriers related to this loss which may cover a portion of the related expenses but not all. The claim is currently under review by the insurance company. The claim has not yet been approved nor has a reimbursement amount been determined which, if any, would be limited by the applicable retention as defined under the policy. Accordingly, the Company has not recorded any provision for insurance reimbursement. The Company expects to record the insurance reimbursement at the time that the amount to be reimbursed is determined and approved by the insurance carrier. Any insurance reimbursement receivable will be recorded at an amount not to exceed the recorded loss and only if the terms of the legally enforceable insurance contracts support that the insurance recovery will not be disputed and is deemed collectible, or if recovery of the loss is probable.

Cash and Cash Equivalents – Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The

Company maintains cash accounts principally at <em style="font-family:'Times New Roman','Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">one financial institution in the U.S., which at times, <em style="font-family:'Times New Roman','Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">may exceed the Federal Deposit Insurance Corporation's limit. The Company has <em style="font-family:'Times New Roman','Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">not experienced any losses from cash balances in excess of the insurance limit. The Company's management does <em style="font-family:'Times New Roman','Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:36pt;">not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institution where its cash is held.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

Prepaid insurance	\$1,277
Prepaid sponsored research	\$1,515
Vendor prepayments and deposits	\$457
Non-trade receivables	\$5
Total prepaid expenses and other current assets	\$2,886
Related party receivables	\$2,723

Fair Value of Financial Instruments

The Company's financial instruments consist primarily of non-trade receivables, accounts payable, accrued expenses and its warrant liability. The carrying amount of non-trade receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such.

The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).

Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:

Level 1 — Unadjusted quoted prices in active markets of identical assets or liabilities.

Level 2 — Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

Level 3 — Unobservable inputs for the asset or liability.

The Company's financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4.

The following table provides the financial liabilities reported at fair value and measured on a recurring basis at June 30, 2024 and

Description	June 30, 2024
Fair Value of Level 1	\$1,704
Fair Value of Level 2	\$4,855
Fair Value of Level 3	\$—

[illegible]

Loss Per Common Share – Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock units subject to vesting and warrants to purchase common stock are considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, because their inclusion would be anti-dilutive. For the three and six months ended June 30, 2024 and 2023, approximately 1.6 million and 0.4 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect.

Subsequent Events – The Company's management reviewed all material events through the date of these unaudited condensed consolidated financial statements.

Recent Accounting Pronouncements – There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company.

Reverse Stock Split – On March 22, 2024, the Company completed a reverse stock split of all the issued and outstanding shares of the Company's common stock at a ratio of 1 to 15. The accompanying consolidated financial statements and notes to the consolidated financial statements gives retroactive effect to the reverse stock split for all periods presented. Certain amounts previously reported include rounding up of fractional shares as a result of the reverse stock split.

Basis of Presentation – Condensed Consolidated Financial Information – The accompanying condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for financial information, and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC) with respect to Form Q and Article 8 of Regulation S. X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements furnished reflect all normal adjustments, which are, in the opinion of management, necessary for a fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of December 31, 2023 and for the year then ended, including the notes thereto contained in the Form K filed with the SEC on March 22, 2024.

Principles of Consolidation – The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. All material long-lived assets of the Company reside in the U.S.

Significant Accounting Policies – The Company's significant accounting policies are described in Note 2, **Basis of Presentation, principles of consolidation and significant accounting policies**, to the consolidated financial statements included in the Company's Annual Report on Form K for the year ended December 31, 2023. There have been no material changes to the significant accounting policies during the six months ended June 30, 2024.

Use of Estimates – The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.

Intangible Assets – The company evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. Due to the sustained decline in the Company's stock price, the Company engaged a third-party valuation firm to complete a quantitative assessment of in-process research and development (IPR&D) asset as of June 30, 2024. We performed our impairment test by comparing the carrying value of the IPR&D asset to its estimated fair value, which was determined by the income approach, using a discounted cash flow model. Based on our quantitative assessment, the carrying value of the IPR&D asset did not exceed its estimated fair value, noting no impairment.

Going Concern and Liquidity – These condensed consolidated financial statements have been prepared on a going concern basis, which assumes

The Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary equity financing to continue operations and the attainment of profitable operations. As of June 30, 2024, the Company had an accumulated deficit of \$140.9 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of \$10.8 million as of June 30, 2024 is not sufficient to fund its planned operations for a period of at least one year from when these consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company intends to seek additional funding through one or more of the following: a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. There can be no assurance that such events or a combination thereof can be achieved.

In March 2022, the Company received a subpoena from the SEC requesting information and documents, including materials related to certain individuals (none of which are the Company's officers or directors) and entities, and materials related to the development of and statements regarding the Company's drug candidate for the treatment of COVID-19. The Company has received, and expects to continue to receive, periodic further requests from the SEC staff with respect to this matter. The Company is not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that it has made, the Company believes in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to the Company states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. The Company cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. The company expended approximately \$0.1 million and \$0.4 million in related general and administrative fees and expenses for the three months ended June 30, 2024 and 2023, respectively, and \$0.1 million and \$0.9 million on for the six months ended June 30, 2024 and 2023, respectively. The Company is in the process of filing a claim with its insurance carriers related to this loss which may cover a portion of the related expenses but not all. The claim is currently under review by the insurance company. The claim has not yet been approved nor has a reimbursement amount been determined which, if any, would be limited by the applicable retention as defined under the policy. Accordingly, the Company has not recorded any provision for insurance reimbursement. The Company expects to record the insurance reimbursement at the time that the amount to be reimbursed is determined and approved by the insurance carrier. Any insurance reimbursement receivable will be recorded at an amount not to exceed the recorded loss and only if the terms of the legally enforceable insurance contracts support that the insurance recovery will not be disputed and is deemed collectible, or if recovery of the loss is probable.

Cash and Cash Equivalents – Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains cash accounts principally at one financial institution in the U.S., which at times, may exceed the Federal Deposit Insurance Corporation's limit. The Company has not experienced any losses from cash balances in excess of the insurance limit. The Company's management does not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institution where its cash is held.

Prepaid Expenses and Other Current Assets – Prepaid expenses and other current assets consist of the following (in thousands):

	June 30, 2024	June 30, 2023
Prepaid sponsored research	\$1,277	\$1,430
Prepaid insurance	\$1,515	\$1,430

564	
457	
545	
5	
95	
2,886	
2,723	
1,515	
1,277	
1,143	
564	

Vendor prepayments and deposits

Related party receivables

Total prepaid expenses and other current assets

June 30, 2024

December 31, 2023

Prepaid insurance

Prepaid

Roman", Times, serif, font-size: 10pt; margin-left: 0pt;">457</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;">545</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"></td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"><p style="font-family: "Times New Roman", Times, serif, font-size: 10pt; font-variant: normal; margin: 0pt;">Non-trade receivables</p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;">95</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"></td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; font-variant: normal; margin: 0pt;">Related party receivables</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"></td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"><p style="font-family: "Times New Roman", Times, serif, font-size: 10pt; font-variant: normal; margin: 0pt;">Total prepaid expenses and other current assets</p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">\$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,886</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">\$</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td></tr></tbody></table>1277000 1515000 1143000 564000 457000 545000 5000 95000 4000 4000 2886000 2723000<p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Fair Value of Financial Instruments -The Company's financial instruments consist primarily of non-trade receivables, accounts payable, accrued expenses and its warrant liability. The carrying amount of non-trade receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such.</p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: left;"></p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a<em style="font: inherit;">three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level<em style="font: inherit;">1) and lowest priority to unobservable inputs (Level<em style="font: inherit;">3).</p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:</p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Level<em style="font: inherit;">1- Unadjusted quoted prices in active markets of identical assets or liabilities.</p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Level<em style="font: inherit;">2- Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.</p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Level<em style="font: inherit;">3- Unobservable inputs for the asset or liability.</p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company's financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note<em style="font: inherit;">4.</p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The following table provides the financial liabilities reported at fair value and measured on a recurring basis at<em style="font: inherit;">June 30, 2024 and<em style="font: inherit;">December 31, 2023 (table in thousands):</p><p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></p><table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; width: 52%; border-bottom: thin solid rgb(0, 0, 0);"><p style="font-family: "Times New Roman", Times, serif, font-size: 10pt; margin: 0pt;">Description</p></td><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; width: 48%; border-bottom: thin solid rgb(0, 0, 0);"><p style="font-family: "Times New Roman", Times, serif, font-size: 10pt; margin: 0pt; text-align: center;"><em style="font: inherit;">Fair Value</p></td></tr><tr><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; padding-bottom: 1px;"></td><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"></td></tr><tr><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; padding-bottom: 1px;"><em style="font: inherit;">Level 1</td><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; padding-bottom: 1px;"></td></tr><tr><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"></td><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt;"></td></tr><tr><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">Level 2</td><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"></td></tr><tr><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">Level 1</td><td style="font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt; text-align: center;"><em style

Level 3

1,704	4,855	4,855
-------	-------	-------

The table below of Level 3 liabilities (table in thousands) begins with the valuation as of the beginning of the second quarter and then is adjusted for changes in fair value that occurred during the second quarter. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Balance, March 31, 2024	Change in fair value - net	Balance, June 30, 2024
3,400	(1,696)	1,704

The table below of Level 3 liabilities (table in thousands) begins with the valuation as of December 31, 2023 and then is adjusted for changes in fair value that occurred during the

"font: inherit;">Six Months Ended June 30, 2024<em style="font: inherit;">June 30, 2024. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Six Months Ended June 30, 2024	
Balance, December 31, 2023	4,855
Change in fair value - net	1,704
Balance, June 30, 2024	6,559

Description

Level 1	Level 2	Level 3
Fair Value of warrant liability as of June 30, 2024	Fair Value of warrant liability as of December 31, 2023	Fair value of warrant liability as of June 30, 2024
4,855	4,855	4,855

Fair value of warrant liability as of June 30, 2024: 1,704

Fair value of warrant liability as of December 31, 2023: 4,855

[illegible]

Recent Accounting Pronouncements

There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company.

	June 30, 2024	December 31, 2023
Accrued expenses and other current liabilities	1,157	765
Accrued payroll and bonuses	1,060	1,060
Accrued research and development	2,845	547
Operating lease liability - current	112	112
Total accrued expenses and other current liabilities	2,913	44
Total accrued expenses and other current liabilities due to related party	2,913	60

Additionally, accounts payable included \$20,000 as of June 30, 2024 and December 31, 2023, respectively, for related party payables.

"Times New Roman"; font-size: 10pt;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">June 30, 2024</p></td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"></td><td style="font-family: "Times New Roman"; font-size: 10pt;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2023</p></td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"></td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued payroll and bonuses</p></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,157</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">765</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued research and development</p></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,060</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,845</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued legal, regulatory, professional and other</p></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">540</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">547</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease liability – current</p></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">112</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued liabilities due to related party</p></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"></td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Total accrued expenses and other current liabilities</p></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,913</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">4,317</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"></td></tr></tbody></table>1157000 765000 1060000 2845000 540000 547000 112000 100000 44000 60000 2913000 4317000 20000 67000<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><em style="font: inherit;">4. Warrants</p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">Liability Classified Warrants</p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company uses the Black-Scholes option pricing model (BSM) to determine the fair value of its warrants at the date of issue and outstanding at each reporting date. The risk-free interest rate assumption is based upon observed interest rates on <em style="font: inherit;">zero coupon U.S. Treasury bonds linearly interpolated to obtain a maturity period commensurate with the term of the warrants. Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Only the volatility of the Company's own stock is used in the Black-Scholes option pricing model.</p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The assumptions used in determining the fair value of the Company's outstanding liability classified warrants are as follows:</p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"><table border="0" cellpadding="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;"><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 68%;"></td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 1%;"></td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt;"></td></tr></table>

[illegible]

Exercise Price

Life (Years)	
Balance at January 1, 2024	
1,082,895	
9.60	
157.50	
24.32	
75,909	
99.00	
99.00	
94.50	
4.4	
9.60	

"Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"/>
 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"/>
 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"/>
 </td><td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"/>
 94.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"/>
 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"/>
 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"/>
 </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"/>
 15.31</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"/>
 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt;"/>
 </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"/>
 4.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif, font-size: 10pt; margin-left: 0pt;"/>
 </td></tr></tbody></table>
 <p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify;"/>
 <em style="font: inherit;"/>
 six months ended <em style="font: inherit;"/>
 June 30, 2024, see Note <em style="font: inherit;"/>
 2 - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Financial Instruments.
 <p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"/>
 Equity Classified Warrants
 <p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"/>
 In <em style="font: inherit;"/>
 March 2024, the Company granted equity-classified warrants to purchase up to 3,334 shares of Company common stock with a
 ten-year term and an exercise price of \$9.15. The warrants vest annually over <em style="font: inherit;"/>
 four years while services are being performed.
 <p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"/>
 At <em style="font: inherit;"/>
 June 30, 2024, the Company
 had 63,105
 equity classified warrants outstanding an
 d 40,658
 warrants were exercisable. At <em style="font: inherit;"/>
 December 31, 2023, the Company had 289,276 equity classified warrants outstanding and 266,350 warrants were exercisable.
 <p style="font-family: 'Times New Roman', Times, serif, font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"/>
 The Company recorded stock compensation expense for the non-employee consulting agreements o
 f \$35,000 and
 \$46,000 for the <em style="font: inherit;"/>
 three months ended <em style="font: inherit;"/>
 June 30, 2024 and <em style="font: inherit;"/>
 2023, respectively, and
 \$68,000 and
 \$92,000 for the <em style="font: inherit;"/>
 six months ended <em style="font: inherit;"/>
 June 30, 2024 and <em style="font: inherit;"/>
 2023, respectively. At <em style="font: inherit;"/>
 June 30, 2024, there was
 \$309,000 of unrecognized stock compensation expense related to the Company's equity classified warrants.
 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"/>
 <tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom;"/>
 <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"/>
 <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"/>
 </td><td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"/>
 <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"/>
 <em style="font: inherit;"/>
 June 30, 2024
 </p></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"/>
 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"/>
 </td><td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"/>
 <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"/>
 <em style="font: inherit;"/>
 December 31, 2023
 </p></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"/>
 </td><td style="background-color: rgb(204, 238, 255); vertical-align: bottom;"/>
 <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%; padding: 0; margin: 0;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 Risk-free interest rate
 </p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 4.3% to 5.2%
 </p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 79.5% to 108.7%
 </p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="background-color: rgb(204, 238, 255); vertical-align: bottom;"/>
 <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%; padding: 0; margin: 0;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 Expected life (years)
 </p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 0.3 to 5.0
 </p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="background-color: rgb(255, 255, 255); vertical-align: bottom;"/>
 <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 0.6 to 4.5
 </p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 0.3 to 5.0
 </p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="background-color: rgb(255, 255, 255); vertical-align: bottom;"/>
 <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 Dividend yield
 </p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 0.3 to 5.0
 </p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0;"/>
 </td><td style="background-color: rgb(255, 255, 255); vertical-align: bottom;"/>
 <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"/>
 <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif;"/>
 0

[illegible]

family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">99.00</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"><p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">Balance at June 30, 2024</p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"></td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,006,986</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">\$</td><td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.60</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">\$</td><td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">94.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">\$</td><td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"><p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">Exercisable at June 30, 2024</p></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"></td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,006,986</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">\$</td><td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">94.50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">\$</td><td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">15.31</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"></td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"></td></tr></tbody></table> 1082895 9.6 157.5 24.32 P5Y1M6D 75909 99 99 99 1006986 9.6 94.5 0 P4Y4M24D 1006986 9.6 94.5 15.31 P4Y4M24D 3334 9.15 63105 40658 289276 266350 35000 46000 68000 92000 309000 <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><em style="font: inherit;">5 Equity</p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><em style="font: inherit;">Equity utilized the <em style="font: inherit;">six months ended <em style="font: inherit;">June 30, 2024. The <em style="font: inherit;">2021 Lincoln Park Agreement terminated in <em style="font: inherit;">June 2024. </p><p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Lincoln Park Equity Line</p><p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Other Components of Equity</p><p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;">March 2024, the Company issued 6,834 shares of common stock to consultants in exchange for services to be provided. In addition, during the <em style="font: inherit;">six months ended <em style="font: inherit;">June 30, 2024, the Company issued 19,743 shares of common stock related to the vesting of restricted stock units. </p><p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Stock-Based Compensation and Outstanding Awards</p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">The <em style="font: inherit;">2015 Stock Plan provides for the grant of stock options, stock awards, stock unit awards, and stock appreciation rights to employees, non-employee directors and consultants. In <em style="font: inherit;">May 2023 and <em style="font: inherit;">2022, the <em style="font: inherit;">2015 Stock Plan (the Plan) was amended to authorize an additional 116,667 shares and 133,334 shares, respectively, such that 366,667 total shares <em style="font: inherit;">may be issued under the Plan. As of <em style="font: inherit;">June 30, 2024, there were e 1,053 shares remaining to be issued under the <em style="font: inherit;">2015 Stock Plan. </p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">Stock-based compensation expense for the <em style="font: inherit;">three and <em style="font: inherit;">six months ended <em style="font: inherit;">June 30, 2024 and <em style="font: inherit;">2023, respectively, is as follows (table in thousands):</p><p style="font-

family: Times New Roman; Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;"></p></td></tr><tr><td colspan=					
--	--	--	--	--	--

[illegible]

[illegible]

The Company is also required to pay additional rent in the form of its pro-rata share of certain specified operating expenses of the building.

In June 2022, the Company extended the lab lease until September 30, 2027, with no further right or option to renew. The Company recorded approximately \$12,000 in sublease income from a related party for the three months ended June 30, 2024 and six months ended 2023, respectively, and \$24,000 and \$25,000 for the six months ended June 30, 2024 and six months ended 2023, respectively. Sublease income is recorded as other income, net on the Company's condensed consolidated statement of operations and comprehensive loss. Operating cash flows from operating leases was \$38,000 for the three months ended June 30, 2024 and \$68,000 and \$75,000 for the six months ended June 30, 2024 and 2023, respectively.

Licenses

MD Anderson - Total expenses related to the Company's license agreements with MD Anderson were \$63,000 and \$64,000 for the three months ended June 30, 2024 and 2023, respectively, and \$117,000 and \$129,000 for the six months ended June 30, 2024 and 2023, respectively.

HPI - The Company has two agreements with a related party, Houston Pharmaceuticals, Inc. (HPI) with total expenses of \$59,000 for each of the three months ended June 30, 2024 and six months ended June 30, 2024 and 2023, respectively.

Sponsored Research Agreements - The expenses recognized under the agreements were \$377,000 and \$176,000 for the three months ended June 30, 2024 and 2023, respectively, and \$533,000 and \$331,000 for the six months ended June 30, 2024 and 2023, respectively.

	Three Months Ended June 30,	Six Months Ended June 30,
Lease cost:	\$377,000	\$176,000
	\$533,000	\$331,000

Operating lease cost

38	33	33	204	75	65	7	7	14	45	40	85	79	38000	33000	75000	65000	7000	10000	14000	45000	40000	85000	79000	4700	0.02	12000	24000	25000	38000	68000	75000	63000	64000	117000	129000	59000	117000	377000	176000	533000	331000
----	----	----	-----	----	----	---	---	----	----	----	----	----	-------	-------	-------	-------	------	-------	-------	-------	-------	-------	-------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	--------	--------	-------	--------	--------	--------	--------	--------

ITEM 5. OTHER INFORMATION.

During the period covered by this Quarterly Report, none of the Company's directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).